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ABSTRACT
Metal Nanomaterials: Immune Effects and Implications of Physicochemical Properties on Sensitization,
Elicitation, and Augmentation of Allergic Disease
Katherine A. Roach
The recent surge in incorporation of engineered metallic and metal oxide nanomaterials into consumer
products and their corresponding use in occupational settings has raised concerns over their potential to induce
material size-specific toxicological effects. Although metal nanomaterials have been shown to induce greater
degrees of lung injury and inflammation than their larger metal counterparts, their size-related effects on the immune
system and allergic disease remain largely unknown. This knowledge gap is particularly concerning since metals
are common inducers of allergic contact dermatitis, occupational asthma, and allergic adjuvancy.
Overall, more scientific knowledge exists regarding the potential for metal-containing nanomaterials to
exacerbate allergic disease than to their potential to induce allergic disease. Furthermore, effects of metal
nanomaterial exposure on respiratory allergy have been more thoroughly-characterized than their potential
influence on dermal allergy. Despite the existence of such knowledge, specific correlations between metal
nanomaterial physico-chemical properties and their allergic effects have yet to be consistently demonstrated. As
the number of emerging nanomaterials continues to increase, the delineation of these relationships has the potential
to advance risk assessment efforts by helping to identify specific agents that may present an elevated risk for allergic
effects.
Two sets of studies were designed to begin addressing some of the knowledge gaps associated with the
immunotoxic potential of metal nanomaterials in the context of allergic disease. The hypothesis of these studies
was that nanomaterials comprised of metal constituents with known immunomodulatory potential augment, induce,
and elicit allergic disease more readily than larger forms of the materials. Moreover, the nature of the immune
responses caused by exposure to these metal nanomaterials, as well as the magnitude of the effects, correlates
best with the parameter of dose surface area.
The first set of studies incorporated NiO particles with different physico-chemical properties into an in vivo
time course study and OVA asthma model. Results from the time course study demonstrated that the smaller NiO
particles caused more pronounced pulmonary injury and inflammation, a discrepancy that could be mitigated by
normalizing the administered particle dose to the surface area of the larger material. In the OVA model,
augmentation of the allergic response was largely conserved with respect to NiO surface area, wherein larger doses
caused polarization of pulmonary immune reposes towards a Th1/17-dominant state and smaller doses induced
Th2-skewed responses. Despite this association, several immune markers, including total IgE production, BAL
eosinophil number, and Penh response correlated better with other metrics, such as particle size.
The second set of studies employed Au particles and nanoparticles to assess size-specific differences in
allergenic potential. Neither particle was associated with potential for skin sensitization, which contrasted with the
potent allergenicity of soluble Au salts. Both particles were also associated with minimal potential for respiratory
toxicity or alterations in pulmonary immune status. However, established contact sensitivity to Au conferred
enhanced lung immune reactivity to the materials. Subsequent immune responses varied in nature, but were largely
conserved with respect to Au surface area. General increases in several prototypical Th1 markers were seen in
animals exposed to higher surface area-based doses of Au particles, whereas several Th2-associated allergic
markers were increased following exposure to lower doses. Notably, higher doses caused the greatest influx of
lymphocytes to the lung, in addition to a selective increase in BAL CD8+ T-cells. Many features of this response
resembled characteristics associated with gold lung, a T-cell-mediated respiratory hypersensitivity response. This
observation suggests the potential for Au inhalation to cause allergic elicitation responses in the airways when
established populations of gold-reactive lymphocytes exist.
Collectively, these two studies demonstrated that the magnitude of acute pulmonary inflammation caused
by both NiO and Au nanoparticles, although differing greatly between the two materials, was exclusively conserved
with respect to dose surface area. Although many immunological markers with relevance to allergic disease were
also altered by these materials with respect to the administered surface area, several other parameters, including
dose mass, also appeared influential. Overall, these findings suggest that the development of nanomaterial-specific
exposure limits derived from surface area-based metrics may be more effective in protecting against metal
nanomaterial-induced acute pulmonary inflammation than traditional mass-based metrics; however, this approach
may not be equally protective with respect to pulmonary immune responses.
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CHAPTER 1:
Introduction and Literature Review

Adapted from Roach et al. (2019):
Metal Nanomaterials: Immune Effects and Implications of Physico-Chemical Properties on
Sensitization, Elicitation, and Exacerbation of Allergic Disease
Published in the Journal of Immunotoxicology on June 14, 2019
DOI: 10.1080/1547691X.2019.1605553
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1.1. INTRODUCTION
1.1.1. Nanotechnology and Nanotoxicology
Matter with dimensions measuring 1-100 nanometers in size (one billionth of a meter) have been
generated by natural processes since the beginning of time. Nanoscale materials are produced as
byproducts of photochemical reactions of plants, volcanic eruptions, forest fires, sea spray, and simple
erosion (1). However, the exceptionally unique physical properties and chemical behaviors of materials
with nanoscale dimensions has only recently been recognized. Over the past 20 years, advances in the
understanding of nanomaterials and their novel characteristics have rendered them remarkably useful in
numerous diverse applications. Accordingly, nanotechnology, the intentional design, manufacture, and
functional application of materials with nanoscale dimensions for the benefit and advancement of society,
has gained significant momentum (2). Subsequent progress in this field has already begun to
revolutionize an extensive number of commercial markets and facilitate modern scientific advances. By
some estimates, the impact of these developments is expected to exceed that of the Industrial Revolution
(3). The far-reaching implications of nanotechnology are clearly visible with respect to global economics,
with a reported compound annual growth rate of 18.1%, estimated to reach a value of US $173.95 billion
by 2025 (4).
The nanotechnology sector encompasses numerous unique fields, all of which involve
manipulation of matter on an atomic and molecular scale. One of the most widespread applications of
nanotechnology is the production of diverse types of materials exhibiting physical dimensions in the 1100 nm range. Thousands of different nanomaterials currently exist, and novel nanomaterials are
continually being developed. The unifying characteristic of all nanomaterials is their size; however,
various types of nanomaterials can exhibit expansive variations in their physical and chemical properties.
Nanomaterials can be categorized by several different approaches. Generation source is often
used to classify nanomaterials as engineered, incidental or natural nano-objects. The Occupational
Safety and Health Administration (OSHA) defines ‘engineered nanomaterials’ as being purposefully
manufactured, synthesized, or manipulated to have a size with at least one dimension in the range of 1100 nm for a specific purpose. ‘Incidental nanomaterials’ are generated as an unintentional by-product
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of an industrial or environmental process (5). These nanomaterials can be generated from anthropogenic
sources including combustion reactions from vehicle engines and incinerators, as well as from cigarette
smoking. Some incidental nanomaterials comprise another category of nanomaterials, referred to as
‘natural nanomaterials,’ which are of particular interest for some sectors. Natural nanomaterials include
viruses and other biomolecules with nanoscale dimensions.
Nano-objects can also be generally classified based on their physical properties and
dimensionality. Diverse morphologies of nanomaterials exist wherein one, two, or all three of the
material’s dimensions can measure 1-100 nm. Moreover, nanostructured materials or multicomponent
nano-objects can consist of larger constituent structures measuring > 100 nm that exhibit distinct
structural regions with nanoscale features or textures (6).
Nanomaterials can also be categorized based on their elemental constituents. Common
categories

derived

from

this

classification

system

include

carbon-based

nanomaterials,

dendrimers/polymers, silicon-based nanomaterials, composites, and metal-containing nanomaterials.
Examples of these categories, specific agents, corresponding industrial applications and production
volumes are shown in table 1.1.
Carbon-based nanomaterials include single and multiwall carbon nanotubes, fullerenes, carbon
black, and graphenes. Dendrimers are nano-sized polymers with unique geometry comprised of
branching units and internal crevices. Silicon-containing nanomaterials are unique, as they are comprised
of silicon, which is considered a metalloid by most accounts. Silicon dioxide nanoparticles are
manufactured in large quantities, but silicon is also frequently used in combination with other elements
(such as metals) to form composite nanomaterials. Moreover, silicon is frequently used as a coating for
other nanomaterials, as well.
Metal-based nanomaterials can be comprised of diverse metal constituents ranging from Noble
metals (e.g. gold, platinum) to transition metals (e.g., nickel, cobalt). A subcategory of metal-based
nanomaterials frequently produced is metal oxide nanomaterials (e.g., titanium dioxide, cerium dioxide).
Metal nanomaterials can also be comprised of multiple metallic elements, forming metal alloy
nanomaterials.
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Although nanomaterials can be generally categorized using these parameters, such schemes
may have limited utility in identifying groups of nanomaterials with specific shared properties or behaviors.
Accordingly, in 2010, the International Standardization Organization (ISO) developed a systematic
approach by which to categorize nano-objects based on a hierarchy of several characteristics (7). The
approach involves categorization of nano-objects using a nano-tree, based on four successive
parameters referred to as ‘columns.’ Within each column, subsequent divisions exist to further categorize
materials with greater specificity.
A schematic of the ISO’s nano-tree is shown in figure 1.1. The first parameter (column 1, C1) is
the number of dimensions the object possesses that fall into the 1-100 nanometer size range. Materials
with one external nanoscale dimension are termed ‘nanoplates’ and include materials such as graphene
sheets. Materials containing two nanoscale dimensions are termed ‘nanofibers.’ Nanofibers can be
further classified based on additional properties- nanorods are solid nanofibers, nanotubes are hollow
nanofibers, and nanowires are electrically-conducting or semi-conducting nanofibers. Lastly, materials
possessing all three dimensions within the 1-100 nm range are termed ‘nanoparticles.’ Variations of
nanoparticles can include unique shapes such as cubes, spheres, and stars (8).
The second parameter (column 2, C2) categorizes materials with respect to similar dimensionality
in the context of internal/external structures. This parameter allows for the discrimination of single- and
multi-component nano-objects, as well as nanostructured materials. Categories of nano-objects
discriminated at the C2 level include nanocomposites, nanoporous materials, and nano-films.
The next parameter (column 3, C3) used to classify nano-objects is their elemental constituents
and chemical identity. Accordingly, materials are differentiated into categories including metallics, semimetallics, ceramics, synthetic or natural polymers, and carbon-based materials. Nanomaterials can also
be categorized as composites, which contain at least 2 or more components from different C3 categories.
The final discriminating parameter presented in column 4 (C4) of the ISO’s nano-tree pertains to
various functional characteristics of nanomaterials. Materials are grouped based on similar physical,
mechanical, chemical, biological, or combined properties. Each of these parameters is extensively
expanded into successive characteristics for further classification of nano-objects. For example, the
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physical properties of nanomaterials constitute several subgroups including magnetic, electric, thermal,
optical, and acoustic behavior. Each of these properties is expanded even further to allow for
categorization of materials with exceptionally specific behaviors and properties.
The ISO’s nano-tree approach was designed to address several challenges associated with the
recent emergence of nanotechnology. It has been instrumental in facilitating scientific advancements by
establishing logical classification schemes for nanomaterials that are relevant to diverse
nanotechnological sectors, standardizing nanotechnological nomenclature between disciplines, and
generating a framework by which relationships between nanomaterial properties and their behaviors can
be delineated.
Many of the properties and behaviors of nanomaterials identified in the ISO’s nano-tree underlie
the increased utility of nanomaterials in their various commercial applications. Nanomaterials are being
increasingly incorporated into various commercial goods as they confer advantageous properties
including antimicrobial activity, corrosion protection, scratch resistance, diffusion barriers, flame
retardancy, and thermal insulation. For example, carbon-based nanomaterials are often used in
applications that exploit their momentous mechanical strength and lightweight nature. Accordingly, they
are frequently used to produce sporting goods and equipment, in electronics, and for
aerospace/automobile production (9).
Industrial applications for nanomaterials continue to increase, leading to inevitable increases in
exposures to these materials. As a result, their potential to cause adverse health effects has become an
area of active scientific investigation. Subsequently, nanotoxicology studies have consistently
demonstrated that the unique physical properties and chemical behaviors of nanomaterials that confer
their enhanced industrial functionality also often implicate unique interactions with biological systems (3).
The potential toxic effects of nanomaterials have been examined with respect to different classes of
materials, target tissues, and routes of exposure. However, many of these effects have been specifically
studied in the context of subpopulations with an elevated risk for exposure to nanomaterials.

1.1.1.1. Occupational Exposures to Nanomaterials
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Workplaces represent one of the major settings associated with increased potential for
nanomaterial exposure. As the global demand for engineered nanomaterials increases, more individuals
are becoming employed by occupations involved in the production, handling, and utilization of
nanomaterials (10). The National Science Foundation has estimated that by 2020, at least 2 million
workers in the United States alone will be employed by nanotechnology-related fields (11). Not only are
these workers exposed to larger quantities of nanomaterials than consumers, they represent one of the
first groups in society to encounter emerging materials with unknown health effects. Accordingly, workers
represent a population particularly vulnerable to the potential toxic effects of nanomaterials.
One of the major mechanisms by which workers are kept safe from adverse health effects is by
the development, establishment, and enforcement of occupational exposure limits (OELs). Although
many countries address these issues differently, in the United States, several government agencies are
involved in OEL generation. The National Institute of Occupational Safety and Health (NIOSH) conducts
research specific to the toxicity of particular agents and sets Recommended Exposure Limits (RELs)
based on their findings. The American Conference of Governmental Industrial Hygienists (ACGIH) is a
nonprofit scientific association that also researches and publishes OELs for specific agents which are
expressed as Threshold Limit values (TLV ®). However, the instatement of legally-enforceable OELs falls
under the authority of the Occupational Safety and Health Administration (OSHA), which establishes
agency-specific OELs called Permissible Exposure Limits (PELs). These values constitute substancespecific concentration-based doses, with which compliance is monitored as a time-weighted average
(TWA) in workers.
Currently, emerging nanomaterials are subject to existing OELs established for agents with similar
chemical compositions. However, numerous studies have shown that these OELs, while effective in
protecting against the toxic effects of larger materials, often exhibit a lack of utility in predicting safe levels
of exposure for nanomaterials (12). This discrepancy is reflective of a distorted relationship between dose
mass and toxic potential when materials possess nanoscale dimensions. This concept has become
increasingly recognized, and in 2012, the NIOSH REL for titanium dioxide (TiO2) was modified to include
exposure limits specific to particle size. Despite the proposed exposure limits of 2.4 mg/m3 for fine TiO2
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and 0.3 mg/m3 for ultrafine and nanoscale TiO2, OSHA has not yet adopted size-specific OEL for TiO2
(13).
The toxic potential of many currently-produced nanomaterials remains largely unknown, which is
concerning given the rapid emergence of new materials. The extensive amount of time, resources, and
money required to thoroughly investigate each individual nanomaterial renders this risk assessment
approach impractical. A proposed method to overcome this challenge involves the identification of toxic
mechanisms and their correlation with specific nanomaterial physico-chemical properties (14).
Subsequently, the toxic potential of emerging nanomaterials can be predicted, allowing for allocation of
time and resources to investigate new materials suspected to present an elevated risk.
In accordance with this approach, the impact of various physio-chemical properties on the toxic
effects of nanomaterials has been studied, to differing degrees, following various routes of exposure.

1.1.1.2. Inhalation Exposures to Nanomaterials
The respiratory system has been frequently studied as a potential portal of entry for
nanomaterials, as well as a target tissue of nanomaterial toxic effects. Several anatomical and
physiological characteristics of the lungs, in addition to numerous physico-chemical properties of
nanomaterials, render inhalation exposure to nanomaterials a growing concern.
First, the respiratory tract is constantly exposed to substances in the external environment, many
of which have potential to cause adverse health effects. At rest, a typical human inhales about 15 times
per minute, whereupon each breath results in intake of about 500 mL of air; however, while exercising,
air intake can increase 10-fold. As a result, the average human is exposed to 10,000 – 12,000 L of air
each day (15). Inevitably, this air can serve as a vehicle facilitating the entry of nanomaterials, in addition
to pathogens and chemicals, into the body where detrimental health effects can ensue.
Additionally, the lungs constitute an epithelial surface with potential to promote extensive physical
interactions with toxic agents, including nanomaterials. The total volume of the conducting airways and
gas exchange region of a human is, on average, about 5 liters; however, the total respiratory surface
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generated by alveolar structures averages between 75 and 140 m2, which is more than 60 times larger
than the external body surface and larger than the surface area of a tennis court (16).
In a similar respect, the respiratory tract exhibits barrier functions less effective than many of
those provided by other tissues. The primary function of the lungs is not to serve as an impenetrable
physical barrier between the body and the external environment, but to facilitate gas exchange between
these two compartments. As a result, inhaled material possessing specific properties can readily pass
through the epithelial surfaces of the respiratory tract, enter systemic circulation, and access distal sites
of the body, following which, toxic responses may occur (17).
These properties of the respiratory tract render it a particularly vulnerable tissue with respect to
nanomaterials; however, nanomaterials also exhibit several features that further implicate the relevance
of the respiratory tract in their toxic potential. For example, nanomaterials exhibit a size profile associated
with a high level of ‘dustiness,’ a property defined as the propensity for a material to generate airborne
dust following its physical disruption (18). The increased likelihood for aerosolization, and extended
duration of suspension in the air, renders the bioaccessibility of nanomaterials much higher than that of
larger materials in the context of inhalation.
Nanomaterials also possess characteristics associated with unique patterns of deposition in the
airways. Nanomaterials deposit efficiently along the entire respiratory tract, however, properties including
morphology and surface charge can contribute to immobilization of these materials in preferential
compartments of the respiratory tract (19). Moreover, the small size of nanomaterials facilitates their
unique capacity to reach the alveolar spaces of the lung (20). The deposition behavior of nanomaterials
is a feature of particular importance since the biological fate of inhaled agents is greatly dependent on its
deposition location within the respiratory tract. Different anatomical compartments of the respiratory tract
exhibit variations in predominant structural cell types, resident immune cell populations, physiological
defense mechanisms, and anatomical proximity to the lymphatics and blood circulation, all of which can
contribute to the toxic potential of inhaled agents (21).
The respiratory tract is generally divided into three compartments: 1) the head region consisting
of the nasal passages, mouth, pharynx, and larynx, 2) the conducting airways consisting of the trachea
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and first 16 bifurcations encompassing the main bronchi, bronchus, large and small bronchi, and
bronchioles, and 3) the gas exchange region consisting of terminal bronchioles, respiratory bronchioles,
and alveoli (16). The fraction of an airborne agent that enters the nose or mouth is called the inhalable
fraction. While larger materials can enter the airways when inhaled by mouth, nasal structures (including
hairs and mucus) filter foreign materials and generally trap materials 10-15 µm in size from reaching
lower into the airways (22). Likewise, materials smaller than 10 µm are generally considered to be
‘respirable,’ meaning they are capable of depositing in the conducting airways. Materials 2-10 µm in size
that escape the defenses of the upper airways can be biologically neutralized or physically trapped by
mucus in the upper airways, trachea, bronchi, and bronchioles (23). Additionally, the sneezing reflex and
mucociliary movement help to dispel inhaled material depositing in this region (24). Materials smaller
than 2 µm are capable of depositing in the lowest segment of the airways- the alveolar, or gas-exchange
region. Generally, insoluble and particulate materials capable of reaching the lowest regions of the lung,
including nanomaterials, are associated with a greater potential for adverse health effects for several
reasons.
Unlike the upper airways, pulmonary mucus and ciliated epithelium are not present in the lower
airways, and thus, cannot contribute the clearance of inhaled material that deposits in this region (25).
As a result, the retention time of material reaching this compartment often far exceeds that of inhaled
matter depositing in higher segments of the respiratory tract. Subsequent clearance of particulates from
the gas exchange region of the lungs is primarily mediated by alveolar macrophages, a resident
phagocytic immune cell of the lower airways (17). These cells internalize the deposited material, following
which, its neutralization can entail intracellular chemical degradation or cell-mediated physical
translocation out of the lungs. Dependence on innate immune cell activity for clearance of particulates
localized in this pulmonary region confers the potential for significant inflammatory responses, illustrating
another toxicological concern associated with the depth of material deposition in the lungs.
Deposition of inhaled agents in the lower airways also increases the potential for their
translocation to extra-pulmonary locations. The architecture of alveolar structures facilitates efficient gas
exchange by optimizing the potential for passive diffusion of oxygen and carbon dioxide across its large
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surface area. Accordingly, the distance between the membrane of an erythrocyte present in pulmonary
capillaries and the air space of the alveolus is less than 1 um (26). This delicate physical barrier can be
compromised by substances reaching the alveolar spaces, following which, they may enter the
circulation, translocate to other tissues, and potentially cause systemic effects (27).
Overall, the most well-characterized relationships between nanomaterial physico-chemical
properties and their toxic potential pertain to their effects in the respiratory tract. Accordingly,
nanomaterial properties including size, agglomeration, and morphology have all been correlated to their
propensity for inhalation, as well as their depth of deposition in the respiratory tract (28, 29). Subsequent
acute localized inflammatory responses have been correlated to properties including size, dispersion
status, dose volume, and particle number (30-33). However, the nanomaterial properties and dose
metrics that are most representative of the toxic potential of nanomaterials depend on the mechanism of
action underlying the toxic response. For example, the inflammatory effects of many insoluble metal
nanomaterials frequently implicate interactions between the particle surface and biological molecules,
leading to perturbation of cellular structures and generation of oxidative stress. Accordingly, the surface
area of the administered dose is often reported as the metric most closely-related to the toxic potential of
these materials in the lungs (34). Contrarily, the propensity for long fiber-like materials such as carbon
nanotubes to induce frustrated phagocytosis in pulmonary macrophages following inhalation exposure
renders particle number a dose metric of particular relevance for this type of mechanism of toxicity (35,
36).

1.1.1.3. Dermal Exposures to Nanomaterials:
Nanomaterials can also enter the body via the skin. As they become increasingly incorporated
into products that are designed to come into contact with the skin, this route of exposure has also been
frequently studied as a potential portal of entry and biological target of nanomaterials.
The skin is composed of three major layers- the epidermis, dermis, and hypodermis- all of which
exhibit different biochemical properties, resident cell types, and biological functions (37). The uppermost
layer, the epidermis, constitutes the most notable defensive functions provided by the dermal epithelium.
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This avascular layer of the skin is comprised predominantly of keratinocytes, which form five distinctive
strata within the epidermis (38). The outermost layer, the stratum corneum, constitutes the major barrier
functions of the epidermis as a collective layer since it is subjected to interactions with external agents.
The stratum corneum is mainly comprised of layers of staggered corneocytes, forming a barrier with an
approximate thickness of 10-20 µm in humans (38). This layer can be penetrated by lipophilic molecules,
but it effectively blocks the passage of ionic and water-soluble compounds (39). The next strata of the
epidermis are the struatum granulosum and stratum spinosum. The stratum spinosum is another
epidermal layer with particular toxicological importance, since agents capable of penetrating to this depth
have the capacity to interact with resident immune cells. Among these one of the most important is the
resident dendritic cell (DC) of the epidermis, the Langerhans cell (LC) (40). The final epidermal layer is
the stratum basale which is separated from the dermis layer by basement membrane.
The dermis contains blood and lymph vessels, nerves, and other structures including follicles and
glands. Likewise, potential cellular and molecular targets of toxicants are more abundant in this layer,
rendering its protection by the epidermis paramount in preventing adverse local and peripheral biological
effects following dermal exposures (41). However, appendages including sweat glands, hair follicles, and
sebaceous glands may facilitate the penetration of some molecules into the dermis, irrespective of
effective restriction by the epidermal barrier.
It was initially suspected that the small size of nanomaterials would certainly facilitate enhanced
potential for skin penetration. However, there is conflicting evidence regarding nanomaterial skin
penetration potential. Although decreases in size have been shown in some instances to promote
penetration of the skin, other studies have demonstrated that size is not a characteristic that confers a
unified potential for skin penetration by nanomaterials (42). In addition to size, other properties including
surface charge and hydrophobicity have also been shown to impact the propensity for nanomaterials to
evade the barrier functions of the skin (43, 44).
As a result of general handling practices, the hands and forearms are major sites of concern in
the context of dermal exposure to nanomaterials (45). These sites are also frequently associated with
compromised barrier functions resulting from various chemical and physical insults, highlighting a major
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consideration for this portal of entry. Compromised skin barrier integrity resulting from injury, pre-existing
conditions such as atopic dermatitis, and behaviors such as excessive skin washing may facilitate their
entry into the body via the dermal route (46). Moreover, indiscriminate passage of these substances
through the skin may cause local injury, but also systemic transport and toxic effects at sites peripheral
to the initial site of contact (47).
The most commonly-reported adverse effect of dermal exposure to nanomaterials is the
development of local inflammatory reactions. Structural cells of the skin are potential targets of
nanomaterial biological activity frequently responsible for such effects (48). For example, selective toxicity
to keratinocytes has been associated with nanomaterial-induced increases in intracellular reactive
oxygen species (ROS) production (49). These effects have been correlated to nanomaterials exhibiting
properties including increased surface area and a high degree of surface reactivity (50). Although these
inflammatory responses are often reported to be self-limiting, subsequent damage to cellular DNA has
been proposed to have the capacity to result in cancerous transformations and tumor growth (51, 52).

1.1.1.4. Other Routes of Exposure to Nanomaterials
Although the respiratory tract and skin are frequently cited as the two most relevant routes of
exposure to nanomaterials, ingestion is another potential portal of entry. Ingestion of nanomaterials can
result from their intentional incorporation into items designed to be ingested, such as foods, beverages,
and supplements (53). Nanomaterial ingestion can also occur by incidental mechanisms following
contamination of consumables, or by passive transfer from the hands to the mouth or items bound for
ingestion. Furthermore, inhalation exposure to nanomaterials can also facilitate the eventual ingestion of
nanomaterials, as the normal physiological clearance mechanisms in the respiratory tract often implicate
their translocation from the trachea to the esophagus, and subsequently into the digestive tract (54).
As the most important site of macronutrient absorption in the body, the gastrointestinal (GI) tract
can easily facilitate absorption and systemic distribution of ingested toxicants. Different regions of the GI
tract exhibit unique physiological functions and anatomical features, which can impact the propensity for
absorption and subsequent disposition of ingested materials (53, 55). In this regard, the size and surface
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modification of nanomaterials has been correlated to preferential anatomical localization within the GI
tract (56, 57). Nanomaterial surface charge has been shown to influence the potential for materials to
penetrate the layer of mucus separating the materials from enterocytes of the small and large intestines
(58). The absorptive surface of the intestines is comprised of epithelial cells that have been shown to be
penetrated by nanomaterials exhibiting selective size profiles and surface charges (59). Subsequent
translocation to other organs and tissues from the GI tract has been shown to be dependent on
nanomaterial size, wherein accumulation within the liver, spleen, and adipose tissue occur, potentially
leading to disruption of normal biological processes at peripheral sites (60).
Exposure to nanomaterials by parenteral routes is the portal of entry least frequently studied with
respect to nanomaterial toxicity. Few current applications for nanomaterials are likely to result in
exposures by this route; however, the expanding uses for nanomaterials in biomedical applications often
implicate their administration by intravenous and intramuscular routes, rendering parenteral exposures
an increasingly relevant route of exposure (61-64). For example, iron nanoparticles are being increasingly
used for biomedical imaging and gold nanoparticles have proposed utility as a drug delivery vehicle (65).
Intravenously-injected nanoparticles have been shown to rapidly enter the circulation and
translocate to various organs (66, 67). Contrarily, intradermal injection has been shown to result in
nanoparticle accumulation in the lymph nodes, while intramuscular injection results in preferential uptake
of particles by neuronal and lymphatic systems (68).The distribution of nanomaterials following parenteral
administration has been shown to correlate to properties including size and surface characteristics (69).
Similar properties have been implicated in other parameters of their pharmacokinetic profiles, impacting
their rate of clearance from circulation and method of excretion (66, 70).

1.1.1.5. Knowledge Gaps Regarding the Toxic Effects of Nanomaterials
Overall, the skin and lungs represent the two portals of entry most likely to be implicated in
exposure to nanomaterials. Accordingly, a substantial amount of information has been generated
regarding the potential for nanomaterials to enter the body by these routes, in addition to the impact of
physico-chemical properties on these processes. Similarly, the skin and respiratory tract represent the
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tissues most commonly studied as potential targets of nanomaterial toxic effects. Relationships between
physico-chemical properties and nanomaterial toxicity have been most frequently profiled with respect to
dermal and pulmonary epithelial cells. Potential adverse effects involving cells and tissues distal to the
site of exposure have been far less frequently examined, and the impact of physico-chemical properties
on such responses remains largely unknown.
One of the biological compartments of major concern in this regard is the immune system. The
lack existing knowledge pertaining to the nanomaterial immunotoxocity is particularly concerning since
toxicants may impact various components of the immune system following any exposure route. Moreover,
as a carefully-regulated, continually-renewing system in which cells are constantly undergoing
differentiation, proliferation, and self-renewal, the immune system serves as a particularly vulnerable
target of toxic effects (71). Given this knowledge, characterization of nanomaterial immunotoxic potential
and investigations into the impact of physico-chemical properties in this context are needed.

1.1.2. Immunotoxicology and Allergic Disease
The immune system is comprised of an extensive combination of tissues, cell types, and
molecular mediators that collectively orchestrate the complex task of protecting the host from both
external threats, including many different types of pathogens, as well as internally-derived threats, such
as cancerous cells (72). Optimal immune functioning requires precise selectivity and adequate regulation
in order to effectively eliminate potential threats without inducing excessive injury to the host. The immune
system is a critical regulator of health and disease, as inflammation is a critical component in the
pathophysiology of nearly all chronic diseases states (73). Accordingly, deviations in optimal immune
functioning can have resounding effects on host health.
Deviations in optimal immune functioning can emerge as a result of numerous factors, including
genetics. However, exposures to immunotoxic agents are also a major contributing factor (74).
Subsequent disruptions in any of the numerous molecular and cellular constituents of the immune system
can result in altered functionality and development of disease. Immune dysfunction can be generally
classified as being suppressive or stimulatory in nature. Immune suppression can result in compromised
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destruction of pathogens, increasing susceptibility to illness, as well as failure to identify internal threats
such as cancerous cells, which can then progress into more advanced phases of disease. Disorders that
involve inappropriate stimulation of the immune system are characterized by a pathological excess of
immune activity that is often misdirected. This can result in immune-mediated destruction of host cells
and tissues, effects which underlie the pathogenesis of autoimmune disorders such as lupus
erythematosus and multiple sclerosis (75). Additionally, the development of immunological memory
specific for innocuous external antigens can result in the development of various forms of allergic disease.
Rates of allergic disease have been on the rise globally for decades. The American Academy of
Allergy, Asthma, and Immunology reports that worldwide, sensitization rates to one or more common
allergens are approaching 40-50% in school-aged children (76). In the United States, allergic diseases
are the sixth leading cause of chronic illness with an annual cost exceeding US $18 billion (75, 77-79).
The enormous global impact and public health burden of allergic disease is projected to remain a major
concern in the coming years. It is anticipated that the prevalence of allergy will continue to grow, the age
of allergy initiation will continue to decrease, and mortality from allergy-related causes will continue to
increase (77).
The term ‘allergic disease’ refers to a collective assortment of disorders triggered by diverse
inciting agents, mediated by different effector cells and mechanisms, and manifesting in various clinical
presentations. The unifying characteristic of all allergic diseases is the development of adaptive immune
reactivity specific to an exogenous antigen that is not inherently dangerous (78). All allergic diseases also
consist of two distinct phases. The first phase, the sensitization or induction phase, is often subclinical in
nature and involves exposure to an allergen resulting in the generation of allergen-specific immunological
memory (80). The second phase, the elicitation or challenge phase, is dependent on successful
sensitization and re-exposure to the same allergen. Subsequently, activation of the adaptive immune
system leads to immune-mediated destruction of the allergen, which results in the characteristic clinical
presentations of allergic reactions.
Although the development of allergy is dependent on a multitude of genetic, behavioral, and
environmental factors, exposures to immunotoxic agents are also frequently implicated (81). Immunotoxic
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agents with the capacity to impact allergic disorders generally exert one of two effects. First, the agent
can act as an allergen or sensitizer. Following exposure to these agents, the resultant adaptive immune
response is specific to this agent, and subsequent encounters trigger allergic reactions. Contrarily, agents
can augment immunological processes involved in allergic disorders specific to a different agent. These
agents are often referred to as ‘adjuvants’ or ‘immunomodulators,’ and their effects can range from
increasing host susceptibility to sensitization, decreasing the allergen dose required to induce
sensitization or elicit allergic responses, or exacerbating the severity of allergic reactions (75).
Among the diverse manifestations of hypersensitivity reactions, two of the most common forms
of allergic disease are allergic contact dermatitis (ACD) and asthma. Accordingly, these disorders
represent two notable conditions susceptible to the adverse effects of immunotoxicant exposure.

1.1.2.1. Allergic contact dermatitis
Immune-mediated reactions of the skin can occur following exposure to an assortment of diverse
agents by many different underlying biological mechanisms. Many of these responses are non-specific
irritant responses, wherein immune involvement is limited to that of cells and mediators of the innate
immune system (82). However, the development of antigen-specific adaptive immune responses
resulting in skin allergy are common, as well.
One of the most common forms of contact allergy is ACD, a delayed-type (Type IV), T-cellmediated hypersensitivity response. Dermal sensitization and the subsequent generation of
immunological memory for the inciting agent requires several key molecular and cellular events (83).
These events have been outlined in an adverse outcome pathway (AOP) adopted by the Organization
for Economic Co-operation and Development (OECD)- an organization that publishes guidelines for the
testing methods used by government, industry, and independent laboratories to identify and characterize
potential hazards of chemicals (84). The AOP steps associated with skin sensitization are shown in figure
1.2.
The preliminary requirement for skin sensitization is bioavailability of the sensitizing agent. Since
a primary function of the skin is to serve as a selective barrier between the host and environment, the
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sensitizing potential of many antigens is often limited by their capacity to evade this barrier (85). Agents
that induce skin sensitization must penetrate the upper layers of the epidermis in order to reach immune
cells that commence the cascade of events associated with the development of ACD. These substances
must first penetrate the ~ 15 layers of interdigitated corneocytes comprising the stratum corneum (38,
56). Next, antigens must pass through cellular junctions sealing the paracellular spaces between adjacent
keratinocytes in the stratum granulosum (40, 86). Passage through these layers is heavily dependent on
antigen physical and chemical properties, as illustrated by the fact that most dermal sensitizers tend to
be low molecular weight (LMW, < 500 Daltons) chemicals with adequate lipophilicity (logP ~2) (87, 88).
The next steps in the skin sensitization AOP involve the molecular initiating event- antigen
formation. The small size required for passage through the stratum corneum is not conducive with cellular
recognition (80). As a result, most dermal sensitizers require binding with host macromolecules to
facilitate their immunological recognition, and are referred to as haptens. Haptens possess inherent
chemical reactivity that promotes their covalent binding to proteins. These effects often involve
electrophilic activity resulting in interactions with nucleophilic groups on proteins, such as thiols or amino
and hydroxyl groups like those found on keratin (89).
Some sensitizing agents are associated with the need for additional chemical modifications in
order to assume a haptenic state. Such substances include prohaptens, which require host-mediated
metabolic activation, and prehaptens, which require transformation by environmental processes such as
UV exposure in order to become immunologically-active haptens (90).
Conjugation of haptens with carrier molecules generates adequate size for recognition by antigenpresenting cells (APC). The APC most frequently implicated in dermal sensitization is the resident
dendritic cell (DC) of the epidermis, the Langerhans cell (LC) (91). LCs represent 2-5% of the total
epidermal cell population and are present in the third layer of the epidermis, the stratum spinosum. The
pivotal role of LCs in the initiating events of dermal sensitization is enabled by several unique cellular
characteristics. For example, LC exhibit a high capacity for antigen-uptake, facilitated by
micropinocytosis. Also, it has been demonstrated that LCs have the potential to extend dendrites through
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the keratinocyte tight junctions of the stratum granulosum and sample antigens located just below the
stratum corneum (92, 93).
LC also exhibit unique morphology and increased expression of adhesion, costimulatory, and
presentation-mediating molecules (85). These properties become integral after sensitizers trigger LC
maturation, which requires two distinct signals. One signal is antigen-dependent and involves recognition
of the hapten/carrier complex by LC, leading to its uptake (94). The second required signal is antigennonspecific, generally signifying an elevated threat level (95). Some of the mediators commonly
associated with allergen non-specific activation signals include interleukin (IL)-1α, an alarmin released
by skin epithelial cells including keratinocytes in response to cellular damage, as well as pro-inflammatory
cytokines released by innate immune cells in response to pathogen recognition receptor (PRR) activation
(96).
Subsequently, activated LC upregulate their expression of the chemokine receptor (CCR) 7 and
release IL-1β. IL-1β triggers the release of tumor necrosis factor (TNF)-a and granulocyte-macrophage
colony stimulating factor (GM-CSF) from keratinocytes, which facilitates LC exit from the skin and
migration to the lymph nodes via the afferent lymphatics. During their migration, LC continue the
maturation process, increasing expression of costimulatory and antigen-presentation molecules.
Simultaneously, the internalized hapten/carrier complex is processed, generating fragments that are
displayed on the cell surface by major histocompatibility complex (MHC) molecules (97).
Inside the lymph nodes, LC interact with T-cells in the paracortical T-cell area. The characteristic
morphology of activated DCs is optimal for simultaneous interaction with multiple cells. This behavior
increases the chance of interaction with a naïve T-cell expressing a T-cell receptor (TCR) capable of
recognizing the surface-expressed MHC-allergen peptide complex (98). Following recognition of the
antigenic epitope by a T-cell and adequate co-stimulation by LC, the T-cell is activated. This results in
proliferation, producing a pool of clonal antigen-specific effector T-cells. As a result, vast numbers of
effector and memory T-cell clones with conserved antigen-specificity are generated, causing a drastic
increase in lymph node size (87).
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Within days, the once naïve T-cells with limited cytokine production capabilities polarize towards
different phenotypic variations and exhibit a newly-acquired repertoire of cytokine production capabilities.
This polarization is dependent on the local cytokine microenvironment, site of contact and molecular
nature of the sensitizer, and various neuroendocrine factors (99). Acquisition of a Th1-dominant cytokine
profile results in production of interferon (IFN)-γ and TNF-β, whereas a Th2-dominant profile results in
release of cytokines including IL-4 and IL-10. The antigen-specific, Th1/Th2-polarized T-cells exit the
nodes via the efferent lymphatics, entering the circulation, where many migrate into peripheral tissues.
The completion of allergic sensitization, which requires 3 days to several weeks, is signified by the
presence of newly-formed populations of allergen-reactive T-cells which can mediate the subsequent
induction/challenge phase of ACD (100).
Upon future exposures to the allergen, memory and effector T-cells are recruited to the site of
exposure. In ACD, CD4+ Th1 cells primarily exhibit regulatory functions, including production of cytokines
such as IL-2 and IFN-γ, which contribute to inflammatory cell recruitment (97, 101). By comparison, CD8+
T-cells are most often associated with immediate cytotoxic effector functions (102). These effector
functions initiate and amplify local inflammatory reactions to destroy the antigen, which results in the
clinical manifestations of ACD, including localized skin redness, swelling, and itching at the site of allergen
contact.
ACD can be clinically evaluated and diagnosed by the intentional elicitation of ACD reactions.
Patch testing involves the placement of a disk containing the allergen on the skin for 48 hr to evoke the
localized inflammation characteristic of ACD. The presence of inflammation confirms sensitivity to a
specific agent, while the magnitude of the response can be measured, indicating the degree of reactivity
towards the agent (103).
Patch testing studies have revealed that ACD is relatively common in the general population,
affecting an estimated 15-20% of individuals (104). Some of the most notable causative agents of ACD
include nickel, thimerosal, and fragrance mix. Each year, the Allergic Contact Dermatitis Society declares
an agent their ‘Allergen of the Year,’ identifying a newly-emerging contact allergen or allergen of growing
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significance. The Society’s Allergens of the Year for the past two decades are shown in table 1.2,
illustrating the diversity of agents associated with ACD.
In addition to its notable prevalence in the general population, ACD also presents a significant
concern in the workplace. Contact dermatitis is the second most commonly reported occupational illness
in the United States, accounting for approximately 20% of all work-related health concerns (98). As a
result, over $1 billion in lost wages, medical costs, and worker compensation are attributable to contact
dermatitis each year (80). Although these figures take into account cases of dermatitis involving both
irritant and allergic mechanisms, ACD is a specific concern in the workplace. Major causative agents and
workplaces associated with increased prevalence of occupational ACD are listed in table 1.3 (105).
The development of ACD in the workplace has been correlated to several exogenous risk factors.
Exposure to irritants, which is common in many workplaces, is one such risk factor. Irritants are
associated with the induction of localized inflammation in the skin, as well as disruption of skin barrier
functions (101). As a result, these effects can act as an adjuvant to sensitization and increase potential
for skin penetration by immunogenic agents. These effects are commonly seen in workers whose jobs
require wet work. Wet work is defined by a new German regulation as “having skin exposed to liquids
longer than two hours per day, use of occlusive gloves for longer than 2 hours per day, or frequent hand
washing (20 times per day, or less if more vigorous scrubbing is required)” (106). Accordingly,
occupations involving wet work have been associated with an increased risk for ACD development.
Although case studies and human reports have led to the identification of many skin sensitizingagents, laboratory-based approaches can also help identify potential skin sensitizers. Numerous in vivo,
in vitro, and in silico/in chemico assays have been developed to assess the potential for various agents
to induce dermal sensitization. Commonly-used approaches and corresponding biomarkers of interest
are summarized in table 1.4, in addition to their OECD-validation status (107-162).
Traditional approaches for the identification of potential skin sensitizers have historically
implicated the use of animal models. Accordingly, in vivo assays frequently used to assess the potential
for compounds to induce dermal sensitization include the Mouse Ear Swelling Test (MEST), Guinea Pig
Maximization Test (GPMT), and Local Lymph Node Assay (LLNA) (163). However, as animal welfare
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has become an increasingly prevalent concern in the field of toxicology, the demand for alternative
approaches has increased significantly. As a result, novel methods for the assessment of dermal
sensitization potential have been proposed using in vitro and computational approaches.
Currently, there are three OECD-validated alternative test methods for hazard identification efforts
related to skin sensitizers, which do not require use of laboratory animals. These tests include the
KeratinoSens and LuSens (ARE-Nrf2 Luciferase) methods, which evaluate the potential for test agents
to induce activation of antioxidant/electrophile response element (ARE)-dependent signaling pathways
in keratinocytes- a feature common to many skin sensitizers (143). The OECD has also validated the
human Cell Line Activation Test (h-CLAT) and U937 cell line activation test (U-SENS), which are based
on the shared capacity for sensitizing agents to induce activation of DC (164). Lastly, the Direct Peptide
Reactivity Assay (DRPA) has been validated for use, wherein the unifying requirement of hapten/carrier
complex formation by chemical sensitizers is assessed (161).

1.1.2.2. Allergic Asthma
Similar to immune-mediated reactions of the skin, immune responses in the respiratory tract can
be limited to acute irritant effects primarily mediated by the innate immune system. However, adaptive
immune reactions can also occur, wherein the development of immunological memory specific to an
otherwise innocuous antigen can lead to the development of respiratory allergy. Allergic asthma is a
common pulmonary hypersensitivity response, wherein inflammation of the airways with reversible airflow
obstruction, and airway hyperreactivity triggered by a specific allergen occur (75). Allergic asthma is most
often associated with IgE-mediated mechanisms, resembling other immediate-type (Type I)
hypersensitivity responses. However, many of the immunological mechanisms involved in asthma remain
unclear. As a result, an AOP specific for asthma has yet to be established and widely-accepted.
Asthma can develop following skin exposure to some agents, but the induction phase of allergic
asthma is more commonly associated with inhalation exposure to an adequate dose of a respiratory
sensitizer by a susceptible individual (165, 166). The lungs are susceptible to inhalation of both LMW and
high molecular weight (HWM) antigens with asthmatic potential, and these agents may be associated
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with differential mechanisms along the pathway of events leading to sensitization. Asthma-inducing HMW
allergens are often proteins from biological sources, such as pollens, animal dander, and wood dusts
(167). Contrarily, LMW allergens associated with asthma include metals, dyes, and reactive chemicals
such as isocyanates (168).
Once deposited in the respiratory tract, HMW sensitizers are large enough to be identified and
intercepted by APC. However, similar to the events required for dermal sensitization, LMW chemicals
must bind with host proteins to form hapten-carrier complexes, facilitating their immunological
recognition. The chemistry of haptens and their formation of antigenic complexes is far better studied
with respect to skin sensitization than respiratory sensitization (89). However, the formation of haptens
from prohaptenic compounds is known to occur in the lungs as a result of the presence of cells with high
levels of phase I and II metabolizing properties. Alveolar macrophages, club cells, and bronchial epithelial
cells all exhibit biological activities capable of promoting hapten formation (169).
Similar to the events of dermal sensitization, the next requirement in respiratory sensitization is
physical association between an immunologically-recognizable antigen and APC. Numerous cell types
in the respiratory tract are capable of presenting antigen to lymphocytes. Several anatomically- and
phenotypically-distinct populations of pulmonary macrophages with potential APC activity reside in the
respiratory tract (170). Airway macrophages are present on the intraluminal surfaces of both the small
and large conducting airways, suspended in or below the mucus layer. Alveolar macrophages are longlived tissue-resident macrophages restricted to the alveolar region of the lungs (171). Finally, pulmonary
intravascular macrophages, which are a resident population of mature macrophages that remain
localized in the lung capillaries, and interstitial macrophages found in the interstitial spaces of the lung
parenchyma are capable of acquiring antigen following inhalation exposure (172). In addition to these
macrophage subsets, B-cells of the respiratory tract are capable of internalizing antigen via B-cell
receptors (BCR) and presenting antigen to naïve T-lymphocytes to induce sensitization (173). However,
macrophages and B cells must be adequately stimulated in order to express the costimulatory molecules
required for the progression of allergic sensitization, rendering them less effective APC than DC.
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DC are the professional APC of the respiratory tract and present antigen with the greatest
efficiency to lymphocytes. DCs are distributed throughout the entire respiratory tract within the epithelium
of the upper airways and in intraseptal junctions of the gas exchange region (170). Many subtypes of
DCs exist in the respiratory tract with corresponding variations in anatomical location and antigen
presenting capacities. The two major populations of conventional DCs in the respiratory tract are
associated with antigen presentation in asthma and are discriminated based on expression of surface
markers CD103 and CD11b (172).
CD103+ CD11blo DCs (CD103 DCs) reside in the epithelium in close proximity to the basal surface
of bronchial epithelial cells. They also express a number of tight junction proteins allowing them to extend
dendrites into the airway lumen to sample inhaled antigen (172). Findings from animal studies suggest
that CD103 DCs preferentially interact with particulate material deposited in the lungs and are more likely
to interact with CD8+ T-lymphocytes via MHC I molecules (174). Furthermore, CD103 DCs have been
shown to exhibit a protective role in house dust mite-induced allergic airway inflammation through the
production of IL-12 (175).
The second major DC population of the respiratory tract is characterized by a CD103- CD11bhi
(CD11b) expression profile. This population of DCs can be found in both the conducting airways and the
lung parenchyma. CD11b DCs do not directly contact the epithelium, but reside in the layers of tissue
directly below the epithelium (172). Although this anatomical location implies compromised potential for
interception of inhaled material in the airway lumen, studies have observed prevalent transepithelial
uptake of antigens by these DC in the lower airways (176). Animal studies demonstrate that CD11b DCs
are more likely to acquire and transport soluble antigens compared to particulate material (174).
Additionally, CD11b DCs are more likely to present antigen to CD4+ T-lymphocytes by MHC II molecules
in the lymph nodes.
Irrespective of DC phenotype, as in the skin, DC activation in the lungs requires both antigenspecific and non-specific signals. In addition to antigen uptake, molecules in the airways capable of
triggering maturation of DC include pathogen-associated molecular patterns (PAMP) and damageassociated molecular patterns (DAMP), which are recognized by various PRR expressed by innate
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immune cells. PAMPs include many structures unique to microorganisms that are recognized by an
assortment of receptors expressed by DCs including toll-like receptors (TLR), c-type lectin receptors, and
protease-activated receptors (177). DAMPs include intracellular proteins such as heat shock proteins
and high motility group protein B1 (HMGB1), as well as extracellular elements including hyaluron
fragments. These elements are released in response to cellular injury or death and are recognized by
DC complement receptors, heat shock protein receptors, and neuropeptide receptors (178).
Many aeroallergens associated with high rates of sensitivity in the population, such as house dust
mite and cockroach, possess enzymatic activity known to trigger the release of these antigen non-specific
signals. Airway epithelial cells are often targets of allergens with proteolytic activity, wherein their effects
often involve epithelial cell cytotoxicity, leading to the release of alarmins and other DAMPs, as well as
increasing epithelial permeability (179). Additionally, IL-33, thymic stromal lymphopoetin (TSLP), and
GM-CSF are all produced by epithelial cells following injury and are known to stimulate DCs to induce
Th2-dominant responses (180, 181).
After antigen uptake and activation, DC travel via the afferent lymphatics to the T-cell area of the
lung-draining lymph nodes. During migration, the antigen is internally processed and proteolyzed into
small peptide fragments for presentation via MHC molecules on the cell surface. DC also upregulate
expression of costimulatory molecules including CD80 and CD86 (182). Once DC reach the lymph node,
they present antigen to naïve T-cells until recognition occurs, leading to activation and clonal expansion.
Respiratory sensitizers are known to induce the preferential polarization of CD4+ T-cells towards a Th2dominant profile, cells which produce high levels of IL-4 to promote isotype switching of B-cells and
production of IgE (183). Subsequent production of antigen-specific IgE molecules completes the
sensitization process.
The elicitation phase of allergic asthma generally consists of an early phase reaction and a latephase reaction. Upon exposure, the allergen is intercepted by allergen-specific IgE bound to FcεRI
receptors on the surface of mast cells and basophils. Binding induces cross-linking of receptors and the
subsequent release of preformed mediators, beginning the anaphylactic cascade responsible for the
early asthmatic reaction, which is experienced minutes after antigen encounter (184). The release of
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histamine, tryptase, leukotrienes, and prostaglandins from granulocytes cause bronchial smooth muscle
constriction. Endothelium and epithelium involvement leads to edema in the airway walls and mucus
hypersecretion. These effects manifest as clinical symptoms ranging from bronchoconstriction and rhinitis
to anaphylactic shock (185, 186).
The late phase asthmatic response occurs 4-6 hr later as a result of mast cell mediators and
recruitment of inflammatory cells (187). Clinical presentations of the late phase asthmatic response tend
to be more severe than early phase responses, and include excessive mucus production, increased
vascular permeability, and airway obstruction.
Chronic cycles of allergic airway inflammation and subsequent repair are associated with
numerous structural alterations collectively referred to as airway remodeling. These alterations include
bronchial smooth muscle hypertrophy, fibroblast accumulation, and epithelial thickening (188). Vascular
remodeling also occurs, resulting in an increase in both the number of vessels and their diameter in the
airways of asthmatics. Goblet cell hyperplasia is also frequently implicated in chronic asthmatic
conditions, which can lead to accumulation of mucus in the airways and subsequent obstructions to
airflow. These anatomical effects can manifest in physiological implications, such as declines in lung
function over time (189).
The gold standard for diagnosis of allergic asthma involves specific inhalation challenge tests, but
these tests are time-consuming and potentially dangerous. As a result, skin prick testing is often used to
confirm the presence of antigen-specific IgE (190, 191). However, this method of evaluation assumes
the dependence of the asthmatic condition on IgE-mediated mechanisms. Some agents are known to
induce allergic lung responses that present in a similar manner as prototypical asthmatic reactions, but
involve T-cell-mediated mechanisms. Accordingly, prick testing would be ineffective in evaluating such
cases.
The prevalence of asthma varies worldwide, but the World Health Survey estimates that as many
as 334 million individuals suffer from asthma (192). Incidence rates of asthma have been increasing since
the 1980s, an effect that has been attributed to modern behavioral and lifestyle factors, many of which
further implicate involvement from genetic factors. Genes linked with increased susceptibility for the
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development of asthma include genes with involved in innate immunity and immunoregulation, epithelial
immunity, Th2-cell differentiation and effector functions, or lung function and airway remodeling (184).
The profound public health burden associated with the increasing frequency of asthma reflects its
potential lethality, which is not a feature commonly associated with allergic diseases. While ACD and skin
allergies can be managed by covering skin and avoiding contact with causative agents, control of asthma
is generally much more difficult, and failure to do so is much more likely to result in mortality. Likewise,
the World Health Organization estimates that asthma causes 250,000 deaths annually (78).
Similar to ACD, asthma is another allergic disorder that can develop following workplace
exposures. Occupational asthma is defined as a case of asthma wherein a causal relationship to some
aspect of an individual’s workplace environment exists (193). It has been estimated that 9 to 15% of adult
asthma cases are caused by the workplace environment and more than 350 agents have been
associated with the capacity to cause occupational asthma (184). Whereas HMW allergens are often
implicated in asthmatic responses in the general population, LMW asthmagens are more commonly
associated with cases of occupational asthma. LMW and HMW agents frequently implicated in
occupational asthma are listed in table 1.5 along with corresponding occupations of relevance.
The identification of agents with potential to cause respiratory sensitization has proven to be a
more complex endeavor than the identification of dermal sensitizers. There are currently no OECDvalidated approaches for use in identifying respiratory sensitizers. As a result, retrospective human data
is often required to identify agents capable of inducing asthma. However, numerous in vivo, in vitro, and
in silico approaches have been reported to be effective in identifying potential respiratory sensitizers.
Some of these proposed assays and their corresponding endpoints of interest are summarized in table
1.6 (111, 113, 132, 194-214).
Although immunotoxic agents can act as respiratory sensitizers that cause asthma, they can also
augment various aspects of asthmatic conditions specific to other allergens. Subsequent modulation of
asthmatic conditions can manifest differentially depending on exposure occurrence with respect to
sensitization and elicitation, as illustrated in figure 1.3. For example, in naïve individuals, exposure to
immunotoxic agents with asthma-modulating potential can result in increased susceptibility to

26

sensitization, as well as a lower threshold of allergen exposure capable of inducing sensitization.
Comparatively, in cases of established asthmatic conditions, exposure to immunomodulating agents can
result in increased severity of symptoms, frequency of elicitation responses, and or accelerated
progression of physiological alterations associated with chronic asthmatic pathogenesis (215).
While the cellular events required to induce respiratory sensitization are largely conserved (e.g.,
DC activation, antigen presentation, lymphocyte activation), immunological mechanisms responsible for
augmentation of asthma can be diverse. Likewise, many different agents including chemicals, proteins,
viruses, bacteria, and particulate matter have been shown to exacerbate asthma via differing
mechanisms (216). Epidemiological studies have repeatedly demonstrated a correlation between
cigarette smoking and increased risk for asthma development, as well as increased response severity in
existing conditions (217, 218). It has been shown that concomitant cigarette smoking and harmless
antigen exposure results in inflammation of airways causing both enhanced epithelial permeability and
induction of TSLP production by airway epithelial cells (219). As a result, antigen uptake and the presence
of ‘danger signals’ in the respiratory tract cause subsequent activation of DC (220). Furthermore,
cigarette smoking has been shown to lead to increased numbers of DC, in addition to many other
inflammatory cells, in the respiratory tract, which can also contribute to sensitization (221).
Viral infections represent another well-established source of immunomodulation with respect to
asthma. Under normal conditions, airway epithelial cells are unresponsive to lipopolysaccharide (LPS),
a prototypical PAMP, as they do not constitutively express the PRR associated with its recognition, TLR4 (222). However, respiratory syncytial virus (RSV) infection has been shown to cause increased TLR-4
mRNA expression in these cells, facilitating their recognition of LPS, and subsequently priming the
airways for sensitization (222). Similarly, infection with rhinoviruses is known to exacerbate asthmatic
conditions by triggering increases in IL-25 production by bronchial epithelial cells (223). The role of IL-25
in asthma involves activation of type 2 innate lymphoid cells (ILC2) and potentiation of Th2 responses,
effects correlated to increased clinical response severity in late-phase asthmatic reactions (224, 225).
Agents suspected of having the potential to augment asthmatic conditions are often evaluated
using different allergy models. In these models, laboratory animals are sensitized to common
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aeroallergens, including the chicken egg protein, ovalbumin (OVA) or house dust mite (HDM) (226).
Exposures to test agents can be incorporated at various phases of the model to elucidate the effects on
specific immunological processes (figure 1.3). Subsequently, asthmatic responses can be elicited by
challenging the animal with the model antigen, and the severity of the immune response can be
measured. Responses can be compared between groups exposed to the test agent and control animals
and the potential for augmentation can be delineated as a function of various different immunological
biomarkers (227).

1.1.2.3. Metals and Allergic Disease
Metals are a class of immunotoxic agents associated with expansively diverse immune effects
ranging from immunosuppression to autoimmunity and allergy, the effects of which can manifest in
various tissues including the kidneys, skin, and lungs (228, 229). However, the development of metalspecific hypersensitivity responses is one of the most common immunotoxic effects associated with
exposure to metals (91).
Contact allergy to metals is very common in the general population. It has been estimated that
10-20% of individuals worldwide suffer from metal-induced ACD (230). Data generated from thousands
of patch test studies reveal that the most common inducers of metal ACD are nickel, gold, cobalt, and
chromium. Interestingly, studies using geographically-distinct test populations have demonstrated that
these four metals are consistently problematic with respect to ACD worldwide (table 1.7) (230-266).
Though less frequently associated with ACD, copper, aluminum, and platinum group metals are also
known to cause dermal allergy in some individuals (267-272).
Metal-induced skin allergy also presents a notable concern in occupational settings. Individual
metals, specific allergic skin conditions, frequency of occurrence, and corresponding industries of
association are shown in table 1.8 (13, 101, 247, 267, 272-376).
Respiratory allergy caused by metals is much less common than contact allergy to metals. The
majority of reports describing the development of metal-specific respiratory allergy have implicated
occupational exposures to airborne metals in workers (377). Although reports are far less common than
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cases of dermal allergies to metals, diverse number of pulmonary immune reactions to metals in the
workplace have been described and are summarized in table 1.9 (13, 283, 294, 295, 316, 340, 377-451).
Many of the underlying immunological mechanisms involved in metal-induced respiratory allergy
remain unclear. Cases are uncommon in the general population, limiting the majority of discernable
knowledge to be yielded from occupational case reports, many of which utilize inconsistent approaches
of clinical assessment and implicate confounding circumstances (452). Despite these limitations, a
consistent finding within the existing collection of studies is that divergent immunological mechanisms
are involved in metal-induced respiratory allergy.
Among existing reports, metals associated with the development of asthma include nickel,
chromium, cobalt, platinum, aluminum, zinc, and vanadium (168, 432, 453). Among these, metal-specific
IgE has only been definitively implicated in cases of asthma caused by nickel, platinum, chromium, and
cobalt (377, 389, 419, 454-456). However, the existence of IgE molecules specific for these metals does
not always coincide with asthmatic symptoms. Numerous reports have described asymptomatic
individuals with existing pools of metal-specific antibodies (286, 383). In addition to IgE molecules
capable of mediating metal-induced asthmatic responses, metal-specific IgG molecules have also been
reported in cases of cobalt and platinum-induced asthma (390, 420). Contrarily, several cases of metalinduced asthma have been associated with the absence of metal-specific antibodies, but presence of
metal-reactive T-lymphocyte populations (412). Collectively, these findings suggest the potential for both
IgE-mediated mechanisms, as well as other underlying mechanisms to contribute to respiratory allergy
caused by metals.
Respiratory exposure to metals in the general population mostly occurs at low levels as a result
of particulate air pollution. These exposures most commonly result in aggravation of asthmatic symptoms,
as opposed to sensitization (457). Exposure to particulate matter and metal-rich ambient air pollution has
been shown to both promote the development of and exacerbate the severity of existing asthmatic
conditions (458-462). Mechanisms underlying these effects on asthma range from the induction of
oxidative stress, alteration of TLR expression and activation state of airway DC, recruitment of
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eosinophils and other inflammatory cells to the lung, and induction of Th2-skewed cytokine responses
(463, 464).
Unique Mechanisms of Metal Interactions with Immune Cells: Compared to the immunogenic
activity of other types of allergens (proteins, reactive chemicals), metals are unique allergens for several
reasons. First, the unique chemistry of metals is fundamental to their diverse immune effects. Expansive
speciation of metals can include metallic and elemental forms, ions, salts, and organified compounds.
Despite conservation of elemental constituents between these species, many exhibit divergent chemical
properties and biological effects (465). Moreover, as illustrated by the transition metals, many metals
exist in and transition between different oxidation states, all with distinctive biological activities (466, 467).
Generally, metallic forms of metal elements are largely toxicologically inert, whereas ionic salts exhibit
enhanced bioavailability and subsequently increased potential to cause adverse health effects.
Organification of metal species often increases their lipophilicity, promoting their passage across
biological barriers, as demonstrated with mercury and tin (465).
This speciation-dependent chemical behavior of metals renders them unique allergens on a
molecular level. These chemical properties of metals have been assocated with the potential to modulate
the activities of various immune cells involved in the development, elicitation, and progression of allergic
disease.
With respect to sensitization, several metals are known to modulate activation of innate immune
cells by PRRs. For example, some metal ions are known to produce functional mimicry of PAMP (468).
Schmidt et al. (2010) demonstrated that nickel ions were capable of binding directly to human TLR-4, a
receptor most commonly associated with the recognition of a common PAMP, LPS. The subsequent
signaling cascade led to the release of pro-inflammatory mediators critical to the development of Ni
hypersensitivity (469). It was later discovered that other transition metals, including cobalt and palladium,
were also capable of binding TLR-4 and inducing similar effects (470). Similarly, gold ions have been
demonstrated to bind and activate TLR-3 on keratinocytes (470, 471). Metal antigen presence and the
simultaneous capacity to activate such signaling pathways fulfills the demand for both antigen-specific
and non-specific signals to DC to induce their maturation. This type of ‘auto-adjuvant’ effect is likely
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implicated in sensitization, as the metals associated with this effect correspond with metals with high
rates of sensitivity in the general population (472).
Metals are also known to modulate mechanisms of communication between innate and adaptive
immune cells, which can have implications for both sensitization and elicitation of allergy. In the context
of antigen presentation, Noble metals, beryllium, and nickel have been shown directly bind to cell surface
MHC proteins resulting in altered interactions between APC and T-cells (473-477). These mechanisms
have been suggested to result in bypassing of steps required for sensitization to other antigens, including
intracellular processing. Some metal cations have also been associated with biochemical interference
with DC antigen presentation to antigen-specific lymphocytes in the context of allergic elicitation (478).
Immune cells can also modulate properties of metals implicated in their immunotoxic and
allergenic effects. For example, gold (I)-based compounds are known to be immunologically inert, but
their uptake by phagocytes can lead to oxidative metabolism and transformation into gold (III). The
enhanced reactivity of gold in this oxidation state is associated with the potential to induce structural
alterations in self-proteins, resulting in sensitization (479).
Metal-specific T-cells have been shown to exhibit paradoxical behaviors with respect to metal
specificity in the context of elicitation responses. Many allergenic metals, notably the transition metals,
are known to exhibit immunological cross-reactivity. For example, CD4+ nickel-specific T-cell clones were
shown to cross-react when presented with other transition meals including copper and palladium (480482). Similarly, promiscuous interactions between gold and lymphocytes has been observed, leading to
activation of both CD4+ and CD8+ T-cells in a MHC-unrestricted manner (483).
Contrarily, some metals have been associated with the generation of metal-specific T-cells that
exhibit precise specificity. For example, following loading of DC with titanium ions in vitro, one study
demonstrated that the subsequently-generated titanium-specific lymphocytes selectively reacted to
titanium(IV), indicating that antigenic peptides formed by metal ions can exhibit oxidation state specificity
(484). Furthermore, another study demonstrated that the antigens generated by ionic and nanoparticulate
forms of titanium induced selective proliferation of CD4+ and CD8+ subtypes and correspondingly
divergent release of cytokines (485).
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Similar observations have been reported with respect to metal-specific antibodies. Antibodies for
anti-metal chelates were shown, in one instance, to exhibit specificity for the antigen-conjugated metal
ion (486). Antibodies have also been shown to have the capacity to discriminate between crystalline
facets of gallium arsenide, suggesting the potential for variations in crystallinity to generate unique
antibodies despite identical chemical constituents (487). Contrarily, aluminum-specific antibodies were
demonstrated in another study to have the capacity to recognize free aluminum ions, various compounds
containing the metal, as well as protein-bound aluminum (488).
These diverse chemical properties of metals and their subsequent interactions with immune cells
during all phases of allergic disease likely underlie their unique association with divergent hypersensitivity
mechanisms. Whereas most protein and chemical allergens are exclusively associated with the induction
of T-cell- or IgE-mediated allergic responses, many metals (i.e. nickel, cobalt, chromium) have the
capacity to induce hypersensitivity responses via both IgE and T-cell-mediated mechanisms (489).
Interestingly, concomitant IgE and T-cell-mediated hypersensitivities to the same metal have been
occasionally reported in patients (414). By comparison, other reports have shown conflicting relationships
between respiratory symptoms caused by metals, including rhinitis, and contact sensitivity to the same
metal (490).

1.1.3. Emerging Concern: Immunotoxic and Allergenic Potential of Nanomaterials
The nanotechnology field is projected to continue expanding into the foreseeable future (2).
Accordingly, exposures to nanomaterials are likely to increase in both occupational settings, as well as
in the general public in the coming years. Simultaneous to the expansion of nanotechnology, the
prevalence of allergic disease continues to increase globally (77). Accordingly, individuals with existing
allergic conditions represent a population that may be particularly susceptible to adverse health effects
following metal nanomaterials. Moreover, since it has been proposed that modern lifestyle and behavioral
factors are responsible for the global increase in susceptibility to allergy development, nanomaterial
exposures may also lead to increases in rates of allergic sensitization (491).
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Profound knowledge gaps currently exist regarding the implications of nanotechnological
expansion on the public health burden of allergic disease. However, established knowledge of allergic
disease processes and nanotoxicological advancements have helped to identify several specific areas
in need of active investigation to begin addressing this overarching concept.
First, although many diverse types of nanomaterials exist, one major class may be exceedingly
relevant in the context of allergy. Unique from carbon-based nanomaterials (e.g., carbon nanotubes,
carbon black, graphenes) and other nanomaterial types (polymers, composites, clays, ceramics), metalbased nanomaterials (e.g., metallic, oxidic, alloy, and salt forms) are one of the most highly-produced
types of nanomaterials. Noteworthy metal nanomaterials, their applications, and corresponding rates of
production are shown in table 1.10. Of the 1,829 nanomaterial-containing products listed in the Consumer
Product Inventory in 2019, the vast majority contain metal-based nanomaterials (492). Some of these
nanomaterials may present a particular threat to the immune system, since many of the constituent
elements are metals known to induce and augment diverse types of allergic disease (254, 468).
Several established toxicological paradigms constitute evidence suggestive of the potential for
nanoscale metals to cause more pronounced immunotoxic effects with implications for allergic disease
than larger forms of these metals. For example, the immunomodulatory effects of air pollution are known
to be size-dependent. Metal-rich particulate matter has been shown to induce more pronounced
asthmatic exacerbations when in the ultrafine range (461).
A similar observation pertains to the development of allergic responses following implantation of
metal-based medical prostheses (493). Metal-on-metal implants are associated with the release of both
metal wear particles and ions over time, following which, these constituents exhibit different propensities
for dissemination, PRR activation, immune cell recruitment, biological molecule interactions, and cellular
responses (494, 495). Subsequently, the preferential release of ions from metal implants is often
associated with the development of delayed-type metal hypersensitivity, whereas release of particulate
debris is often preferentially associated with chronic inflammatory reactions and foreign body responses
leading to aseptic loosening and rejection of implants (496). These discrepancies underlie the
discernment between “ion” and “particle” diseases caused by metal constituents released from implanted
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devices (497-500). Moreover, metal debris particles released from implants can assume a variety of
sizes, morphologies, and surface textures, all of which have also been shown to impact their
immunogenic potential (501).
Another concern with respect to metal nanomaterials and allergic disease is that many of the
properties associated with the allergenic effects of metals are known to be altered on the nanoscale. For
example, the sensitizing potential of beryllium is known to be dependent on its physical form and
dissolution potential (502). Allergic sensitization is preferentially associated with soluble beryllium
compounds which readily dissociate into ionic constituents upon entry into the lung. The increased
surface area characteristic of metal nanomaterials is known to enhance the propensity for ion release, a
property which may render these materials more immunogenic than larger forms of the metals (503).
Similarly, the spatial geometry of transition metal species has been correlated with their potential for
cross-reactivity, representing another property with implications for nanoscale metals (479, 504). The
enhanced catalytic activity, diverse morphologies, and modulated surface properties of metal
nanomaterials may also facilitate novel mechanisms of interaction with components of the immune
system leading to effects with potential implications for allergic disease.
In a similar regard, it is plausible that metal nanomaterials may assume different antigenic forms
capable of inducing sensitization. Soluble metal nanomaterials that rapidly dissociate into ionic
constituents may generate antigenic determinants associated with haptenic metal ions. Insoluble metal
nanomaterials may also release haptenic ions, but may also have the capacity to act as particulate
antigens. Soluble and particulate antigens are processed differently by APC, which often results in the
generation of different allergy effector mechanisms, and may be a discrepancy relevant to metal
nanomaterials (505).
Another major concern regarding metal nanomaterials and allergic disease is their enhanced
bioaccessibility. The capacity for an agent to cause allergic disease, or any other general biological effect,
is dependent on its passage through the anatomical and physiological barriers separating its presence
in the external environment from components of the host’s immune system. Accordingly, the
immunogenic potential of many larger materials is often limited as a result of an inability to penetrate
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various epithelial barriers. However, the barrier functions of the skin and respiratory tract may be less
effective in restricting passage of nanomaterials, increasing the immunogenic potential of metal
nanomaterials. Furthermore, the two most common routes of exposure to nanomaterials, dermal contact
and inhalation, implicate the two tissues most commonly associated with allergic sensitization.
Finally, evidence suggests that the acute inflammatory responses associated with metal
nanomaterial exposure may prime the immune system for allergic sensitization. Similar adjuvant activity
may also lead to aggravation of existing allergic conditions. Subsequent effects may include enhanced
severity of allergic reactions and allergic responses occurring in higher frequency.
The following sections summarize the current scientific knowledge regarding metal nanomaterial
immune effects with respect to the aforementioned concerns. Nanomaterial bioaccessibility, sensitizing
capacity, and allergy-augmenting potential are discussed separately with respect to dermal and
respiratory allergy. In addition to studies that examine specific metal nanomaterial effects, studies
designed to delineate the role of physical and chemical properties in these effects are emphasized. Other
relevant in vivo and in vitro immunological studies are also discussed. Finally, considerations and
knowledge gaps in the field are highlighted as potential directions for future research.
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1.2. LITERATURE REVIEW

1.2.1. Metal Nanomaterials and Dermal Allergy
The potential for adverse immune effects following dermal exposure to metal nanomaterials is a
growing concern due to their increasingly frequent incorporation into consumer goods intended to have
prolonged contact with the skin (506). The unique optical properties of TiO2 nanoparticles (NP) and zinc
oxide (ZnO)NP have led to their incorporation in sunscreens and cosmetics for their protective effects
against ultraviolet radiation (UVR) (507, 508). Silver (Ag)NP are being incorporated into clothes, medical
textiles, toys, and cleaning products due to their antimicrobial properties, and silica-based nanoparticles
(SiNP) have been frequently used in cosmetics and as a coating material to alter the properties of other
materials (509, 510). Likewise, the dermal effects of TiO2NP, ZnONP, AgNP, and SiNP are a particular
concern with respect to the general public (511). These nanomaterials are also a concern for workers,
but other metal nanomaterials with high rates of production (listed in table 1.10) are also associated with
dermal exposures in the workplace.
The potential for metal nanomaterials to penetrate the skin, induce dermal sensitization, and
modulate skin allergy development/responses are the three main areas discussed in this section with
respect to size and other physico-chemical properties. In correspondence with the review of the literature,
table 1.11 summarizes studies characterizing effects of individual metal nanomaterials on skin allergy
and table 1.12 summarizes studies designed to examine the effect of physico-chemical properties of
metal nanomaterials on dermal allergy. Tables 1.13 and 1.14 highlight key events involved in dermal
sensitization and elicitation, respectively, that have been shown to be subject to modulation by metal
nanomaterials and their corresponding physico-chemical properties (46, 512-551).

1.2.1.1. Skin Penetration and Translocation Studies
Adverse immune effects following dermal exposure to an agent are heavily dependent on the
degree to which the skin protects from their entry into the body. Likewise, one mechanism by which
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dermal exposure to metal nanomaterials may lead to increased potential for adverse immune effects
compared to larger-sized metals is by size-mediated evasion of skin barrier function. Although it seems
logical that the small size of nanomaterials would inherently provide increased opportunity for absorption
via the skin, there is currently no general consensus on the skin-penetrating capabilities of nanomaterials
as a collective class of agents (38, 552, 553).
Numerous studies have demonstrated that metal nanomaterials (< 100 nm) can penetrate the
skin in various in vivo and in vitro models. Iron-containing (Fe)NP, gold (Au)NP, palladium (Pd)NP, nickel
(Ni)NP, AgNP, SiNP, aluminum (Al)NP, and metal-based quantum dots (QD) have all been shown to
penetrate the skin (43, 46, 515, 554-561). Moreover, many of these studies have established a
relationship between decreased particle size and increased potential for skin permeation (44, 562-564).
Hydrophobicity, surface charge, and morphology are additional properties that have been shown to be
influential in the capacity for these nanomaterials to pass through the stratum corneum (43, 565-570).
AuNP, specifically, were shown to compromise keratinocyte tight junction integrity in a surface
modification-dependent manner, following which paracellular penetration of nanoparticles was observed
(512). This observation highlights that while some metal nanomaterials may not exhibit an inherent
capacity to passively penetrate the upper layers of the epidermis, they may be capable of causing
structural alterations in the skin that subsequently facilitate their penetration.
The majority of studies investigating the skin-penetrating potential of metal nanomaterials have
been conducted with ZnONP and TiO2NP, which have not generated equally consistent findings as
studies with other metal nanomaterials Numerous studies have demonstrated that the stratum corneum
effectively restricts passage of TiO2NP. Repeated application of different forms of TiO2NP did not lead to
skin penetration in hairless rats, elevated levels of titanium in lymph nodes of minipigs, or penetration of
human skin transplanted onto immunodeficient mice (571-573). Although TiO2NP were shown to
accumulate in and around furrows of the skin, microscopic analysis was used to confirm that 20 – 100
nm TiO2NP remained restricted to the uppermost 3 – 5 layers of corneocytes of the stratum corneum
(574-577). Contrarily, a few studies using TiO2NP-containing sunscreens have reported penetration of
particles into the viable epidermis of human skin (578-580). In many of these studies, TiO2NP exhibited
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size profiles identical to other metal nanomaterials shown to penetrate the skin in other studies,
suggesting that size alone is not a property capable of facilitating skin penetration.
Similar observations have been reported regarding different forms of ZnONP. Despite physical
associations with hair follicles, ZnONP were not capable of penetrating the stratum corneum in multiple
models, irrespective of alterations in size, morphology, and surface characteristics (516, 581, 582).
However, ion release from ZnONP and ZnONP-containing sunscreens has been observed, highlighting
a potential risk uniquely associated with metal nanomaterials upon skin exposure (583).
Adverse biological effects may emerge following dermal contact with metal nanomaterials as a
result of skin penetration by either the particulate material, or ions released from the parent material.
Accordingly, different physico-chemical properties may be implicated in the toxic potential of soluble and
insoluble metal nanomaterials in this context.
With respect to penetration of the skin by metal ions, physico-properties associated with
nanomaterial dissolution potential have been correlated to the subsequent bioaccessibility of the metal
constituents (91, 584, 585). The rate of ion release from metal nanomaterials has been shown to be
proportional to the specific surface area (SSA; surface area per mass unit) of the material (586-588).
Nanoscale dimensions are associated with exponential increases in SSA, explaining the observation that
application of sunscreens containing ZnONP caused greater increases in blood, urine, and organ zinc
ion levels than sunscreens containing larger-sized ZnO particles (589-591). Other properties of relevance
to the dissolution potential of metal nanomaterials, such as particle coating, vehicle, and suspension pH
have also been shown to influence metal ion release from nanomaterials following dermal exposure (516,
583).
Although physico-chemical properties of metal nanomaterials have been shown in some
instances to impact skin penetration, an assortment of host factors can also impact this process. Genderand ethnicity-specific physiological characteristics associated with variations in the skin’s defensive
capabilities are known to exist, indicating that specific groups of individuals may exhibit an increased risk
for adverse effects following skin exposures. Similarly, transient alterations in the anatomical integrity of
the epidermis, skin pH, and degree of hydration can also influence penetration of materials through the
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dermal barrier (592-594). Vast discrepancies in epidermal thickness also exist between different
anatomical locations of the body, which renders some areas of exposure a greater concern than others.
One of the most well-studied processes involving host-dependent alterations in the skinpenetrating potential of metals in contact with the skin is the modulation of physico-chemical properties
upon contact with sweat. Studies using biological fluids designed to simulate the biochemical
environment of sweat have demonstrated that the dissolution behavior, zeta potential, and degree of
agglomeration of various metal nanomaterials are subject to modulation upon interactions with the
molecular components of sweat (587, 595). Since many of these properties have been previously
correlated to the potential for metal nanomaterials to penetrate the skin, sweat-induced biochemical
alterations in the skin present a notable contributing factor in the potential for dermal absorption.
In addition to promoting the release of larger quantities of bioavailable metal ions from parent
materials, the biochemical characteristics of sweat can also facilitate alterations in metal ion valence state
(596). Since the passage of Cr ions through the epidermis is known to be dependent on oxidation state,
these interactions may, therefore, greatly contribute to the biological activity of metal nanomaterials (597).
Structural appendages of the skin represent another host-dependent variable with potential to
facilitate or impede the passage of metal nanomaterials. The primary mechanism of skin penetration by
topically-applied agents generally involves movement through the extracellular spaces between
corneocytes in the stratum corneum. However, appendages including hair follicles, sebaceous glands,
sweat glands, and skin folds can also mediate the penetration of epidermal layers. These pathways
appear to be increasingly relevant in the context of metal nanomaterial exposure, as evidenced by the
notable efficacy of nanoscale pharmaceutics and vaccines delivered transfollicularly (598).
Compared to the thickness of the stratum corneum, which measures 10 – 20 µm, hair follicles
can reach a tissue depth of 2,000 µm (599). Accordingly, hair follicles and other dermal appendages may
enhance the capacity for metal nanomaterials to pass through the upper layers of the epidermis and
reach deeper layers of the skin. Although transfollicular penetration routes can lead to increased
bioaccessibility of metal nanomaterials, these mechanisms also present a particular concern with respect
to dermal immune responses. The base of hair follicles can extends all the way into the dermis, where
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the structure receives generous lymph and blood supply, which can facilitate translocation of
nanomaterials into the circulation (56). Moreover, since hair follicles are surrounded by dense networks
of LC and specialized keratinocyte subpopulations known to have critical roles in the early events of
sensitization, this route of penetration may increase the likelihood for metal nanomaterials to cause
adverse immune responses (553, 600, 601).
Dermal structures such as hair follicles also present a potential risk for adverse effects caused by
metal nanomaterials that remain effectively restricted by the stratum corneum to the outermost epidermal
layer. Hair follicles and other appendages can serve as a reservoir for topically-applied agents, facilitating
their accumulation within the epidermal layers (602). Retention of materials in hair follicles can extend
the duration of exposure ten-fold, raising specific concerns for nanomaterials capable of releasing
biologically-active metal ions (570, 603-606). Since frequent low dose exposure is known to promote
sensitization of the skin by contact allergens, retention of metal nanomaterials in follicles of the skin may
constitute a significant concern with respect to dermal allergy (607).
The diameter of hair follicles can vary greatly in response to anatomical location, but the smallest
follicles tend to be located on the forehead and forearm and measure between 66 and 78 µm (608).
Interestingly, the optimal size for penetration of hair follicles is significantly larger than the < 100 nm size
range associated with increased skin penetration of several metal nanomaterials. Particles with 600 - 700
nm diameter have been shown to deposit in the deepest depths of hair follicles, suggesting that
agglomerates of nanomaterials in this size range are potentially more hazardous than primary particles
(603, 609). Furthermore, preferential accumulation within hair follicles and sweat ducts of the skin has
been observed by nanomaterials with specific properties, such as hydrophobic and neutrally-charged
surface chemistries (570, 610).
The role of disrupted skin barrier integrity is another host factor that has been commonly studied
in the context of metal nanomaterials and skin penetration. The potential impact of compromised dermal
barrier functions also has notable relevance to allergic disease, specifically, since skin permeability can
be increased 4 – 100 times in individuals with skin allergy (45). Scratching to alleviate itching associated
with allergic skin lesions leads to mechanical damage in the upper layers of skin. Similar degrees of
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barrier disruption have been shown to increase in vivo penetration of some metal nanomaterials in
humans and rodents (611-614). In vitro simulations using a human skin model called the Franz Method
have demonstrated increased capacity for passage through damaged skin by 25 nm AgNP, 6 nm
platinum (Pt)NP, 5 nm rhodium NP (RhNP), 10 nm PdNP, 78 nm NiNP, 17 nm cerium oxide (CeO2)NP,
and 80 nm cobalt (Co)NP (515, 555, 615-618). Contrarily, studies have shown that penetration by various
sizes of TiO2NP and ZnONP was not increased when skin had been damaged by chemical irritants, tapestripping, hair removal, or mechanical force (575, 619-623).
A few in vivo studies have also investigated the effects of skin barrier dysfunction resulting from
existing skin allergy on the penetration of metal nanomaterials (45). In a mouse model of skin allergy,
penetration of allergic skin by ZnO was size-dependently increased, wherein 240 nm ZnO particles did
not penetrate the skin to a similar extent as 20 nm ZnONP (624). Studies using non-metal nanomaterials
have also demonstrated that penetration of nanomaterials in allergic skin is size-dependent (552).
ZnONP were also shown to penetrate allergic skin ex vivo using human skin samples (625). Contrarily,
application of 35 nm ZnONP to skin of living human subjects with atopic dermatitis did not result in
penetration of viable skin (623). Discrepancies between these studies may be reflective of varying
exposure durations, as the study reporting penetration involved continuous exposure of up to 2 weeks,
compared to the 4 hour exposure wherein no penetration was observed.
Comparatively, equally prolonged exposure to AgNP-containing textiles did not lead to increased
skin penetration in individuals suffering from atopic dermatitis compared to control subjects. Sleeves
containing silver particles (30 – 500 nm) were worn by human subjects for 8 hr each day for 5 days,
following which levels of AgNP and aggregates in the skin were quantified. Compromised skin barrier
was not associated with increases in AgNP skin accumulation; moreover, no differences in urine silver
ion levels were observed, indicating that atopic dermatitis did not impact the absorption of ions released
from the textiles either (626, 627).
Several factors may be responsible for the discrepancies in findings regarding the importance of
skin barrier integrity on metal nanomaterial skin penetration. First, differing degrees of epidermal barrier
function disruption likely exist between the different models, representing a potential source of variation
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between studies. Complete ablation of epidermal function is only observed in response to severe burns
and lacerations; likewise, the diverse mechanisms of experimentally-induced disruptions of the stratum
corneum should be compared cautiously. In addition, many features of atopic dermatitis are likely to differ
between experimentally-induced disease states in animal models and human subjects with established
conditions. In human studies, individuals are likely to exhibit expansive variations in existing lesion
severity, as well as differences in the degree of influence from chronic effects. Since chronic skin
inflammation can result in epidermal thickening, enhanced barrier function is not uncommon in many skin
disorders (628). All of these factors could have contributed to the divergent findings reported amongst
the existing studies.
The capacity for metal nanomaterials to penetrate the skin appears to be influenced by both
nanomaterial properties and host factors in many instances. However, environmental factors may also
impact this process. One environmental factor with particular relevance to metal nanomaterials and their
use in sunscreens in UVR. UVR has been shown to augment the skin penetrating potential of
nanomaterials as a result of modulatory effects on both host skin barrier functions and biological activity
of metal nanomaterials. In the context of host-mediated factors influencing skin permeability, high levels
of UV exposure and subsequent sunburn can significantly disrupt epidermal barrier function. However,
low doses of UV exposure are also known to compromise the integrity of the epidermis (629-631).
Accordingly, several studies have demonstrated that UV exposure prior to topical application of
nanomaterials results in greater depth of penetration by ZnONP, TiO2NP, and QD (514, 632, 633).
UVR can also induce alterations in physico-chemical properties of metal nanomaterials that may
facilitate their passage through the stratum corneum. UVR has been shown to induce nanomaterial
agglomerate disaggregation, as well as enhanced ion release, both of which are effects capable of
enhancing the passage of nanomaterials through the upper layers of skin (634-637). Another effect of
UVR capable of increasing the skin penetrating potential of metal nanomaterials is photoactivation. In
vitro, UVR-induced ROS production by TiO2NP, QD, and ZnONP has been associated with DNA damage,
lipid peroxidation, and mitochondrial permeability in skin cells (638-643). Subsequent cytotoxicity to
dermal fibroblasts, keratinocytes, and melanocytes is another mechanism by which skin barrier integrity
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can become compromised as a result of UVR. In vivo, UVR-induced photoactivation of TiO2NP has been
associated with increased adherence to the skin, structural rearrangement of the lipid bilayer, and
facilitation of large molecule transdermal penetration (634, 644-647). Since the degree of ROS produced
in response to UVR has been associated with nanoparticle surface area and reactivity, other related
properties such as size, degree of agglomeration, and surface modification may also contribute to skin
penetration following UVR exposure (648-651).
These observations demonstrate the potential for UVR to enhance skin penetration of metal
nanomaterials following dermal exposure. While this effect can result in increased biological activity of
metal nanomaterials, it also presents a unique concern with respect to skin allergy. Many signaling
pathways and pro-inflammatory mediators involved in sensitization have been associated with UVRdependent photoactivation of metal nanomaterials (652, 653). UVR is also known to modulate the
immune status of the skin by a number of mechanisms, which can impact allergic processes. For
example, UVA and UVB are known to augment costimulatory molecule expression, compromise antigen
presentation, and induce apoptosis of LC (654-656). These effects have been shown to impact the
immunological activity of metal nanomaterials following skin exposure in a few studies. In one report,
significant depletion of LC (~80%) following UVR exposure increased skin penetration of QD in vivo, but
resulted in lower levels of metal ion constituents in the lymph nodes (633). Accordingly, UVR has been
shown to enhance penetration of the skin by metal nanomaterials, alter the immune status of the skin,
and modulate the transport of nanomaterials from the skin to lymphoid tissues, all of which are effects
with potential implications for dermal allergy.

1.2.1.2. Skin Sensitization Studies
The skin-sensitizing potential of metal nanomaterials has been investigated in a few studies using
traditional in vivo approaches. SiO2NP, ZnONP, and TiO2NP have all been incorporated into studies
employing the LLNA (657, 658). Accordingly, it was demonstrated that topical exposure to 100 nm
mesoporous and colloidal SiO2NP, 7 nm SiO2NP, and ZnONP were not capable of inducing the three-
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fold increase in lymphocyte proliferation associated with classification as a dermal sensitizer (529, 659,
660). Similarly, topical exposure to 25 nm TiO2NP did not induce dermal sensitization in multiple studies;
however, subcutaneous injection of equal doses resulted in significant increases in lymphocyte
proliferation, suggesting that the inability for TiO2NP to penetrate the skin might be a limiting factor in the
potential to induce dermal sensitization (661, 662).
The GPMT is another in vivo technique used to evaluate dermal sensitization potential that has
been employed in the investigation of several metal-based nanomaterials. In one study, five UVabsorbing materials containing SiO2NP, ZnONP, and TiO2NP were assessed. One out of 10 animals
exhibited slight erythema following topical exposure to the ZnONP and TiO 2NP-containing agents,
leading to their classifications as mild skin sensitizers (664). In another study, 1 out of 20 animals
exhibited discrete patchy erythema following intradermal injection with 10 nm AgNP, leading to its
classification as a weak skin sensitizer (665). Similarly, AgNP were classified as a Grade II (mild
sensitizer) after 2 out of 10 guinea pigs exhibited lesions 48 hr after application of AgNP-containing sterile
gauze (666). However, similar AgNP-containing dressings were actually shown to improve the healing of
burn wounds in rats over an 18 day period as compared to rats with dressings lacking AgNP, but the
study only examined the localized effects (667). The GPMT has also been used to demonstrate that
surface-modified FeNP, AlNP, and hydroxyapatite nanoparticles did not induce skin sensitization (668670).
Using a different approach, the sensitizing potential of 5 and 10 nm AgNP was investigated by
Hirai et al. (2016) in vivo. Mice were injected with AgNP or Ag ions and LPS once a week for four weeks,
then intradermally challenged. Interestingly, mice administered Ag ions in the sensitization phase did not
develop ear swelling following challenge with any form of silver. Contrarily, AgNP exposure induced
sensitization, wherein the smaller AgNP appeared to have stronger sensitizing potential, which was
dependent on CD4+ T-cells and IL-17a, but not IFN-γ. Moreover, ear swelling was observed in response
to additional sizes of AgNP (50 and 100 nm) and silver ions, suggesting that the immune response was
not nanoparticle-specific. Further examination revealed that 3 nm NiNP was also capable of inducing
sensitization in the model, whereas minimally-ionizable 10 nm AuNP and 10 nm SiNP were not (671).
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In one of the few existing studies that has examined metal nanomaterial effects with respect to
existing metal allergy in vivo, Shibuya et al. (2019) used a mouse model of metal allergy to evaluate the
potential for metal nanomaterials to elicit allergic responses in the skin. Following sensitization with LPS
and Pd salts, allergic responses were differentially elicited in response to PdNP or Pd salt exposure. Pd
salts were associated with more severe skin responses than those induced by PdNP. Subsequent testing
of human subjects generated similar findings, wherein the soluble metal salt selectively triggered allergic
skin reactions (672).
In addition to in vivo approaches to assess skin sensitization, three non-animal alterative
assessment methods based on different steps of the skin sensitization AOP are currently validated by
the OECD. While metal nanomaterials have not been incorporated into any of the assays, studies with
similar cell lines and endpoints have indicated that many metal nanomaterials can induce effects similar
to those of other skin sensitizers. Studies generating findings with relevance to the DRPA and DC
activation with be discussed in a future section, given the potential relevance of these findings for both
ACD and asthma. However, keratinocyte-based assays exhibit specificity for the events of skin
sensitization, and may represent an approach capable of predicting the potential for metal nanomaterials
to sensitize the skin.
Keratinocytes are a source of numerous mediators that facilitate LC migration, antigen
presentation, and T-cell activation during sensitization (673). Since many of these mediators are released
in response to sensitizer-induced activation of the antioxidant/electrophile sensing pathway
Keap1/Nrf2/ARE, its activation is suggestive of potential for the test agent to contribute to the cellular
response of the sensitization AOP (143, 144, 674). The human keratinocyte cell line associated with the
assay, HaCaT, has been frequently used to investigate potential metal nanomaterial effects on the skin
in vitro. Correspondingly, PdNP, AuNP, and PtNP have all been shown to activate the Nrf2 pathway in
keratinocytes in vitro (675, 676). Similarly, Zn-containing QD, ZnONP, and CuONP have all been shown
to alter expression of several specific genes associated with the Nrf2 pathway, including HMOX1 (677679).
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Prior to the establishment of the Nrf2 pathway’s involvement in the keratinocyte response to skin
sensitizers, in vitro cytokine release by keratinocytes was often evaluated as an indicator of sensitizing
potential (680, 681). TNF-α is a keratinocyte-derived cytokine involved in sensitization that is critically
involved in skin sensitization by chromium and nickel (682, 683). Dose-dependent TNF-α release has
been observed following keratinocyte exposure to AgNP, QD, and ZnONP, indicating that high doses
may promote LC maturation and dermal sensitization (679, 684, 685). IL-18 and IL-1β are also cytokines
critical for LC activity that have been shown to be increased following exposure to QD, SiO2NP, TiO2NP,
and AgNP (679, 684, 686-689).
Another mediator involved in skin sensitization that is differentially-released by keratinocytes in
response to irritants and sensitizers is IL-1α (680, 690). Although it can also be actively secreted following
inflammasome activation, IL-1α is an intracellular molecule that functions as an alarmin (691). During
programmed cell-death, IL-1α remains associated with chromatin and its sequestration prevents any
effector functions; contrarily, under necrotic conditions, it is passively released and exhibits bioactive
potential. Accordingly, the mechanism of metal nanomaterial-induced keratinocyte cytotoxicity may
significantly impact the development of ACD as a result of differential IL-1α release. Although
mechanisms associated the preferential induction of necrosis or apoptosis by nanomaterials have yet to
be established, some properties have been correlated to these effects (692, 693). For example, surface
charge of 1.5 nm AuNP was demonstrated to be responsible for the mechanism of cell death in HaCaT
cells in vitro. Charged AuNP led to disruptions in mitochondrial membrane potential and intracellular
calcium levels causing apoptosis, whereas neutral AuNP were associated with necrotic cell death (549).
Preferential HaCaT apoptosis or necrosis has also been associated with AgNP surface coating and
TiO2NP crystal phase (694, 695). Interestingly, cytotoxic effects of Ag nanowires on human primary
keratinocytes was shown by one study to be dependent on particle number (696). Collectively, these
findings assert that surface chemistry/reactivity of metal nanomaterials may be a critical property in
determining whether dermal exposure results in irritation responses or allergic sensitization.
Very few studies have been conducted that examine metal nanomaterial effects specifically on
LC. However, topical exposure to < 100 nm AgNP in guinea pigs was shown to increase the number of
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LC at the site of exposure in a dose- and time-dependent manner in one study (524). This observation is
relevant to skin sensitization since the concentration of LC in the skin has been correlated with increased
susceptibility to ACD development. In vitro, associations with LC have been shown to be influenced by
SiNP size and surface functionalization (43, 553). Smaller SiNP size has also been correlated to
increased uptake, ROS production, and cytotoxicity to LC in vitro (86, 525).
Other in vivo studies have confirmed that metal nanomaterials including QD and AuNP are taken
up by LC and subsequently transported to the regional lymph nodes (697, 698). In one study, Santini et
al. (2015) demonstrated that the surface modification, and subsequent hydrophobicity, of FeNP was
associated with preferential uptake of the particles by specific cell types within the skin. Following topical
application, FeNP suspended in aqueous suspension were more commonly associated with local
phagocytic cells, which subsequently translocated to the lymph nodes (699). Contrarily, FeNP applied in
cream formulations were selectively internalized by epidermal and structural cells of the skin. These
observations illustrate the capacity for a specific physio-chemical property to directly contribute to the
early immunological processes involved in allergic sensitization.
An observation regarding metal nanomaterial DC effects with specific implications for ACD and
dermal sensitization is the finding that some metal nanomaterials can promote DC cross-presentation.
Cross-presentation describes the uptake of exogenous antigens and their subsequent processing by
pathways normally associated with endogenous antigens (700). As a result, the exogenous antigen is
presented by MHC I molecules to CD8+ T-cells, following which, populations of cytotoxic effector cells
characteristically seen in ACD are established.
AlNP, AuNP, FeNP, and SiNP have all been shown to modify DC antigen cross-presentation
capacity (517, 530, 531, 701-704). The mechanism of antigen uptake by DC is known to influence the
preferential association of antigens with MHC I or II molecules. Small lipophilic haptens associated with
skin sensitization often enter APC via passive diffusion and bind cytoplasmic proteins, favoring their
processing by endogenous pathways and presentation by MHC I molecules (705). Accordingly, passive
diffusion through cell membranes similar to that demonstrated by charged 15 nm AuNP may result in
promotion of cross-presentation (706-708). Contrarily, receptor-mediated endocytosis of larger antigens
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has been associated with cross-presentation when uptake occurs by Fc and mannose receptors (709).
In this regard, the adsorption of macromolecules, including immunoglobulins, to the surface of
nanomaterials and physico-chemical properties associated with the adsorption of proteins may be
critically influential in determining the route of antigen processing.
Another major determinant of preferential antigen association with MHC I or II is persistence
inside DC. Antigens resistant to degradation in endosomes are more likely to be processed by MHC I
pathways (710, 711). Likewise, metal nanomaterials with physico-chemical properties capable of
compromising lysosomal acidification (dissolution rate, surface reactivity) may promote crosspresentation (712, 713). Similarly, endosomal escape following uptake by DC can result in binding to
cytosolic proteins and subsequent perception as an endogenous antigen (710). One of the major
mechanisms of endosomal antigen release leading to cross-presentation is oxidative stress and lipid
peroxidation causing antigen leakage from compromised endosome membranes (714-716). Oxidative
stress induced by CuNP, FeNP, and TiO2NP have been shown to cause lipid peroxidation, and these
metal nanomaterials have also been associated with enhancing DC cross-presentation (52, 717, 718).
Metal nanomaterials have also been associated with the induction of autophagy and production of
exosomes by DC, both of which have also been associated with antigen cross-presentation (531, 719722).

1.2.1.3. Augmentation of Existing or Developing Skin Allergy
Since dermal exposure to metal nanomaterials nearly always occurs simultaneous to other
exposures, their potential to augment skin allergy has been investigated using various allergy models.
Metal nanomaterial effects on skin allergy have been studied with respect to both T-cell-mediated ACD
and IgE-mediated atopic dermatitis.
Incorporation of metal nanomaterials into ACD models has generated findings suggestive of their
potential to modulate immunological processes involved in both allergic sensitization and elicitation. In
one study, subcutaneous exposure to TiO2NP 1 hr prior to skin sensitization with dinitrochlorobenzene
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(DNCB) increased susceptibility of mice to sensitization, as evidenced by a lower concentration of DNCB
required to induce sensitization (535, 723). The authors noted that although DNCB is known to induce a
Th1-dominant response characteristic of ACD, exposure to TiO2NP resulted in a Th2-dominant response
in the regional lymph nodes. In a similar study, TiO2NP were applied topically 1 day prior to sensitization
with DNCB, and the same effect on sensitization was observed (535). A diminished Th1 response was
observed and TiO2NP were detectable in the lymph nodes. Contrarily, SiO2NP and AgNP did not induce
alterations to DNCB sensitizer potency in the same model.
In another study, a panel of metal nanomaterials with various physico-chemical properties was
analyzed for effects on chemical-induced ACD both during sensitization and challenge. When mice were
sensitized to dinitrofluorobenzene (DNFB), co-administration of QD did not impact the severity of the
challenge response to DNFB, irrespective of particle charge. However, QD administration simultaneous
to DNFB challenge did impact the allergic response, wherein the effect was dependent on the surface
charge of the material. The negatively-charged particles suppressed allergic inflammation, whereas the
positively-charged materials enhanced skin swelling following allergen challenge. The authors confirmed
that sensitization to QD did not occur and suggested that variations in the skin penetrating capacity of
the differently-charged materials was responsible for the observed effects. The conclusions regarding a
critical role for nanomaterial size and charge on modulation of ACD elicitation responses is supported by
other findings, as well. ACD reactions to DNFB and 2-deoxyurushiol were shown to be attenuated
following topical application of 20 nm SiNP and cream containing < 50 nm AgNP (724). Contrarily,
exposure to positively-charged, surface functionalized 56 nm SiNP did not augment the severity of
oxazolone-induced elicitation responses when topically applied for 5 consecutive days in another study
(725).
As highlighted by Jatana et al. (2017), ACD responses may be subject to modulation as a result
of allergen chemical modifications induced by interactions with metal nanomaterials. In their study, topical
application of nanomaterials and subsequent removal prior to application of DNFB, implying that the
modulation of allergic skin inflammation was not reflective of nanomaterial-induced blockage of adduct
formation. Although metal nanomaterials exhibit characteristically increased surface reactivity and
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catalytic potential, their capacity to alter the chemical properties of skin-sensitizing agents associated
with triggering the molecular initiating events of dermal sensitization has not been extensively studied.
However, a few studies have demonstrated the potential for such effects to impact both ACD sensitization
and elicitation. For example, AlNP and AuNP have both been shown to act as non-protein carriers of
haptens capable of facilitating the generation of hapten-specific adaptive immune responses in vivo (520,
726). Similarly, topical application of ointment containing calcium-based nanoparticles has been shown
to capture nickel ions by cation exchange, compromising bioavailability and subsequently preventing the
elicitation of nickel-specific ACD (727).
In addition to ACD, metal nanomaterial effects on IgE-mediated atopic dermatitis have also been
examined using skin allergy models. Compared to the LMW reactive chemicals traditionally associated
with ACD, atopic dermatitis generally involves protein allergens, which under normal circumstances are
not able to penetrate the skin (728). However, 100 nm ZnONP and 5 nm AuNP have been shown to
enhance skin penetration of albumin and protein drugs (729, 730). Likewise, increased permeability of
the skin associated with some metal nanomaterials may represent a mechanism by which exposure may
increase susceptibility to atopic dermatitis onset.
Simultaneous exposure to TiO2NP, AgNP, and SiO2NP during sensitization to HDM in atopic
dermatitis models has been associated with an amplification of Th2 responses. This effect was shown to
be more pronounced with decreasing size with respect to AgNP and SiO2NP, but not for TiO2NP (534,
550, 551). Exposure to 5 nm AgNP during sensitization was associated with augmentation of mast cell
activity that resulted in more severe skin lesions that appeared earlier than those induced by 100 nm
AgNP (544). Decreases in SiO2NP size were also associated with enhanced Th2 responses, as
evidenced by increased TSLP and IL-18 production (550). Decreased particle size has been associated
with increased aggravation of atopic dermatitis skin inflammation by non-metal nanoparticles, as well
(731).
Metal nanomaterial-induced modulation of allergic inflammation in the challenge phase of atopic
dermatitis has also been demonstrated. In one report, topical application of both 240 and 20 nm ZnONP
resulted in diminished local allergic inflammation caused by OVA. The smaller particle was associated
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with more pronounced suppression of local skin inflammation, but simultaneous increases in systemic
production of IgE (624).
An interesting observation by Hirai et al. (2015) highlights a potentially critical variation between
studies that may explain discordant immune effects induced by similar nanomaterials in atopic dermatitis.
The authors demonstrated that, in their study, exacerbation of allergic sensitization was dependent on
co-administration of HDM and SiO2NP. When SiO2NP agglomerates were administered at a peripheral
site from the allergen, the altered antibody response was no longer observed. The dependence of
nanomaterial/antigen physical associations on the subsequent adaptive immune response has been
similarly demonstrated by FeNP. In multiple studies, intravenous administration of 58 nm FeNP 1 hr prior
to subcutaneous OVA sensitization resulted in decreased levels of IgG1 and IgG2 and suppression of
Th1 and Th17 responses in mice (732-734). Contrarily, when FeNP and OVA were co-administered
intravenously or subcutaneously, enhanced antibody responses were seen in mice (735, 736). Similar
immune-stimulating effects of FeNP have been demonstrated when used as an adjuvant by various
exposure routes during immunization to various other antigens in the context of vaccine studies (737741).

1.2.1.4. Mechanisms of Skin Allergy Augmentation by Metal Nanomaterials
Allergy model studies have demonstrated the potential for various metal nanomaterials to
augment various aspects of dermal hypersensitivity responses. Despite this, many of the molecular and
cellular mechanisms responsible for these observations remain unclear. However, findings from other
studies may help elucidate some of the potential mechanisms by which metal nanomaterials can
exacerbate skin allergy and further clarify the role of physico-chemical properties in these effects.
Most skin sensitizers exhibit inherent irritancy potential, an effect that can act as an adjuvant to
promote sensitization. Accordingly, skin irritation may represent a mechanism by which metal
nanomaterials can promote the development of metal-induced ACD or other dermal allergies. Although
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metal nanomaterial-induced skin irritation has not been directly studied in this context, their general skin
irritation potential has been extensively profiled.
Historically, rabbits have been the preferential animal model for use in the assessment of acute
skin irritation, as established by the OECD test guideline 404. Test materials are applied to the skin for
up to 4 hr, following which, local responses are used to classify the irritation potential (742). A few studies
been conducted with metal nanomaterials based on this assay. Accordingly, several nano-enabled UV
absorbers (containing AgNP, SiO2NP, and TiO2NP) were shown to cause skin irritation in rabbits,
although the effect was minimal in most cases (664). Smaller sizes of AgNP (10, 20 nm) were shown to
induce more severe skin irritation following exposure when compared to larger particles (30 nm) (547).
Comparatively, TiO2NP (< 25 nm, 20 – 40 nm), QD (18 nm), SiO2NP (7, 10 – 20 nm), ZnONP (20 – 100
nm), and AgNP (10 nm) did not induce irritation of the skin in rabbits in other studies (660, 662, 665, 743746). A few studies have also examined the skin irritation potential of metal nanomaterials in other animal
models. AgNP were shown to induce inflammatory effects in porcine skin following 14 days of exposure
in a size- and surface modification-dependent manner, although the effects were minimally observed
(684). Chronic skin exposure to ZnONP was shown to cause local irritant effects in rats, as well (747).
As the use of animal models in toxicity testing is becoming increasingly unfavorable, numerous in
vitro models have been developed to identify compounds with potential to cause skin irritation. Many of
these approaches utilize various commercially-available 3D reconstructed models of human skin
including EpiSkinTM, EpiDermTM and SkinEthnicTM. These and other human skin equivalent models
(HSEM) are used to identify skin irritants based on their capacity to cause reductions in cell viability in
these in vitro models. Generally, agents are classified as skin irritants if they produce a reduction in cell
viability to below 50% after 3 minutes of exposure.
These guidelines have been used to investigate the skin irritating potential of several metal
nanomaterials in vitro; however, none have reported effects justifying their classification as irritants after
3 minutes of exposure. After 1 hr of exposure, SiO2NP were shown to cause irritation in a size and surface
charge-dependent manner (748). By comparison, exposure to AgNP (10-100 nm), TiO2NP (22-214 nm),
and cerium dioxide (CeO2) NP (15-40 nm) for 1 hr did not cause irritant effects (662, 749). In similar

52

models, ZnONP (20, 50, 100 nm), AgNP (< 100 nm), Ag nanowires (2 µm x 40 nm, 20 µm x 50 nm),
TiO2NP (21 nm), AlNP (30 – 60 nm), and FeNP (35 – 45 nm) were also determined to be non-irritating,
even following exposure for longer durations of time (24 – 72 hours) (696, 742, 743, 750). It remains
unclear if the same metal nanomaterials associated with irritant responses in the skin are also associated
with sensitizing potential, however, this represents a potential mechanism that may contribute to the
development of ACD.

1.2.1.5. Knowledge Gaps in Metal Nanomaterial Effects on Skin Allergy
Despite the large number of studies that have investigated the skin-penetrating potential of metal
nanomaterials, there has yet to be a definitive conclusion regarding this capability. Discrepancies in
findings test materials with identical size profiles suggest that the parameter of size, alone, may not confer
skin penetrating capacity to materials. However, variations in test model, exposure duration, application
techniques, test material formulation, methods of endpoint evaluation, and various external factors also
exist between studies and represent sources of variability between findings that may account for
discordant conclusions. As noted by Gulson et al. (2012), specific considerations should be given to the
source of test materials used in different studies, since some studies used pristine metal nanomaterials,
and others used commercially-available TiO2NP/ZnONP-containing sunscreens. The sunscreen used in
their study contained isopropyl myristate, a chemical known to enhance the permeability of the skin, as
well as EDTA, a chelating agent which may have influenced the release of ions from ZnONP (751).
Accordingly, excipients of commercial sunscreens can greatly impact metal nanomaterial skin
penetration.
Also, most studies have overlooked potentially critical features of the skin, such as metabolic
activity, ablation of which has been associated with enhanced penetration by AuNP (752). Overall, it
appears that different mechanisms of penetration (e.g., paracellular, intracellular, follicular routes) may
implicate different toxic responses, which should be investigated further. Irrespectively, it is evident that
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metal nanomaterials possess many unique properties that render them unique hazards to the skin
compared to carbon-based nanomaterials or nanoscale pharmaceuticals.
Overall, knowledge of the effects of metal nanomaterials on skin allergy are largely limited to
metals including TiO2NP, SiO2NP, and ZnONP. Although the selective investigation of the skin sensitizing
potential of these metals is likely reflective of their significance to consumer skin exposures, titanium,
silver, and zinc are not historically associated with clinically significant rates of ACD in the general
population. However, the observation that some of these metals may have increased potential to induce
skin sensitization when in nanoparticulate form raises concerns over the lack of investigations into
nanomaterials comprised of metals commonly associated with ACD (nickel, gold, cobalt).
While the adjuvant effects of metal nanomaterials have been studied to a greater degree than
their sensitizing potential with respect to the skin, a definitive role for physico-chemical characteristics
during the sensitization and elicitation phases of ACD remain unclear. However, there does appear to be
an established connection between alterations in the early events of atopic dermatitis development and
simultaneous exposure to metal nanomaterials. Moreover, the requirement for antigen and nanoparticle
administration by the same exposure route indicates adjuvant effects that are dependent on physical
interactions between the two.
The skin microbiome is known to significantly influence many aspects of skin allergy. Many metal
nanomaterials are being utilized for their antimicrobial properties, but it remains unclear if their capacity
to alter normal microbial populations presents implications for ACD. Interestingly, the effects of SiNP on
DC activation and inflammatory cytokine release were shown in one study to be altered in the presence
of extracellular media from cultures of commensal bacteria. Moreover, the strain of bacteria was also
implicated in various responses (753). This observation further highlights the impact metal nanomaterialinduced alteration of normal flora may have on skin allergy.

1.2.2. Metal Nanomaterials and Asthma
With respect to the respiratory tract, metal nanomaterials of concern for consumers include many
of the materials mentioned above, such as ZnONP, AgNP, TiO2NP, and SiO2NP. Their incorporation into
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construction materials, sunscreen sprays, disinfectants, and cosmetic powders can facilitate their
inhalation upon use. Workers may be exposed to these and other highly-produced metal-based
nanomaterials (table 1.10), including FeONP, CeO2NP, and CuONP (754).
Although it is unclear whether nanoscale dimensions of metals increase the likelihood for
bioaccessibility following dermal contact, size is a critical parameter known to impact the propensity for
inhalation of materials, their deposition in the respiratory tract, and subsequent potential for systemic
distribution (755). Decreases in size contribute to the lightweight nature of metal-based nanomaterials
and their characteristic ‘dustiness,’ which is correlated with the increased potential for inhalation exposure
compared to larger particles (18, 756). The deceased size profile of nanomaterials results in efficient
deposition along the entire respiratory tract, as well as the unique potential for deposition in the deepest
regions of the lung (21). Deposition of nanomaterials in the alveolar region poses unique toxicological
implications as increased time is required for clearance by normal pulmonary mechanisms, leading to
prolonged retention (757). Moreover, deposition in the alveolar region increases potential for penetration
of the blood-air barrier, facilitating entry into circulation, and translocation to distal tissues (758-761).
Accordingly, the size profile of metal nanomaterials increases their potential for entry into the body
via the respiratory tract, circumventing one of the major barriers responsible for limiting adverse
pulmonary immune effects caused by larger metal particles (21). As a result, the effects of metal
nanomaterials on pulmonary immunity and asthmatic conditions have been extensively studied. Table
1.15 summarizes studies characterizing individual metal nanomaterial effects on pulmonary immunity
and table 1.16 summarizes studies designed to examine specific effects of physico-chemical properties
of metal nanomaterials on asthma. Tables 1.17 and 1.18 highlight processes involved in respiratory
sensitization and elicitation, respectively, subject to modulation by metal nanomaterials and their physicochemical properties (18, 469, 518, 519, 521-523, 526, 527, 532, 539, 546, 726, 761-800).
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1.2.2.1. Human Studies Demonstrating Pulmonary Immune Effects of Metal Nanomaterials
A potential association between metal nanomaterial inhalation and subsequent allergic responses
of the respiratory tract was notably illustrated in a 2014 case report describing a chemist who accidentally
inhaled NiNP in the workplace. The subject subsequently developed clinical symptoms suggestive of
metal-specific IgE-mediated respiratory allergy, which included throat irritation, nasal congestion, facial
flushing, and respiratory distress upon future encounters with NiNP. The chemist also developed
previously-nonexistent dermal eruptions upon contact with her earrings and belt buckle, indicative of
development of T-cell-mediated nickel-specific ACD (801).
This case report reinforces existing concerns over the increased potential for inhalation of metal
nanomaterials and subsequent potential for allergic sensitization as a result of their decreased size.
However, the case also emphasizes additional concerns reflective of the unique mechanisms of metal
allergy. The report findings suggest that sensitization via one exposure route may not limit future
elicitation reactions to the same tissue; moreover, sensitization by metal ions, irrespective of original
parent material size, may result in elicitation reactions following exposure to both nano- and bulk-sized
metal materials.
Several studies have been conducted to evaluate potential adverse immune effects in human
subjects at risk for inhalation exposure to metal nanomaterials in their workplaces. In one study, it was
shown that workers employed by nanomaterial-handling facilities located in Taiwan exhibited an
increased prevalence of sneezing, dry cough, and productive cough compared to workers with no
nanomaterial exposures (802). Although the workers were employed by facilities handling SiO2NP,
Fe2O3NP, AuNP, AgNP, and TiO2NP, it is unclear whether the observed respiratory effects were
mediated by adaptive immune responses specific to the metals, or non-specific irritant mechanisms.
Interestingly, increased rates of ACD were also observed in the workers of the nanomaterial-handling
facilities, but the inciting agents were not determined. Accordingly, it is unknown if exposure to the
nanomaterials induced sensitization or caused increased susceptibility to ACD development in workers.
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Similar studies have also demonstrated that exposure to nanomaterials in the workplace can
cause elevations in various immune-related biomarkers indicative of potential allergic effects (803-805).
Elevations in breath condensate leukotriene levels have also been observed in subjects exposed to
TiO2NP aerosol and welding-derived metal nanoparticles (<100 nm) in their workplaces (806, 807). The
exposed workers had elevations in leukotriene B4, a lipid mediator associated with the recruitment,
activation, and prolongation of survival of leukocytes in the lung, as well as multiple cysteinyl leukotrienes
(C4, E4, D4), which are known to be potent mediators of bronchoconstriction (808, 809). Although no
alterations in lung function were observed in the exposed workers, elevations in levels of lipid mediators
involved in the pathogenesis of asthma suggest the potential for exposure to TiO2NP in the workplace to
enhance the severity of asthmatic conditions.
Collectively, these reports illustrate that inhalation exposure to metal nanomaterials has the
potential to result in adverse immune effects with potential implications for allergic disease. However, it
remains unclear if the observed responses were indicative of exposure leading to sensitization or
exacerbation of respiratory allergy. Limitations of human studies arise from inconsistencies between
exposure conditions, subject histories, and the requirement for non-invasive, measurable endpoints.
Accordingly, the effects of metal nanomaterials on pulmonary immunity and underlying mechanisms have
been assessed in animal models wherein controlled dosing, consistent environments, and additional
endpoints have helped identify some of the potential underlying mechanisms of metal nanomaterialinduced pulmonary immune effects.

1.2.2.2. Evidence for Increased Potential for Respiratory Sensitization from Animal Studies
The identification of agents capable of causing respiratory allergy presents numerous challenges.
Currently, there are no validated in vivo, in vitro, or in silico approaches for the identification of potential
respiratory sensitizers. Moreover, there has yet to be an AOP adopted that highlights the key events
associated with the development of respiratory allergy. The capacity for both HMW and LWM agents to
induce asthma, in addition to these complicating factors, renders the identification of potential respiratory
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sensitizers a historical challenge for immunotoxicologists. Accordingly, no studies have directly
investigated the potential for any metal nanomaterials to sensitize they airways. Despite this, several
studies have reported findings that, when compared to proposed methods of respiratory sensitization
assessment, may provide insight into their potential hazards.
Biomarkers with proposed utility for in vivo identification of potential respiratory sensitizers
following pulmonary exposure include IgE and Th2 cytokines (169, 196). These markers have not been
employed for direct evaluation of respiratory sensitization potential by metal nanomaterials; however,
numerous studies have reported increased IgE levels following in vivo pulmonary exposure to TiO2NP,
PtNP, FeNP, AgNP, and ZnONP (782, 791, 793, 810, 811). Many of the same nanomaterials have also
been associated with increased Th2 cytokine levels (IL-4, IL-5, and IL-13) in the lungs and blood following
pulmonary exposure (780, 812, 813). Although these findings are suggestive of the potential for metal
nanomaterials to induce asthma, since the specificity of IgE molecules was not determined in any studies,
the capacity for respiratory sensitization remains speculative.
In vitro co-culture models have also been proposed to be effective tools for the evaluation of
respiratory sensitization potential. Similar models have also been suggested to have utility in risk
assessment efforts involving nanomaterials. In 2015, a 3D alveolo-capillary barrier model utilizing the
NCI-H441 (epithelial) and ISO-HAS-1 (endothelial) cell lines was developed and tested with several
different sensitizing compounds. Following exposure to subtoxic concentrations, all respiratory
sensitizers were shown to induce a unique pattern of cytokine release in the basolateral compartment
(209). Although the same model has not been employed to test the potential for any metal nanomaterials
to induce sensitization of the respiratory tract, similar models have been used to test general toxic
potential and reported similar responses. A model utilizing the same epithelial cell line and a different
endothelial line supplemented with THP-1 cells reported activation of endothelial cells following exposure
to ZnONP. Basolateral release of IL-8 and IL-6 was reported, mirroring similar effects as other known
respiratory sensitizers in similar models (814).
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Many steps of the AOP associated with dermal sensitization are likely to be conserved with
respect to respiratory sensitization. Likewise, analysis of metal nanomaterial effects on these individual
steps represents another potential mechanism of predicting their capacity to cause asthma.
Similar to dermal sensitization, the induction of respiratory sensitization is ultimately dependent
on the bioaccessibility and bioavailability of antigen. The respiratory tract presents a portal of entry known
to be increasingly susceptible to absorbing materials of small sizes (755). Likewise, this step of respiratory
sensitization, a frequent limitation of the immunogenic potential of larger-sized metal particles, may be
readily overcome by metal nanomaterials and their unique physico-chemical properties.
Sensitization via the respiratory tract also requires antigen interactions with APC. The respiratory
tract is equipped with an expansive repertoire of defense mechanisms to prevent such interactions;
however, many studies have demonstrated that metal nanomaterials with specific properties exhibit an
increased capacity to evade many of these mechanisms, subsequently increasing their potential for
interception by pulmonary DC or other APC.
In the upper respiratory tract, a layer of mucus lining the airway walls functions to trap inhaled
particulate antigens and facilitate their translocation out of the trachea via the mucociliary escalator (815).
Evasion of the ~5 µm thick mucus layer has been associated with nanomaterial physico-chemical
properties including size, surface modification, and surface charge (23, 762, 816, 817). Generally,
hydrophilic, neutrally-charged nanomaterials with smaller diameters have been shown to penetrate
mucus to a greater degree than counterparts with opposing properties (818). It has been shown in vivo
that AuNP penetration of the mucus layer and subsequent adherence to the respiratory epithelium
resulted in delayed clearance from the respiratory tract, an effect capable of increasing the potential for
subsequent particle interactions with APC (819).
Compared to insoluble metal nanomaterials, delayed clearance and extended retention within the
respiratory tract are not likely to impact the biological fate of soluble metal nanomaterials to the same
degree. Metal particles with high dissolution potential in the biochemical environment of the airway lumen
are likely to dissociate into ionic constituents before the intact material is able to be neutralized by the
normal clearance mechanisms implicated in the management of insoluble particulate materials (820).
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The ensuing immunological effects triggered by the release of large quantities of metal ions have been
associated with increased potential for sensitization by some metals. The propensity for allergic
sensitization following pulmonary exposure to beryllium, palladium, nickel, and platinum has been
correlated to the physical form and corresponding dissolution behavior of the inhaled material (503, 821,
822). Some of the underlying mechanisms responsible for this association include cytotoxic ion-induced
release of alarmins and Th2 cytokines by epithelial cells, increased haptenic metal ion concentration for
conjugation with carrier proteins, and intracellular processing-independent antigenic determinant
formation, all of which are preferentially associated with soluble forms of the metals (823, 824).
Collectively, this knowledge suggests that soluble metal nanomaterials or nanomaterials possessing
physico-chemical properties correlated to an enhanced propensity for ion release may constitute an
increased risk for sensitization of the airways.
Metal nanomaterials that deposit in the upper airways may exhibit enhanced sensitizing potential
resulting from physico-chemical property-mediated evasion of clearance mechanisms (insoluble
materials) and rapid dissolution and release of haptenic metal ions (soluble materials). Comparatively,
inhaled nanomaterials that reach the lower airways may also trigger the generation of adaptive immune
responses, although different immunological mechanisms may be implicated in this compartment of the
respiratory tract.
Selective deposition of sensitizing metal particles within the alveolar region of the lungs has been
demonstrated in several studies to correlate with increased potential for allergic sensitization. Kent et al.
(2001) showed that the propensity for inhaled airborne beryllium particles to induce sensitization was
strongly correlated to particle number, surface area, and mass concentration of the particle dose
measuring < 3.5 µm, an association that was concluded to be reflective of the metal alveolar-deposition
dose concentration (825). It has been suggested that beryllium particles are more likely to induce
sensitization following deposition in the lower airways, as opposed to the upper airways, because the
alveolar region constitutes a greater potential for systemic absorption of the metal and subsequent
translocation to lymphoid tissues (826).
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In the lower airways, a similar mechanism of antigen neutralization associated with pulmonary
mucus of the upper airways is facilitated by pulmonary surfactant (24). In addition to optimizing the
mechanics of respiration, surfactant contains proteins capable of binding aeroallergens, accelerating their
clearance, and preventing their uptake by APC, thereby inhibiting antigen-specific responses (827-830).
Two of these proteins, SP-A and SP-D, have been shown to bind to various metal nanomaterials leading
to accelerated clearance by phagocytic mechanisms (830). Accordingly, nanomaterials with properties
that deter binding to surfactant proteins, such as surface charge, may exhibit increased potential for
evasion of clearance by this mechanism, increasing potential for interception by pulmonary APC (831).
Many of the physiological defenses and clearance mechanisms responsible for preventing
antigen/APC interactions in the upper airways are not present in the alveolar region of the lungs.
Clearance of deposited material in the lower airways largely involves uptake and sequestration by
pulmonary macrophages, following which the material undergoes intracellular chemical degradation or
physical translocation out of the lungs, preventing interception by DC (17). Nanomaterials in the lower
airways can evade this clearance process by various mechanisms involving different physico-chemical
properties, which may confer increased allergenic potential.
First, since macrophages have been shown to selectively phagocytose nanomaterials according
to size, charge, and surface modification, specific physico-chemical properties may contribute to metal
nanomaterial persistence in the lower airways (832). Their clearance may also be compromised as a
result of selective cytotoxic effects on pulmonary macrophages, resulting in fewer numbers of viable
macrophages capable of neutralizing the nanoparticles. Pulmonary macrophage cytotoxicity has been
associated with physico-chemical properties including morphology, surface charge, and rate of
dissolution (763, 775, 833). Metal nanomaterial-induced alterations in phagocytic activity of pulmonary
macrophages, as demonstrated by TiO2NP, ZnONP, and AlNP, may also contribute to evasion of
clearance mechanisms (834-836). In addition to compromising the cell-mediated clearance capacity of
the respiratory tract a cellular level, nanomaterials are also associated with an increased potential to
exceed the maximum clearance capacity of the collective pulmonary phagocytic system. Volumetric
loading of alveolar macrophages following inhalation of large doses of nanomaterials decreases the

61

likelihood for their clearance from the lungs. The extended biopersistence of nanomaterials in the airways
increases the potential for interception by DC, and often results in inflammatory responses that further
promote immune effects (837, 838).
Metal nanomaterial-induced pulmonary macrophage cytotoxicity can also promote sensitization
by additional mechanisms. Since alveolar macrophages are known to antagonize Th2 responses in the
lung and downregulate APC functions, cytotoxic effects may disrupt the maintenance of an existing
immunologically tolerant state (839). Moreover, the depletion of this cell population leads to significant
increases in recruitment of DC and DC precursors to the lungs (840, 841). Numerous metal nanomaterials
are also known to trigger the release of alarmins including IL-1β and IL-1α by alveolar macrophages,
which can activate DC and facilitate sensitization (765, 772, 775, 788, 842, 843).
Some metal nanomaterials have been shown to enhance antigen-presenting behaviors of
pulmonary macrophages, an effect which could also promote sensitization by generating an additional
population of cells capable of stimulating adaptive immune cells. FeNP and TiO2NP have been shown to
increase expression levels of several activation markers by pulmonary macrophages that indicate
enhanced antigen presenting capacity (773, 844). Several metal nanomaterials have also been shown
to alter macrophage chemotactic ability, which may further impact their potential to act as APC in the
lungs (845).
Similar to their roles in the development of skin allergy, epithelial cells of the respiratory tract are
integral contributors in the development of asthma, and their disruption by inhaled materials can have
profound influence on the early events of sensitization (846). A major function of airway epithelial cells is
to serve as a physical barrier between inhaled agents that deposit in the airway lumen and DC residing
in the epithelium (847). The importance of barrier integrity in preventing the development of asthma is
emphasized by the characteristic barrier-disrupting proteolytic activity shared by many aeroallergens with
high rates of sensitivity in the population (848, 849). The frequent observation that metal nanomaterials
are capable of inducing cytotoxicity to pulmonary epithelial cells suggests their potential to increase
permeability and passage of antigens from the airway lumen to compartments associated with DC.
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Airway epithelial cell cytotoxicity induced by some metal nanomaterials has also been associated
with the release of alarmins that have potential to promote DC activation and sensitization. Similar to
keratinocytes in the skin, the mechanism of cell death can critically influence the nature of the resultant
immune response. For example, the necrotic cell death following pulmonary exposure to beryllium results
in release of extracellular DNA, which is recognized as a DAMP by TLR-9, and promotes the unique Th1mediated effects associated with chronic beryllium disease (823). NiNP, AgNP, and CoNP have been
shown to induce similar necrotic cell death of bronchial and alveolar epithelial cells (171, 841, 850-852).
Contrarily, ZnONP, CuONP, TiO2NP, and CrNP have all been associated with induction of apoptotic cell
death in pulmonary epithelial cells (853-857). This effect may further influence the development of
respiratory allergy since uptake of apoptotic cells is a function exclusive to CD103+ DC, a subset of DC
also associated with cross-presentation and the subsequent induction of CD8+ effector responses (858).
Metal nanomaterials have also been shown to induce effects on airway epithelial cells that mirror
one of the most well-established mechanisms implicated in increasing susceptibility to asthma
development. RSV, cigarette smoke, and other environmental exposures are known to induce
upregulation of TLR-4 expression by airway epithelial cells (859, 860). As a result, the cells are more
responsive to immunologic stimuli, triggering the production of Th2 cytokines required to initiate DC
maturation under conditions that would not normally result in stimulation of innate immune responses.
TLR-4 and TLR-2 signaling has been shown to be augmented in airway epithelial cells in response to
ZnONP, TiO2NP, and AuNP as a function of size (861-865). Based on this observation, these metal
nanomaterials may promote sensitization and the development of asthma by mechanisms involving
priming of airway epithelial cells.
One of the Th2 cytokines released in response to airway epithelial cell TLR-4 activation is GMCSF. Although GM-CSF has numerous roles in initiating and potentiating asthmatic processes, it is also
associated with the induction of an alveolar macrophage phenotype associated with enhanced antigen
presenting capacity (866). Likewise, metal nanomaterials capable of enhancing GM-CSF production in
the lungs, dependently or independently of TLR-4 signaling modulation, may promote sensitization by
increasing the number of potential APC in the airways. TiO2NP, QD, and ZnONP have been shown to

63

increase surface expression of CD11c, CD80, CD86, and MHC II by pulmonary macrophages, as well
as enhance their antigen presenting capacity in vitro (773, 867-869).
Overall, there have yet to be any studies conducted that directly examine the potential for metal
nanomaterials to induce respiratory sensitization; however, many of the biological effects of metal
nanomaterials suggest the potential for the development of asthma following respiratory exposure.
Several physico-chemical properties have been associated with evasion of clearance mechanisms, which
increases the likelihood for interception by APC. Additionally, several Th2 cytokines and alarmins
required in the early events of sensitization have been shown to be released by resident immune cells
and epithelial cells following exposure to some metal nanomaterials.

1.2.2.3. Incorporation of Metal Nanomaterials into Asthma Models
Many metal nanomaterials have been incorporated into asthma models to assess their potential
to augment immunological processes involved in respiratory allergy. Many of these studies report similar
conclusions regarding ‘allergy augmenting potential,’ yet report conflicting roles for physico-chemical
properties in these effects. These divergent findings reflect the extensive potential for variations in allergy
model study design, wherein a lack of consistency in any number of variables may result in discrepancies
in the underlying immunological mechanisms involved in the observed effects. Accordingly, the results
from all studies utilizing metal nanomaterials and asthma models should not be compared collectively.
Studies should be discriminated based on similarities in specific underlying immunological mechanisms
assessed in accordance with the model design, following which, study results can be compared
categorically.
In this context, one of the most important variables of the asthma model study design is
nanomaterial exposure occurrence with respect to the different phases of allergy. Findings from existing
studies have been similarly categorized based on this feature for collective analysis.
Studies that have employed asthma models wherein nanomaterial exposure occurs prior to
sensitization can uniquely evaluate if exposure has the capacity to enhance susceptibility to sensitization.
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Currently, the impact of metal nanomaterial exposure prior to sensitization has only been addressed by
a few studies. In one study, aspiration of ZnONP, TiO2NP, NiONP, CuONP, or SiO2NP occurred one day
before inhalation sensitization to OVA, which was then followed by inhalation challenge and subsequent
assessment of asthmatic severity. Soluble metal nanomaterials (NiONP, ZnONP, and CuONP) were
associated with elevations in OVA-specific IgE, whereas insoluble particles (SiO2NP and TiO2NP) were
not. Subsequent investigations confirmed the importance of metal ion release in the adjuvant effects on
sensitization. The increase in OVA-specific IgE production associated with soluble NiONP was not
conserved in response to insoluble NiO microparticles in the same model (781). However, ZnCl2 also did
not exert the same increase in OVA-specific IgE caused by ZnONP. As a result, it was concluded that
continuous ion release from nanoparticles was required for the induction of the observed effects (870).
Exposure to residual oil fly ash particles prior to allergen sensitization has also been associated with
adjuvant effects attributable to soluble metal constituents (871). Likewise, these properties appear to
influence asthma, specifically with respect to the early phases of allergic disease.
The most common exposure scheme used in existing asthma model studies involves concurrent
exposure to metal nanomaterials during allergen sensitization. This approach has been explored
extensively in order to evaluate the potential adjuvant effects of metal nanomaterials on sensitization,
specifically with respect to the magnitude of the adaptive response generated. This concept has been
explored with respect to both systemic and respiratory sensitization routes. Moreover, the effects of this
exposure scheme have been evaluated independently of allergen challenge, as well as in a challengedependent manner.
Nanomaterial exposure simultaneous to allergen sensitization by intraperitoneal injection has
been shown to enhance antigen-specific antibody production in several studies. Co-administration of
AgNP and ZnONP with antigen during systemic sensitization has been associated with elevated levels
of allergen-specific IgE, as well as increased levels of Th2 cytokines (872, 873). As demonstrated with
SiO2NP, enhanced antibody production has been associated with both increasing dose and decreasing
particle size (874). The impact of the most extensive number of physico-chemical properties with respect
to adjuvant effects on systemic OVA sensitization use polystyrene nanoparticles (PSP). Nygaard et al.
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(2004) used PSP ranging from 58 nm to 11.4 µm to evaluate the influence of particle size, mass, surface
area, and particle number. Similarly, Granum et al. (2000) used six sizes of spherical PSP to administer
doses with constant mass (12.25 mg), size (0.1 µm), particle number (8 x 1010), or surface area (1,300
cm2). Both studies demonstrated that serum OVA-specific IgE levels best correlated with particle number
and surface area (875, 876).
The results from these studies demonstrate that metal nanomaterial exposure can enhance the
magnitude of immune reactivity in response to systemic sensitization. However, the absence of an
elicitation phase in these studies renders the relevance of these findings, specifically on asthmatic
responses, somewhat speculative. Increases in systemic immune markers, such as circulating antigenspecific IgE and serum Th2 cytokine levels, are generally correlated to enhanced asthmatic response
severity. However, the lack of pulmonary-specific immune markers evaluated by these models requires
consideration when interpreting the results in the context of asthmatic conditions (877, 878).
Similar adjuvant activity has been observed following respiratory sensitization and co-exposure
to TiO2NP, SiO2NP, CeO2NP, and ZnONP (811, 879-881). Increases in OVA-specific IgE and Th2
cytokine levels were similarly associated with decreasing size of SiO2NP (882). Moreover, SiO2NP
surface properties were shown to impact sensitization independent of allergen challenge. Intranasal
exposure to three variations of SiO2NP (spherical, mesoporous, and PEGylated) simultaneous to OVA
sensitization exacerbated pathological changes, inflammatory cell influx, and Th2 cytokine responses.
These effects were specific to the unique surface chemistry of each type of SiO2NP, but the most severe
responses were associated with the nanoparticle with the highest surface area (883).
The absence of allergen challenge in these studies helps elucidate the direct effects of metal
nanomaterials on immunological processes involved in sensitization. Metal nanomaterial exposure during
both respiratory and systemic sensitization was shown to enhance the magnitude of antigen-specific IgE
production. However, the direct implications of these effects on asthmatic response elicitation requires
the incorporation of a challenge phase into the asthma model. Studies utilizing this approach have
demonstrated amplification of pulmonary immune reactivity in OVA-challenged mice when systemic
sensitization occurred simultaneous to TiO2NP and ZnONP exposure (868, 884-886).
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Similar adjuvant effects on elicitation response severity have been observed following respiratory
sensitization and simultaneous metal nanomaterial exposure. Simultaneous administration of SiO2NP,
CeO2NP, Co3O4NP, QD, and TiO2NP with allergen during sensitization led to enhanced asthmatic
response severity, as measured by antigen-specific antibody levels, inflammatory cell influx, and Th2
cytokine levels after challenge (783, 887-890). Studies using similar sensitization procedures and
endpoints have also implicated TiO2NP crystal structure in adjuvant effects on sensitization (879, 887).
However, these observations should be interpreted cautiously as these responses may reflect residual
local effects of prior metal nanomaterial lung exposure.
Metal nanomaterial exposure has also been incorporated into the challenge phase of asthma
models to evaluate the potential modulation of asthmatic elicitation responses in established asthmatic
conditions. Although some metals, including CuONP, have been exclusively shown to induce significant
aggravating effects on elicitation responses, others, including AuNP, appear to exert protective effects
against asthmatic responses (798, 891-893). Contrarily, other metal nanomaterials, including TiO2NP,
have been associated with divergent effects on asthmatic elicitation, effects which appear increasingly
susceptible to variation during this phase of asthma. These responses have been differentially observed
depending on the dose, duration of exposure, and endpoints of assessment (894-897).
Similarly, following OVA sensitization via intraperitoneal injection, AgNP exposure during allergen
challenge has been reported to induce various aggravating and attenuating effects on allergic
inflammation. Inhalation exposure to 1.5 and 6 nm AgNP was shown in multiple studies to suppress
inflammatory cell influx, airway hyperreactivity (AHR), mucus hypersecretion, and other measures of
asthmatic response (898-900). Contrarily, in another study with very similar exposure conditions, 33 nm
AgNP caused increased airway response, inflammatory cell influx, and OVA-IgE levels over control
animals (901, 902). Discrepancies in the findings between these studies may be attributable to the AgNP
size difference, as well as potential variations in particle coating, which have been associated with
differential effects on asthmatic responses (903). Additionally, the first two studies utilized the Th1dominant C57BL/6 mouse strain, whereas the second study used the Th2-biased BALB/c strain (904).
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Strain-specific immune responses following respiratory exposure to metal nanomaterials during allergen
challenge have been demonstrated in other studies, as well (905).
Studies using SiNP, CuONP, and zirconium oxide (ZrO)NP with variations in surface properties
demonstrate that, when administered during allergen challenge, surface properties of nanomaterials can
differentially aggravate allergic inflammation (789, 812, 906, 907). It has been suggested that particles
with higher oxidant potential amplify asthmatic inflammation to a greater degree, which would implicate
physico-chemical properties such as surface modification in these effects (908).
Overall, studies that have employed asthma models to assess the modulatory effects of metal
nanomaterial exposure on various phases of allergic disease have generated seemingly inconsistent
findings. However, when studies are discriminated based on specific study design features, results that
implicate similar underlying immunological mechanisms can be discerned. Accordingly, respiratory
exposure to metal nanomaterials prior to pulmonary allergen exposure appears to increase susceptibility
to allergic sensitization. Exposure to metal nanomaterials simultaneous to systemic sensitization has
been consistently shown to result in enhanced humoral responses, the magnitude of which is dependent
on properties including surface area. Similar effects have been repeated observed following respiratory
sensitization and metal nanomaterial exposure. By comparison, the elicitation phase of asthma appears
to be the phase most susceptible to variations in responses caused by metal nanomaterial exposure.
While surface properties have been consistently implicated in metal nanomaterial-induced modulation of
response severity following allergic challenge, additional studies are required to accurately delineate the
relationship between these effects and various physico-chemical properties (907).

1.2.2.4. Potential Mechanisms of Asthma Augmentation by Metal Nanomaterials
Respiratory exposure to metal nanomaterials may increase susceptibility to sensitization by
aeroallergens as a result of similar mechanisms previously proposed to contribute to their respiratory
sensitization potential. Amplification of pulmonary oxidative stress, release of alarmins by airway
epithelial cells and resident immune cells, and increased antigen presenting activity of immune cell
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populations may all contribute to the development of asthma following metal nanomaterial exposure.
Disruption of the Th1/Th2 balance in the lung is another effect commonly reported following respiratory
exposure to metal nanomaterials, that may increase susceptibility to allergic sensitization. Polarization of
the pulmonary immune state towards a Th2-dominant state, as observed following exposure to ZnONP
and PtNP, suggests the potential for these metal nanomaterials to induce conditions in the lung conducive
with sensitization (780, 868).
In the context of established, pre-existing asthmatic conditions, several findings from existing in
vivo studies suggest mechanisms by which metal nanomaterial exposure may exacerbate allergic
pathophysiology. One such effect involves modulation of mast cell activity. As one of the major effector
cells responsible for asthmatic symptoms, an increase in mast cell presence may facilitate enhanced
symptom severity. Accordingly, several metal nanomaterials including SiNP, CeO2NP, and FeNP have
been shown to recruit additional populations of mast cells to the respiratory tract following exposure (880,
909, 910). Numerous metal nanomaterials have also been associated with inducing alterations in mast
cell degranulation both in the presence of antigen, and independently of antigen (546, 784, 911-916).
Moreover, several metal nanomaterials have been shown to alter the contents of mast cell granules and
their kinetics of release. Mast cell granules contain numerous mediators responsible for many of the
pathophysiological mechanisms involved in allergic responses, including vascular permeability,
bronchoconstriction, and inflammatory cell recruitment, suggesting that modulation of granule contents
by nanomaterials can greatly impact the severity of allergic elicitation responses (917, 918). Metal
nanomaterial effects on mast cells will be discussed in the future in vitro section in detail, since mast cells
also play critical roles in ACD.
Extensive evidence also suggests that metal nanomaterial exposure can modulate the
inflammatory phenotype of existing asthmatic conditions. Two major heterogeneous asthma phenotypes
are differentiated based on the presence of neutrophil-(Th1/Th17) or eosinophil-(Th2) dominant
inflammation (919, 920). These different disease phenotypes are associated with enhanced severity of
different clinical symptoms, variations in the course of symptom resolution, and contrasting
responsiveness to corticosteroid treatment (920). Particulate and soluble metals are known to
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differentially impact the nature of existing allergic airway inflammation by skewing this balance (921).
Likewise, dissolution kinetics appear influential in this regard, as CoNP, NiNP, ZnONP, and CuONP and
their corresponding ions have been shown to differentially recruit eosinophils and neutrophils to the lungs
of rats following exposure (787, 793). Several metal nanomaterials have also been shown to skew the
Th1/Th2 status of the pulmonary immune system following respiratory exposure. FeNP, SiO2NP, TiO2NP,
NiONP, AlNP, and CeO2NP have all been associated with modulation of this balance, suggesting their
potential to modulate the phenotype of established asthmatic conditions (922-927).
In existing asthmatic conditions, exposure to metal nanomaterials may result in the exacerbation
of symptoms as a result of particle-induced alterations in normal respiratory physiology and anatomy. For
example, increased mucus production by epithelial cells is a hallmark symptom of the early and late
phase asthmatic response (189). The observation that TiO2NP and CuONP both increased mucin
secretion in human epithelial cells suggests potential to exacerbate asthmatic conditions by contributing
to obstruction of airways (790, 798). Similarly, TiO2NP, AuNP, and AgNP have been shown interfere with
optimal pulmonary surfactant functioning, which can cause AHR and increased resistance to airflow (799,
827, 928-930).
AHR may also be modulated by metal nanomaterials as a result of alteration of airway smooth
muscle (ASM) contractility. ZnONP, CuONP, and TiO2NP have all been shown to alter human ASM
mechanical function in vitro (931). Similarly, CoFe2O4 nanoparticles were shown to potentiate both
histaminergic and cholinergic ASM contractility in vivo, which has the capacity to exacerbate the
symptoms of asthma associated with bronchoconstriction (792). Promotion of neurogenic inflammation
in asthmatic conditions, as demonstrated by TiO2NP, can also exacerbate allergic responses (932).
Metal nanomaterial exposure may also exacerbate established asthmatic conditions by
accelerating the progression of pathological alterations associated with chronic asthmatic conditions.
Repetitive cycles of allergen-induced inflammation and subsequent resolution are responsible for
numerous anatomical alterations collectively referred to as ‘airway remodeling’ (933). Thickening of the
epithelial basement membrane, ASM cell hypertrophy, and increased vascularization of bronchial walls
are examples of the anatomical changes associated with this complication commonly seen in cases of
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chronic asthma (933). Many of these effects have also been reported following pulmonary exposure to
various metal nanomaterials including SiNP (926). Similarly, cellular indicators of accelerated airway
remodeling have also been observed following exposure to various metal nanomaterials. For example,
fibroblast accumulation and increased extracellular matrix deposition has been observed in response to
NiNP, SiO2NP, and CeO2NP exposure (188, 795, 926, 934, 935).

1.2.2.5. Knowledge Gaps in Metal Nanomaterial Effects on Asthma
Despite the known capacity for many metals to induce IgE-mediated asthma following inhalation,
it remains unclear if nanoparticulate forms of these metals are also able to induce metal-specific asthma.
However, studies suggest that metal nanomaterials may present an increased threat compared to larger
metal particles in the context of respiratory sensitization. Their increased deposition efficiency in the
respiratory tract, capacity to evade defense mechanisms, and innate immune stimulatory activity may
facilitate allergic sensitization; however, these claims remain largely speculative, and future studies
should directly investigate this potential effect.
In a similar regard, it has been proposed that metal nanomaterials may have the capacity to act
as both soluble/LMW or particulate/HMW antigens in the respiratory tract. Despite this, information on
metal antigen formation with respect to asthma is currently non-existent. However, studies have
demonstrated the generation of antibodies that selectively recognize ZnONP, CoONP, AlNP, AuNP, QD,
TiO2NP, and several carbon-based nanomaterials in a protein conjugate-specific context (936-941).
Moreover, antibodies exhibiting specificity for various crystalline facets of gallium semiconductor crystals
has also been demonstrated (487). Given the diverse crystal structures associated with metal
nanomaterials such as TiO2NP and SiO2NP, this observation suggests that despite similar elemental
composition, the unique chemistries of metal nanomaterials may present expansive numbers of potential
allergenic epitopes and a subsequently diverse repertoire of antigen-specific antibodies (487). However,
this concern has yet to be confirmed by any existing investigations.
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Numerous studies have investigated the potential effects of metal nanomaterials on asthmatic
processes by incorporating exposures into allergy models. Subsequent findings have demonstrated that
many metal nanomaterials can augment allergic processes involved in asthma. However, expansive
variations in model designs implicate study conclusions that often reflect unrelated immunological
mechanisms. Allergic conditions involve an endless number of systemic and local immunological
processes subject to disruption by immunotoxicants, many of which are exclusive to the specific phases
of allergy. These different immunological mechanisms are likely to be differentially impacted by various
nanomaterial physico-chemical properties. In order to accurately correlate physico-chemical properties
with the allergy-augmenting activity of metal nanomaterials, these relationships need to be established
in a mechanism-dependent context. Accordingly, future studies should take into consideration the
timeline of exposures in the allergy model, exposure techniques, routes of exposure, and dose
parameters to accurately elucidate the immunomodulatory effects of metal nanomaterials.
Several interesting aspects of pulmonary immunity have not yet been widely-addressed with
respect to metal nanomaterials, and may have relevance to current observations regarding their effects
on asthma. For example, the numerous metal nanomaterials being used for their antimicrobial activities
have been shown to alter the microbiome of the skin, lungs, and GI tract (903, 942). The microbiome is
known to significantly impact numerous aspects of allergic disorders, but the implications of such effects,
specifically with respect to allergy, remain unknown (943). Additionally, the capacity for metal
nanomaterials to disrupt or prevent the development of immunological tolerance has not been explored
in any existing studies. This potential effect is likely relevant to both phases of asthma, but also likely to
be implicated in other forms of allergic disease, as well.

1.2.3. Metal Nanomaterials as Vaccine Adjuvants
Numerous metal nanomaterials have been shown to augment allergic processes following their
incorporation into allergy models. More specifically, many of these nanomaterials have been shown to
enhance the magnitude of antigen-specific adaptive immune responses generated in response to
sensitization. Many of the underlying mechanisms responsible for these observations remain unclear.
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Vaccine studies represent a related area of active investigation that may provide some mechanistic
insight with relevance to the adjuvant activity of metal nanomaterials observed in allergy models. Given
the historical use of aluminum-based adjuvants, the emergence of metal nanomaterials quickly generated
scientific interest regarding their potential utility as novel vaccine adjuvants. As a result, numerous studies
have investigated the potential use of metal nanomaterials as vaccine platforms and demonstrated
findings that may help explain findings from allergy studies. Select studies investigating metal
nanomaterial adjuvant effects on the development of antigen-specific immune responses are
summarized in table 1.19 (61, 517, 527, 533, 734-737, 739-741, 800, 872-874, 885, 944-971).
The immune responses associated with allergic sensitization and vaccine administration involve
nearly identical mechanisms. Innate immune stimulation is required to recruit adaptive immune cell
involvement, following which, antigen-specific immunological memory is generated (972). Generally
speaking, the discriminating feature of these two adaptive responses is the inherent pathogenicity of the
antigen and corresponding intentionality of response induction. Allergic sensitization involves the
unintentional generation of immunological memory specific for antigenic entities that exhibit an inherent
lack of pathogenic potential. Contrarily, vaccines are used to induce an intentional immune response to
an agent exhibiting inherent pathogenic potential in order to protect the host upon future encounters.
Given these similarities, metal nanomaterials that have been shown to promote sensitization to allergens
may involve mechanisms similar to those elucidated by studies employing metal nanomaterials as
vaccine adjuvants.
The capacity for vaccine adjuvants to enhance the development of antigen-specific immunity can
be involve numerous mechanisms. Collectively, these mechanisms can be classified as effects that are
immunostimulatory and or vehicle/delivery-based. The efficacy of some adjuvants results from a
combination of these mechanisms. Adjuvants that exert immunostimulatory effects often bear structural
resemblance to PAMP, illustrating similar mechanisms of innate immune activation that promote antigenspecific adaptive responses. Since these adjuvants alter the systemic immune environment, their effects
are not necessarily dependent on physical association with the antigen (973). More frequently, adjuvants
employ mechanisms of immunopotentiation based on their capacity to modulate antigen delivery by
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serving as a carrier or vehicle for the antigen. The strength and nature of the subsequent adaptive
immune response is heavily dependent on the dose and duration of antigen presented to lymphocytes,
so many adjuvants enhance adaptive immune responses by augmenting this process (974). Accordingly,
physical association with antigen is required for these adjuvants. Based on these two different
mechanisms of immunopotentiation, studies using metal nanomaterials as vaccine adjuvants have
correlated some physico-chemical properties with specific mechanisms of adjuvant activity.
Agents with adjuvant activity resulting from vehicle/delivery-based effects often facilitate the
formation of an antigen depot at the site of deposition. This is a common mechanism associated with
many subcutaneously-administered adjuvants that involves extending the duration of local antigen
retention. Delayed diffusion of antigen from the depot results in prolonged stimulation of lymphocytes,
resulting in higher antibody titers.
Several nano-based vaccine adjuvants have been associated with adjuvant effects resulting from
mechanisms involving depot formation (975). For example, nanoparticulate formulations of aluminum
hydroxide have been shown to promote delayed diffusion of antigen by trapping antigen molecules in
void spaces of agglomerated particles. Similarly, a cationic nanoparticulate adjuvant formulation has also
showed promise as a result of enhancing depot formation via electrostatic interaction-mediated antigen
retention (976). Subsequent inflammatory cell recruitment and cytokine production can further enhance
the effects of nanomaterial adjuvants implicated in these effects.
Adjuvants administered with antigen via intradermal, intramuscular, and intraperitoneal
administration routes also involve alterations in antigen trafficking to the lymph nodes, although depot
formation is not conducive with this route of administration. In this context, size is known to be a critical
property associated with nanoparticle-mediated translocation of antigen to lymphoid tissue. Smaller
particles can directly diffuse to the nodes via lymphatics, whereas the 200 nm pores in lymphatic walls
render the transport of larger particles by cell-mediated active transport (977). This knowledge can be
exploited to modulate the route of antigen delivery associated with vaccines. Moreover, similar modes of
lymphatic transport are further subject to size-dependent drainage patterns, as demonstrated with AuNP.
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When conjugated with OVA antigen, 22, and 33 nm AuNP were delivered more efficiently to the draining
nodes than 10 nm AuNP, illustrating the potential impact of minor alterations in particle size (517).
When adsorbed to nanoparticle surfaces, differential trafficking routes associated with particle
size can also result in antigen deposition within selective compartments of the lymph nodes, which can
also impact the development of immunological memory. Following injection, smaller nanomaterials and
antigens that freely diffuse to the lymph nodes have been shown to accumulate at the boundary of the
lymph node follicles and subscapular sinus where B-cells encounter antigen. Deposition in this area
facilitates their unique association with CD8a+ lymph node-resident DC, which notably are capable of
priming CD8+ T-cells (978). Contrarily, larger particles that enter lymph nodes via cell-mediated transport
enter the lymph nodes in the T-cell zone (977). Likewise, nanoparticle properties can be modulated to
alter vehicle-mediated transport of antigens and foster antigen interactions with specific populations of
cells within the lymph nodes.
Adsorption of antigen to nanoparticle carriers can also impact another parameter of the delivery
kinetics- retention time in the lymph nodes. An inverse relationship between nanoparticle size and
duration of lymph node retention has been established (979). Strong humoral responses are dependent
on the persistence of antigen presence within the lymph nodes, indicating a role for size in the nature of
the immune responses following co-administration of nanomaterials and antigen (977).
Physical associations between nanomaterials and antigen can also modulate adaptive responses
by concentration of antigen and display of epitopes in a manner that influences interactions with
lymphocytes. The generation of antigen-neutralizing antibodies is dependent on efficient antigen
recognition and cross-linking of B-cell receptors by antigenic epitopes. Accordingly, the spatial
organization of antigens adsorbed to the nanomaterial surface can be modulated to facilitate these
interactions. AuNP have been employed to demonstrate this effect, wherein spatial arrangement of
various bacterial and viral antigens on the nanoparticle surface was optimized to generate higher
antibody titers (980, 981).
In addition to these demonstrations of nanomaterial-induced adjuvant effects involving
carrier/delivery-based mechanisms, several studies have also demonstrated immunostimulatory effects

75

of metal nanomaterial adjuvants capable of potentiating immune responses. For example, Niikura et al.
(2009) utilized Au nanorods, nanospheres, and nanocubes as a vaccine platform for West Nile Virus
antigen. When the particles were adsorbed with normalized doses of viral antigen, immunization of mice
resulted in variations in levels of antigen-specific antibodies. Additional in vitro studies were conducted,
and it was determined that variations in resultant responses were attributable to morphology-dependent
inflammasome activation. Au nanorods were the only material that activated IL-1β and IL-18 release by
DC, which corresponded to the treatment associated with the highest level of antibody production in vivo
(61). In addition to inflammasome activation, the immunostimulatory effects of nanomaterial adjuvants
have also been suggested to include surface adsorption of antigen leading to enhanced uptake by APC,
modulation of antigen processing routes, induction of cytokine release, and polarization of lymphocyte
responses.
Nanomaterials have also been suggested to have potential utility in the development of mucosal
vaccines. Mucosally-administered vaccines represent an ideal formulation for many respiratory
pathogens, since they should induce both systemic and local immunity in mucosa-associated lymphoid
tissue (MALT). However, the efficacy of intranasal vaccines has been historically limited as a result of
several unique characteristics of the respiratory tract. The mucosal immune system often effectively
generates a state of immunological tolerance, and the development of antigen-specific responses is often
impeded by numerous defense mechanisms responsible for physical translocation and biochemical
degradation of antigen. Nanomaterials have been shown to have significant potential to overcome many
of these barriers, and may represent an effective vaccine platform and adjuvant for successful mucosal
immunization.
Enhanced potential for penetration of the respiratory mucus layer has been shown to be
dependent on the surface charge of nanomaterials, which can facilitate an increased potential for
localization with APC and subsequent antigen delivery. Additionally, the capacity for nanomaterials to
induce innate immune stimulation as a constituent of mucosal vaccines has been shown to promote the
generation of immunological memory (982). Similar effects were proposed to be responsible for the
findings reported in one study, where the surface charge of nanomaterial adjuvants was critically
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influential in the nature of immune responses generated following pulmonary immunization. Fromen et
al. (2016) demonstrated that conjugation of OVA to nanoparticles that varied only with respect to surface
charge differentially stimulated antibody production in vivo. Cationic nanoparticles were associated with
robust germinal center B-cell expansion and increased activation of CD4+ T-cells, which they attributed
to charge-selective activation of DC (983).
Another specific mechanism associated with the increased efficacy of nanomaterial-based
mucosal vaccination platforms involves the preservation of epitope structure for APC sampling. Proteasemediated degradation of antigen is a challenge associated with intranasal immunization that is
traditionally overcome by administering significantly larger doses of antigen than those used for systemic
immunization. Nanoparticle-based vaccines have been proposed as a mechanism to overcome this
barrier since surface adsorption of antigen can protect against its degradation and preserve epitope
structures (984). This mechanism has been suggested to be responsible for observations reported by
several in vivo studies utilizing metal nanomaterials for intranasal immunization. Accordingly, when
simultaneously administered intranasally, the size of nanoparticles has been correlated to the magnitude
of the subsequent antigen-specific immune response. Stano et al. (2012) demonstrated that 30 nm
particles were more effective inducers of systemic and mucosal humoral responses to OVA than 200 nm
particles. They attributed this observation to the capacity for smaller particles with larger surface areas
to bind more antigen, preserving the structural integrity of antigenic epitopes, and delivery of increased
concentrations of antigen to the lymph nodes (985).
These observations regarding the mechanisms responsible for metal nanomaterial adjuvant
activity during vaccine-induced immunization appear consistent with many of the adjuvant effects
reported by allergy models. In allergy models where sensitization is achieved by subcutaneous injection,
the enhanced immune responses observed following simultaneous administration of metal nanomaterials
may reflect effective depot formation by the nanomaterials. For example, Hirai et al. (2012) demonstrated
that the intradermal co-administration of amorphous SiNP and HDM led to enhanced HDM humoral
immunity in a size-dependent manner. Smaller particles were associated with enhanced adjuvant effects,
which is conducive with a potential mechanism involving depot formation where smaller size/greater
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surface area increases surface loading capacity, resulting in increased retention of antigen at the site of
injection (550).
Antigen adsorption to nanomaterial surfaces and facilitation of delivery to APC may also explain
the observation that particle size was associated with enhanced immune responses following intranasal
sensitization. Yoshida et al. (2011) showed that levels of OVA-specific IgE were inversely related to SiNP
size (30, 70, 300, or 1000 nm) when exposure occurred simultaneously with sensitization. The increase
in surface area associated with the smaller particles would have been associated with higher antigen
loading, promoting larger degrees of antigen interception by APC (882). This conclusion is supported by
another study that demonstrated the surface properties of SiNP were also responsible for variations in
adjuvant effects following mucosal sensitization (883).
Surface adsorption of antigen also appears responsible for the differential adjuvant activities of
two different nanomaterials, as reported by de Haar et al. (2008) In their asthma model, mucosal
sensitization to OVA was associated with different effects as a result of its co-administration with carbon
black (CB) or TiO2NP. The authors proposed that different binding affinities for OVA by CB and TiO2NP
surfaces during sensitization may have contributed to the different effects on asthmatic responses. CBbound OVA 100%, whereas TiO2NP only bound 10% of OVA. Subsequent differences in local and
systemic presence of OVA were cited as potential contributing factors in the different adjuvant effects on
asthmatic responses (879).
In one of the few studies of its kind, Peng et al. (2018) examined the potential for a SiNP-based
vaccine to mitigate allergic inflammation in the context of immunotherapy. In their study, mice were
sensitized to HDM by intraperitoneal injection on days 0, 7, and 14. On days 28, 33, and 38, mice were
subcutaneously administered mesoporous SiNP (100 nm) loaded with HDM antigen. 2 weeks later, mice
were challenged with HDM by inhalation and mice that had been administered SiNP-HDM exhibited
lowered levels of specific IgE, lung inflammatory cells, and BALF Th2 cytokines (986). The induction of
immunological tolerance was associated with low dose, extended release of HDM antigen from SiNP
pores. Allergic tolerance has rarely been investigated with respect to metal nanomaterials, but this study
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demonstrates that metal nanomaterials with properties including porous surface structures may have
utility in novel immunotherapy approaches.
Overall, existing studies that have investigated the potential adjuvant effects of metal
nanomaterials in the context of vaccine-mediated immunization suggest similar mechanisms of
involvement during allergic sensitization. The two general mechanisms associated with adjuvant activity
constitute different requirements for physical associations between antigen and nanoparticles.
Nanomaterial-induced immunostimulatory effects do not require co-administration with antigen, as
stimulation of innate immune responses can occur systemically or locally to potentiate sensitization.
Surface charge has been consistently implicated in effects resulting from this mechanism. By
comparison, adjuvant effects resulting from nanoparticle-mediated carrier/delivery effects require
interactions between antigen and nanomaterials. Subsequent effects can involve altered kinetics of
antigen delivery to the lymph nodes, localization in specific compartments on the nodes, and modulation
of antigen interactions with lymphocytes. In accordance with these mechanisms, enhanced responses
have been associated with decreases in particle size, increases in surface area, and surface
characteristics with implications for surface loading capacity.

1.2.4. Metal Nanomaterials and Immune Effects In Vitro
Allergic sensitization, progression, and elicitation involve numerous complex molecular and
cellular processes that manifest on the level of tissues and entire organisms. As a result, allergic disease
is often studied in vivo, where animal models can account for the expansive number of cell types and
tissues involved in these processes. Moreover, animal models can account for other variables involved
in allergic disease, including exposure route-dependent effects, host metabolism, and clinical
manifestations. However, these expansive sources of input associated with in vivo models often prevent
the identification or analysis of specific molecular mechanisms involved in allergy. As a result, in vitro
studies have become instrumental in helping to elucidate some of the underlying molecular mechanisms
responsible for in vivo observations regarding allergy. In this section, selected studies examining the role
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of metal nanomaterial physicochemical properties on specific immune cells and corresponding cellular
processes involved in allergy are detailed.

1.2.4.1. Molecular Alterations in Immunogenicity
The immunotoxic effects of an agent are fundamentally dependent on the molecular and
biochemical properties that mediate its interactions with components of the immune system. Many of
these properties are subject to modulation prior to interactions with immune cells. For example, many
potent dermal sensitizers are considered prehaptens, which are not capable of inducing sensitization
until they are transformed by autoxidation or photoxidation into their haptenic forms. Similarly, prohaptens
require bioactivation in order to induce sensitization (90). The chemical transformation of these chemicals
prior to encounters with immune cells dictate their immunogenic potential. The immunogenic activity of
metal nanomaterials is also subject to alteration following interactions with various chemicals and
macromolecules, and in vitro studies have been utilized to study such effects.
With regards to metal nanomaterials and their immunotoxic potential, one of the major sources of
alterations in the biochemical and molecular properties that render them immunogenic is the formation
of a biocorona. Following entry into biological media, macromolecules present in the media are attracted
and adsorb to the surface of the nanomaterial within minutes, forming a layer that defines the bioidentity
of the nanomaterial. Qualitative and quantitative properties of the biocorona are influenced by
nanomaterial properties including size, charge, morphology, surface modification, and hydrophilicity,
among other properties (987-993). Moreover, biocorona formation is also dependent on environmental
factors such as pH and the quantitative and qualitative profile of proteins can vary greatly in response to
host disease states, such as asthma (994).
Metal nanomaterial interactions with macromolecules have been extensively studied using in vitro
approaches. These interactions can impact the subsequent immunological response following exposure
to metal nanomaterials by numerous mechanisms. However, these effects can be generally categorized
based on whether altered immunogenicity emerges as a result of interactions leading to 1) altered
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immunogenicity of the nanomaterial, 2) formation of complexes with novel immunological activity, or 3)
alterations in immunogenicity of the interacting macromolecule. Studies demonstrating examples of these
effects following metal nanomaterial biocorona formation and corresponding implications for allergic
disease are summarized in figure 1.5.
The first mechanism associated with alterations in immunogenic potential following nanomaterial
interactions with biomolecules involves modulation of metal nanomaterial immune activity. An example
of such an effect is the non-specific adsorption of biomolecules to nanomaterial surfaces, which results
in alterations in physico-chemical properties implicated in the nanomaterial’s biologic activity. For
example, biocorona formation on 25 nm FeNP was shown to cause a five-fold increase in hydrodynamic
diameter of the nanomaterials (995). Given the importance of particle size on cellular processes including
internalization, this effect has the capacity to alter the potential for the material to induce an immunological
response on the cellular level. Surface-adsorbed proteins have also been shown to modulate the degree
of AuNP agglomeration, which can result in similar alterations in interactions with immune cells (996).
The propensity for ion release from metal alloy nanoparticles was also shown to be altered depending
on the amino acids present in solution (997). Given the allergenic potential associated with haptenic metal
ions, this effect can greatly impact the allergenic potential of metal nanomaterials. In another study, the
capacity for ZnONP to induce ROS production was mitigated as a result of protein corona formation
(998). Surface-adsorbed molecules can mask reactive surfaces of metal nanomaterials, and as a major
mechanism involved in alarmin release and activation of pro-inflammatory cell signaling, corona-induced
alterations in surface reactivity can significantly impact the immunogenicity of metal nanomaterials.
The immunological effects of metal nanomaterials can also be augmented as a result of surface
adsorption of specific endogenous molecules. For example, immunoglobulins, cytokines, and
complement proteins are all constituents of the serum and lung lining fluid capable of binding metal
nanomaterial surfaces (987, 999). Since many of these proteins are involved in opsonization, their
adsorption to the surface of metal nanomaterials can result in enhanced clearance of the nanomaterial
by phagocytic cells (1000-1003). Contrarily, these proteins may also facilitate receptor-mediated uptake
of the nanomaterial, as demonstrated by AuNP, Ni-containing nanowires, and CeNP in vitro (1003-1005).
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Complement proteins that differentially adsorbed to gold nanomaterials as a function of their morphology
were also shown to induce complement activation (1006).
Specific exogenous macromolecules can also adsorb to the surface of metal nanomaterials
leading to altered immunogenicity. One of the most notable examples is endotoxin, a frequent microbial
contaminant of nanomaterial surfaces that is capable of activating innate immune cells and inducing proinflammatory signaling via the TLR-4 pathway. Adsorption of LPS to nanomaterial surfaces has been
shown to enhance inflammatory responses in lung epithelial cells and various immune cells (1007-1010).
The chemical structure of LPS favors its adsorption to hydrophobic, positively-charged metal
nanomaterial surfaces, indicating a role for physico-chemical properties such as surface modification in
the propensity for associations with immunogenic exogenous molecules such as LPS (523, 1011).
Intentional surface modification of metal nanomaterials with various functional groups may also
implicate alterations for the immunogenic potential of the nanomaterial. Functionalization of metal
nanomaterial surfaces with various inorganic or organic ligands is often employed to modulate their
chemical and biological behavior and optimize their functionality for specific applications. For example,
surface modification can be used to stabilize nanoparticles to prevent their agglomeration. Similarly, the
attachment of biomolecules to nanomaterial surfaces has been employed in the selective targeting of
cells for therapeutic purposes (1012). Although surface functionalization is often used to improve metal
nanomaterial biocompatibility, the presence of some functional groups on nanomaterial surfaces has
occasionally been associated with the generation of antibodies specific for the functionalized
nanomaterial. For example, fullerene-specific IgG antibodies have been generated following in vivo
exposure to surface functionalized particles (938).
The second potential mechanism associated with altered immunogenic potential following
nanomaterial interactions with biomolecules involves the formation of complexes with novel
immunological activity. For example, as demonstrated by Deng et al. (2010), macrophages did not
recognize AuNP or two biomedically-relevant peptides individually. However, their conjugation facilitated
recognition via TLR-4 and the subsequent induction of pro-inflammatory cytokine production (521).
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In addition to the formation of complexes exhibiting innate immune stimulatory effects, complexes
of metal nanomaterials and molecules can also result in the generation of antigens capable of inducing
specific immune responses. AlNP, GdNP, and AuNP have been shown to act as non-protein carriers of
LMW haptens, which following injection into animal models, facilitated the generation of hapten-specific
antibodies (1013). Similarly, the adsorption of protein antigens to metal nanomaterial surfaces can also
augment their immunogenic potential as a result of complex formation resulting in modulated transport
to lymphoid tissues, as previously discussed (1014).
Nanomaterials can also form complexes with immunologically-active molecules wherein binding
results in their sequestration and subsequent neutralization. Binding of immunoglobulins, complement
proteins, cytokines, and alarmins to the surfaces of metal nanomaterials has been shown to effectively
immobilize these proteins, subsequently inhibiting their immunological activities. For example, TiO2NP
have been shown to adsorb the chemokine CXCL8, compromising its functional activity, and inhibiting
the recruitment of neutrophils to the site of exposure (1015).
Nanoparticles can also immobilize haptenic metal ions, compromising their allergenic potential.
Co ions were shown to adsorb to the surface of nanodiamonds in one study, preventing the elicitation of
ACD reactions to the metal (1016). Interactions between metal ions and nanoparticles have been shown
to augment many other immunological processes including DC maturation and macrophage activation in
vitro, as well as pulmonary inflammation and ACD elicitation in vivo (727, 769, 1017, 1018) Likewise,
sequestration of haptenic or immunogenic metal ions as a result of adsorption to nanomaterials has the
capacity to impede their capacity to induce or elicit allergic responses.
The third mechanism associated with altered immunogenic effects following interactions between
metal nanomaterials and biomolecules involves alterations in the immunogenic activity of the molecular
constituent. Numerous studies have reported that following adsorption of proteins to metal nanomaterial
surfaces, conformational changes in the secondary and tertiary structure can occur. AgNP, SiNP, and
AuNP have been shown to bind and induce conformational changes of a diverse number of proteins
including ribonuclease A, apolipoprotein A-I, heme, myoglobin, lysozyme, and albumin (1019-1026).
Some of these conformational changes can manifest as compromised functionality, as binding to
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nanomaterials has been shown to modulate the iron-binding capacity of transferrin, interfere with
fibrinogen clotting activity, and alter catalytic activity of hydrolase enzymes (1027-1029). One of the
critical properties association with such changes is nanomaterial morphology. The curved surfaces of
spherical nanoparticles have been shown to compromise the secondary structure of adsorbed proteins
to a greater degree than planar surfaces of nanosheets (1030).
The potential immunological implications of such alterations has been demonstrated by Deng et
al. (2010) in vitro. They showed that functionalized AuNP were capable of binding fibrinogen
independently of nanoparticle size, but certain sizes of AuNP were associated with the induction of
conformational changes in the protein. The normally non-immunogenic protein’s structure was altered,
conferring immunogenic activity as a result of its recognition by and activation of the Mac-1 receptor,
resulting in the subsequent induction of NF-κB signaling in innate immune cells (770). Similarly,
interactions between AuNP and TGF-β1 were shown to cause conformational changes in the protein
responsible for attenuation of the cytokine’s biological activity (1031).
Conformational changes in protein structure following their interactions with metal nanomaterials
can result in exposure of cryptic epitopes (1032). Some of these novel epitopes are recognized in a
manner that results in responses limited to innate immune stimulation. However, cryptic epitopes are also
associated with the generation of novel antigenic determinants capable of causing allergic sensitization.
Collectively, the impact of the biocorona on the immunological response to metal nanomaterials
has been demonstrated by numerous in vitro studies where different cellular effects have been reported
in response to the same metal nanomaterial, depending on pre-exposure incubation with biological fluids
enabling corona formation. Biocorona-dependent variations in metal nanomaterial interactions with
cellular membranes, propensity for internalization, intracellular fate, and cytokine release have all been
reported. Although the immune effects of the biocorona have been mostly studied with respect to innate
immune cell effects, the potential for these effects to manifest as alterations in adaptive immunity in vivo
have been demonstrated. In one such study, B-cells were able to be selectively targeted leading to
enhanced antigen-specific antibody production in mice when FeNP corona formation was manipulated
(736).
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1.2.4.2. Metal Nanomaterial Effects on DC and Sensitization In Vitro
As the cell type most frequently associated with antigen presentation during allergic sensitization,
the capacity for metal nanomaterials to modulate DC activity represents a prominent mechanism by which
they can modulate the development of allergic disorders (1033). Metal nanomaterial effects on DC have
been frequently investigated by in vitro studies and findings from these studies suggest several potential
mechanisms of metal nanomaterial augmentation of DC activity that may have notable implications for
allergic disease. However, considerations should be given to the diverse DC subtypes, which often
express differing levels of TLRs and other PRR, which may implicate tissue-specific DC effects on allergic
processes.
In vitro approaches for the identification of potential skin sensitizers frequently employ DC or DCprecursor cell lines. Two such approaches are currently validated for use by the OECD, and involve the
assessment of the test agent’s capacity to induce upregulation of activation marker expression in
surrogate DC cell lines. The first assay, the h-CLAT, method uses undifferentiated THP-1 human
monocytic leukemia cells, which are exposed to an agent for 24 hr and their activation status is
subsequently assessed by quantification of CD86 and CD54 activation marker expression (121, 164,
1034).
The h-CLAT assay has not been employed to evaluate the sensitizing potential of any metal
nanomaterials; however, several studies have investigated metal nanomaterial effects on undifferentiated
THP-1 cells following a 24 hr exposure and reported subsequent expression levels of activation markers.
Accordingly, increased expression of CD86 was observed following exposure to surface-modified FeNP,
SiO2NP, and mixed-metal alloy nanoparticles (1035). De Marzi et al. (2017) exposed THP-1 cells to a
wide range of SiO2 particle sizes (10-1430 nm); while all particles promoted activation marker expression,
the 240 nm SiO2 particles induced the greatest degree of CD80 expression. Similar findings were
reported by an investigation that assessed the potential for metal debris released from orthopedic
implants to trigger immune activation. Both ~ 2 µm cobalt-chromium-molybdenum alloy particles and
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soluble metal ions induced elevations in THP-1 co-stimulatory molecule expression, suggesting that a
wide range of metal particle sizes have the capacity to induce immune effects involved in allergic
sensitization (497, 1036). Contrarily, no elevations in THP-1 expression of CD86 or CD54 were observed
following exposure to 100 nm AgNP or 5/50 nm PtNP in vitro (1037, 1038).
Though CD86 and CD54 are the validated biomarkers used to infer sensitization potential in the
THP-1 line, a limited number of studies have evaluated these specific markers following metal
nanomaterial exposure. However, other markers indicative of DC activation, such as MHC II, CD11b,
CD14, CCR2, and CCR5 are often have been reported to be up-regulated in response to metal
nanomaterials including ZnONP and FeNP, which may also be indicative of the potential for these
materials to promote allergic sensitization (1039, 1040).
The second validated in vitro assay for the identification of skin sensitizers based on DC-activating
potential is the U-SENS assay. In this approach, the U937 human monocytic cell is exposed to the test
agent for ~ 45 hr, following which the quantification of CD86 expression is measured and used to
determine sensitizing potential. Similar to the h-CLAT assay, no metal nanomaterials have been tested
using this assay. Although the U937 cell line has been used in many studies to evaluate responses to
metal nanomaterials, CD86 expression has only been an endpoint of interest in a few studies.
Accordingly, expression of CD86 by U937 cells was shown to be upregulated following in vitro exposure
to CoCr microparticles and nanodiamonds (1041).
The potential for metal nanomaterials to induce DC activation has been more extensively
examined using human and murine primary DC than the THP-1 and U937 cell lines used in the validated
assays (1042). Although the expression of activation markers in murine bone marrow-derived DC
(BMDC) or human monocyte-derived DC (MDDC) has not been validated by OECD for use in determining
sensitization potential in vitro, several studies have reported their capacity to accurately predict
sensitizers (131, 134).
In human MDDC, CD80, CD86, CD54, human leukocyte antigen- DR isotype (HLA-DR), and MHC
II have all been reported to become upregulated in response to exposure to sensitizing metals (131,
1043). Many metal nanomaterials, including AuNP, GdNP, SiNP, and a PtNP-containing agent have all
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been reported to induce elevated expression of these molecules in MDDC following in vitro exposure
(538, 953, 1044, 1045). Moreover, several properties of metal nanomaterials have been shown to impact
the degree to which DC activation markers are upregulated following exposure. TiO2NP crystal structure
was shown to be influential in this response, wherein anatase forms were more immunogenic (887).
Similarly, SiNP surface modification was shown to influence DC-activating potential in vitro (701).
Numerous different SiNP with diverse surface modifications comprised of various chemical constituents
were used to show that SiNP with more nitrogen or oxygen in the outermost backbone layer were less
immunostimulatory to DC than those with carbon and hydrogen-based structures (532).
Murine BMDC have also been studied as potential reporter cells for the identification of potential
skin sensitizers. Studies have demonstrated that elevations in CD80, CD86, CD54, HLA-DR, and MHC
II expression occur in response to exposure to sensitizing agents. Accordingly, increased expression of
several of these markers has been shown following in vitro exposure to AlNP, TiO2NP, ZnONP, SiNP,
and FeNP (771, 774, 867, 947, 1046-1049). The degree of activation has been further correlated to
properties including size, surface modification, crystallinity, and morphology (527, 538, 1042, 1050,
1051). Several studies have also reported increases in many of the same markers on DC isolated from
animals exposed to metal nanomaterials in vivo (773, 844, 1052).
A few studies have also reported upregulation of activation markers in DC cell lines including the
DC2.4 and JAWS II lines. AuNP, AgNP, and SiNP were shown to activate these cells as a function of
properties including crystal structure and surface modification (887, 1051).
The only current endpoints validated by the OECD for the in vitro assessment of potential
sensitizers using DC and DC-precursor cell lines are activation markers. However, as the molecular
mechanisms involved in the early events of sensitization are becoming better understood, additional
approaches and endpoints have been proposed to be effective indicators of sensitization potential. One
of these approaches involves genetic analysis of various cell types involved in the sensitization process.
Sensitizer-induced alterations in the expression of several specific genes have been profiled in various
DC and DC-precursor cell types. Modulation in expression of 60 genes - several of which were correlated
to monocyte differentiation and maturation - were observed in response to PtNP exposure (1053).
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Another in vitro approach for identification of potential sensitizers involves analysis of ROS
production following exposure. The THP-1 cell line has been used to identify potential skin sensitizers in
vitro based on a unifying property of rapid increases in ROS production following exposure to skin
sensitizing chemicals (1054). A similar response has been demonstrated in the cell line following
exposure to < 100 nm Ag-Cu alloy nanoparticles, AgNP, CoO NP, PdNP, and NiNP (1055). The degree
of ROS production by THP-1 cells has been correlated to properties including particle size and biocorona
presence, as well as exposure dose and duration (1056-1058). Subsequent activation of the p38 MAPK
signaling pathway, alterations in expression of HMOX1 and other oxidative stress genes have also been
used as in vitro biomarkers suggestive of sensitizing potential. Numerous metal nanomaterials have been
associated with these effects on THP-1 cells, which suggests their potential to activate DC and promote
sensitization (1059-1062).
Direct activation of DC is not the only potential mechanism by which metal nanomaterials may
induce allergy-modulating effects. Some metal nanomaterials have been shown to have no impact on
DC activation marker expression, but have demonstrated other effects with potential to augment allergic
processes (702, 1063-1065). In vitro studies suggest that irrespective of their DC activating potential,
metal nanomaterials can induce alterations in DC antigen processing efficacy, propensity for maturation,
migratory capacity, and lymphocyte stimulation/polarization.
It has been proposed that although uptake of metal nanomaterials may not augment DC
maturation or phenotype, their accumulation in endocytic compartments may interfere with antigen
processing (1066-1069). In this regard, CeNP have been used to demonstrate that following uptake,
localization in different cellular compartments, such as the cytoplasm or lysosomes, is based on surface
charge (1070). Moreover, following uptake by DC, the size and charge of nanomaterials has been shown
to augment the biochemistry of the lysosomal compartment, also potentially interfering with antigen
degradation (1071, 1072). These mechanisms may underlie the observation that exposure to some metal
nanomaterials results in altered CD4+ or CD8+ T-cell presentation efficiency (1074). FeNP, SiNP, and
TiO2NP have all been shown to alter antigen presentation, stimulation, and proliferation of T-cells by DC
depending on size, shape, crystallinity, and surface modification (536, 702, 703).
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Numerous metal nanomaterials have been shown to alter DC responses to maturation stimuli in
vitro. QD comprised of Zn and Cd, AuNP, and SiNP were shown to decrease DC activation in response
to LPS (774, 1042, 1075). Contrarily, uptake of AuNP and AgNP resulted in an enhanced capacity for
DC maturation in response to other immune stimuli (1051). AuNP were shown to differentially affect DC
response to LPS as a function of particle size (1076). This finding suggests that uptake of antigens
normally incapable of activating DC may trigger their maturation in the presence of nanomaterials.
DC migration is another mandatory step of sensitization that appears to be subject to modulation
by metal nanomaterials. AlNP and FeNP have both been shown to augment DC responses to
chemotactic mediators and subsequent migratory capacity (771, 1077). Similarly, Al-containing layered
double hydroxide nanoparticles were shown to augment DC expression of CCR7 by DC as a function of
the chemical constituent proportionality (771).
Polarization of DC and the subsequent preferential generation of Th1/Th2 effector T-cells is
another step in the development of allergy that has been shown to be susceptible to modulation by metal
nanomaterials. GdNP, AuNP, TiO2NP, and FeNP have been shown to polarize DC towards Th1-dominant
responses in vitro (739, 953, 1078). Contrarily, CeONP and SiNP have been implicated in promoting
Th2-biased DC responses (536, 1049).
Dermal and respiratory sensitizers are associated with divergent oxidative stress responses that
induce selective alterations in three major signaling pathways responsible for DC polarization (1079,
1080). Polarization of DC towards Th1-promoting functions has been associated with the propensity for
skin sensitizers to react with cytoplasmic glutathione, following which, its rapid depletion leads to ROS
accumulation. The immediate induction of oxidative stress induced by contact sensitizers is responsible
for the selective activation of the p38 MAPK and JNK signaling pathways within minutes of encounter
(1081). Contrarily, polarization of DC towards Th2-dominant functions has been associated with delayed
induction of oxidative stress resulting from the preferential association of respiratory sensitizers with
intracellular amine groups (113). Subsequently, selective activation of the NF-KB and ERK pathways
occurs.
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Knowledge of these pathways and their differential modes of activation explain the observation
that metal nanomaterials with opposing catalytic properties induce different polarization profiles in DC in
vitro. The oxidant effects of TiO2NP were shown to result in potentiation of DC maturation leading to Th1biased responses, whereas treatment with the antioxidant activity of CeO2NP resulted in secretion of
anti-inflammatory IL-10 and a Th2-dominant T-cell profile (536). FeNP, AuNP, and gadolinium (Gd)NP
have also been associated with modulation of DC polarization in vitro with respect to size and surface
chemistry (739, 778, 953, 1076).
Aside from conventional DC subsets in the context of antigen presentation, metal nanomaterials
may also exert effects on other DC subsets with contributions to allergic processes. For example,
plasmacytoid DC (pDC) circulate in the blood and are known for their production of high levels of type 1
interferons (1082). This DC subset has been shown to selectively take up nanoparticles, but not
microparticles, and modulation of particle nanostructures can result in their selective targeting in vivo
(1083, 1084). Although depletion of pDC leads to sensitization and IgE-mediated responses to inhaled
antigen, numbers of pDC are also elevated in asthmatics and are associated with enhanced Th2 allergic
responses and exacerbations of asthma (1085-1089). pDC have also been shown to be involved in
inflammatory skin diseases and have the capacity to cross-present antigen following nanoparticle-based
targeting of specific surface receptors (1090, 1091). Likewise, the potential for metal nanomaterials to
augment antigen-presentation and cytokine production by pDC may have implications for allergic disease
(1092).

1.2.4.3. Metal Nanomaterial Effects on Processes Involved in Allergic Elicitation In Vitro
Several in vitro studies have directly demonstrated the potential for metal nanomaterials to
influence cellular processes involved in allergic elicitation. Both IgE-mediated and T-cell-mediated
responses appear subject to interference in the presence of nanomaterials. Moreover, similar
observations have been shown in the context of allergic elicitation responses specific to both
environmental proteins and metal allergens.
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In asthma, mast cells are sources of many of the molecular mediators responsible for the
pathogenesis of elicitation reactions. Upon activation, mast cells release granules containing
prostaglandins, leukotrienes, pro-inflammatory cytokines, and numerous other effector molecules (1093).
IgE-dependent degranulation by mast cells in the presence of allergen has been shown to be enhanced
by some metal nanomaterials (AgNP), while unaffected (TiO2NP) or inhibited by others (ZnONP,
Fe2O3NP) (546, 911, 912). Several divergent mechanisms involved in the modulation of mast cell
degranulation have been elucidated and reveal why some metal nanomaterials and specific physicochemical properties may selectively facilitate modulation of degranulation.
As demonstrated with AuNP, one major mechanism capable of impacting the propensity for
allergen-induced degranulation of mast cells results from particle interactions with IgE molecules on the
surface of mast cells. Mast cells have been reported to express an estimated 3.0 x 105 FcεRI receptors
per cell with a distance of ~32.6 nm between receptors. The RBL-2H3 mast cell line was utilized to
demonstrate that precise control of AuNP size and surface modification could selectively promote or
inhibit nanoparticle-mediated IgE dimerization and subsequent degranulation in vitro (784). In the same
cell line, another study demonstrated that the propensity for degranulation can be modulated when both
allergen and cells are pre-exposed different types of nanomaterials. TiO2NP, CeO2NP, ZnONP, and
FeNP interacted with immune structures depending on size, degree of agglomeration, and charge and
were subsequently capable of modulating the degranulation process (916). This capacity for metal
nanomaterials to interfere with IgE/receptor binding can result in modulations in mast cell propensity for
degranulation upon exposure to antigens, independent of particle uptake by cells.
Another mechanism associated with metal nanomaterial-induced modulation of mast cell
activation is dependent on nanomaterial internalization, which subsequently disrupts the intracellular
signaling cascades responsible for degranulation. Compared to negatively-charged particles of the same
size (30 nm), positively-charged AuNP and AgNP were demonstrated to be taken up by mouse peritoneal
mast cells more efficiently (914). QD with varying surface charges showed similar effects on mast cells
in vitro. The electrostatic forces between positively-charged particles and the cell membrane facilitated
particle adherence and passive penetration, whereas negatively-charged particles were internalized by
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endocytosis (1094). Surface porosity has also been shown to be influential in nanomaterial uptake by
primary culture mast cells, as variations in internalization of porous, nonporous, and mesoporous SiNP
have also been observed in vitro (785). In addition to these physico-chemical properties, the profile of
adsorbed constituent present on the surface of metal nanomaterials may also impact the propensity for
uptake since mast cells express Fc receptors for IgA and IgG, TLRs, and various scavenger receptors,
(1095, 1096).
Following IgE dimerization, an increase in free cytosolic Ca2+ triggers the release of granules by
mast cells. Accordingly, the internalization of materials with the capacity to interfere with the flux of ions
may subsequently impact activation. In one study, TiO2NP were shown to disrupt membrane L-type Ca2+
channels in RBL-2H3 cells resulting in increases in cytosolic Ca2+ levels and subsequent degranulation
in the absence of IgE or allergen (1097). A similar response has been noted in various mast cell lines
following exposure to AgNP with different physico-chemical properties (915, 1098). In one study,
selective modulation of mast cell Ca2+ levels was observed following exposure to 5 nm, but not 100 nm
AgNP, resulting in granule release. This observation is not surprising given that the increased surface
area of the smaller particle generates additional reactive surfaces capable of inducing more profound
disruptions in cellular electrochemical balance (544). Zeta potential, morphology, and surface
modification of metal nanomaterials have also been implicated in the potential for disruption of signaling
leading to altered mast cell degranulation in vitro (546, 912, 913). Furthermore, variations in the
propensity for ion release from fine, ultrafine, and soluble Zn compounds has been correlated to
differential effects on OVA-induced mast cell degranulation in vitro (1099). These findings are conducive
with a previously established relationship relating transition metal ions to interference with allergeninduced mast cell degranulation with respect to air pollution (1100). Collectively, these studies
demonstrate a clear mechanism associated with alterations in mast cell activity and identify several
properties of metal nanomaterials that are likely to influence this effect.
Basophils are another population of granulocytes with similar effector functions as mast cells in
IgE-mediated allergic diseases. However, as a circulating cell population that is both shorter-lived and
far outnumbered by tissue-resident mast cells, they are less frequently studied (1101). Very few studies
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have investigated the potential effects of metal nanomaterials on basophils in vitro. However, one study
has demonstrated that allergen-induced degranulation of basophils is susceptible to modulation by AuNP.
Accordingly, basophils from subjects with established sensitivity to common environmental allergens
including birch pollen, timothy grass pollen, and HDM were isolated and exposed to the corresponding
allergens either in the presence or absence of AuNP. Although stable coronas were formed on AuNP by
all three allergens, physical associations with 50 nm AuNP enhanced the activation of basophils following
HDM challenge, as well as birch pollen in some individuals. The authors suggested that the enhanced
propensity for basophil activation may have been reflective of AuNP-mediated epitope display in a
manner more conducive with antigen-mediated IgE cross-linking and subsequent degranulation (522).
Metal nanomaterials have also been demonstrated in a few studies to have potential to modulate
elicitation responses mediated by antigen-specific T-cells. For example, when exposed to OVA, OVAspecific T-cells produced significantly different levels of IFN-γ and IL-2 depending on the presence of
surface-modified 51 nm SiNP. Interestingly, co-exposure to SiNP enhanced antigen specific responses
exclusively in CD8+ cells (1074). A similar response was observed when OVA-specific T-cells were pretreated with FeNP prior to stimulation with OVA. FeNP exposure modulated lymphocyte production of IL2 and INF-γ, which was postulated to be associated with the depletion of cellular glutathione levels (1102).
Nanomaterial effects on metal-specific T-cell-mediated allergic elicitation responses have also
been investigated by a few in vitro studies. In one study, peripheral blood mononuclear cells (PBMC)
isolated from Pd-sensitive women were challenged with either 5-10 nm PdNP or Pd salts in vitro.
Subsequent production of TNF-α and IL-10 was shown to vary significantly between cells of the different
treatment groups, indicating a potential role for metal solubility in T-cell-mediated metal allergy elicitation
(545). Similar findings have been observed in lymphocytes from patients with metal sensitivity associated
with metal-on-metal implant debris release. Metal-specific lymphocytes have been shown to react
differently in response to particulate alloy particles and metal ions. Co-Cr-Mo alloy particles, Co-Cr wear
debris, and metal constituent ions have also been shown to cause significantly different profiles of
cytokine release by lymphocytes with respect to IL-1β, TNF-α, IL-2, IFN-γ, and IL-6 (497, 1103).
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Although in vitro studies that directly demonstrate metal nanomaterial-induced modulation of
allergic elicitation reactions are somewhat limited, numerous studies have been performed to evaluate
metal nanomaterial effects on specific immune cells involved in elicitation responses. Metal
nanomaterials have been shown to induce diverse effects on T- and B-lymphocytes, and granulocytes,
many of which may have implications for their effector functions in elicitation reactions.
In vivo, ZnONP, CuONP, CeONP, and many other metal nanomaterials administered by various
exposure routes have been shown to alter T-cell population ratios, proliferative capacity, and cytokine
responses to various stimuli (1104-1106). As the major effector cell of ACD and other Type IV
hypersensitivity reactions, metal nanomaterial interference with T-lymphocyte activity represents a
potential mechanism of augmentation with notable relevance to the elicitation phase of allergy. In vitro
studies using T-lymphocytes have demonstrated that metal nanomaterials can directly impact several
cellular processes that may correlate to in vivo observations.
Exposure to ultrasmall SiNP (1.8-16 nm) was shown in one study to induce expression of
activation markers in both CD4+ and CD8+ T-cells. It was proposed that the “ultrasmall” size range of
these materials, which has not been frequently studied, may be somehow responsible for the observed
effect; however, FeNP and AuNP of similar sizes did not induce the same response, indicating that size
alone is does not confer T-lymphocyte activation potential (538, 1107). Other metal nanomaterials have
also been shown to be ineffective activators of T-cells. Irrespectively, their presence has frequently been
associated with modulation of reactivity upon stimulation. FeNP, TiO2NP, and CrCoNP, AgNP and AuNP
have all been shown to augment T-cell cytokine production following stimulation by non-specific mitogens
(1064, 1108-1112). Properties including surface modification have been further correlated to
discrepancies in T-cell cytokine responses as a result of nanomaterial exposure (1113).
Some metal nanomaterials have also been associated with the potential to polarize T-cell cytokine
profiles, an effect which has notable relevance to allergic disease. PdNP, AuNP, CoNP, SiNP, and GdNP
have all been shown to induce differential Th1/Th2-biased cytokine production by lymphocytes in vitro
dependent on properties including size, solubility, and hydrophobicity (1107, 1114-1117). Some of the
same physico-chemical properties have also been associated with disruptions in cell redox status and
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ion homeostasis in T-cells, effects which may underlie observations reporting alterations in cell signaling
patterns (1118, 1119). For example, FeNP have been shown to suppress the activity of Kv1.3 ion
channels in murine T-lymphocytes, illustrating another potential effect of metal nanomaterials on T-cells
capable of altering numerous cellular functions (1120).
Although selective cytotoxic effects on lymphocytes is an immunotoxic effect most frequently
associated with immunosuppressive responses, a similar effect could be associated with implications for
allergic conditions, as well (1121). Accordingly, metal nanomaterial cytotoxic and genotoxic effects have
been investigated in murine and human lymphocytes in vitro and correlated to properties including size
and morphology (1122-1128). Interestingly, lymphocytes have been demonstrated to be more resistant
to adverse effects of ZnONP compared to other immune cell types (1129). Susceptibility to cytotoxicity
was also shown to be dependent on cell cycle status, explaining the observation that memory T-cells
were more sensitive to metal nanomaterial effects compared to naïve T-cells (1129, 1130).
The cytotoxic potential of FeNP on T-cells was characterized by one study wherein size, surface
properties, surface area, and particle number were all considered. Accordingly, 10 and 50 nm FeNP did
not induce dose-dependent cytotoxicity with respect to the mass administered, but the effects were
dependent on surface area and particle number (1131). This finding is conducive with the observation
that the cytotoxicity induced by ZnONP and PdNP was associated with the release of ions correlated to
cytotoxicity and alteration in gene expression; however, one study reported that T-cell DNA damage
induced by CoNP was more severe than that induced by cobalt ions (1132-1135).
Alterations in mitogen-induced cytokine production and cell viability have been the most
frequently-reported effects associated with in vitro exposure of T-lymphocytes to metal nanomaterials.
However, other T-cell responses with potential to impact allergic elicitation have been occasionally
reported following metal nanomaterial exposure. For example, human antigen-specific cytotoxic Tlymphocytes maintained effective cytolytic activity following exposure to FeNP, but cells exhibited
compromised proliferative capacity (1136). Interference with lymphocyte proliferation may not only impact
allergic responses in the elicitation phase, but may also impact sensitization, as well. Findings from
studies have also reported nanomaterial-induced alterations in adhesion molecule and chemokine
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receptor expression, TLR singling, and morphological alterations in T-cells, all of which may also impact
T-cell effector functions during allergic elicitation (540, 1137-1139).
The majority of the existing studies pertaining to lymphocytes as potential targets of metal
nanomaterial-induced biological effects have specifically investigated T-lymphocytes. B-lymphocyte
responses to metal nanomaterials have been characterized by far fewer studies. In vivo, exposure to
various metal nanomaterials has been associated with alterations in immune parameters indicative of
alterations in B-cell activity. Alterations in circulating B-cell frequency, distribution within lymphoid organs,
and proliferative capacity have all been reported following nanomaterial exposure (780, 782, 1140-1142).
Modulation of antibody levels have also been frequently reported following metal nanomaterial exposure
in vivo (527, 946, 951, 959, 1143-1145). However, whether these responses are reflective of the capacity
for metal nanomaterials to directly impact B-cell functions remains unclear.
In vitro evaluation of metal nanomaterial effects on B-cells are largely limited to studies that have
employed AuNP. Accordingly, in a murine B-lymphocyte cell line (CH12.LX), 10 nm AuNP were shown
to induce activation of the NF-κB signaling pathway, resulting in increased antibody production (1146).
Similarly, AuNP ranging from 2 – 50 nm in size were associated with size-dependent enhancement of
IgG secretion in B-cells isolated from mouse spleens. The 10 nm AuNP were associated with maximal
responses, which were associated with modulation of the blimp1/pax5 signaling pathway (779). Contrary
to these findings, ~15 nm AuNP with variations in surface modifications and 60 nm Au nanorods were all
reported to interact poorly with B-cells isolated from humans. No decreases in cell viability, increases in
activation marker expression, or inflammatory cytokine production was reported following 24 hr exposure
to the highest dose. However, a decrease in IL-6 production was observed in activated lymphocytes
exposed to the uncoated Au nanorods, which the authors noted to be suggestive of potential for functional
impairment (1147).
Despite their critical functions in asthmatic conditions and other Type I hypersensitivity responses,
including IgE production, B-cells represent a cell type associated with expansive knowledge gaps
pertaining to nanomaterial toxicity. This lack of investigation is surprising given that the vast majority of
in vivo studies have examined metal nanomaterial effects on IgE-mediated allergic processes. Moreover,
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while fewer allergy models have been employed to study dermal allergy, many of the existing studies
have investigated atopic dermatitis as opposed to ACD, wherein the effector functions are IgE-mediated,
and thus, dependent on B-cell functions. As a result of this discord, it remains largely unclear if in vivo
observations reflect direct effects of metal nanomaterials on B-cell functions. The potential for metal
nanomaterials to directly alter B-cell processes, such as antigen-specific interactions with T-cells, isotype
switching, and affinity maturation, events critical to their effector functions in IgE-mediated allergic
disorder such as asthma, remain largely unstudied (1148).
In addition to B- and T-lymphocytes, granulocytes also execute critical effector functions in allergic
elicitation responses, and have been frequently studied as potential targets of metal nanomaterials in
vitro. Although the release of these mediators following degranulation is most frequently associated with
antigen-induced dimerization of surface-bound IgE molecules, mast cell degranulation can be triggered
by numerous other immunological and non-immunological mechanisms (1149). Likewise, in addition to
the previously-mentioned studies demonstrating augmentation of allergen-dependent mast cell
degranulation, additional studies have also demonstrated other implications of metal nanomaterial
exposure on mast cells with the potential to impact allergic responses independent of allergen presence.
IgE-independent mast cell degranulation has been observed in vitro following exposure of cells
to AgNP, TiO2NP, and AuNP (546, 784, 915, 1097, 1150). Properties including size, morphology, and
surface modification have been shown to impact this response (913). Metal nanomaterial-induced
degranulation of mast cells has the potential to induce inflammatory responses resembling allergic
inflammation in the absence of allergen exposure. This effect may further exacerbate allergic severity in
existing conditions.
Several metal nanomaterials have also been associated with potential to alter the qualitative
profile of mast cell granule constituents in vitro. Positively-charged AuNP and negatively-charged AgNP
have been shown to decrease the serotonin content in granules released by murine mast cells. Similarly,
SiNP have been associated with a collective decrease in the number of molecules encapsulated within
mast cell granules (785). Since granule contents regulate many of the pathomechanisms central to
allergic responses including AHR, vascular permeability, and inflammatory cell recruitment, metal
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nanomaterial-induced alterations in the contents of mast cell granules can greatly impact the severity of
elicitation responses. The kinetics and efficiency of mast cell degranulation can also be impaired following
metal nanomaterial exposure, as demonstrated by TiO2NP (785, 1151).
Other occasional reports of metal nanomaterial-induced modulations in mast cell activity exist,
suggesting additional mechanisms by which mast cells may be targeted by nanomaterials resulting in
altered allergic processes. Interestingly, 10 nm SiNP and 26 nm AuNP were shown to be incorporated
into mast cell granules prior to exocytosis (1152, 1153). Although the implications of these findings remain
unknown, the sequestration of metal nanomaterials within mast cell granules suggests potential for their
release upon subsequent cell activation, which may result in numerous implications for allergic
responses. Additionally, ZnONP have been shown to suppress proliferative activity of mast cells and
doping of ZnONP with Al has been shown to decrease the release of various Th2-promoting mediators
by mast cells (1154, 1155).
Most of the reported mast cell effects induced by metal nanomaterials seem largely relevant to
the elicitation of IgE-mediated allergic responses such as asthma. However, mast cells have been
increasingly recognized as critical regulators of sensitization and chronic allergic inflammation in both the
skin and lungs. Mast cells are capable of releasing alarmins and cytokines known to promote DC
maturation, migration to the lymph nodes, polarized lymphocyte responses, and inflammatory cell
recruitment (98, 705, 1095, 1156-1159). With respect to ACD, mast cells are involved in allergic elicitation
since they exhibit antigen presentation capabilities, enhance CD8+ T-cell effector functions, and release
cytokines regulating the severity of chronic reactions (1096, 1160-1166). Likewise, observations of metal
nanomaterial-induced endocytic antigen retention, alterations in cytokine production, and suppression of
proliferation in mast cells suggests the potential for effects to impact more than just asthmatic elicitation
(1154, 1155, 1167, 1168).
The KU812 human basophil line was exposed to Au nanorods with varying surface modifications
in vitro and subsequent release of allergic mediators was monitored. Within 20 min of exposure, release
of granules containing histamine and β-hexosaminidase was detected, indicative of IgE-independent
degranulation. Similar to the observations reported for mast cells, the gold nanorods modulated
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intracellular Ca2+ levels in a surface coating-dependent manner, leading to discrepancies in cellular
activation. Moreover, the different nanorods were associated with differential induction of apoptosis in
basophils, as well (1169).
The contributions of mast cells and basophils to allergic processes have often been historically
described collectively. However, recent advances in basophil biology have led to identification of
functionally-distinct subpopulations of basophils and recognition of their involvement in helminthic
infections, autoimmune diseases, and allergy (1170). Although similar findings have been reported
regarding metal nanomaterial effects on mast cells and basophils, several unique properties of basophils
render the lack of metal nanomaterial studies specific to this cell type a concern.
First, observations that AuNP can induce degranulation of basophils by allergen-independent
mechanisms presents a unique concern given their presence in the circulation. Metal nanomaterials
including AuNP and FeNP are being increasingly used in biomedical applications that involve their
systemic administration (1171, 1172). This raises concerns over the potential for these metal
nanomaterials to trigger degranulation of basophils, resulting in systemic immune responses such as
anaphylaxis (1067).
Additionally, in vitro studies using both mast cells and basophils have demonstrated a critical
importance of surface-adsorbed proteins in the biological activity of metal nanomaterials. However, their
interactions with metal nanomaterials are likely to occur in vastly different biological compartments,
implicating different coronal profiles in subsequent effects. Basophils also exhibit unique humoral immune
functions that differentiate their potential effects on allergic disease from those of mast cells (1173).
Basophils have been associated with an alternative pathway of anaphylaxis mediated by IgG, as well as
IgD-dependent mechanisms of activation (1174, 1175). Furthermore, basophils can participate in antigen
presentation, implicating the effects of metal nanomaterials on basophils in both sensitization and
elicitation of allergy (1176). Given the minimal number of existing studies that specifically investigate
metal nanomaterial effects on basophils, future studies should address this knowledge gap, taking into
consideration the different biological activities associated with mast cells and basophils.
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1.2.4.4. Metal Nanomaterial Effects on Other Immune Cells In Vitro
Monocytes: Monocytes are a short-lived circulating leukocyte that undergo differentiation into
macrophages and DC upon extravasion into tissues (1177). Given these properties, monocytic cell lines
have notable utility in the previously-mentioned in vitro approaches to identify potential sensitizers;
however, they are not a commonly investigated cell type with respect to the toxic effects of nanomaterials.
Monocytic cell lines and primary monocytes are often differentiated and used to study metal nanomaterial
effects on macrophage and DC functions in vitro. However, a few studies have reported that metal
nanomaterials can induce diverse effects on monocytes ranging from over cytotoxicity to augmentation
of phagocytic activity and modulation of cytoskeletal function (1178, 1179). However, observations that
metal nanomaterials can induce modulation of monocyte migratory capacity, inflammatory mediator
release, and differentiation may have specific relevance in the context of allergic disease.
Many macrophage and DC subtypes involved in allergic processes are monocyte-derived
populations. Likewise, their effector functions at sites of inflammation are dependent on chemotaxis.
Increased expression of adhesion molecules and subsequent alterations in endothelial adhesion by
monocytes has been reported in vitro following exposure to SiNP, ZnONP, and AgNP (1180-1182).
SiO2NP size, TiO2NP crystallinity, and FeNP corona have all been associated with differential expression
of adhesion molecules by monocytes in vitro, impacting subsequent adhesion strength to endothelial
cells (1183-1185). Similarly, FeNP were shown to augment monocyte chemotaxis to monocyte
chemotactic protein (MCP)-1 in a surface modification-dependent manner (1186). These effects may
have implications for allergic disease, since monocyte migration into inflamed tissues are integral to
inflammatory cell replenishment and they can be sources of allergy-promoting cytokines.
Metal nanomaterials have also been shown to induce the release of numerous pro-inflammatory
mediators by monocytes which may impact all phases of allergic disease (1187, 1188). Many of these
mediators, including IL-1β, TNF-α, IL-6, and IL-8, have critical roles in sensitization and have been shown
to be released following exposure to ZnONP, QD, AgNP, and SiO 2NP in vitro (1178, 1181, 1189-1191).
Matrix metalloprotease (MMP)-2 and MMP-9 production by monocytes has also been reported following
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exposure to NiNP and CoNP (1192, 1193). Many of these mediators are released following activation of
signaling pathways driven by elevated levels of oxidative stress. ROS-induced activation of NF-kB and
MAPK signaling pathways in monocytes have been associated with ZnONP, AuNP, and QD exposure
(1188, 1191, 1194). As demonstrated by FeNP, these effects can also result in augmented monocyte
responses to immunological stimuli other than the nanomaterials. FeNP were shown to suppress NF-kB
activation in primary human monocytes in response to LPS (1195).
In addition, SiO2NP and AgNP have also been associated with inflammasome activation in
monocytes, an effect capable of further amplifying pro-inflammatory signaling (1196, 1197). Although
ROS production has been implicated as an underlying mechanism, other effects may also be involved.
For example, it was shown that SiONP-induced inflammasome activation was dependent on uptake by
scavenger receptor A, which was dependent on particle size (1198). Lysosomal rupture has also been
implicated in inflammasome activation, and Ag nanomaterials have been used to demonstrate the impact
of morphology on this process (1199) Modulation of K+ ion channel function and ion efflux in monocytes
is another mechanism related to inflammasome activation and has been observed in monocytes following
exposure to AgNP and FeNP (1179, 1196). Similarly, AgNP have been shown to degrade the ATF-6
sensor, promoting inflammasome activation (1200).
Although many metal nanomaterials have been shown to induce detrimental cellular effects as a
result of ROS production, some nanomaterials have demonstrated the capacity to mitigate monocyte
oxidative stress. Accordingly, some of these same physico-chemical properties have been implicated in
these effects. Size-dependent quenching of ROS observed by CeONP was attributed to increased crystal
lattice defects in the smaller material (1201). A similar finding has been demonstrated using TiO2NP,
wherein modulation of the surface nanostructure was employed to mitigate ROS production (1202).
Many metal nanomaterials have been shown to induce dose-dependent cytotoxic effects on
monocytes resulting in apoptotic, autophagic, or necrotic cell death (1203-1205). Several studies have
correlated cytotoxic potential of ZnONP, NiONP, SiO2NP, AlNP, and AgNP to decreasing size (1036,
1057, 1178, 1196, 1206, 1207). Furthermore, AuNP corona formation, ZnONP charge and surface
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coating, and AgNP dissolution potential have been implicated in cytotoxic effects on monocytes (523,
1039, 1058, 1206).
Studies have also compared the susceptibility of monocytes to these cytotoxic effects with other
immune cells, generating interesting findings. Due to their inherent functions in the innate immune
system, phagocytic cells have been shown to be up to ten times more sensitive to uptake-dependent
metal nanomaterial cytotoxicity compared to non-phagocytic cells. Accordingly, monocytes were shown
to reach a ‘critical cellular load’ of 25-35 nm SiO2NP more readily than other non-phagocytic immune cell
types, resulting in cell type-specific cytotoxic effects (1208). Simialrly, the cellular effects of FeNP were
differentially induced in human monocyte subsets with known variations in phagocytic activity (1209).
Similarly, the U937 monocytic cell line was used to demonstrate an increased sensitivity to metal
nanomaterial effects following its differentiation into a macrophage-like phenotype, known to exhibit
increased phagocytic potential (1201).
In addition to phagocytic activity, another cell-specific characteristic shown to impact susceptibility
to metal nanomaterial-induced cell death is cell cycle status and proliferative potential. ZnONP have been
repeatedly shown to induce selective cytotoxic effects on immune cells with elevated proliferative
potential, and monocytes were shown to be one of the immune cell types most susceptible to the
production of cell death-inducing levels of ROS (1129, 1210). It has been suggested that the production
of ROS following uptake is extensively greater in proliferating cells than differentiating cells, resulting in
more pronounced toxic effects (1105, 1211).
Macrophages: Macrophages are one of the most frequently studied immune cell targets of metal
nanomaterial effects in vitro. However, the collective implications of these findings for metal nanomaterial
effects on allergic disease are difficult to discern for several reasons. First, the majority of in vitro studies
have used macrophage cell lines, which do not accurately represent the distinctive properties of tissueresident macrophages. The respiratory tract, spleen, skin, lymph nodes, adipose tissue, GI tract, and
numerous other biological compartments harbor distinctive populations of tissue-resident macrophages
that originate from different developmental pathways, exhibit specialized immunoregulatory functions,
and display distinctive phenotypic profiles (1212, 1213). Accordingly, the biological fate of metal
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nanomaterials following macrophage interaction can vary greatly depending on the specialized functions
unique to each subpopulation. For example, the characteristically high levels of scavenger receptor
expression by Kupffer cells, the resident macrophage population of the liver, has been associated with
increased recognition and uptake of nanomaterials compared to other macrophage subsets (1214-1216).
Similarly, the optimal particle size for uptake has been shown to differ significantly between alveolar
macrophages and peritoneal macrophages (1000).
Similar to the different biological activities of macrophages with respect to specialized phenotype,
the activation status of macrophages has also been shown to impact interactions with metal
nanomaterials (1217). Accordingly, in vitro studies using inconsistent protocols for differentiation of
primary immune cells or cell lines into macrophages may generate different phenotypes of cells that may
generate conflicting study results. Although the classification scheme of alternatively and classicallyactivated macrophage activation scheme has received increasing criticism, it remains a frequently-used
classification scheme for macrophage activation state. In accordance, in vitro studies using cell lines
have demonstrated notable discrepancies in nanoparticle uptake by macrophages with respect to
polarization status (1218).
Lastly, the unique roles of macrophages with respect to ACD and asthma should be considered
when interpreting the results of in vitro studies and the implications for allergy. Pulmonary macrophages
are known to play critical roles in the regulation of DC activity that can promote or impede the early events
of sensitization. Moreover, as reservoirs for inhaled antigens, their capacity to internalize foreign material
is also critically important with respect to respiratory sensitization. In the skin, macrophages play critical
roles in elicitation responses, contributing to the tissue destruction characteristic of ACD elicitation
reactions.
Metal nanomaterials have been shown to induce a variety of alterations in macrophage activity
including altered podosome formation, gelatinase degradation, and antigen recognition/uptake (1219).
Moreover, the impact of metal nanomaterial physico-chemical properties on cellular activity has been
well-studied with respect to macrophages. However, given the vast amount existing literature and the
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previously-mentioned limitations, only studies reporting metal nanomaterial effects on select macrophage
functions will be discussed with regards to potential augmentation of allergic processes.
One of the most notable effects of metal nanomaterials on macrophages with potential
implications for allergic disorders is their capacity to induce phenotypical alterations associated with
enhanced antigen presenting capacity. FeNP, QD, ZnONP, and AgNP have all been shown to increase
the expression of antigen presenting molecules including CD80, CD86, and MHC II in several
macrophage cell lines in vitro (844, 1219-1221). Many in vivo studies investigating metal nanomaterialinduced immune effects have also reported increased expression of these markers by macrophages
(1222, 1223). Furthermore, increased populations of macrophages with similar APC phenotypes have
been reported in patients experiencing metal sensitivity as a result of metal wear debris from orthopedic
implants (1224).
Similarly, metal nanomaterial-induced polarization of macrophage activation status may represent
a notable effect with implications for many phases of allergic disorders. The dynamic capacity of
macrophages to both amplify immune responses and mitigate them is commonly described in terms of
two polarized activation states reflective of their propensity to promote the destruction of intracellular
pathogens (M1, classically-activated) or contribute to wound healing and elimination of helminthic
infections (M2, alternatively-activated) (1225, 1226). Although the validity of the M1/M2 paradigm has
recently come into question, the potential for metal nanomaterials to interfere with these opposing
macrophage functions has notable implications for the elicitation of allergic reactions and their resolution
(1226, 1227). The induction of a M1-like macrophage phenotype has been observed in response to FeNP
and SiNP (1219, 1228-1230). Contrarily, M2-polarization of macrophages has been observed in response
to CeONP exposure in a shape-dependent manner (1231). Some metal nanomaterials have also been
shown to modulate the capacity for macrophages to transition between activation states (777, 1230,
1232). The preferential induction of M1 and M2 macrophage phenotypes may have critical implications
for allergic disease given the association of these states with different levels of scavenger receptor
expression, phagocytic activity, and potential for inflammatory mediator release (777, 832, 1217, 1218,
1229-1233).
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Several metal nanomaterials have been implicated in inducing alterations in PRR expression and
TLR signaling in macrophages. TLR-3, TLR-7, TLR-9, and TLR-10 expression by macrophages have
been demonstrated to be modulated following exposure to ZrONP, TiO2NP, SiNP, and CoNP (1229).
AgNP and QD have also been shown to augment macrophage TLR signaling in a surface modificationdependent manner (1234, 1235). A study using QD revealed that differences in surface modification of
particles weas responsible for divergent mechanisms of internalization. The pro-inflammatory effects
were associated with functional groups (-COOH, -NH2, -OH, and OCH3) that facilitated uptake by lipid
raft and class A scavenger receptors, inducing NF-kB signaling (1236). TLRs and adaptor proteins have
been implicated in the uptake and inflammatory response induced by many metal nanomaterials, but
these signaling pathways are also critical mediators of the innate immune events involved in allergy and
adjuvant effects. Likewise, the capacity for metal nanomaterials to modulate these signaling pathways
may represent a notable mechanism of nanomaterial-induced immunological interference (862, 885,
1008, 1237).
One of the most commonly-investigated biological effects of macrophages investigated with
respect to metal nanomaterials in vitro is inflammasome activation. Inflammasome activation is known to
contribute to the effects of many adjuvants, including aluminum hydroxide. Moreover, NLR Family Pyrin
Domain Containing 3 (NLRP3) inflammasome signaling is known to facilitate the transition to
hypersensitive disposition from immunological tolerance in subjects exposed to metal implant debris
(500). Activation of the NLRP3 inflammasome in macrophages has been observed following exposure to
SiNP, TiO2NP, and AgNP (689, 1196, 1238, 1239). Inflammasome activation by some of these materials
has been shown to involve mechanisms related to ROS production and endosomal rupture; likewise,
activation has been correlated to properties including dissolution rate, crystal structure, and surface
modification (775, 1240, 1241). Interestingly, smaller sizes of CeO2NP were associated with a lower
incidence of inflammasome activation in one report. However, since smaller particles were shown to have
more crystal lattice defects capable of scavenging of ROS, higher levels of ROS induced by larger CeO2
particles explain this observation (1242).
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In addition to inflammasome activation, alarmin release by macrophages is another mechanism
by which metal nanomaterials can promote macrophage involvement in sensitization. Cytotoxic effects
of metal nanomaterials on macrophages have been correlated to surface modification and size of AuNP,
corona composition of SiNP, ion release from NiONP, and hydrophilicity of TiO 2NP (1243-1246).
However, differential mechanisms of cell death have been observed following macrophage exposure to
various metal nanomaterials. SiNP have been shown to induce plasma membrane damage leading to
necrotic cell death (1247). Contrarily, in a panel of metal oxide nanoparticles, transition metal oxides were
shown to preferentially induce apoptotic macrophage cell death, whereas rare-earth oxide nanoparticles
were associated with pyroptosis (1248). This distinction can have significant implications for the early
events of sensitization, as necrotic cell death is associated with the passive release of many alarmins
known to activate inflammasomes (1239).
A few in vitro studies evaluating metal nanomaterial effects on macrophages have highlighted
some important considerations for the correlation of physico-chemical properties with immunotoxic
effects. In one of these studies, the J774.A1 macrophage cell line was used in one of the few studies that
has investigated the immunotoxic effects of CrNP. The study used 60 or 700 nm CrNP and reported
dose-dependent production of inflammatory cytokines and cytotoxicity, wherein the highest doses were
associated with necrotic cell death. Interestingly, the authors reported that the observed effects were
dependent on CrNP dose volume, which is not a dose metric that is frequently considered in other existing
studies (764). Another study investigating the effects of clinically-relevant alumina ceramic wear particles
(5-20 nm, 0.2->10 µm) reported a similar finding, wherein activation and TNF-α production by human
blood mononuclear phagocytes was dependent on the particle dose with respect to volume (1249).
Although particle volume may appear correlated to the cellular response induced by metal nanomaterials,
Ingham et al. highlight a notable consideration regarding this metric. Their study showed that macrophage
activation was not necessarily dependent on the volume of the entire administered dose, but on the
volume of particles within the critical size range (0.2 – 0.8 µm) associated with macrophage activation
(1250). This finding emphasizes that studies designed to correlate metal nanomaterial physico-chemical
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properties with toxic effects should take into consideration that most samples likely contain particles
exhibiting a range of values with respect to any physico-chemical characteristic.
In the context of metal implant debris release, Reddy et al. (2014) investigated the impact of CrCo
alloy particle size on the inflammatory response of macrophages in vitro. Using both the THP-1 cell line
and primary human macrophages, the authors demonstrated a clear discrepancy in responses to 5 and
70 µm particles. When the particles were incubated with serum proteins prior to exposure, discordant
responses were also observed, irrespective of dose normalization for surface area. The authors
subsequently highlighted a consideration with notable applicability for nanomaterial studies that is often
overlooked. Although cells were exposed to similar surface area-based doses of the metal particles, the
adsorbed constituent profile was not conserved between particles, as differences in surface chemistry
were associated with the adsorption of different proteins. This consideration is importance since many
studies have correlated nanomaterial toxic effects with surface area dose. However, biocorona formation
has the capacity to compromise this dose-response relationship, as size (or other physico-chemical
property)-mediated adsorbate profiles can influence toxic effects.
Neutrophils: Neutrophils are innate immune cells recruited from the circulation to sites of
inflammation where they play critical roles in the destruction of invading pathogens and antigens.
Neutrophils can also exhibit significant promoting effects on allergic inflammation, rendering this
population another potential target of metal nanomaterial effects with potential implications for allergy.
Metal nanomaterials have been shown to both recruit neutrophils to exposure sites, as well as
augment some of their functions. Many metal nanomaterials have been shown to be taken up by
neutrophils in a size-dependent manner (1251, 1252). Neutrophils are capable of projecting cellular
extensions, called neutrophil extracellular traps (NET), coated with neutralizing peptides and enzymes to
intercept invading agents (1253). Upon adhesion, AgNP, FeNP, and AuNP have been shown to induce
the release of NET by neutrophils, which was shown to be influenced slightly by shape, but significantly
influenced by surface modification, biocorona presence, and charge (1254-1256). TiO2NP and ZnONP
have been shown to increase both FcR-mediated (opsonized antigen) and complement-mediated
phagocytosis in human neutrophils, as well (1257).
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The capacity for metal nanomaterials to impact neutrophil activation and degranulation has also
been examined in vitro. TiO2NP, CeO2NP, and ZnONP were all shown to alter different aspects of
neutrophil degranulation in vitro, illustrating the potentially diverse effects capable of modulating
neutrophil activity. Interestingly, TiO2NP exposure was shown to result in enhanced MMP-9 enzymatic
activity and alterations in the enzymatic activity of myeloperoxidase released by neutrophils in vitro (1258,
1259). Surface modification has also been shown to be critically important in the induction of neutrophil
oxidative burst by GdNP and FeNP (1260, 1261). Alterations in these different aspects of neutrophil
granule release may greatly impact allergic processes, especially in the context of tissue injury and
chronic effects of allergic inflammation.
A particularly interesting observation regarding metal nanomaterial effects on neutrophils with
potential to impact allergic disease is their capacity to modulate apoptosis. Phagocytosis primes
neutrophils for apoptosis, following which they are disposed of by macrophages. This process functions
to prevent further translocation of pathogens or antigens internalized by neutrophils at the site of
exposure (1262). Accordingly, the observation that FeNP was capable of modulating apoptotic signaling
in human neutrophils raises concerns that metal nanomaterial exposure may compromise the effective
sequestration of antigens by neutrophils (1261). Similarly, ZnONP were shown to delay apoptosis of
neutrophils, suggesting another potential effect that may facilitate translocation of antigens (1263).
Other studies have shown that metal nanomaterials can augment normal biology of neutrophils
by mechanisms including modulation of cytoskeletal proteins, morphology, and de novo protein synthesis
(1251, 1264). The implications of these effects on allergic disease remain speculative, but given the
recent recognition of neutrophils on adaptive immunity, they represent another potential target of metal
nanomaterial-induced alterations in allergic disease (1265).
Eosinophils: Eosinophils are another immune cell that may be subject to modulation by metal
nanomaterials leading to potential implications for allergic disease. Eosinophils are known to be one of
the major cell types involved in the pathogenesis of asthma (182). Although an expansive number of
studies have reported the capacity for metal nanomaterial exposure to recruit eosinophils to the lungs in
vivo, the direct effects of metal nanomaterials on eosinophil functions has not been frequently examined
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in vitro (663). However, the few existing studies have generated findings suggestive of the potential for
metal nanomaterial to augment several biological functions of eosinophils implicated in their effector
functions in asthma.
One such finding is the observation that several metal nanomaterials can modulate components
of the eosinophil cytoskeleton. PdNP and TiO2NP were shown to alter human eosinophil cytoskeleton
dynamics, subsequently increasing adhesion to endothelial cells (1266, 1267). Contrarily, ZnONP and
AgNP were shown to induce cytoskeletal breakdown in a human eosinophilic cell line in vitro. ZnONP
and AgNP have been shown to increase the release of pro-inflammatory cytokines including IL-8 and IL1β by eosinophils in vitro, as well (1268). Similarly, ZnONP were shown to increase de novo protein
synthesis and delay apoptosis of eosinophils (1269). Since the major effector functions of eosinophils in
asthma are dependent on their chemotactic ability and release of inflammatory mediators, these findings
suggest metal nanomaterials may have the potential to modulate eosinophil activity leading to alterations
in asthmatic processes.
NK Cells: One of the cell types least frequently studied with respect to metal nanomaterials is the
NK cell. Historically, NK cell contributions to allergy have not been as highly regarded as those of other
cell types; however, they have recently become recognized as critical contributors to allergic processes
(1270, 1271). In the lungs, NK cells are involved in regulation of various immune responses, including
DC maturation, T-cell priming, and Th2 cytokine production, implicating potential effects of these cells on
both sensitization and elicitation (1272-1275). Similarly, dysregulation of NK cell function in the skin has
been associated with the pathogenesis of both ACD and atopic dermatitis (1276, 1277).
The potential impact of NK cells on allergic disease is further highlighted by numerous reports of
altered peripheral NK cell populations in human subjects with allergic disorders (1278-1280).
Interestingly, similar shifts in NK cell populations have been observed in animal models following
exposure to TiO2NP, PtNP, AgNP, SiO2NP, and ZnONP by various exposure routes (1066, 1140, 12811287). These findings highlight that NK cells are subject to modulation by metal nanomaterials, and they
represent a target cell frequently overlooked in immunotoxicity studies.
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In vitro studies examining the direct effects of metal nanomaterials on NK cells are limited.
Although some metal nanomaterials including AgNP and FeNP have been shown to compromise NK cell
viability, functional alterations in NK activity have also been reported (1288-1290). NK expression of Fc
receptors and various other markers have been observed following metal nanomaterial exposure,
mirroring characteristic alterations seen in allergic subjects (1291). Alterations in target cell killing
capacity by NK cells and altered cytokine production have also been observed in vitro (1292). Moreover,
these effects have been correlated to AuNP size and charge, AgNP ion release, and SiO 2NP charge,
highlighting the potential impact of nanomaterial physico-chemical properties on NK function (538, 1078,
1285, 1290). The specific implications of these observations on allergic disorders remains unknown, but
given the current knowledge of NK cell influence on allergy, this is an area in need of scientific attention.

1.2.4.5. Knowledge Gaps in Metal Nanomaterial Effects on Immune Cells and Processes In Vitro
In vitro studies present a notable opportunity to advance the understanding of the potential for
metal nanomaterials to act as allergens. Although one study has demonstrated size-dependent formation
of titanium antigens, the generation of antigenic determinants from nanomaterials comprised of
sensitizing metals is a concept that could be addressed particularly well by in vitro studies.
Another major knowledge gap particularly well-suited to be addressed by in vitro studies is the
immunological effect of exposure to mixtures of metal nanomaterials, since a few studies have
demonstrated that interactions between nanoparticles in vivo can modulate subsequent biological
responses (1293). Co-exposure to cobalt and nickel during allergic sensitization has been shown to
enhance the severity of elicitation responses to a single metal, indicating that interactions between the
metals can greatly impact their immunogencitiy (1294). Similar to the activity of prehaptens and
prohaptens, the immunogenicity, and even allergenicity, of some agents requires chemical modifications
dependent on interactions with other agents. Given the enhanced reactivity of metal nanomaterials, their
interactions other nanomaterials, sensitizing chemicals, and metal ions have the capacity to induce
notable alterations in subsequent immune responses.
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For example, titanium-induced IL-1β release from macrophages was shown to be mitigated when
simultaneous exposure to cobalt ions occurred (1018). Similarly, ultrafine particles and metal ions were
shown to interact and potentiate toxic responses when co-administered in vivo (1017). A similar potential
impact of mixture toxicology on the immune effects of metal nanomaterials may also significantly impact
allergic effects. In one study, DC maturation was shown to be altered when inclusion of both AuNP and
NiSO4 in physiological media resulted in alterations in AuNP charge and subsequent corona formation
(769). Furthermore, the elicitation of nickel skin allergy was abrogated in the presence of nanoparticles,
which captured nickel ions by cation exchange, as previously mentioned (727). These findings suggest
a notable potential for complex interactions between metal nanomaterials that may result in various types
of combined toxicity responses. Moreover, exposures to a single agent are unrealistic under normal
circumstances, highlighting the translational relevance of studies investigating the effects of exposure to
combinations of materials.
Another knowledge gap associated with the existing collection of in vitro studies involves the
biocorona and specific molecular constituents. Nanomaterial biocorona formation has been almost
exclusively investigated with respect to the adsorption of proteins. Nanomaterials are also subject to
interactions with other macromolecules present in biological fluids, such as nucleic acids and lipids.
Adsorption of these molecules may have notable impacts on the immune effects of nanomaterials since
different nucleic acids are alarmins recognized by PRR and lipid mediators play critical roles in many
aspects of allergic disorders (1295, 1296). Accordingly, more research should be directed towards
investigating the biological implications of surface-adsorbed macromolecules other than proteins.
Furthermore, corona constituents have been extensively studies with respect to lung lining fluid and
serum, but the formation of coronas in lymph and other immunologically-relevant environments has not
been addressed.
Another critical aspect of toxicology risk assessment that has potential to be advanced by in vitro
studies is the development of alternative approaches of safety assessment. As countless new agents
emerge and require safety evaluation, the fields of immunotoxicology and nanotoxicology are both in
demand of novel alternative testing methods to reduce the use of laboratory animals, maximize the
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amount of data generated from studies, and expedite toxicity evaluations (1297). One such example, the
establishment of quantitative structure activity relationships (QSAR) has been proposed as a statisticalbased approach for predicting the adverse effects of agents with respect to both nanotoxicity and allergic
disease (1298).
In vitro studies have been advantageous in the development of nanomaterial QSAR as they
permit the simultaneous evaluation of numerous materials, physico-chemical properties, and cell types
in order to delineate relationships between physico-chemical properties and mechanisms of toxicity
(1299, 1300). Correspondingly, studies using expansive numbers of metal nanomaterial test agents have
helped establish relationships between physico-chemical properties and toxic potential specific to human
pulmonary epithelial cell lines, microorganisms, human keratinocytes, and murine macrophages (1301,
1302) These studies have also helped identify additional descriptors associated with the toxic potential
of metal nanomaterials, such as atomic number, element-specific catalytic activity, atomization energy,
and band gap energy (1303-1305).
Similar in vitro studies using dermal, pulmonary, and immune cell types involved in allergic
sensitization have led to progress in the development and validation of alternative methods for
identification of skin and respiratory sensitizers (212, 213, 1306-1310). Despite the shared potential utility
of this approach for both niches of toxicology, QSAR pertaining to the immunogenic effects of metal
nanomaterials have yet to be established, but represent an increasingly relevant area of interest for future
studies.

1.2.5. Collective Knowledge Gaps and Considerations for Future Studies
Overall, the potential for metal nanomaterials to induce allergic sensitization and the subsequent
development of metal-specific hypersensitivity responses has not been thoroughly investigated. A few
studies have examined the potential for metal nanomaterials to cause dermal sensitization. However,
these studies have all involved the selective investigation of a few specific agents. As a result, although
TiO2NP, AgNP, and SiO2NP have all been shown to pose minimal risk for the induction of contact allergy,
the skin sensitizing potential of most metal nanomaterials remains unknown.
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While a small number of studies have evaluated the potential for select metal nanomaterials to
induce skin sensitization and the development of ACD, no studies have been executed to determine the
potential for metal nanomaterials to induce sensitization via the respiratory tract. Although the
identification of agents with potential to induce respiratory sensitization has been historically problematic,
many proposed approaches have been developed and shown to have predictive utility. Despite this, the
lung-sensitizing potential of nanoscale allergenic metals has not been investigated.
The majority of existing studies have examined metal nanomaterial effects on allergic disease in
the context of a single tissue; however, since metals are known to cause both dermal and respiratory
allergy, metal nanomaterial exposure may implicate the emergence of novel connections between allergic
responses in the skin and lungs.
Contact allergy to metals is common in the general population, but given the low frequency of
high dose inhalation exposures to these metals, the pulmonary effects of allergenic metals in individuals
with established contact sensitivity remain largely unknown. A few studies have been conducted wherein
distinct pulmonary immune responses to cobalt and chromium were observed in guinea pigs who had
been previously sensitized via the skin when compared to naïve animals (1311, 1312). As global
production of metal nanomaterials continues to increase and they become more frequently encountered
by the general public, these observations suggest that the large number of individuals with existing metalinduced ACD may be particularly susceptible to pulmonary immune effects of nanoscale metals. This
concept has only recently been recognized, and connections between metal-specific allergic responses
of the skin and lung with respect to metal nanomaterials remains a significant knowledge gap (881).
In addition to their potential to induce allergic sensitization, one of the most critical knowledge
gaps regarding the immunotoxic potential of metal nanomaterials is the discord between metals that have
been investigated by existing studies and metals with historical relevance to allergic disease. The majority
of the immunological responses caused by respiratory and dermal exposure to metal nanomaterials have
employed test agents including TiO2NP, AgNP, and SiO2NP. The existence of these studies reflects the
increased demand for investigations into their safety, as they are some of the metal nanomaterials being
produced in the largest quantities. Additionally, their commercial applications are associated with notable
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potential for dermal and respiratory exposures in consumers following the use of nano-enabled
sunscreens, cosmetics, and other goods. However, these three metals are some of the metals least
commonly associated with allergenic effects. The most common inducers of metal ACD (nickel, cobalt,
chromium, palladium, gold) have yet to be tested for their dermal sensitization potential in nanoparticulate
forms. Moreover, the metals most commonly implicated in metal-induced asthma (nickel, cobalt,
chromium, platinum) have also yet to be evaluated.
Correspondingly, the vast majority of metal nanomaterials that have been incorporated into
existing immunotoxicity studies are among the top 15 materials being produced in the highest volumes.
However, hundreds of metal nanomaterials have been developed and manufactured globally. Many of
the metal nanomaterials being produced in low volumes are overlooked by scientific efforts, despite
evidence that they may pose a significant immunological hazard. Moreover, the demand for many of
these nanomaterials is projected to increase in the upcoming years, increasing the relevance of their
unknown immune effects. For example, the immune effects of CrNP and PtNP have rarely been studied,
despite the known immunogenicity of their metal constituents. Similarly, mercury-containing
nanoparticles, and nanoparticulate forms of indium tin oxide, vanadium oxide, beryllium, and manganese
oxide have been associated with size-dependent inflammatory effects in vivo and in vitro, but their direct
immune effects remain largely unstudied (1313-1317).
In addition to the knowledge gaps constituted by specific nanomaterial entities, many specific cell
types remain under-investigated as potential targets of metal nanomaterial-induced effects capable of
impacting allergic disease processes. For example, the majority of in vitro studies that have characterized
metal nanomaterial effects on immune cells have investigated target cells of the innate immune system,
including macrophages and DC. As a result, the potential for metal nanomaterials to induce alterations
in functionality and immunological activity of adaptive immune cells is not as well understood.
Accordingly, the potential for metal nanomaterials to augment cellular processes specific to the elicitation
phase of allergy constitutes a notable knowledge gap.
Several specific immune cell subpopulations also constitute existing knowledge gaps with
relevance to allergic disease (1318). For example, the effects of metal nanomaterials on regulatory T-cell
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functions have rarely been investigated and, despite their known involvement in metal allergy, invariant
natural killer T-cells (iNKT) have also rarely been studied in this context (1319). Similarly, plasmacytoid
DC have rarely been studied in this context, despite their critical roles in the development of
immunological tolerance, and the specialized functions of LC have not been frequently investigated as
targets of metal nanomaterials (1320).
Furthermore, the recent identification of novel immune cell populations involved in allergic
disorders has resulted in additional knowledge gaps with potential to delineate many of the immunological
mechanisms responsible for observations from in vivo studies. For example, innate lymphoid cells are a
newly-identified subset of immune cells that exhibit notable effector functions in immune responses
associated with mucosal tissues. Three phenotypically-distinct subsets of innate lymphoid cells have
been currently described, each with unique roles in the regulation of allergic responses (1321). Despite
this, metal nanomaterial-induced alterations in innate lymphoid cell activity have yet to be characterized.
Additionally, respiratory M cells have been recently identified as a functionally-distinct population of
immune cells populating MALT involved in sampling of antigens present in the airways (1322). This
population of cells represents another cell type with unknown susceptibility to allergy modulating effects
caused by metal nanomaterials.
Although immune cells are considered to be the primary mediators of allergic processes, other
cell types are also critically involved in immunological responses. These cells’ responses following metal
nanomaterial exposure are often overlooked by immunotoxicity studies, despite notable potential for
contributions to various allergic processes. In this respect, epithelial cells of the skin and airways have
been frequently studied as potential targets of metal nanomaterial toxic effects. Subsequent findings have
helped generate a more complete understanding of the immunotoxic potential of metal nanomaterials,
as these cells produce large quantities of pro-inflammatory cytokines, release alarmins, and exhibit
barrier functions that limit the bioaccessibility of many antigens.
Disruptions in any of these activities following metal nanomaterial exposure can have profound
effects on allergic responses, illustrating the importance of investigations into metal nanomaterial effects
on non-immune cells. Although epithelial cells have been frequently studied in this regard, other cells
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types with similar immune-mediating potential have not been equally investigated. For example,
endothelial cells are critical mediators of immune responses, but are not a cell type commonly studied
with respect to metal nanomaterials. Endothelial cells express various PRR, release numerous Th1/2
cytokines, and facilitate effective migration/mobilization of immune cells, effects which are all critical in
both allergic sensitization and elicitation responses. Accordingly, metal nanomaterial-induced alterations
to any of these cellular functions can result in modulation of various allergic processes. Furthermore,
endothelial cells also produce numerous molecular mediators involved in allergy-related vascular
responses, such as angiogenic remodeling, which is a pathologic process characteristically observed in
asthmatic airways. Since the number of blood vessels in the airway walls has been correlated to
asthmatic response severity, this represents another process associated with the chronic progression of
allergic disease that is mediated by endothelial cells, and may be subject to modulation following metal
nanomaterial exposure (1323).
Another major knowledge gap with respect to metal nanomaterials and allergic diseases is their
potential to induce adverse immune effects following exposure routes other than inhalation or dermal
contact. One of these routes, ingestion, is becoming increasingly relevant as the food industry is another
sector adopting nanotechnological advances. Following oral administration, AuNP, AgNP, CeNP, and
FeNP have all been shown to accumulate in lymph nodes and spleen, suggesting the potential for their
ingestion to cause subsequent immune effects (57, 1324-1327). Ingestion of AlNP, AuNP, AgNP, CuNP,
TiO2NP, and ZnONP has also been associated with effects ranging from increased B-cell distribution and
activation, elevated IgE and IgG levels, modulations in TLR-4 signaling, suppressed innate immunity,
activation of macrophages, and splenic toxicity in mice (1128, 1282, 1283, 1328-1334). The potential for
such effects to specifically impact allergic disease processes has been illustrated by a few studies. For
example, ingestion of SiNP and PtNP were associated with increases in antigen-specific antibody
production following immunization of mice and rabbits (956, 958). Interestingly, oral administration of
AgNP has been shown to block the development of oral tolerance to OVA in sensitized mice, directly
demonstrating the potential for metal nanomaterials to augment allergic disease resulting from an often
overlooked route of exposure (800).
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In addition to ingestion, the potential for metal nanomaterials to induce sensitization or elicitation
of allergic responses following systemic administration is another emerging knowledge gap. While most
current applications of metal-based nanomaterials are not likely to result in large doses of systemic
exposures, animal studies have demonstrated that systemic administration of many metal nanomaterials
including AuNP, AgNP, AlNP, TiO2NP, SiNP, PdNP, and FeNP exhibit physico-chemical propertydependent kinetics, accumulation in lymphoid organs, and adverse immune effects (768, 1142, 1287,
1335-1344). These immune effects may have implications for allergic disease as systemic administration
of GdNP, FeNP, SiNP, and AuNP have been shown to augment antigen-specific antibody production in
mice (533, 734, 874, 953). Similarly, increased rates of T-cell-mediated metal hypersensitivity in patients
with metal on metal joint replacements has been suggested to be related to the release of nanoscale
metal debris (1345).These observations are concerning as the number of biomedical applications for
nanotechnology continues to grow, and systemic exposures to some metal nanomaterials, including iron
and gold are increasing (1171).
The concerning lack of knowledge regarding systemic effects of metal nanomaterials is most
profoundly illustrated by the numerous adverse effects in patients who were administered Feraheme
(ferumoxytol). Feraheme is an intravenously-administered iron replacement product comprised of 17 –
31 nm colloidal Fe3O4NP originally approved for the treatment of iron-deficiency anemia in patients with
chronic kidney disease (1346). In the 5 years between its approval for use (June of 2009) and the Food
and Drug Administration (FDA)’s publication of a safety announcement in 2014, 79 anaphylactic reactions
were reported, of which 19 were fatal despite immediate medical intervention efforts. The underlying
mechanisms of the reactions remain unclear, but more than half of the reactions occurred in patients with
a history of drug allergy, suggesting a potential connection to atopic disposition and true adaptive
immunity-mediated allergy (1347). Contrarily, the 2017 observation that iron nanomedicines are capable
of activating TLR-3, -7, and -9 and activating the complement cascade suggests that innate immunemediated pseudoallergic reactions might have been involved (1348).
Gold nanomaterials are also being used in biomedical applications including diagnostic imaging,
drug delivery, and photothermal therapy, and have been proposed for use in various novel therapeutic
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approaches including vaccine production (1172, 1349). Although gold nanomaterials have been generally
regarded as toxicologically inert, the historical use of immunomodulatory gold-based pharmaceutics in
the treatment of rheumatoid arthritis and gold’s increasing recognition as a dermal sensitizer raise
concerns over potential for gold nanomaterials to induce adverse immune effects (1350). Studies have
demonstrated that systemic administration of AuNP can cause immune effects ranging from enhanced
lymphocyte proliferation, accumulation in the spleen, and enhanced allergen-specific antibody production
in mice and rats (533, 1339, 1351). In addition to systemic exposures, the increase in use of gold
nanomaterials in healthcare settings also results in increased risk for dermal contact or inhalation
exposure by both patients and healthcare workers. Since rates of dermal sensitivity to gold are surpassing
the historically prominent rates of nickel allergy by some estimates, the impact of existing sensitivity to
gold on the immune response following exposure to gold nanomaterials remains unknown (255).
The existing collection of knowledge regarding the immunotoxic potential of metal nanomaterials
and corresponding knowledge gaps highlight several notable considerations for future studies. As
continuous efforts are made to correlate physico-chemical properties with mechanisms of nanomaterial
toxicity, many of these considerations pertain to the accurate measurement and reporting of nanomaterial
characteristics of interest. One of the preliminary considerations should be the source of acquisition for
the test materials. As highlighted by Casals et al. (2017), commercially-available nanomaterials and
nanomaterials synthesized in laboratories by wet chemistry are often presented under the same name
between studies. However, differences in their purity and storage conditions can manifest as
discrepancies in properties such as aggregation, which can become a significant source of variation in
biological effects reported between studies. It has been suggested that the expansive discrepancies in
reports of CeO2NP toxicity and anti-inflammatory effects may be reflective of such an issue (1352). As a
result, the source of test materials should be reported by studies and considered by readers when
comparing results between studies.
The delineation of relationships between nanomaterial physico-chemical properties and
mechanisms of toxicity, irrespective of tissue of interest, is dependent on thorough material
characterization and accurate reporting of subsequent findings. Methodology used for material
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characterization is rarely conserved between studies, and the measurements generated by different
techniques can often differentially represent parameters of interest. Despite this, properties of test
materials are often similarly reported following variations in assessment.
The surface area of test materials has become a standard metric reported in most toxicity studies.
However, this parameter illustrates the potential complications associated with variations in metrology
and subsequent conclusions regarding the impact of this property on the observed toxic response.
Studies often report the SSA of test materials, generated from analysis by gas adsorption. While SSA
has been correlated to the degree of nanomaterial-induced toxicity by some measures, other measures
of surface area have been shown to be more representative. Sager et al. (2016) report that nanomaterial
delivered structure surface area, derived from the hydrodynamic diameter acquired from dynamic light
scattering, was a more accurate predictor of NiONP-induced pulmonary inflammation in vivo. Although
many studies simply report material ‘surface area’ irrespective of measurement method, discrepancies
in arise from the state of the material during measurement. Since SSA is measured on the dry powder, it
is a property independent of suspension media, contrary to structure surface area, which takes into
account alterations in material behavior upon introduction into suspension for in vivo or in vitro delivery.
Variations in SSA measurements also arise from the multiple models of calculation from gas adsorption
data (1353, 1354). The impact of alterations in material characteristics upon entry into suspension are
illustrated by the differential toxic effects of the same NiONP suspended in four different delivery media
(1355). Given the existence of additional variations of surface area, such as volume-specific and
geometric surface area, studies should consider the use of multiple assessment methods and accurate
reporting of such (1356, 1357).
The existence of numerous approaches for the assessment of properties including surface area
highlights another consideration for test materials used in future studies. Given the recent widespread
emergence of nanomaterials, discrepancies in standard nomenclature and definitions in the field also
have the capacity to complicate collective analysis of study results. Although the size of nanomaterials is
their unifying characteristic, numerous organizations differentially define the size range for inclusivity.
Similar discrepancies exist in the reporting of nanomaterial properties, as well, which can significantly
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impede the establishment of relationships between physico-chemical properties and mechanisms of
toxicity. A notable example is the tendency for non-discriminate reporting of aggregates and
agglomerates of primary particles. The irreversible bonds of aggregates and reversible bonds of
agglomerates can manifest as different biological effects in vivo as demonstrated by the administration
of AuNP aggregates and agglomerates which differentially distributed to organs and within cells (13581361). Variations in toxicity may arise from differences in the effective dose surface area and size of
conserved aggregates compared to agglomerates subject to breakdown and release of primary particles
(1362, 1363). Degree of agglomeration has been shown to influence metal nanomaterial cellular uptake,
oxidative stress, cytokine response, indicating agglomerates and aggregates should be differentiated
prior to in vivo studies and reported accordingly (1364, 1365). Despite the differential biological impact of
nanomaterial aggregates and agglomerates, the two terms are often used interchangeably in studies.
The correlation of physico-chemical properties and nanomaterial toxic potential is limited
ultimately limited by the accuracy of characterization measurements. As our understanding of
nanomaterials and their interactions with biological systems progresses, many properties have become
recognized as dynamic and dependent on their compartment. Likewise, additional considerations for
characterization have emerged, such as the potential need for characterization of nanomaterials in their
primary (powder), secondary (delivery media), and tertiary (nano-bio interface) forms. Efforts by the ISO
have helped standardize some of the methods used in these efforts, as well as accurate nomenclature.
Likewise, these documents should be consulted, and multiple methods of material characterization are
likely to help accurately relate properties of the nanomaterials to the subsequent study endpoints.
Although reporting of some physico-chemical properties, including size, have become standard
for nanotoxicology studies, an additional parameter of critical relevance to immunotoxicology studies is
often overlooked. As a result of production and handling in non-sterile conditions, engineered
nanomaterials are often carriers of impurities including bacterial LPS (1366). LPS is known to be a potent
adjuvant inducing stimulation of immune cells via the TLR-4 signaling pathway, activating the NF-κB
signaling pathway, and promoting DC maturation (837). In fact, LPS has been historically required as an
adjuvant to induce sensitization to some metals in laboratory rodent models by facilitating antigen-non-
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specific activation signals (1367, 1368). Likewise, the presence of endotoxin on metal-based
nanomaterials’ surfaces could induce a subsidiary but sufficient amount of immunostimulation required
to induce allergic sensitization to the metal itself, or to other allergens. Accordingly, exposure to metal
nanomaterials with negligible immunotoxic potential that are contaminated with endotoxin can result in
misidentification of their potential to augment allergy. Recent recognition of the toxicological implications
of LPS contamination has led to the addition of endotoxin assessment as a pivotal step in the material
characterization phase conducted prior to the incorporation of nanomaterials into in vivo studies (13681370). However, many of the studies published prior to this development do not report the presence or
absence of endotoxin in samples, and results should be interpreted with caution.
The critical roles of TLR-4 activation in allergic sensitization not only highlight the importance of
assessing test materials for endotoxin contamination, but also highlight another major consideration for
animal model selection in future studies. In 2010, Schmidt et al. eloquently demonstrated that the capacity
for nickel ions to bind and activate TLR-4 on human monocytes was not conserved between species. A
structural variation in rodent TLR-4 prevents activation by nickel ions, explaining the historical
discrepancy in susceptibility to nickel sensitization between humans and laboratory rodents. A similar
finding regarding cobalt ions was also demonstrated. This finding has notable implications for both past
and future studies using rodents to investigate immunotoxic potential of transition metals. Since the
release of nickel and cobalt ions and subsequent TLR-4 activation is critically influential in the
immunogenicity of these metals in humans, the absence of this mechanism in mice and rats may limit
the translational capacity of study results using nanomaterials comprised of nickel and cobalt.
A mouse model expressing humanized TLR-4 previously developed by an investigator has
recently become available for purchase from laboratory animal vendors in 2018. Based on existing
information, this model might represent an approach for studies to address the confounding variability of
metal immunogenicity between species, but it has yet to be utilized for any large-scale studies.
In addition to TLR-4 activation susceptibility, other considerations for animal model selection exist.
As previously eluded to, use of various mouse strains in many of the previously-mentioned studies likely
contribute to discrepancies in findings despite similar test materials, exposure conditions, and assessed
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endpoints. The use of Th1- or Th2-dominant mouse strains, such as C57BL/6 and BALB/c, strains
respectively, not only has critical influence on preferential immune responses, but is also known to affect
nanomaterial disposition following exposure (904, 1371). Moreover, mouse age is also known to have
critical influence on immune responses, and should be considered during study design, but also when
comparing results from studies (1372).

122

1.3. SPECIFIC METALS OF INTEREST

1.3.1. Nickel
1.3.1.1. Toxic Potential of Nickel and Nickel-Containing Compounds
Nickel is a naturally-occurring metal found in the earth’s crust and is the 5th most abundant
element by weight after iron, oxygen, magnesium, and silicon (1373). Nickel is a silvery-white metal with
a high melting point (1453°C), is resistant to corrosion and oxidation, and is magnetic at room
temperature. These properties make nickel optimal for combination with other metals including iron,
copper, chromium, and zinc to form over 3,000 nickel-containing alloys. One of the most common alloys
comprised of nickel is stainless steel, whose other metal constituents generally include chromium and
iron. Nickel, stainless steel, and other nickel-containing alloys are fundamental to many diverse industries
including transportation and aerospace engineering, architecture and construction, power generation,
and biomedical technology (1374).
The expansive applications for nickel implicate frequent exposures to the metal in the general
population, as well as in workers. As a result, the biological effects of nickel have been extensively
studied. Nickel is known to induce numerous diverse toxic effects, all of which are fundamentally
dependent on its speciation (1375). As a member of the transition metal series, nickel exists in five
oxidation states: -1, 0, +2, +3, and +4. The most common valence state of nickel is nickel (II). Nickel can
form complexes with diverse elements including oxygen, nitrogen, chlorine, and various other metals.
Despite this diverse potential for speciation, the toxic potential of nickel compounds is generally
conserved between agents similarly classified as organic/inorganic or water soluble/insoluble (1376).
Dermal Exposure to Nickel: The toxic potential of nickel is also dependent on the route of
exposure. In the general population, dermal contact is the most common type of encounter with nickel
and nickel-containing items. Nickel is incorporated into over 300,000 different products that most
individuals use daily including cooking utensils, currency, and electronics (1377). However, jewelry is one
of the most commonly-encountered sources of nickel that facilitates dermal exposure. Interactions
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between nickel and the skin can result in both acute or chronic effects which can both remain localized
to the skin or induce peripheral/systemic responses. Dermal exposure to nickel is most frequently
associated with irritant responses, allergic contact dermatitis, and urticarial reactions of the skin (1378).
Inhalation Exposure to Nickel: Inhalation exposures to nickel are also common. Given its
abundance in the earth’s crust, the presence of atmospheric nickel often results from natural processes
(1379). Disruption of dust and soil by wind and other environmental forces, as well as processes such as
volcanic eruptions can lead to the release of nickel into the air. However, anthropomorphic processes
generally constitute the release of larger amounts of nickel into the atmosphere. Nickel refining, steel
production, combustion of fossil fuels, and incineration of nickel-containing goods all result in the
generation of ambient nickel (1374). Metallic nickel, nickel oxides, nickel sulfate, and numerous other
nickel-containing compounds are released by these processes, facilitating their potential for inhalation by
humans. Although concentrations of nickel in ambient air can vary greatly as a function of geographical
location, the EPA has reported that average atmospheric nickel concentrations range between 7 and 12
ng/m3 in the USA (1380). However, point sources can be responsible for airborne nickel concentrations
of up to 150 ng/m3.
Nickel is a known respiratory toxicant capable of causing lung inflammation, fibrosis, asthma, and
many other adverse effects in the lungs. The toxic potential of nickel compounds in the respiratory tract
tends to be conserved with respect to material solubility (1380). Generally, soluble nickel compounds are
associated with more severe toxic effects in the lungs resulting from their propensity for rapid dissolution
and subsequent release of large quantities of cytotoxic ions. One of the most toxic soluble nickel
compounds is nickel carbonyl. Comparatively, insoluble nickel compounds are generally regarded as less
toxic following inhalation exposure, but are more frequently associated with the development of lung
cancers than soluble nickel compounds (1381).
Oral Exposure to Nickel: As a major constituent of soil, nickel is also present in many foods and
beverages, implicating ingestion as another potential route of exposure to nickel. Legumes, whole grains,
cocoa, tea, and soy products are some of the foods known to contain the largest amounts of nickel (415).
Furthermore, preparation of food using nickel-containing utensils and cookware can also increase dietary
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intake of nickel (1382). Collectively, the average diet results in a daily ingestion of approximately 300600 µg nickel (1383). Average levels of nickel in the drinking water supply of the United States average
between 2 and 4.3 µg/L and represent another source of nickel ingestion. Although its roles in the human
body remain unclear, nickel is considered an essential micronutrient required for normal physiological
processes (1384).
The toxic effects of nickel following ingestion have been studied less frequently than effects
following skin contact and inhalation. A small number of reports have suggested that ingestion of large
doses of nickel can induce gastrointestinal upset, reproductive effects, and kidney damage (1385).
Moreover, ingestion of large doses of nickel have been shown to trigger allergic responses in some
sensitized individuals (328).
Parenteral Exposure to Nickel: Systemic exposures represent the route of exposure least
commonly associated with nickel. However, in some instances, nickel ions are capable of entering the
circulation and inducing adverse health effects. For example, orthopedic implants comprised of stainless
steel or other nickel-containing alloys can release nickel ions systemically (374). Both mechanical wear
and biochemical corrosion of these implants has been associated with dissemination of nickel particles
and ions systemically (493). Systemic exposures to nickel are also known to occur as a result of frequent
use of the metal in dentistry. Orthodontic appliances and dental implants can present a significant source
of exposure to nickel ions, as the release of ions tends to be accelerated in the unique biochemical
conditions of the mouth. Subsequent ion release can result in localized dermal exposures, as well as
systemic absorption leading to their circulation (327). One of the most common adverse effects
associated with the release of nickel ions into the body from both scenarios is the development of allergic
sensitivity (1386).

1.3.1.2. Occupational Exposures to Nickel
Millions of jobs worldwide are involved in the acquisition, purification, transformation, recycling,
and disposal of nickel and nickel-containing agents (1387). Workers involved in these processes are
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known to be exposed to much larger doses of nickel than the general public, and accordingly, are a
population particularly vulnerable to toxic effects resulting from nickel exposure.
Occupations associated with increased risk for exposure to nickel and nickel-containing
compounds are generally grouped by nickel-producing industries and nickel-using industries, wherein
distinct exposure risks exist (1374). Nickel-producing industries include mining, milling, concentrating,
smelting, and refining. Ores containing nickel are mined in more than 23 countries and are smelted or
refined in more than 25 countries including Russia, Canada, Brazil, and South Africa. Annual world
production of nickel averages in excess of 1.4 million tons, 65% of which contributes to the yearly global
production of 800 million tons of steel. Generally, exposures to nickel in these settings involve insoluble
and moderately soluble species of nickel, and often particulate forms of the metal (1387).
Contrarily, nickel-using industries include more diverse processes ranging from alloy production
and catalytics to welding and construction. These settings are associated with exposures to nickel in
diverse forms including soluble and insoluble compounds (1388). For example, soluble nickel compounds
are likely to be encountered in operations including hydrometallurgy. These workplaces are more likely
to generate nickel-containing vapors and fumes, increasing the risk for aerosolization and inhalation of
nickel compounds (1389).
Similar to trends present in the general population, one of the most common adverse health
effects associated with nickel exposure in the workplace is the development of allergy. Nickel is one of
the most frequently-cited causative agents of occupational ACD (1378). Occupations associated with
increased rates of contact allergy to nickel share commonalities including increased presence of nickel
in the workplace. Jobs requiring frequent handling of nickel-containing objects and destruction of
materials resulting in increased release and bioavailability of nickel can result in conditions conducive to
the development of allergic sensitization. Accordingly, increased prevalence of nickel contact allergy is
commonly reported in specific worker populations including retail clerks, metalworkers, hairdressers, and
domestic cleaners (290). Several other occupational risk factors have been correlated to the increased
likelihood for dermal sensitization by nickel in the workplace. One such factor is frequent concomitant
exposures to skin irritants. Many of the reactive chemicals used in cosmetology are irritants and have
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been shown to promote the development of contact allergy to nickel (1390). Similarly, compromised skin
barrier functions are common in workers that perform frequent wet work, which can increase susceptibility
to skin sensitization. ACD caused by nickel in the workplace most often manifests as hand dermatitis as
a result of these risk factors.
Nickel-induced respiratory allergy is far less common than nickel-induced contact allergy, but
nearly all cases of asthma caused by nickel have been reported to originate from workplace exposures
(416, 1391, 1392). Existing reports of nickel-induced asthma and rhinitis have been almost exclusively
observed in workers involved in occupations including welding, electroplating, and other forms of metal
work. Moreover, most cases have detailed the development of symptoms in response to the inhalation
of soluble nickel compounds (413, 1393).
Overall, the development of nickel-induced asthma is uncommon. Inhalation of nickel in the
workplace is far more likely to result in adverse pulmonary effects that do not involve the development of
adaptive immune responses. The toxic effects of major concern with respect to nickel inhalation include
hard metal disease, reactive airways dysfunction syndrome, bronchitis, metal fume fever, pneumonitis,
and cancer (1391). Accordingly, OELs specific for nickel compounds are established with the primary
objective of protecting workers from these adverse pulmonary effects, which are far more likely to impact
workers than nickel-induced respiratory sensitization.
In the United States, NIOSH and OSHA recognize distinct occupational exposure limits for nickelbased compounds based on their classification into one of three groups- nickel carbonyl, insoluble nickel
compounds, or soluble nickel compounds (1394). ACGIH also recognizes nickel carbonyl, but further
distinguishes between respirable fractions of elemental nickel, soluble inorganic compounds, insoluble
inorganic compounds, and nickel subsulfide (1395). US agency-specific exposure limits for each category
of nickel compounds are shown in table 1.20.
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1.3.1.3 Immune Responses and Nickel Allergy
Although nickel exposure can induce a diverse array of adverse health effects, many of the toxic
responses triggered by nickel involve selective targeting of the immune system. One of the most common
manifestations of nickel-induced immunotoxicity is the development of allergic disease. Exposure to
nickel by dermal contact, inhalation, ingestion, and systemic ion release have all been associated with
the development of nickel-specific hypersensitivity responses (1396). However, these responses can
involve diverse cellular mechanisms and manifest in various tissues of the body.
Nickel has been associated with many different adverse immune reactions in the skin. Although
nickel has been associated with irritant contact dermatitis, contact urticaria, and atopic dermatitis, the
most common nickel-induced allergic response seen in the general population is ACD (286, 330). The
development of nickel-specific T-cells following skin exposure results in a delayed-type hypersensitivity
reaction mediated by both CD4+ and CD8+ subsets of effector T-cells (1397-1399). Nickel-induced ACD
is a chronic allergic skin disorder that more commonly affects women than men, affecting an estimated
10-20 % of the general population (1400). Among the vast number of dermal sensitizers and contact
allergens, nickel is consistently reported as the most common inducer of ACD worldwide. Because of the
high frequency of sensitivity to nickel in the general population, the metal was named Contact Allergen
of the Year by the American Contact Dermatitis Society in 2008. It remains unclear why nickel is such a
universally immunogenic agent, however, several ideas have been proposed.
The high frequency of nickel-induced ACD has been suggested to be at least partially fueled by
both frequent interactions with the metal and prolonged durations of contact with the skin (474). Dermal
sensitization by nickel has been most commonly associated with the release of adequate concentrations
of haptenic nickel ions from objects such as watches and rings. The release of nickel ions is known to be
accelerated by biochemical mediators including sweat, which can contribute to accumulated exposures
to the metal (1378). Ions subsequently penetrate the upper layers of skin, bind host dermal proteins, and
are then capable of being recognized by innate immune cells to facilitate allergic sensitization.
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Another mechanism proposed to be responsible for the high frequency of dermal sensitivity to
nickel is its capacity to bind and activate PRR expressed by structural cells of the skin and dermal immune
cells. The innate immune stimulation triggered by the binding of nickel ions to human TLR-4 mimics a
well-established mechanism of sensitization adjuvancy (469). Likewise, the capacity for nickel ions to
induce both antigen-specific and non-specific signals required to facilitate allergic sensitization has been
suggested to be a contributing factor to the global prevalence of nickel contact allergy.
Nickel-induced respiratory allergy is also known to occur, although far less frequently than nickelinduced ACD. Nickel-induced rhinitis and asthma have been most commonly associated with workplace
exposures leading to the generation of immediate, IgE-mediated immune responses (414). Occupational
settings where dusts, fumes, and vapors containing nickel are routinely generated have been associated
with an increased risk of nickel-specific asthma development in workers. Likewise, occupations such as
electroplating and welding are often implicated in cases of nickel-induced asthma (383, 397, 416). NiSO4
and NiCl are compounds that have been specifically associated with sensitization of the airways by nickel.
Nickel ions released from these and other soluble nickel salts have been shown to bind host
macromolecules including human serum albumin, generating antigenic determinants responsible for
nickel sensitivity (453, 456, 1401, 1402).
Although the vast majority of nickel-induced asthma cases have demonstrated an existence of
nickel-specific IgE antibodies in subjects, a few cases have reported asthmatic responses to nickel in the
absence of specific antibodies. Inhalation challenge was shown in one study to induce a late asthmatic
reaction to nickel in a worker with asthma who did not possess nickel-reactive antibodies (413).
Identification of nickel-specific T-cells in the respiratory tract of individuals with nickel-induced asthma
also suggests that nickel-specific lymphocytes may contribute to the pathogenesis of nickel-induced
asthmatic reactions in some individuals (412).
Ingestion of nickel has not been associated with any cases of subsequent allergic sensitization.
However, ingestion of nickel has been reported to trigger allergic elicitation reactions in subjects with
established sensitivity to nickel. Ingestion of foods containing high nickel content have been reported in
occasional cases to induce both systemic ACD and asthmatic reactions (1403).
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Systemic nickel exposure caused by the release of ions from orthopedic implants and dental
materials is one of the exposures most frequently associated with the development of adverse allergic
effects (1404). Patents with metal on metal implants consistently exhibit higher incidences of sensitivity
to nickel than subjects without such implants. With respect to metal arthroplasty, the development of
nickel sensitivity often results in rejection and implant failure (1405). Nickel-containing dental materials
are also frequently associated with allergic sensitization and subsequent elicitation reactions that
manifest locally in the oral mucosa.
Interestingly, concomitant Type I and Type IV hypersensitivity responses to nickel have been
reported in several subjects (1392, 1406). The existence of both nickel-specific antibodies and T-cells
has been shown in several studies (412). In one subject, this condition was associated with chronic
systemic effects of nickel allergy that could be triggered by nickel ingestion (415). In another case, an
individual exhibiting both immediate and delayed nickel allergy experienced simultaneous symptoms of
ACD, allergic contact urticaria, and rhinitis (414).

1.3.1.4. Nickel Nanomaterials
Among the vast number of metals being manufactured in nanoparticulate form, nickel is also being
utilized for numerous nanotechnological applications. Although metallic nickel nanoparticles (NiNP) are
occasionally utilized for industrial applications, nickel oxide nanoparticles (NiONP) are one of the most
commonly produced forms of nickel nanomaterials (1407). Compared to larger particles, nanoscale nickel
exhibits a higher level of surface energy, enhanced magnetism, and altered thermokinetic properties, all
of which contribute to the novel uses for nanoparticulate forms of the metal. Nickel nanomaterials have
notable utility in applications ranging from optimization of fuel cells, solar energy absorption, magnetic
fluids, propellants, optical displays, and catalytics (754). Accordingly, major consumer markets for nickel
nanomaterials include industries involved in energy generation and electronics, as well as academia and
research.
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Compared to other metal nanomaterials, such as TiO2NP and AgNP, the toxic effects of nickel
nanomaterials have been less frequently investigated. However, a few studies have examined the toxic
potential of nanoscale nickel with respect to the skin and lungs. Several studies have also established a
correlation between some of the physico-chemical properties of nickel nanomaterials, subsequent
molecular behavior, cellular effects, and toxic potential in vitro and in vivo.
The toxic potential of nickel is known to be critically related to species’ propensity to release toxic
ions. Likewise, the dissolution behavior of nickel nanomaterials have been examined in vitro in order to
help explain potential toxic effects observed following exposure in vitro and in vivo. Accordingly, NiNP
have been shown to release significantly more ions when in the presence of amino acids (1408). Cysteine
has been shown to cause almost complete dissolution of nickel alloy nanoparticles in solution, resulting
in cysteine complexes with nickel ions (997). The release of ions from NiNP is also known to be increased
when parent particles have higher surface oxide content (1409).
Many in vitro studies have investigated the biological activity of nickel nanomaterials and
characterized subsequent cellular responses following exposure. NiNP and NiONP have been shown to
induce diverse cellular effects ranging from DNA damage and morphology changes to cytokine release
and cell death (1410). The magnitude of these cellular responses has been correlated to the degree of
nickel particle uptake in cell types including macrophage cell lines, other innate immune cells, and various
epithelial cell types (51, 851, 1411). Consistent with reports using other metal nanomaterials, physicochemical properties including size, solubility, and surface charge have been correlated to the uptake of
nickel nanomaterials by cells. The similar insoluble nature of the two most commonly studied forms of
nanoscale nickel (NiNP and NiONP) has led to a general consensus that micropinocytosis is most
frequently implicated in their uptake by cells.
Following uptake by cells, nickel nanomaterials have been observed to accumulate in the cytosol,
become sequestered in vacuoles, and or bind macromolecules. A commonly-reported observation is that
nickel can induce lysosomal acidification and ion release within 48 hr of uptake (1057, 1412).
Subsequently, cells experience elevations in oxidative stress and free Ni ions can penetrate the nuclear
envelope- both of which are effects that have been associated with the induction of DNA damage by
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nickel nanomaterials in vitro (1410). As a result, cell death by apoptosis, necrosis, and autophagy have
all been reported when cells are exposed to nanoscale nickel materials (1408).
Nickel nanomaterials’ toxic potential with respect to the skin has been examined in a few in vivo
studies. In one study, 77 nm NiNP were shown to penetrate and permeate through the skin in an in vitro
model. Moreover, damaged skin was more susceptible to penetration than intact skin (555). This
observation may be critically relevant, as nickel nanomaterials have been shown to induce cytotoxic
effects on many structural cells of the skin, including human epidermal cells and keratinocytes (51).
Nanoscale nickel-induced destruction of skin cells may, thus, result in increased penetration of particles,
as well as localized irritant responses in the skin. However, nickel’s potential to cause local adverse
effects on the skin have been far more frequently-investigated than their potential to cause other toxic
responses following skin exposure. Accordingly, the potential for nickel nanomaterials to cause adverse
health effects systemically or in peripheral tissues as a result of skin contact remain largely unknown.
Compared to the skin, more scientific investigations have been conducted to determine nickel
nanomaterial toxic potential following pulmonary exposure in vivo (1413, 1414). Accordingly, these
materials have been shown to induce various physiological alterations and toxic responses in the lungs
including compromised surfactant protein function, lung fibrosis, and carcinogenic responses (14151418). Generally, smaller particles have been associated with more pronounced toxic effects in the
respiratory tract than larger particles of the same chemical composition (1419-1421). Solubility of
nanoscale nickel, similar to knowledge regarding bulk nickel, has been shown to be critical in the toxic
potential of nickel nanomaterials in the lung (1422). Other properties related to the rate of ion release
from nickel nanomaterials, such as surface modification and morphology, have also been shown to
modulate lung toxicity (1423, 1424). The lack of ion release from insoluble nickel nanomaterials, such as
NiO, results in increased biopersistence in the lungs by insoluble species of nanoscale nickel (14241426).
In addition to localized adverse effects in the respiratory tract, inhalation of nanoscale nickel has
also been associated with toxic responses in peripheral locations. For example, pulmonary NiNP
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exposure has been shown to induce adverse vascular responses and compromised hematopoiesis
(1427-1429).
Immune Effects of Nickel Nanomaterials: Despite numerous findings that the smaller size profile
of nickel nanomaterials is correlated with more pronounced toxic responses in the skin and lungs, it
remains unclear if these materials are capable of inducing more severe immunotoxic responses than bulk
nickel. This knowledge gap is concerning given then known immunogenic properties of nickel. The
increasing relevance of this knowledge gap was emphasized by a 2014 publication entitled Occupational
Handling of Nickel Nanoparticles: A Case Report. The article depicts a chemist who inhales a dose of
nickel nanoparticles during handling. Subsequently, the worker developed “throat irritation, nasal
congestion, post nasal drip, facial flushing, and new skin reactions to her earrings and belt buckle” (801).
This case report highlights several considerations with respect to the unknown immunogenic
potential of nickel nanomaterials. First, the report suggests that the subject had regular routine
encounters with nickel and nickel-containing objects, but the development of nickel allergy was triggered
by an exposure to NiNP. This suggests that nanoscale nickel may exhibit increased sensitizing potential
compared to other forms of nickel. Moreover, the inhalation of NiNP resulted in the development of
hypersensitivity responses that were not limited to reactions caused by NiNP. Subsequent allergic
responses were incited by various forms of nickel. Additionally, the elicitation of hypersensitivity reactions
were not restricted to the lungs. The subject experience both allergic reactions in the skin and lungs
following encounters with nickel.
Another major concern emphasized by this case report is that established metal-specific OELs
may be ineffective in protecting workers from nanoscale materials. Despite demonstrations that the
decreased size profile of nickel nanomaterials is associated with more pronounced toxic effects than
larger particles, nickel, like most other metal nanomaterials, are subject to size non-discriminatory OELS.
Nickel-specific OELs may protect workers from potential toxic responses following inhalation of larger
forms of particulate nickel, but equal doses of nanoscale nickel may induce significant adverse effects.
Moreover, these exposure limits may not be protective with respect to toxic responses in tissues other
than the lungs, such as immune responses.
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Lastly, this case highlights a potential population of individuals who may be particularly vulnerable
to the adverse health effects of nanomaterials. As the prevalence of allergic asthma continues to
increase, asthmatic or atopic individuals represent a subpopulation that may be particularly susceptible
to the adverse immune effects of metal nanomaterial exposure (1430).
The potential for respiratory exposure to metal nanomaterials to exacerbate asthmatic conditions
has become an area of active investigation. Several metal nanomaterials have been incorporated into
asthma models and have been shown to augment numerous processes involved in the development and
progression of allergic conditions, but nanoscale nickel has not been frequently studied (1431). Moreover,
there are relatively few studies that examine the relationship between physico-chemical properties and
these effects (550, 624, 882, 887). Subsequently, the capacity to identify emerging nanomaterials that
present a particular risk with respect to asthma remains largely unaddressed.

1.3.2. Gold
Gold is a Nobel metal with many desirable properties including malleability, chemical stability, and
exceptional resistance to corrosion. Gold is also an excellent conductor of heat and electricity and exhibits
a distinctive lustrous appearance (271). These properties have rendered gold one of the most widelyrecognized metals extensively utilized by humans throughout history in various applications. In addition
to uses for ornamental and decorative purposes, gold has been a fundamental constituent of jewelry,
currency, and other valuables since ancient times. The biological activity of gold has also been harnessed
for medicinal purposes in some civilizations, dating back thousands of years (1432).
Currently, gold is still used in many of the same applications. Gold therapy remains one of the
most common therapeutic options for the treatment of rheumatoid arthritis in the 21 st century. However,
gold has also become increasingly utilized in other modern biomedical applications. The metal has
exhibited notable potential utility as a vehicle for gene therapy, as a platform for vaccine development,
and an agent capable of optimizing the efficacy of photothermal ablation and radiation therapy (1433).
Gold is also frequently used as a major constituent of various prosthetic devices including orthopedic
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implants, pacemakers, and endovascular stents. Gold is also a metal that is frequently used in dentistry
for crowns and fillings, restorative implants, and orthodontic appliances.
In addition to these modern biomedical applications, gold is also frequently used in various other
sectors including aerospace, currency and finance, transportation, and electronics. However, the use of
gold in the production of jewelry remains one of its most common applications (1434). Given its widespread use for such diverse applications, gold is a metal that most individuals encounter on a daily basis.
Likewise, the potential for gold and gold-containing compounds to induce adverse health effects is a topic
of notable scientific interest.

1.3.2.1. Toxic Potential of Gold and Gold-Containing Compounds
Fundamentally, the biological activity of gold is tremendously dependent on its chemical
speciation. Metallic gold (0) is one of the least reactive metals, even withstanding acid challenge (1432).
In addition to its ground valence state, gold can exist in numerous other oxidation states including -1, +1,
+2, +3, +4, and +5. The most biologically-relevant oxidation states of gold are +1 and +3. Gold (III) is
very reactive and is a strong oxidizing agent reduced by biological molecules such as thiols. Contrarily,
gold (I) preferentially reacts with S-donors, is water soluble, and is more chemically stable than gold (III)
(1435). These oxidation state-dependent characteristics of gold are associated with differences in
bioavailability, molecular and cellular interactions, pharmacokinetic profiles, and ultimately, potential to
induce toxic effects. In addition to its chemical speciation, the toxicity of gold and gold-containing
compounds is also dependent on the exposure route associated with its encounter and the subsequent
target tissues subject to interactions with gold (1432).
Dermal Exposure to Gold: In the general population, dermal contact with gold-containing items is
the most common route of exposure associated with gold (1436). Accordingly, the skin represents a
notable potential portal of entry associated with gold, as well as a tissue potentially susceptible to goldinduced adverse health effects. The skin is generally considered to be an effective physical barrier that
prevents the passage of many materials from the external environment into the body. With respect to
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gold, the dermal barrier effectively restricts larger particulate forms of gold to the outermost layers of the
epidermis (1437). However, gold ions are small enough to penetrate the upper layers of skin and enter
deeper layers of tissue. As a result, the propensity for gold-containing materials to cause toxic effects
following skin contact is critically dependent on their propensity to release gold ions.
Jewelry is one of the most common sources of dermal exposure to gold. Although gold is
commonly incorporated into metals used to make jewelry, the amount of gold comprising these metals
can differ greatly. The proportion of gold comprising jewelry items is denoted by a measurement referred
to as a ‘karat,’ wherein 24 karats indicates a composition comprised exclusively of gold. The
proportionality of gold constituting the metal used to make jewelry items is correlated to the propensity
for gold ions to be released from the materials (1438). Pure, 24 karat gold is chemically stable and not
often associated with skin reactivity resulting in any notable biological effects (1439, 1440).
Comparatively, lower karat gold jewelry is generated by alloying gold with other metals including copper,
zinc, nickel, and silver (281). This process significantly alters the chemical behavior of gold present in the
material, often resulting in compromised chemical stability and an enhanced propensity for dissolution.
Accordingly, increased copper content in jewelry items has been associated with increased dissolution
of the gold constituents and the release of larger quantities of gold ions (271). As a result, jewelry
containing a lower content of gold has been more commonly implicated in adverse biological effects
following skin contact.
In addition to the chemical behavior of gold and gold-containing agents, host factors can also
contribute to the propensity for gold to enter the body via the skin. For example, metallic gold is known
to release more ions under acidic conditions and upon interaction with thiol-containing molecules,
including cysteine and glutathione (1441). Likewise, interactions with skin proteins and biochemical
alterations, such as those caused by increased presence of sweat, can influence the release of gold ions
from gold-containing materials in contact with the skin. Gold jewelry has also been associated with an
increased potential for biological effects depending on the nature of contact with the skin. For example,
jewelry such as rings, which remain on the external surface of the skin are less frequently associated
with adverse skin reactions. Comparatively, the majority of skin reactions resulting from gold jewelry have
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been exclusively related to jewelry associated with piercings (309, 1442). The invasive nature of piercings
facilitates increased access to internal tissues, compromising the protective barrier functions of the skin
(1443). These types of exposures are also often associated with extended durations of contact, which
facilitate the release of higher cumulative doses of gold ions over time. As a result, lymphomatoid contact
dermatitis, granulomatous dermatitis, lymphomatoid eosinophilia, and nodular dermatitis have all been
reported in subjects following piercing of ears with gold earrings(1444, 1445). Similar reactions have been
reported to emerge on the eyelids and face, as well (1446). Removal of the jewelry typically promotes
cessation of the localized inflammatory reactions and subsequent resolution of symptoms.
Although dermal exposure to gold is very common in the general population, gold-induced skin
toxicity is uncommon (281). The chemical stability of the metal results in minimal risk for adverse
biological effects following skin contact, unless significant amounts of ions are generated. Under such
conditions, the most common adverse response caused by skin exposure to gold is the development of
contact allergy specific to the metal.
Respiratory Exposure to Gold: Gold is rarely associated with respiratory exposures, as few
scenarios present the potential for aerosolization of gold, facilitating its inhalation. Since the generation
of airborne gold particles, fumes, or vapors is rare, even in specialized settings such as the workplace
which are discussed in more detail below, the effects of gold on the respiratory tract remain largely
unknown (424). However, in one of the few published reports describing a case of respiratory exposure
to gold, two subjects working as restorers were reportedly exposed to gold leaf and gold dust. The
inhalation of these materials was not associated with any local adverse effects in the lungs, but the
exposure did lead to dermal eruptions, a response termed ‘airborne ACD’ (304).
Oral Exposure to Gold: Similarly, ingestion of gold is also uncommon. However, occasional uses
of gold in consumable items can facilitate ingestion of small amounts of the metal. For example, gold has
been used for decoration of baked goods, and gold flakes have been incorporated into some novelty
liquor beverages (1436). Additionally, some gold-based therapeutics are orally-administered, resulting in
the ingestion of gold-containing compounds with potential to cause biologic effects. Aurofin, a gold saltbased drug used in the treatment of rheumatoid arthritis has been associated with adverse effects ranging
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from GI upset and skin rashes to alterations in blood profiles (1447). Although these reports illustrate the
potential for various toxic responses following ingestion of gold, the overall frequency of exposures to
gold by these routes is exceptionally low.
Parenteral Exposure to Gold: The majority of the toxic effects associated with gold exposure
involve systemic exposures. Systemic exposure to gold occurs less frequently than dermal contact in the
general population, but several uses of gold are associated with these types of exposures in specific
subsets of the population. Gold-based therapeutics, dental gold, and endovascular implants containing
gold are all potential sources of systemic gold exposure, many of which can induce notable toxic effects
(1435, 1437, 1448).
In 1890, gold salts were shown to be cytotoxic to bacteria, leading to its use as an anti-tuberculosis
agent until the 1930s (1449). In 1935, gold was shown to be beneficial in the treatment of rheumatoid
arthritis, and numerous gold-based drugs were subsequently developed (1435). In the 1970s, recognition
of the antitumor activity of the platinum-containing agent, cisplatin, led to similar uses for gold as an
anticancer agent (1450). There are also occasional reports suggesting potential efficacy of gold-based
compounds in treating other diseases such as bronchial asthma (1451, 1452). However, the most
common use of gold-based therapeutics in modern times is for the treatment of rheumatoid arthritis and
other autoimmune disorders. Gold therapy most often involves intramuscular or intravenous
administration of various formulations of gold salts, however, use of these drugs has recently declined
as high rates of adverse reactions limit their utility in many patients.
Adverse effects associated with gold therapy can manifest in various tissues, leading to
nephrotoxicity, liver dysfunction, alveolitis, and hematological abnormalities (1453, 1454). However, the
most common adverse effects caused by systemic administration of gold-based drugs involve
immunotoxic responses. Although gold salts are often used to treat autoimmune conditions, they have
also been implicated in the development of autoimmunity. Most gold-based therapeutics are formulations
comprised of gold (I) salts, but its transformation to gold (III) in the body has been associated with
increased potential for toxic effects. Gold (III) is inherently more reactive that gold (I) and can undergo
redox cycling in lysosomes of immune cells, leading to oxidation and denaturation of proteins (1432,
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1436, 1455, 1456). Gold (III) has been subsequently shown to induce conformational changes in
molecules such as HLA, leading to their recognition by immune cells as foreign antigens. Subsequent
reactivity to self-proteins results in adaptive immune responses to endogenous entities and chronic
inflammatory responses associated with autoimmune reactions (1457).
Systemic administration of gold-based drugs has also been associated with the development of
hypersensitivity reactions. Sensitivity to gold has been reported to impact up to 50% of patients receiving
gold therapy (280, 1458). Allergic responses caused by gold often present in the skin and mucus
membranes, resembling prototypical ACD reactions. Other dermal reactions including popular eruptions,
rosea, eosinophilia, and chelitis are also frequently reported following treatment with gold salts (1459).
Less often, hypersensitivity reactions to gold have been reported to occur in the respiratory tract following
gold therapy (305, 1172).
Another notable source of systemic gold exposure occurs as a result of intraoral appliances and
medical implants that contain gold (293). Gold is a metal frequently used in dentistry for fillings,
restorations, and orthodontic appliances due to its resistance to corrosion. However, the biochemical
environment of the oral cavity facilitates the release of ions from these metals, which can be absorbed
systemically (1437). As a result, some patients with intraoral metals experience mucosal and cutaneous
lesions, stomatitis, lichenoid reactions as well as gingival hyperplasia (1460, 1461). Dental metals have
also been frequently implicated in the development of hypersensitivity responses specific to gold. A
positive correlation has been established between the surface area of gold-containing dental implants
and the risk of developing contact sensitivity to gold (1462). Subsequent allergic elicitation reactions often
resemble the clinical manifestations of prototypical ACD reactions. Responses can remain localized
around the mouth and mucus membranes, whereas peripheral skin eruptions have been reported in
others (284).
Gold-containing stents and endovascular implants have also been shown to release gold ions
systemically, potentially leading to adverse reactions. The presence of gold in stent materials has been
associated with a significantly increased risk of endothelial complications, restenosis, and major cardiac
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events (1463-1466). However, similar to the exposures associated with gold therapy and dental gold, the
most common adverse reaction associated with gold stents is the development of contact allergy to gold.
Gold Toxicity Summary: Overall, gold is considered to be relatively toxicologically inert. Although
it is a metal that is frequently encountered by the general population, most exposures are limited to dermal
contact from jewelry items. Skin exhibiting normal barrier functions is largely protective from any adverse
toxic effects, although invasive exposures, such as those presented by ear piercings, can induce
localized inflammatory effects or the development of contact allergy. Inhalation and ingestion of gold are
uncommon, so the toxic effects of gold in the lung and GI tract have rarely been reported, and likewise,
rarely investigated. Comparatively, systemic exposures to gold may occur in particular conditions, such
as following implantation of gold-containing medical devices or dental gold. The majority of the adverse
health effects associated with these exposures have implicated the development of hypersensitivity
responses specific to gold. However, the most pronounced toxic effects caused by gold have been
associated with the parenteral administration of therapeutic gold salts. These exposures have been
correlated to many adverse effects, the most common of which is the development of gold allergy.

1.3.2.2. Occupational Exposures to Gold
Industrial uses for gold have been estimated to generate an annual demand of approximately 400
tons (1434). Accordingly, the acquisition of gold from mining implicates potential for workplace exposures
to gold. Similarly, workers employed in processes including the purification, smelting, and recycling of
the metal are also subject to occupational settings in which exposure to gold can occur. The highest
demand for gold is associated with electronics and dentistry, constituting additional sectors with potential
risk for gold exposures in the workplace. Workers are also exposed to numerous gold-based compounds
as a result of involvement in gold plating processes, glass etching, photography, and jewelry handling
(1467). Chemists and laboratory researchers are also workers with increased potential for occupational
exposures to gold and gold compounds.

140

Similar to the general population, skin contact is the most frequently-cited exposure route
associated with gold in occupational settings. Among the potential skin responses to gold in the
workplace, ACD is frequently reported. Many of the previously-mentioned occupations have been
associated with increased rates of dermal sensitivity to gold (1468, 1469). Notably, many occupations
associated with increased risk for the development of gold-induced ACD involve simultaneous exposures
to gold in conditions of elevated temperatures. Both heat and acidity of sweat are known to increase the
corrosion of gold, resulting in the release of soluble gold ions and salts capable of being absorbed by the
skin. As a result, workers involved in processes such as gold smelting and electroplating have been
shown to have an increased risk for the development of gold ACD (303, 1470).
Respiratory exposure to gold particles, fumes, and vapors in the workplace is far less common
than dermal contact with the metal. Although it would seem to be one of the settings wherein notable
respiratory exposures to aerosolized gold would occur, inhalation of gold during its mining has been a
negligible occupational concern historically. The adverse health effects most commonly associated with
gold miners rarely implicate toxic effects associated with exposure to gold. Although the USA, Canada,
and Brazil have been historical exporters of gold, South Africa is the modern leader in mining and export
of gold, and the majority of occupational health and safety information pertaining to gold miners currently
originates from this region (1471). Epidemiological studies of South African gold miners report increased
risk for numerous diverse injuries and illnesses. Gold mining is associated with increased prevalence of
various bacterial and viral diseases, noise-induced hearing loss, lung cancers, and carbon monoxide
poisoning. Some of these health effects are reflective of increased prevalence of comorbidities in
workers, such as human immunodeficiency virus (HIV) infection and tuberculosis, as well as increased
prevalence of behavioral factors, such as smoking (1472). However, some of these effects are also
associated with exposure conditions associated with the mining of gold. Mining operations generate
complex exposure scenarios. The toxic metal presenting the most immediate threat to gold miners is
mercury, which is frequently used in the extraction of gold. The most commonly-cited respiratory threat
for gold miners is the inhalation of silica particles. Gold is rarely cited as a notable occupational respiratory
hazard to gold miners.
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As a result, minimal scientific attention has been directed towards characterizing the potential
toxic effects of gold on the lung. Since gold is not often cited as a notable toxicological threat, specific
OEL for gold do not currently exist. Inhalation exposures to gold are currently subject to values applied
non-specifically to agents associated with a minimal threat level. Accordingly, inhalation exposure limits
for gold are regulated by OSHA as a ‘particulate not otherwise regulated,’ or ‘nuisance/inert dust’ with a
PEL of 5 mg/m3 for the respirable fraction and 15 mg/m3 of total dust.
Despite the absence of substantial evidence suggesting any overt pulmonary toxic potential of
gold, a few reports have described adverse skin responses following respiratory exposure to gold. For
example, one case study reported a chemist who was routinely exposed to aerosolized gold salts and
subsequently developed ACD (346). Inhalation of gold has been also been associated with a few cases
of airborne ACD in workers. ACD eruptions were reported following the inhalation of gold dust by
individuals working as restorers and glass etchers (304, 1473). These findings emphasize that although
gold appears to exert minimal toxic effects in the lungs, inhalation can lead to adverse effects that
manifest in other tissues.
Overall, gold does not currently present a notable occupational threat for many workers. The
majority of workplace-related health issues caused by gold involve exposures leading to the development
of contact allergy. Because of the low frequency of situations involving inhalation of gold and lack of
knowledge regarding the pulmonary effects of gold, respiratory exposures limits specific for gold are nonexistent. Although its regulation under non-specific nuisance dust OELs may have been adequate in
protecting workers from gold in the past, the recent emergence and widespread use of gold nanomaterials
may challenge this paradigm.

1.3.2.3. Immune Responses and Gold Allergy
Collectively, irrespective of the route of exposure, the immune system is the most frequent target
of adverse effects caused by gold. A summary of the various adverse immune effects reported in
response to gold exposure is presented in table 1.21 (304, 305, 309, 404, 406, 408, 409, 1439, 1442,
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1444, 1445, 1459, 1470, 1473-1502). Although the propensity for selective alteration of immunological
processes by gold has been exploited to develop gold-based therapeutics to treat many immunemediated disorders, gold-induced immunomodulation is also associated with many of its aforementioned
diverse pathologic effects. The most common manifestation of gold-induced immunotoxicity is the
development of hypersensitivity responses specific to the metal, and gold allergy has recently become a
notable public health concern and a concern for exposures in occupational settings (271).
Historically, the allergenic potential of gold was largely disregarded until the early 1990s, when
increasing numbers of patients with intraoral metals began reporting skin sensitivity to gold. As reported
by a 1994 study conducted in Sweden, 832 consecutive patients were patch tested with gold sodium
thiosulfate, wherein 8.6% patch test positivity was observed (1438). Subsequently, many countries
adopted gold into the standard series of ACD patch test agents, and significant rates of positivity to gold
compounds began being reported (280). Populations of subjects from the United States, Japan,
Singapore, Korea, Lithuania, and Israel were shown in several studies to exhibit incidence rates of gold
contact sensitivity that were comparable to the frequency of nickel sensitivity (236, 240, 248, 255, 256,
1503, 1504). Among these studies, the prevalence of dermal sensitivity to gold has been consistently
reported to be higher in women than in men, as with many other allergic conditions (1437). In accordance
with these findings, gold was named the 2001 Contact Allergen of the Year by the American Contact
Dermatitis Society, demonstrating its recent emergence as an allergen of concern.
Gold has been associated with many unique molecular and cellular effects that have been
proposed to contribute to its allergenic potential. Innate immune stimulation by gold is a mechanism
suggested to promote the early events of sensitization. Similar to the capacity for nickel and cobalt to
activate TLR-4 signaling in innate immune cells, gold has also been associated with PAMP functional
mimicry. TLR-3 is traditionally associated with the recognition of viral dsRNA by cells, but ionized gold
has the capacity to activate this pathway in keratinocytes. The subsequent innate immune stimulation by
PRR recognition has been proposed as a mechanism responsible for the high rates of sensitivity to
intraoral gold (471).

143

Antigen presentation is another step of allergic sensitization that has been shown to be subject to
modulation by gold as a result of modulation of APC and lymphocyte interactions. Accordingly, gold (III)
has been shown to bind MHC II molecules on APC, interfering with peptide presentation both in vivo and
in vitro (476). The spatial geometry of gold compounds has been implicated in these interactions (1505).
The alteration of MHC-peptide complexes by gold ions has also been associated with the generation of
gold-specific T-cells independent of antigen processing (1506).
In addition to the capacity to modulate cellular processes during allergic sensitization, similar
interactions between gold and immune cell surface receptors have been shown to impact allergic
elicitation reactions. Using T-cells isolated from gold-sensitive patients, it was shown that recognition of
gold occurred by both conventional MHC-restricted, as well as MHC-unrestricted pathways (483).
Subsequent simultaneous activation of CD4+ and CD8+ T-cells was observed, leading to diverse
cytokine production profiles characteristic of Th0, Th2, and Tc1, cells. It was suggested that these
promiscuous interactions between gold and lymphocytes may contribute to the metal’s allergenic
potential. Similar responses were observed when PBMC of patients with gold contact allergy were
stimulated with gold salts in vitro, resulting in mixed Th1/Th2 cytokine responses (1507).
Gold has also been associated with various molecular and cellular effects with the potential to
impact both gold-specific hypersensitivity responses, as well as allergic responses specific to other
antigens. For example, gold has been shown to induce oxidation state-specific conformational changes
in host protein structures. The subsequent exposure of cryptic epitopes has been associated with the
generation of novel antigenic determinants leading to allergic sensitization (1508, 1509). The majority of
the immunotoxic effects associated with gold implicate gold (III) species. Skin sensitization potential, host
protein conformational changes, and many cell receptor interactions associated with gold have been
correlated to this specific oxidation state (479, 1510). Interestingly, it has been shown that internalization
of gold compounds by mononuclear phagocytes can facilitate the oxidation of gold (I) to gold (III),
conferring these immunogenic effects (1508). Likewise, biological transformation of gold species by host
processes can significantly contribute the allergic potential of gold.
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Gold-induced alterations in innate immune cell activity have been commonly reported. Various
gold compounds have been demonstrated to induce modulation of cell signaling processes in monocytes,
macrophages, and DC (1511-1513). Alterations in cytokine production profiles are often observed as a
result of these effects, but altered release of other immune-mediating molecules by innate immune cells,
such as prostaglandins, is also frequently observed (1514). Other immunomodulatory effects of gold
include the allosteric inhibition of APC MHC II functionality, alterations in alarmin biological activity, and
differentiation/maturation capacity of various innate immune cells (476, 1515-1517). Furthermore, gold
has been shown to accumulate in macrophage lysosomal compartments, forming aureosomes, where
gold interferes with antigen processing (1515). Gold has also been shown to modulate mast cell activity.
One study demonstrated that gold salts can trigger the induction of calcium-dependent degranulation,
independent of allergen, which can lead to pseudo-allergic reactions (1518, 1519).
The normal cellular processes of adaptive immune cells have also been shown to be particularly
susceptible to disruption by gold. For example, auranofin has been shown to enhance the rapid flux of
ROS in activated T-cells, resulting in alterations in intracellular signaling, and subsequent inhibition of
proliferation and cytokine release (1520). Polarization of lymphocyte populations is a potential
consequence of these effects, as mixed responses to gold have been demonstrated. Upregulated
production of Th2 cytokines including IL-4, as well as prototypical Th1 cytokines, such as IFN-γ have
been observed by T-cells following exposure to gold (1515, 1521). The modulation of T-cell activity by
gold often results in deviations in the immunoregulatory balance between helper and suppressor
functions, an effect consistently reported in subjects undergoing gold therapy (1522).
Interestingly, it has been reported that B-cells are significantly more sensitive to the suppressive
activity of gold compounds than T-cells. Significantly lower concentrations of sodium thiomalate were
required to compromise human B-cell activation and inhibit the expression of activation molecules than
concentrations associated with similar effects in T-cells (1523). Combinations of gold salts have been
shown to synergistically inhibit the initial activation of B-cells (1524). This compromised B-cell maturation
capacity caused by gold explains the prevalence of hypogammaglobulinemia (low production of
immunoglobulins) as a complication of gold therapy (1525).
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Collectively, the selective effects of gold on T-cells and B-cells likely contribute to the
predominance of T-cell-mediated mechanisms reported to be involved in gold allergy. Gold-specific IgE
has not been implicated in any cases of gold allergy, and several studies have conducted gold prick tests
with no reports of positivity (303). Similarly, the development of gold allergy has been shown to exhibit
no relationship to atopy and serum IgE concentrations were shown not to be predictive of gold toxicity
following gold therapy (1526, 1527). The suppressive effects of gold on B-cells may prevent their
maturation and subsequent immunoglobulin producing capacity, impeding the development of humoral
immune responses.
Moreover, the differential modulatory effects of gold on lymphocyte subpopulations is likely
responsible for the frequent resurgence of cutaneous hypersensitivity responses in patients undergoing
gold therapy (1528). Impaired lymphocyte recall responses to various antigens associated with T-cell
reactivity are often observed in patients with rheumatoid arthritis; however, following the commencement
of gold therapy, delayed-type responses to antigens including DNCB and tuberculin are often restored
(1502, 1529). It has been suggested that anergic status is abolished following the commencement of
gold therapy as a result of gold-induced T-cell stimulation (1530).
The selective promotion of cell-mediated immunity by gold is also apparent given the similar
characteristics of allergic reactions triggered by gold, irrespective of exposure route. As previously
mentioned, the development of gold hypersensitivity in humans has been reported following exposure to
gold by various routes. Dermal contact with gold can induce sensitization, and the likelihood for ACD
development has been correlated to increasing number of ear piercings (280). The presence of intraoral
metals also constitutes an elevated risk for sensitization to gold (1531). Both dermal exposure to gold
ions released from dental metals and their systemic absorption can facilitate sensitization. In addition,
gold therapy administered by intravenous and intramuscular injections or oral formulations can lead to
sensitization. Interestingly, the elicitation of gold allergy in individuals sensitized by these various
mechanisms has been most frequently reported to selectively manifest as dermal eruptions, irrespective
of exposure route (1498). Outbreaks of systemic ACD have been reported following systemic or oral
administration of gold-based therapeutics (293, 305). Similarly, inhalation of gold dust has been
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associated, albeit rarely, with airborne ACD (303, 304). These responses have been associated with
gold-reactive T-cells bearing both CD4+ and CD8+ phenotypes (483, 1532).
Given the shared propensity for gold hypersensitivity responses to be mediated by T-cell-driven
mechanisms, lymphocyte reactivity assays and patch testing have been frequently used to assess
contact sensitivity. However, gold presents several challenges that limit the utility of these traditional
approaches for clinical assessment (1533). For example, there has yet to be a standard, widely-accepted
formulation for use in gold patch testing. Existing formulations of gold that have been used in patch tests
include gold trichloride, sodium aurothiosulfate, potassium dicyanoaurate, gold leaf, gold sodium
thiomalate, and many others, all in varying concentrations (1534, 1535). Despite conservation of gold
oxidation state, different monovalent and trivalent gold salts have been known to induce skin reactions
of varying severities (1536). Some of these formulations are also capable of inducing irritant responses
or immunological cross-reactivity, complicating the interpretation of test results. Furthermore, many gold
compounds used for patch testing fail to induce dose-dependent skin responses in patients, further
complicating the establishment of an effective test agent (255, 1537).
The time course of skin reactions induced by gold patch testing has also been demonstrated to
be inconsistent with those induced by other prototypical dermal allergens. Delayed development of
reactions (up to 3 weeks) has been reported, and some reactions have been shown to persist for
extended durations of up to 2 months (1473, 1536). As a result, false negative patch tests to gold have
been problematic for the accurate assessment of gold allergy. However, lymphocyte reactivity tests have
been shown to be reliable in diagnosing sensitivity to gold (1538). Irrespective of the challenges
associated with the clinical assessment of gold ACD, as of 2014, gold chloride has been categorized as
a Group 2 sensitizer. These substances are not in the highest sensitizer potency category, but still
possess “strong intrinsic potency” (1539). This category of sensitizers is classified as “likely to sensitize
1 to 10% of those with regular exposures to moderate concentrations.
Although several notable challenges complicate the clinical evaluation of gold allergy, the use of
laboratory animals to study gold allergy has proven useful. Unlike several other metal allergens (i.e.,
nickel, cobalt), studies using rodent models have generated translationally accurate results with respect
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to gold allergy. In the LLNA, GPMT, and MEST, gold salts have been demonstrated to be potent inducers
of skin sensitization (657, 1540). Many other immune effects of gold reported by animal studies mirror
findings from clinical studies. For example, gold salts have been shown to alter antigen-specific IgE
responses, lymphocyte gene expression, cytokine production, and mast cell degranulation in vivo (1521,
1541). Development of autoimmune responses and antinuclear antibodies have also been reported
following administration of gold drugs in rats and mice (479, 1457, 1542). Additionally, animal and human
studies have consistently demonstrated the existence of genetic susceptibility for gold immunotoxic
effects, many of which are associated with MHC genotype (1457, 1542, 1543).
Despite neighboring platinum on the periodic table being a potent metal asthmagen, gold has not
been associated with any cases of IgE-mediated asthma in humans. Gold has also not been tested in
any animal studies for its potential to sensitize the respiratory tract. The absence of evidence suggesting
the potential for gold to induce adverse pulmonary immune effects, however, does not necessarily
indicate that gold is immunologically inert with respect to the respiratory tract. The lack of existing cases
reporting pulmonary immune effects caused by gold maty simply reflect the exceptionally uncommon
frequency of gold inhalation. Since inhalation of gold is less common route of exposure, even in the
workplace, no case reports currently exist. Likewise, the lack of scenarios associated with gold inhalation
have rendered the demand for scientific investigations into the metal’s pulmonary immunotoxicity
negligible.
Despite a lack of evidence suggesting the potential for gold to cause asthmatic reactions, a few
reports of gold-induced pulmonary immune responses exist. Nearly all of these cases have been
associated with a unique complication of gold-therapy. In some patients receiving gold therapy, the
systemic administration of these agents has resulted in a disorder commonly referred to as ‘gold lung’.
This condition is mediated by T-cells, and the underlying immunological mechanisms more closely
resemble the pulmonary hypersensitivity responses associated with beryllium than typical cases of metalinduced asthma. However, beryllium lung disease is primarily mediated by metal-specific CD4+ T-cells,
whereas CD8+ T-cells appear more influential in cases of gold lung (406-408). Despite this immunological
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discrepancy, both conditions have been similarly associated with specific MHC genotypes that confer an
increased susceptibility for the development these reactions (1544, 1545).
It remains largely unclear why systemic gold exposure in these instances results in adaptive
immune reactions in the respiratory tract. However, numerous studies have demonstrated wide-spread
distribution of gold particles following gold therapy, wherein particles were detected in the dermis, bone
marrow, conjunctiva, and liver (1546-1549). Similarly, among a group of patients undergoing systemic
gold therapy for rheumatoid arthritis, gold particles were detectable in alveolar macrophages retrieved
from 90% of the subjects (1550, 1551). Gold has also been detected in the lung tissue of all subjects
undergoing gold therapy, irrespective of gold lung symptom presentation (407). Gold has been shown to
persist in synovial fluid and other tissues for up to 23 years following cessation of gold therapy, further
implying that retention of gold in tissues such as the respiratory tract may persist for extended durations,
promoting local immune responses (1552).

1.3.2.4. Gold Nanomaterials
The increase in use and manufacture of gold nanomaterials has led to expansive investigations
into their biological activity and toxic potential. Accordingly, gold nanomaterials are one of the most
frequently-studied nanomaterials in nanotoxicity studies. As a result, numerous physico-chemical
properties of gold nanomaterials have been correlated to their biological effects on a molecular, cellular,
and organismal level.
Gold nanomaterials are easily synthesized, exhibit unique optical properties, and their surfaces
can be easily modified and conjugated with endless chemical functional groups or biomolecules. Gold
nanomaterials also exemplify the diversity of potential nanomaterial morphologies, as they can be
produced as nanospheres, nanorods, nanocubes, nanoclusters, nanoshells, and nanostars (1172).
Among the expansive number of metals being manufactured in nanoparticulate form, gold represents
one of the metals being used in the most novel and diverse applications. In addition to uses in electronics,
decorations, and catalytics, biomedical applications represent one of the highest volume applications for
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gold nanoparticles (AuNP). Although they are not one of the most highly-produced nanomaterials by
mass, AuNP had a 2014 demand of 1-3 tons with significant potential to translate into higher volume
production within 5-10 years (754).
As a proposed platform for drug delivery applications, diagnostic imaging, vaccine delivery, and
photothermal therapy, AuNP interactions with biological molecules have been commonly studied in vitro
(63, 1433). Many different macromolecules have been shown to adsorb to the surfaces of AuNP (990).
Glycine was shown in one study to bind AuNP facets in a selective manner depending on the size of the
particles (1553). The kinetics and affinity of protein adsorption to AuNP surfaces have also been
correlated to properties including size, shape, and surface charge (1554, 1555).
Interactions between AuNP and various biomolecules can result in alterations in physico-chemical
properties of AuNP, leading to implications for subsequent interactions with cells. For example,
adsorption of biomolecules to AuNP surfaces can increase particle hydrodynamic diameter and modulate
surface charge (1556). Alterations in these properties are known to impact the nature of interactions with
cell surface membranes and propensity for internalization by cells. The dissolution potential of AuNP is
also known to be influenced by interactions with macromolecules. For example, cysteine and glutathione
are known to enhance the release of ions from metallic gold nanoparticles upon physical interactions
(1441, 1557).
AuNP/biomolecule interactions can also result in alterations in the biological activity of the
interacting molecule. For example, the adsorption of certain proteins to AuNP surfaces can induce
conformational changes resulting in compromised functional activity of the protein (1558). Subsequent
alterations in enzymatic activity, ineffective substrate binding, and compromised ligand interactions are
commonly reported effects of such interactions. Accordingly, although AuNP may exhibit negligible toxic
potential in some instances, their potential to alter the biological activities of other molecules may
generate toxic potential.
In addition to the molecular behavior of AuNP in biological systems, their effects on various cell
types have also been studied in vitro. AuNP internalization by cells can be influenced by numerous
properties. In some instances, AuNP can passively enter cells following penetration of the cell membrane
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in a size- and surface charge density-dependent manner. Electrostatic interactions between cationic
AuNP and negatively charged cell membranes can result in structural disruptions in the membrane,
subsequently facilitating the entry of AuNP into cells (707, 1358, 1556). By comparison, AuNP surface
protein adsorption can facilitate particle internalization by receptor-mediated uptake. Size and
morphology are known to be critically influential in the receptor-independent internalization of AuNP by
cells. As demonstrated with various gold-based nanomaterials, shape is an important determinant in this
process, as the energy required for membrane wrapping and endocytosis can vary significantly between
gold nanomaterials with different aspect ratios. Overall, size, morphology, and surface chemistry have
been demonstrated to be critically important in determining both the propensity for cellular uptake of
AuNP, as well as the route and dynamics of their internalization by cells (1559-1561).
Following internalization, AuNP have been most frequently reported to remain localized in
endosomes. Free dispersion of AuNP in the cytoplasm has been observed less frequently (1562). AuNP
have been shown to interact with various intracellular structures including the nucleus, mitochondria, and
lysosomes, generating a potential source of adverse cellular effects (1563). While some studies have
demonstrated an inability for AuNP to penetrate the nuclear envelope, other studies have demonstrated
divergent findings. The capacity for AuNP (3-50 nm), to enter the nucleus of cells was been shown to be
dependent on their size (1564). 1.4 nm AuNP were shown to bind DNA in melanoma cells with high
efficiency, wherein 24.5% of the internalized particles subsequently bound DNA (1565). Correspondingly,
the mutagenic potential of AuNP has also been correlated to size. These in vitro observations also explain
the dependence of AuNP size in the efficacy of nano-gold-based cancer therapeutics (1566).
AuNP can interact with organelles, interfere with intracellular signaling processes, and induce
numerous functional alterations in cellular activity. However, the most commonly studied effect of AuNP
on cells is their capacity to cause cell death. Accordingly, variations in AuNP cytotoxic potential have
been reported. Some studies have shown that uptake of AuNP does not result in any notable adverse
cellular effects, whereas others have reported notable cytotoxic potential of AuNP (1567). In addition to
disruption of organelle function, cytotoxic effects of AuNP have been associated with mechanisms
involving DNA damage, intracellular ROS accumulation, catastrophic membrane damage, as well as
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impedance of proliferation. Subsequently, cell death by apoptosis, autophagy, and necrosis have all been
reported following AuNP uptake (549, 1244). Size, surface modification, and charge are all properties
that have been correlated to both the cytotoxic potential and mechanism of cell death caused by AuNP
(1078, 1562).
In addition to the physico-chemical properties of AuNP, cellular characteristics have also been
shown to be critical in determining the cytotoxic potential of AuNP in vitro. AuNP cytotoxicity has been
examined in various cell types including DC, keratinocytes, endothelial cells, epithelial cells, and many
others (1568). As a result, susceptibility to AuNP toxic effects has been shown to differ depending on cell
cycle status, phagocytic activity, and phenotype with respect to wild type and cancerous cells (1244,
1569).
The biological activity and toxic potential of AuNP has also been extensively examined in vivo.
AuNP have been incorporated into numerous animal models to evaluate the responses implicated in
different routes of exposure and with relevance to various target tissues. Accordingly, AuNP have been
shown to be absorbed by the GI tract in size-dependent manner following ingestion (1556). After systemic
administration, AuNP biodistribution, primary site of accumulation, and duration of retention in circulation
are all parameters shown to differ depending on physico-properties including size and surface
modification (67). However, the effects of AuNP following dermal contact and inhalation exposure have
been most frequently studied.
It remains unclear if gold nanomaterials have the capacity to penetrate the skin. Some studies
have reported penetration of the skin by AuNP < 100 nm, whereas other studies have reported
contradictory findings (560, 1570). However, several AuNP properties have been implicated in the nature
of interactions between gold nanomaterials and the skin that may influence their potential to penetrate
the skin. For example, surface charge and hydrophobicity of gold nanomaterials has been associated
with the potential for accumulation in hair follicles, as well as the modulation of interactions with skin
proteins (570, 1571). AuNP have also been shown to have the capacity to compromise epithelial cell
junctions, an effect which may further enhance their potential to penetrate the skin. Surface charge was
particularly influential in this observation as disruption of keratinocyte tight junction barriers was
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associated with negatively-charged AuNP (512). Similarly, citrate-coated AuNP were shown to inhibit
extracellular matrix protein synthesis and compromise stress fibers in fibroblasts, causing similar
structural alterations in the dermal barrier capable of enhancing the penetrating capacity of AuNP with
specific characteristics (1558). Metabolic processes of the skin have also been shown to impact AuNP
penetration, as ablation of activity by toluene resulted in enhanced penetration by 15 nm in one study
(752). Despite these observations, few studies have investigated the potential for AuNP to cause adverse
effects in other tissues following dermal exposure.
AuNP have been consistently shown to exhibit general biocompatibility within the respiratory tract.
Exposure to AuNP in a diverse range of sizes has not frequently been associated with notable pulmonary
injury, increases in oxidative stress, or release of significant levels of pro-inflammatory cytokines in vivo
(1559, 1572, 1573). Following deposition in the airways, AuNP are rapidly internalized by airway-resident
phagocytes in a size, surface modification, protein corona, and surface charge-dependent manner (15741576). The intracellular fate of AuNP has been shown to differ with respect to size and morphology, but
sequestration of AuNP inside pulmonary phagocytes has rarely been associated with overt cytotoxic
effects (1559, 1577-1580). AuNP can also be internalized by bronchial epithelial cells in the upper
airways, and to lesser extent, alveolar type I epithelial cells in the lower airways. The efficiency of AuNP
uptake by these cells following particle deposition in the airways has been correlated properties including
agglomeration state (1581). AuNP are subsequently retained in the lung tissue until cleared or neutralized
by other mechanisms (1582). Occasionally, studies have reported AuNP-induced histological alterations
in lung tissue, minor alterations in lung function parameters, and changes in the lipidomic profile of the
lungs

(1583-1585). However, existing studies consistently demonstrate a lack of significant toxic

potential of AuNP following pulmonary exposure.
AuNP have also been extensively studied with respect to potential for systemic translocation
following respiratory exposure. Generally, the clearance of AuNP from the lungs occurs in a sizedependent manner, wherein the elimination half-life of smaller particles is shorter than that of larger
particles (1586). Decreases in AuNP size have been associated with more efficient deposition in the
alveolar region of the lungs, increased potential for active uptake by alveolar epithelial cells, as well as
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enhanced potential for passive penetration of the air-blood barrier (757, 1587, 1588). In some instances,
AuNP have been shown to contribute to compromised epithelial barrier integrity in the alveolar spaces,
further promoting their entry into circulation and relocation to distal tissues (1589). AuNP surface
modification and charge have been established as properties with significant potential to impact these
processes (1590).
In addition to particle-specific characteristics, several host factors are also known to be influential
in determining the biological fate of AuNP in the lungs. For example, the species and age of animal
models have been shown to impact AuNP deposition in the airways, while the translocation potential of
particles can be gender-dependent (1591, 1592). Prior inflammatory responses in the airways, in addition
to pre-existing disease states such as asthma and chronic obstructive pulmonary disease (COPD), have
also been shown to impact the translocation potential of inhaled AuNP (819, 892, 1593, 1594).
Subsequent accumulation of AuNP following their escape from the respiratory tract has been reported to
occur primarily in the liver, spleen, and kidneys (1595).
Immune Effects of Gold Nanomaterials: Many types of immune cells have been shown to be
susceptible to AuNP-induced alterations in biological activity and functionality. One of the cell types most
commonly investigated with respect to AuNP are DC. Morphology, surface properties, and aspect ratio
have all been shown to impact AuNP interactions with DC, resulting in modulation of various cellular
processes (533, 769, 1596). In addition to DC migratory capacity, DC activation and polarization are also
known to be susceptible to modulation by AuNP as a function of properties including size (538, 1068,
1076, 1078). Morphology and surface modification have also been shown to be properties critically
involved in the release of pro-inflammatory cytokines by DC (61, 1069).
Other innate immune cells have also been studied as potential targets of AuNP in vitro. AuNP
have been shown to augment inflammatory signaling by monocytes, as well as disrupt neutrophil
cytoskeletal structure (1188, 1251). Modulation of macrophage phagocytic activity and LPS stimulation
responses are also known to be subject to interference following AuNP exposure (1578). Additionally,
AuNP are capable of interacting with both cell surface receptors and ligands involved in the
immunological responses of granulocytes, ultimately leading to alterations in mast cell and basophil
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reactivity to antigen (1169). Size and surface properties are known to be critically influential in this regard
(784). In addition to changes in granulocyte reactivity, several studies have also shown that AuNP can
modify the molecular contents of granules secreted by activated granulocytes as a function of the
particles’ zeta potential (914).
Adaptive immune cells also appear to be susceptible to modulation upon interactions with AuNP.
< 50 nm AuNP have been shown to alter splenocyte responses to immunological stimuli, as well as alter
activity of B and T-cells isolated from mice and humans (1111, 1597). T-cell-specific effects associated
with AuNP exposure have been largely associated with alterations in cytokine production profiles, effects
which have been correlated to AuNP size and surface modification (1598). By comparison, interactions
with B-cells have been shown to be dependent on AuNP morphology and surface modification, following
which the modulation of intracellular signaling pathways can induce functional alterations in antibody
secretion (1113, 1146, 1147, 1599). AuNP have also been shown to enhance NK cytotoxic activity in a
size-dependent manner in vitro (1292).
The immunomodulatory effects of AuNP have been far more frequently examined in vitro than in
vivo. However, some of the observations reported by in vitro studies have been similarly demonstrated
by studies employing animal models. Various systemic immune effects and alterations in immune
markers have been reported following AuNP exposure in vivo. Many of these effects are dependent on
the site of AuNP localization and accumulation following systemic exposure. Surface functionalization
has been shown to influence this propensity, wherein neutrally-charged 15 nm AuNP were associated
with preferential accumulation in the lymph nodes, and positively-charged AuNP localized primarily in the
spleen (66). Subsequent alterations in lymphocyte proliferation capacity, cytokine release, and antibody
production have been observed following AuNP administration as a function of material size,
hydrophobicity, and morphology (950, 1115, 1335). The implications of these effects on adaptive immune
responses has been an area of active investigation, as AuNP have been proposed to have utility for
optimization of newly-developed vaccines. Accordingly, AuNP have been shown to alter the kinetics of
antigen delivery to lymphoid tissue, selectively promote the stimulation of a particular effector cell
phenotype, and polarize the nature of the subsequent immune responses in a physico-chemical property-
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dependent manner. Particle size has been identified as an important property in the modulation of antigen
delivery kinetics to the lymph nodes, leading to the generation of different effector cells (517). Similarly,
AuNP morphology has been correlated to discrepancies in levels of antigen-specific antibody titers
produced following immunization in vivo (61).
The immunological effects of AuNP, specifically in the respiratory tract, have been occasionally
characterized. In one study, pulmonary APC were shown to preferentially take up positively-charged
AuNP, resulting in increased activation marker expression (776). Subsequent translocation of AuNP from
the airways to the lymph nodes involved cell-mediated mechanisms, however, cell-independent
translocation of AuNP to the lymph nodes has also been observed. Translocation of AuNP to the lymph
nodes can facilitate interactions with APC and lymphocytes, an effect that has been proposed to be
responsible for observations of AuNP-induced adjuvant activity following mucosal immunization (1351,
1600). AuNP can also augment pulmonary immune responses in established states of hypersensitivity,
as demonstrated in other studies. AuNP have been shown to attenuate some asthmatic processes,
including mucus hypersecretion and inflammatory cell recruitment by some reports. Comparatively, AuNP
have also been shown to exacerbate asthmatic symptoms in some cases, resulting in responses
including enhanced airway hyeprresponsiveness (891, 892, 894).
Although AuNP-induced effects on pulmonary immunity often implicate particle interactions with
immune cells, structural cells of the airways may also be targets of AuNP that are responsible for altered
immune responses in the lungs. Their expression of PRR, recognition of PAMP/DAMP, release of
alarmins, and production of immunomodulatory cytokines renders airway epithelial cells critical mediators
of innate immune cell reactivity (179). In this regard, AuNP have been shown to alter transcriptional
activity of many pro-inflammatory signaling pathways, including NF-kB, in airway epithelial cells. Similarly,
upregulation of TLR-2/4 expression by epithelial cells in the lungs has been observed in response to
AuNP exposure (865). These effects can promote a diverse assortment of immune responses in the
respiratory tract, including activation of APC and other innate immune cells, illustrating another potential
mechanism of AuNP-induced alterations in pulmonary immunity (861).
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Compared to the pulmonary studies, fewer studies have profiled the immune effects of AuNP in
the skin. Despite this, there are several existing studies that have demonstrated immunological effects of
skin exposure to AuNP that may facilitate local immune reactivity, as well as the development of systemic
immune responses. In one study, exposure to 20 nm AuNP simultaneous to DNFB in previouslysensitized mice was not associated with any alterations in skin reactivity (724). Although dermal exposure
to AuNP was not associated with the augmentation of ACD elicitation in this study, many other studies
have shown that dermal AuNP exposure can result in translocation of particles to lymphoid tissues,
constituting far more potential interactions with immune cells. For example, 5 nm AuNP covalently
conjugated to autoantigen were shown to be readily internalized by LC in another study. However, the
subsequent T-cell activating potential of LC was diminished in response to AuNP uptake (698). This
response is suggestive of suppressive activity induced by AuNP, an effect which may impede the
likelihood for skin sensitization, but implicating immunomodulatory effects, nonetheless. In addition to
LC, AuNP have also been shown to be taken up by dermal macrophages and transported to the lymph
nodes. Although this study did not characterize the immunological implications of this process, cellmediated transport of AuNP by macrophages following subcutaneous injection suggests another
potential mechanism of immunomodulation by AuNP. Interception of AuNP by these cell populations
requires access to lower layers of the epidermis populated with resident immune cells, indicating that
properties implicated in the skin penetrating potential of AuNP may also be implicated in their potential
to translocate from the skin to the lymph nodes (1601).
Similar to their involvement in immune reactions of the respiratory tract, dermal epithelial cells are
also critically influential in immune reactions originating in the skin. Accordingly, several AuNP physicochemical properties have been correlated to skin epithelial cell responses capable of promoting immune
reactions following exposure. For example, 1.5 nm AuNP surface charge was correlated in one study to
the mechanism of keratinocyte cell death (549). Since many alarmins are released following necrotic cell
death, AuNP surface charge has the potential to amplify the early events of dermal sensitization by
inducing preferential mechanism of cell death in epithelial cells (693). Similarly, inflammasome activation
and subsequent release of IL-1β by dermal fibroblasts has been shown to occur in a AuNP size and
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surface modification-dependent manner (1602, 1603). As a result, these properties of AuNP may be
associated with an increased potential for exposure to result in dermal immune responses.
Despite ample evidence demonstrating AuNP immunomodulatory potential in vivo and in vitro,
the functional implications of such effects, specifically on allergic disease, remain largely unclear. All
existing studies that have investigated the potential for AuNP to impact allergic processes have examined
their effects on allergic processes involved in responses to environmental allergens. For example, AuNP
have been shown to act as non-protein carriers of haptens, facilitating the generation of adaptive immune
responses specific to small molecules in vivo (520). The potential for interactions between AuNP and
small molecules to generate antigenic epitopes is a mechanism with significant potential to promote
allergic sensitization following exposure to AuNP. AuNP have also been shown to modulate interactions
between antigens and effector cells in vitro, demonstrating a mechanism by which AuNP exposure may
modulate elicitation responses in established allergic conditions. In one such study, interactions between
protein allergens and AuNP resulted in both enhanced allergen protease activity, as well as increased
basophil responsiveness to antigen. As a result, activation of granulocytes was associated with a higher
maximal activation response in the presence of AuNP, demonstrating an effect with potential to
exacerbate the severity of allergic elicitation responses to aeroallergens (522). Similarly, a few studies
have incorporated AuNP into in vivo asthma models, subsequently demonstrating the potential for
exposure to augment asthmatic responses to TDI and OVA in animal models (891, 892, 894).
Although AuNP have been shown to have potential to confer allergenicity to small molecules,
enhance allergen-mediated degranulation of granulocytes, and augment asthmatic responses to different
allergens, the capacity for AuNP to induce gold-specific hypersensitivity has yet to be investigated.
Established knowledge regarding the potent skin sensitizing potential of gold compounds emphasizes
the importance of addressing this knowledge gap. Among the vast number of emerging metal
nanomaterials, many have been suggested to have the potential to induce alterations in many allergic
processes. However, gold nanomaterials present a particularly unique concern for several reasons.
First, unlike most metals, the pulmonary effects of gold are largely unknown. Although gold has
not been historically associated with overt respiratory toxicity, this may simply reflect the exceptionally
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low incidence of respiratory exposures to gold. Inhalation of gold particles, vapors, or fumes is rare, even
in specialized occupational settings. Accordingly, no agencies have currently endorsed gold-specific
OELs and inhalation exposure limits for gold fall under those set for nuisance dusts, which constitute the
highest doses among all agents. While the lack of knowledge regarding gold’s pulmonary effects and
absence of a gold-specific OEL has not yet proven problematic, the recent emergence of gold
nanomaterials may challenge this paradigm. Since nanomaterials exhibit a significantly increased
propensity for aerosolization, their size profiles constitute an elevated risk for inhalation exposure to the
constituent elements. Accordingly, the increasing use of gold nanomaterials is likely to result in a novel
exposure route of concern for gold.
Secondly, the unique biomedical applications of gold nanomaterials are likely to result in unique
exposure conditions with potential to cause adverse immune effects. AuNP have enabled many novel
medical advancements with respect to drug delivery, gene therapy, vaccinology, and diagnostic imaging
(1172). However, these uses present risks for AuNP exposure in both healthcare workers and patients
by inhalation and skin contact. Given the high rates of patch test positivity to gold in the general
population, the impact of these exposures on individuals with existing sensitivity to gold are unclear.
However, in patients with existing skin sensitivity to cobalt and nickel, pulmonary exposure to these
metals was been shown to result in the recruitment of metal-specific T-cells to the respiratory tract,
following which, delayed asthmatic-like responses were observed (391, 412). Likewise, evidence
suggests that established skin sensitivity to the metal may predispose individuals for the development of
pulmonary immune responses following inhalation of AuNP.
Lastly, some biomedical applications for gold nanomaterials may implicate their systemic
administration to patients. Numerous animal studies have correlated systemic AuNP exposure with
various adverse immune effects, but it remains unknown if systemic administration may result in the
development or elicitation of allergic responses. The development of contact allergy to gold is one of the
most common complications of systemic gold therapy for rheumatoid arthritis, suggesting that systemic
administration of AuNP may present a risk for allergic sensitization. Moreover, in the increasing number
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of individuals with existing sensitivity to gold, systemic AuNP may trigger allergic reactions leading to an
assortment of detrimental effects that have yet to be investigated.
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1.4. HYPOTHESIS AND SPECIFIC AIMS
Many metals known to induce allergic sensitization and augment allergic disease are being
manufactured in nanoparticulate forms. While many of these materials have been consistently associated
with increased potential to induce acute pulmonary inflammation, it remains largely unclear if metal
nanomaterials exhibit a similar size-dependent increase in immunotoxic potential. Some metal
nanomaterials have been shown to augment various allergic processes; however, few studies have been
able to establish relationships between specific physico-chemical properties and these effects.
Successful correlation of physico-chemical properties with immunological activities of metal
nanomaterials represents a novel risk assessment approach with proposed utility in identifying emerging
nanomaterials that pose an increased risk of causing adverse immune responses.
The central hypothesis of these studies is that metal nanoparticles cause more pronounced
immunomodulatory effects on allergic processes when compared to larger forms of the respective metals,
and that the magnitude of these immunotoxic effects correlates better with the surface area of the
administered dose than with mass.
In order to address this concept, two commonly-produced metal nanomaterials, NiO and Au, and
larger particulate forms of each metal were acquired and thoroughly characterized prior to in vivo studies.
The first aim is presented in chapter 2, and was designed to evaluate the potential for fine and ultrafine
NiO particles to cause pulmonary injury and inflammation and to augment allergic responses in an OVA
asthma model, as well as compare the impact of various physico-chemical properties on these effects.
The second aim is presented in chapter 3 and was designed to investigate the following: (1) determine
the potential for fine and ultrafine gold particles to induce skin sensitization following dermal exposure,
(2) characterize immune responses in the lung following pulmonary exposure, and (3) delineate the
impact of existing dermal contact sensitivity to gold on immune responses following pulmonary exposure
with respect to different dose metrics.
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CHAPTER 1 TABLES

Table 1.1: Classes of Nanomaterials Being Produced, Applications, and Production Volume
Nanomaterial Class

Metallic

MetalBased

Metal
Oxide

Alloys
Quantum Dots
Nanoclays
Carbon-Based
Nanopolymers and
Dendrimers

Nanomaterial

Applications

Prod. Vol. (tons)

AuNP
AgNP
FeNP
NiNP
TiO2NP
SiO2NP
Al2O3NP
ZnONP
CeO2NP
Pd alloy NP
Cd
Composites
Fullerenes
Graphene
C-Nanotubes
Nanocellulose
Dendrimers

Drug delivery, electronics, biosensors

1-5

Antimicrobial, cosmetics, water purification, food packaging

185-500

Biomedical imaging, magnetic separations, env. remediation

15-85

Catalytics, conductive coatings, fuel cells

5-35

UV filter, cosmetics, coatings and paints, catalytics

74,000-190,000

Adhesives, automotive, catalytics, biomedicine

280,000-2.2 million

Wear-resistant coating, thermal barrier, electronics

5,750-12,500

Adhesives, automotive, UV filter, textiles, electronics

31,000-40,000

Electronics, catalytics, UV absorber

900-1600

Catalytics, hydrogen storage

<1 ton

Electronics displays, lighting, biomedicine, batteries

<50

Packing barrier, automotive, flame retardant

28,000-60,000

Lubricant additive, cosmetics, energy generation

70-150

Batteries, anti-corrosion coatings, aerospace

<350

Sporting goods, aerospace composites, plastic additives

2,000-3,150

Building insulation, aerospace, automotive, cosmetics

<2200

Cosmetics, plastics additive, hydrophobic coating

<1 ton

Table 1.1. Major classes of nanomaterials, specific agents currently being produced, along with corresponding
applications and global production volume in tons. Adapted from The Global Market for Nanomaterials, 2010-2030,
Future Markets.
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AMERICAN CONTACT
DERMATITIS SOCIETY

ALLERGEN OF THE YEAR
2000-2020

2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000

Isobornyl Acrylate
Parabens
Propylene glycol
Alkyl glucosides
Cobalt
Formaldehyde
Benzophenones
Methylisothiazolinone
Acrylate
Dimethyl fumarate
Neomycin
Mixed dialkyl thiourea
Nickel
Fragrance
p-Phenylenediamine
Corticosteroids
Cocamidopropyl betaine
Bacitracin
Thimerosal
Gold
Disperse Blue Dyes

Table 1.2. The American Contact Dermatitis Society’s Allergen of the Year from 2000-2020.
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Table 1.3. Examples of Common Contact Allergens Associated
with Occupational Skin Allergy
Agent

Job/Industry

Rubber additives:
Mercaptobenzothiazole
Carbamates
Thiurams
Thioureas
Biocides:
Formaldehyde
Glutaraldehyde
Isothiazolinones
Cosmetics:
Paraphenylenediamine
Glyceryl thioglycolate
Parabens and other preservatives
Fragrances and essential oils
Metals:
Nickel
Chromium
Cobalt
Mercury
Platinum
Gold
Plastics and Resins:
Epoxy
Peroxide catalysts
Colophony
Plants:
Sesquiterpene lactones
Penta and heptadecylcatehols

Rubber manufacturing,
healthcare, housekeepers,
beauticians, construction

Healthcare, professional
cleaning, water treatment

Cosmetology manufacturing,
beauticians, dermatology

Metal working, jewelry,
dentistry, electronics,
transportation

Manufacturing, painters,
aerospace
Farmers, gardeners,
florists, food handlers

Table 1.3. Common allergens associated with occupational allergic contact dermatitis and corresponding industries
and jobs associated with increased rates of sensitivity. Adapted from Occupational Contact Dermatitis, 2008.
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Table 1.4. Approaches for the Identification of Potential Dermal Sensitizers
IN VIVO APPROACHES
Biomarker

OECD
Valid?

Cit.

Draining lymph node lymphocyte expansion

Yes

(107)

Local skin inflammatory responses

Yes

(108)

Ear swelling following allergen challenge

Yes

(109)

Local skin inflammatory responses

Yes

(110)

TH1 cytokine production

No

(111)

OECD
Valid?

Cit.

No

(112-120)

Yes

(121)

No

(122)

Yes

(123)

Model/Approach
Local Lymph Node Assay (LLNA)
Guinea Pig Maximization Test (GPMT)
Mouse Ear Swelling Test (MEST)
Buehler Test
Dermal Exposure in BALB/c mouse

IN VITRO APPROACHES
Model/Cell Type

Biomarker
Surface Marker Expression

Cytokine Release

Gene Expression

Other Marker

CD80, CD40, CD83

TNF-α, IL-8, MIP-1β

p38 MAPK, hmox1,
nqo1, CXCR4

Rapid GSH depl, ROS
Phospholipidomic profile

Antigen Presenting Cells
THP-1 Monocytic Cell Line
Human cell line activation test (h-CLAT)

CD54, CD86

U937 Monocytic Cell Line
Myeloid U937 Skin Sensitization test (U-SENS)
MUTZ-3
Human Monocyte-Derived DC
Primary Human Plasmacytoid DC (CD123+/CD11c-)
Murine Bone Marrow-Derived DC
XS52 Immature DC Cell Line
Fetal Skin-Derived DC Cell Line
Mature Primary Murine Langerhans Cells

IL-1b, IL-8
CD86
CD86

CXCL8, IL-8, MIP-1α

AHR, Nrf2

CD86, CD54, HLA-DR, PD-L1, DCIR

TNF-a, CXCL10, IL-12p70,
MIP-1α, NAP-2, IL-16

CREB1, TNFa, CCR2,
COX2, IL-1β

Migration to CXCL12

No

(124-128)

No

(127, 129-132)

CD86

No

(133)

MHC II, CD40, CD54, CD86

No

(134)

MHC II

No

(135)

CXCR4, CD40, IL-12R, CCR6

No

(136-138)

33D1

No

(139)

Keratinocytes
HaCaT Cell Line

IL-1α

HMOX1

No

(140-142)

KeratinoSens

Nrf2

Yes

(143)

LuSens

ARE

Yes

(144)

No

(145)

IL-1α, IL-6

HaCaSens
NCTC2455 Cell Line

IL-18

No

(146, 147)

IL-1α, MIP-2

No

(148)

IL-18

No

(149)

CD86, CD54

No

(150)

HEL-30 Murine Epidermal Keratinocyte Cell Line
Other Cell Types
NCTC 2544 Epithelial-Like Cell Line
Co-Culture Models
THP-1 + HaCaT
THP-1 + Primary Keratinocytes (LCSA)
LCSA + Human PBMC (LCSA-ly)
HaCaT + Peripheral Blood Mononuclear Cells

NF-Kβ, p38 MPK

Phospholipidomic profile

THP-1 CD86, CD54

No

(151)

Lymph CD124, CD44

No

(152)

DC CD86

No

(153)

165

TNF-α, IFN-γ

Human MDDC + Lymphocytes

No

(154)

No

(155)

No

(156)

No

(157)

No

(158)

No

(159)

No

(160)

Reconstructed Epidermis Models
Reconstructed Human Epidermis (RHE) (EpiSensA)

ATF3, DNAJB4, GCLM, HSPA6, HSPH1

RHE + MUTZ-3 or monocyte-derived LC-like cells
RHE + THP-1
RHE + Dermal Fibroblasts

IL-6, IL-8

CD83, PD-L1, CXCR4

CD86, CD40, CD54, HLA-DR
CD86

IL-8

EpiSkin Model (SENS-IS)

REDOX, SENS-IS genes

Epidermal Skin Model EST/AST-1000

Model/Approach

p38, JNK1/2

IN SILICO AND IN CHEMICO APPROACHES
Biomarker

Direct Peptide Reactivity Assay
Amino Acid Derivative Reactivity Assay

OECD
Valid?

Cit.

Cysteine/lysine depletion

Yes

(161)

Amino acid depletion

No

(162)

Table 1.4. Proposed approaches for the identification of potential skin sensitizers are summarized. Model/assay and corresponding biomarker of interest are
grouped by in vivo, in vitro, and in silico/in chemico-based approaches. Assays validated by the OECD for use in identification of dermal sensitizers are also
denoted.
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Table 1.5. Examples of High and Low Molecular Weight Agents
Associated with Immune-Mediated Occupational Asthma
Agent

Job/Industry

Low Molecular Weight (LMW) Agents
Isocyanates:
Plastics, adhesives,
• Toluene diisocyanate (TDI)
foams, automotive
• Diphenylmethane diisocyanate
Anhydrides:
Plastics, resins,
• Phthalic anhydride
paints, polymers
• Trimellic anhydride
Amines:
Rubber, photography,
• Ethylenediamine
paint, dyes
• Piperazine
Metals:
Mining,
• Hexachloroplatinate
welding
• Chromium salts
Dyes:
Textile,
• Remazol black B
hairdressers
• Paraphenylaminediamine
Drugs:
Medical,
• Chlorhexidine
pharmaceuticals
• Ampicillin
High Molecular Weight (HMW) Agents
Microbial Sources:
Baking,
• Bacillus enzymes
detergents industry
• Aspergillus amylase
Insect Sources:
Farmers,
• Spider mites
greenhouse workers
• Mealworms
Animal Sources:
Laboratory animal handlers,
• Rodent urinary proteins
pharmaceuticals
• Pancreatin extract
Plant sources:
Medical, dental,
• Latex
meat processing
• Papain

Table 1.5. Common allergens associated with occupational asthma and corresponding industries/occupations
associated with increased rates of sensitivity. Adapted from Immunotoxicity and Immunopharmacology Third
Edition, 2007.
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Table 1.6. Approaches for the Identification of Potential Respiratory Sensitizers
IN VIVO APPROACHES
Model/Approach
Respiratory exposure

Biomarker

Cit.

Respiratory LLNA

Lung-draining lymph node lymphocyte expansion

(194)

Allergen-IgE and IgG

(195)

IL-4, IL10

(196)

BALF G-CSF

(197)

Th2 cytokine production

(111)

Serum IgE

(198)

Lymph node cells- # IgE+, IL-4 production

(199)

Serum IgE, BALF cellular profile

(200)

Mouse intranasal test (MINT)
Ex Vivo lymphocyte stimulation
BALF and serum cytokine analysis

Dermal exposure
Serum cytokine profile
Serum antibody response
Dermal sensitization, dermal challenge
Dermal sensitization, respiratory challenge

IN VITRO APPROACHES

Model/Cell Type

Biomarker

Cit.

Antigen Presenting Cells
THP-1
Human MDDC

Delayed GSH depletion

(113)

IL8, CCL17, TNFRSF1A, CCR7, CCL22, CD86, CXCR4, PPIA expression; IL-10 prod.

(132, 201)

Altered expression of 389 genes

(202)

EIF4E, PDGFRB, SEMA7A, ZFP36L2

(203)

PTEN pathway- BC042064, A_24_P229834, DOCK11, THC2544911, DLGAP4, NINJ1, PFKM, FLJ10986, IL28RA, CASP9

(204)

DNAJB4, HSPA5, AKIRIN2-AS1, ARVCF, PIGQ, SEC61A2, SERPINE1, SERPINE1, SLITRK5, STC2, UPP1

(205)

MUTZ-3

Other Immune Cells
THP-1 differentiated macrophages

Respiratory Epithelial Cells
BEAS-2B
A549
16HBE14o-

CTLA4

(206)

PPP1R12A, SIS1, AKAP9

(207)

Co-Culture Systems
BEAS-2B, immat. DC (CD14+ mono), MCR-5 fibroblast
NCIH441 epithelial, ISO-HAS-1 capillary endothelial
A549, EA.hy926 (endo),THP-1 (PMA-diff. mac + undiff. DC)
MucilAir

Model/Approach

DC OX40L expression

(208)

Basolateral CCL5 release

(209)

GM-CSF, IL-10, IL-1R1 production

(210)

RANTES, IL-6, MCP-1, Gro-1α production

(211)

IN SILICO AND IN CHEMICO APPROACHES
Biomarker

QSAR- Compound physico-chemical properties
QSAR- Compound 2D/3D structure properties
QSAR- Compound protein binding

Molecular orbital
12 chemical properties
Electrophilic index

Cit.
(212)
(213)
(214)

Table 1.6. Proposed approaches for the identification of potential respiratory sensitizers are summarized. Model/assay and corresponding biomarker of
interest are grouped by in vivo, in vitro, and in silico/in chemico-based approaches.
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Table 1.7. Global Epidemiology of Metal-Induced ACD
Location

Years

Sub #

Inclusion criteria

Taiwan (231)
Japan (232)
Japan (233)
Japan (234)
Thailand (235)
Singapore (236)
China (237)
China (238)
Hong Kong (239)
Korea (240)
Europe (230)
Europe (241)
Europe (242)
Denmark (243)
Norway (244)
Germany (245)
Germany (246)
Finland (247)
Lithuania (248)
Lithuania (249)
Sweden (249)
Italy (250)
Spain (251)
Spain (252)
Czech Republic (253)
North America (254)
USA (255)
Israel (256)
Turkey (257)
Turkey (258)
UAE (259)
Kuwait (260)
Iran (261)
India (262)
India (263)
Ethiopia (264)
Nigeria (265)
Uganda (266)

1978-2003
1990-2009
2000-2005
2006-2016
2003-2004
2001-2003
1990-2009
2004-2009
1995-1999
2004-2011

3,559
931
212
1,225
129
3,407
1,858
2,758
2,585
44
6,708
906
3.119
22,506
1,236
38,878
206
2,543
546
214
428
19,966
1,092
839
12,058
4,308
1,112
134
542
1,038
373
2,461
1,137
358
200
514
375
34

Suspected ACD
Suspected ACD
Suspected ACD to intraoral metals
Suspected ACD
Suspected ACD
Diagnosed with ACD
Diagnosed with ACD
Suspected ACD
Suspected ACD
Patients with oral symptoms

2002-2010
2011-2012
2010
1977-2009
2006
2010-2012
2003-2008
1991-1997
2014-2016
2010-2012
2010-2012
1996-2010
2000-2005
2005-2010
1997-2001
2009-2010
2000-2009
2000-2004
1996-1999
1992-2004
1989-1996
2014-2015
2004-2008
2015-2016
1997
2007-2008
1997-2003
2013-2014

Ag

Al

Au

Be

5.3

25.0

Non-metal allergens tested also
Suspected of having metal allergy

4.9
35.6

+

-

Suspected ACD to intraoral metals
Suspected ACD
Clinical diagnosis of ACD
Presenting with cutaneous allergy
Clinical diagnosis of ACD
Clinical diagnosis of ACD
Clinical diagnosis of ACD
Suspected ACD

23.3

+

14.0

Diagnosed with ACD
Suspected ACD
Clinical diagnosis of ACD

Al

Au

7.18
9.3
15.9

+

Be

Metal
Cu
Fe
+

Hg

Mn

5.2
11.5

8.7
15.9
7.5

5.2

2.1
3.8
2.8
5.1
1.9
1.6
8.7
7.5
6.3
9.9
10.8
4.5
2.0

0.8
2.7
0.8
2.97

6.2
+

2.3
+

20.5

4.5

4.5

16.7
25.2
14.5
10.4
17.6
15.3
4.9
6.9
29.6
25.7
18.9
25.4
29.3
25.9
13.8

1.9
5.6
6.6
6.1
2.8
8.1
7.5
7.6
4.0
+

+

+

20.2

9.9

8.0

11.8
4.6
7.2
6.3
6.2
32.5
20.5

8.0
3.2

6.4
16.0

Co

Cr

Ni
17.7
27.2
25.0
22.5
18.6
19.9
25.7
39.5
24.4
25.0

16.7

+
+
13.5
4.3
22.7

5.0
8.5
5.3
6.4
9.1
8.0

0.7

Ag

Cr

17.1
8.2

8.3

11 countries, patients 1-16 y.o.
6 countries, suspected intraoral metal ACD
5 countries, general pop. random sample
Patients with dermatitis
Randomly selected subjects
Tested for all standard patch agents
Suspected ACD to intraoral metals
Cases from occupational disease registry
Suspected ACD
Suspected ACD
Suspected ACD
Suspected ACD
Patients from allergic unit
Suspected ACD
Suspected ACD

Co

Pd

Ti

Zn

7.2
24.4
14.8

+

11.5

-

+

Ti

Zn

6.8
24.3

4.9
+

11.7

15.5
22.5
13.2
19.1
17.6
15.0
23.9
20.0
28.7
16.5

7.4
9.4

17.7
7.7
29.4

Cu

Fe

Hg

Mn

Ni

Pd

Table 1.7. Patch test studies investigating the prevalence of metal-induced ACD in various countries are summarized. Study years, subject number, study
inclusion criteria, and percent patch test positivity are reported for each metal. Columns denoting +/- indicate study results where metal-specific positivity
rate was not reported, but the presence or absence of subjects exhibiting positivity to the corresponding metal was noted.
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Table 1.8. Metals Associated with Occupational Skin Allergy
Metal

ACD

Aluminum
Beryllium
Cadmium
Cobalt
Chromium
Copper
Gold
Indium
Iron
Iridium
Lead
Manganese
Mercury
Nickel
Palladium
Platinum
Rhodium
Silver
Tin
Titanium
Vanadium
Zinc
Zirconium

(267)
(278)
(282)
(284)
(292)
(297)
(303)
(310)
(312)
(315)
(317)
(319)
(322)
(286)
(339)
(345)
(350)
(352)
(354)
(357)
(315)
(364)
(369)
(373)

Mixed metal/alloys

aACD

sACD

ICD

AD

URT

sURT

LICH

STO

(273)
(279)
(279)
(279)
(304)

GRA

MIX

Frequency

Industry/Occupation

(274)

(275)

Rare
Occasional
Rare
Common
Common
Occasional
Common
Occasional
Rare
Rare
Rare
Rare
Occasional
Common
Common
Occasional
Occasional
Rare
Occasional
Rare
Occasional
Rare
Occasional
Occasional

Machine construction plant (276), alloy production (277)

(280)
(285)
(293)
(298)
(305)

(286)
(101)
(299)
(306)
(313)
(316)

(294)
(300)

(287)
(287)
(301)
(307)
(287)

(280)
(308)

(288)
(295)
(302)
(309)

(314)
(316)

(320)
(279)
(279)

(328)
(298)

(346)
(279)
(355)

(329)

(286)

(101)

(323)
(330)
(340)
(347)

(331)

(324)
(332)
(341)
(341)

(333)
(342)
(341)

(325)
(334)
(343)
(334)

(326)
(335)
(348)

(293)
(356)
(358)
(361)

(359)

(360)

(362)
(365)

(366)
(370)

(374)

(375)

(376)

(367)
(371)

Aerospace, dentistry (281)
Mining, welding (283)
Cement workers, brick layer (289), cleaning (290, 291)
Brick layers, cement workers (296), leather workers (247)
Laundry, electrical, plumbing (281, 297)
Electroplating (303), photographers (306), dentistry (272)
Electronics, semiconductors, medical imaging (311)
Welding, steelwork, toolmaker (312)
Electrochemical manufacture (316)
Painter, construction, automotive (317, 318)
Welding, alloy production, automotive (321)
Healthcare, dental (327)
Electroplating (336), banking (337), hairdressers (338)
Jewelry, telecommunications (289), dental (344)
Catalytics, automobile manufacture, jewelry (280, 349)
Jewelry, automotive, electrochemical (350, 351)
Jewelry, sanitation, electronics (353)
Electrical soldering (355), smelting (356)
Alloy production, welding, food industry (13)
Toolmakers, machinery production, aerospace (363)
Welding, galvanizing, electroplating (368)
Handfinishers of metal reactor components (372)
Dentistry (375)

Table 1.8. Metals associated with various manfiestations of dermal allergy, frequency of reports, and corresponding industries/occupations associated with
responses are summarized. ACD = allergic contact dermatitis, aACD = airborne allergic contact dermatitis, sACD = systemic allergic contact dermatitis, ICD
= irritant contact dermatitis, AD = atopic dermatiits, URT = urticaria, sURT = systemic urticaria, LICH = lichenoid allergic contact dermatitis, STO = allergic
contact stomatitis, GRA = granulomatous skin hypersensivitiy, MIX = mixed responses involving multiple allergic manifestations.
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Table 1.9. Metals Associated with Occupational Respiratory Allergy
Metal
Aluminum
Beryllium
Cadmium
Cobalt
Chromium
Copper
Gold
Iron
Iridium
Manganese
Nickel
Palladium
Platinum
Rhodium
Titanium
Tungsten
Vanadium
Zinc
Zirconium

ASTHIgE

ASTHIgG

ASTHT-cell

ASTHUNKN

RHIN

BHR

(378)

(379)

(380)

IHL

HP

(385)

Frequency

Industry/Occupation

(381)

Occasional

Smelting (378, 382), welding (383, 384)

(386)

Common

Aerospace, nuclear energy (387)

GRAN

MIX

(388)
(389)

(390)

(399)

(391)

(392)

(393)

(294)

(400)

(401)

(404)

(394)

(405)

(406)

Rare

Mining, welding (283)

(395)

Common

Tools (377), automotive (396), welding (397), jewelry (398)

(295)

Common

Aerospace (393), welding (397), construction (402, 403)

(383)

Rare

Welding (383)

(407)

Rare

No occupational cases- all involving gold therapy (408, 409)

(410)
(316)

(316)

(383)
(399)

(412)

(413)

(417)
(419)

(411)
(414)
(340)

(420)

(421)
(425)

(422)

(428)

(430)

(432)

(433)

(435)

(436)

Rare

Welding (383, 397)
Welding (397) electroplating (416)

(418)

Occasional

Electroplating (417), catalyst laboratory work (340)

(423)

Common

Refinery work (424)

Mixed metal dusts

(443)

(444)

Stainless steel

(447)

(441)
(448)

(428)

(437)

(438)
(442)

(445)
(449)

Electrochemical manufacturing (316)

Common

(427)

(429)

Welding (383, 410)

Rare
(415)

(425)
(426)

Rare

(450)

Occasional

Electroplating (425)

Rare

Alloy production, welding, food industry (13)

Rare

Hard metal production, sintering (431)

Occasional

Oil tank cleaning (434)

Occasional

Welding (383, 439), metal jointing (440)

Rare

Ceramics, construction (441)

Occasional

Dentistry (445), welding (446)

Occasional

Welding (447, 449, 451)

Table 1.9. Metals associated with various manfiestations of occupational respiratory allergy and corresponding industries associated with these responses
are summarized. ASTH-IgE = IgE-mediated asthma, ASTH-IgG = IgG-mediated asthma, ASTH-T = T-cell-mediated asthma, ASTH-UNKN = asthma caused
by unknown immunological mechanisms, RHIN = rhinitis, BHR = bronchial hyperreactivity, IHL = immediate hypersensitivity laryngitis, HP = hyeprsensviity
pneumonitis, GRAN = granulomatous lung hypersensitivity repsonses, MIX = mixed-mechanisms of pulmonary hypersensitivity resposnes.

171

Table 1.10. 2017 Global Market for Metal-Based Nanomaterials Reported in Tons
Scale of
Production

MediumHigh
Volume

Low
Volume

Nanomaterial

Global Production
(tons)

Silicon dioxide
Titanium dioxide
Zinc oxide
Aluminum oxide
Cerium oxide
Copper oxide
Silver
Antimony tin oxide
Quantum dots
Iron oxide
Cobalt oxide
Nickel
Manganese oxide
Gold

280,000 – 2.2 million
74,000 – 190,000
31,000 – 40,000
5,750 – 12,500
900 – 1,600
385 - 790
185 - 500
150 - 320
< 50
15 - 85
5 – 10
5 - 35
2-6
1-5

Applications
Nanocomposite filler, cement additive, drug delivery, cosmetics
Ceramics, sunscreens, construction, energy, cosmetics
Sunscreen, LED and LCD displays, antimicrobial, water filtration
Drilling equipment, energetic fuels and additives, filtration
Catalysts, slurry polishing, UV absorption, anti-corrosion additive
Heat transfer, batteries, antimicrobials, sensors, semiconduction
Biomedicine, antimicrobial textiles, cosmetics, conductive inks
Electronics, composites, coatings, research
Photovoltaic devices, photodetecting devices, electronics
Ground and wastewater cleanup, color imaging, drug delivery
Electronics, catalysts, drug delivery, solar energy absorption
Ceramic additive, catalyst, energy absorption, electronics
Bleaching agent, biomedical diagnostics, plastics additive
Data storage, gene therapy, biosensors, fuel cell additive

Adapted from: The Global Market for Nanomaterials 2010-2030

Table 1.10. Most commonly-produced metal nanomaterials, 2017 global production in tons, and applications for each
material are summarized. Adapted from The Global Market for Nanomaterials 2010-2030.
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Table 1.11. Summary of Major Findings from Studies Characterizing the Effect of Metal Nanomaterials on
Biological Processes Involved in Dermal Allergy Grouped by Metal

SILICA

NICKEL

IRON

GOLD

CHROMIUM

COBALT

ALUMINUM

Met
al

Author/Year

Material

Size

Animal or Cell Type

Model

Exposure
Route

Varlamova et al.
2015

Al2O3

-

M/F BALB/c, CBA/CaLac, outbred
mice and guinea pig

LLNA

sq, im, iv,
id

TcAl2O3

BALB/c mouse

DTH

sq

10 mM

Varlamova et al.
2015

52-77 nm
Guinea pig

APHX

iv

0.12 – 1.2 mL/kg

Brown et al.
2008

Al2O3

50 – 120 nm

HaCaT human keratinocytes

Cho et al.
2012

Co3O4

18.4 ± 5.0 nm

F C57BL/6 mouse

OVA

sq

25 µg

Prokhorenkov
et al. 2014

Co

-

Guinea pig

-

Dermal

-

Nanodiamonds adsorbed Co ions, but not Cr ions, inhibiting their
capacity to induce dermatitis reactions

Brown et al.
2013

CoCr

32 nm

Mouse

PLNA

Injection
into knee
joint

0.0005-0.1 mg

Mice exposed to the micron sized, but not nanoparticles became
immunologically sensitized to Cr(III), Cr (VI) and Ni(II). The
response was Th1 driven, indicative of DTH

Horie et al.
2013

Cr2O3

26.5 nm

HaCaT keratinocytes

0.1-10 mg/mL

Smaller size particles released more Cr ions, causing ROS
production, caspase-3 activation and compromised viability

Ishi et al.
2008

Au

5.2 ± 1.3 nm

F Japan White Rabbit

-

id

1 mg

Hirai et al.
2016

Au

10 nm

F BALB/c, BALB/c nu/nu,
C57BL/6, C.B-17 SCID mouse

-

sq

0.8 mg

Shen et al.
2012

Fe3O4

58.7 nm

M BALB/c mouse

OVA

iv

0.2-10 mg/kg

Mohanan et al.
2014

Fe3O4

< 25 nm

Albino rat, guinea pig

-

Dermal

80 mg

Hsiao et al.
2018

Fe3O4

58.7 nm

M BALB/c mouse

OVA

iv

1 – 100 µg

Attenuation of Th17 responses

Vemula et al.
2011

Ni

-

F C3H/HeJ mouse

-

Dermal

20% Ni sln.

CaCO3/CaPO4 NP captured nickel ions by cation exchange,
preventing the elicitation of skin allergy

Sugiyama et al.
2014

Ni/NiO

40-50 nm

C57BL/6 mouse

-

Dermal

20 mL 5% w/v

Hirai et al.
2016

Ni

3 nm

F BALB/c, BALB/c nu/nu,
C57BL/6, C.B-17 SCID mouse

-

sq

0.8 mg

Choi et al.
2011

SiO2

7 nm

CBA/N mouse

HSEM
LLNA

Dermal

10 – 1,000 µg

No phototoxicity or skin sensitization

Hirai et al.
2015

SiO2

30 nm

F NC/Nga slc mouse

HDM

Dermal

20 µL @ 12.5
mg/mL

Concurrent exposure to allergen/Si resulted in low-level production
of specific IgG subtypes and increased sensitivity to anaphylaxis

In vitro

Major Findings
No intensification of anaphylaxis systemic reaction, no
inflammatory reaction to ConA, no delayed allergic reaction, no
redness or edema at site of application

10 – 10,000
µg/mL

In vitro
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Dose

No induction of delayed-type hypersensitivity
No induction of anaphylaxis
24 hr exposure resulted in IL-8 expression, IL-1α release, indicating
potential for irritation or sensitization
Balanced Th1/Th2 response when used as adjuvant, causing
higher specific IgG2c and IgG1 and lower IgE

Azobenzene hapten conjugation to AuNP led to high yield of
specific IgG indicating capacity to act as carrier and adjuvant

No induction of sensitization, even in the presence of LPS
Decreased footpad swelling, infiltration of macrophages and Tcells, and IFN-y, IL-6, TNF-α levels
No irritation or sensitizing effects

High surface area of NiNP triggered allergic response by releasing
more ions than Ni salts
NiNP plus LPS induced allergic sensitization

Ostrowski et al.
2014

SiO2

55 ± 6 nm

M SKH1 mouse

OXA

Dermal

-

Hirai et al.
2016

SiNP

10 nm

F BALB/c, BALB/c nu/nu,
C57BL/6, C.B-17 SCID mouse

-

sq

0.8 mg

Smulders et al.
2015

SiO2

19 nm

M BALB/c mouse

DNCB

Dermal

0.4, 4.0, or 40
mg/mL x 3 d

SiO2NP exposure prior to sensitization with DNCB did not alter the
stimulation index

M SPF guinea pig

GPMT

id

0.1 mL @ 1:1
(v/v)

No eye/skin irritation or corrosion, 1/20 animals developed
erythema after sq. injection, classified as weak sensitizer

M New Zealand White rabbit

-

Occular
application

100 mg

TITANIUM

SILVER

Kim et al.
2013

No induction of sensitization, even in the presence of LPS

10 nm
No eye irritation effects 1-72 hr after exposure

Bhol et al.
2005

Ag

< 50 nm

F BALB/c mouse

DNFB

Dermal

100 mg 1%
nanocrystaline

Reductions in ear swelling, erythema, and inflammation seen after
4 days of treatment with nanoparticle-containing cream

Smulders et al.
2015

Ag

25 - 85 nm

M BALB/c mouse

DNCB

Dermal

0.4, 4.0, or 40
mg/mL x 3 d

Exposure prior to sensitization with DNCB did not alter stimulation
index

Zelga et al.
2016

Ag

-

Guinea pig

GPMT

Dermal

2%

2/10 animals developed slight erythema that resolved after 72 hr,
leading to classification as a mild sensitizer

Korani et al.
2011

Ag

< 100 nm

M Harley Albino guinea pig

-

Dermal

100 – 10,000
µg/ml

Dose-dependent increase in number of Langerhans cells recruited
to skin

Park et al.
2011

F CBA/N mouse

LLNA

Dermal

10 – 1000 µg/mL

TiO2

< 25 nm
F Hartley Albino guinea pig

-

Dermal

50 µg

No skin sensitization
No phototoxicity or acute cutaneous irritation

Hussain et al.
2012

TiO2

12 ± 2 nm

M BALB/c mouse

DNCB

sq

0.004 - 0.4
mg/mL

Auttachoat et al.
2014

TiO2

< 25 nm

F BCC3F1 mouse

-

Dermal, sq

1.25-250 mg/kg

Smulders et al.
2015

TiO2

15 nm

M BALB/c mouse

DNCB

Dermal

0.4, 4.0, or 40
mg/mL x 3 d

Jafari et al.
2018

Dermal
Irritation

Dermal

0.5mL
10-20% NP

No skin irritation in acute dermal irritation test

20 – 40 nm

Rabbit

TiO2

Mouse

DNCB

Dermal

10-20% NP

No alterations in skin sensitization

New Zealand albino rabbit

Dermal
Irritation

Dermal

0.5 g

Dunkin-Hartley guinea pig

GPMT

Dermal

0.1 mL/site

APS 396 nm,
containing
nanoparticles

New Zealand albino rabbit

Dermal
Irritation

Dermal

0.5 g

Dunkin-Hartley guinea pig

GPMT

Dermal

0.1 mL/site

20 – 50 nm,
13.1 m2/g

M Sprague-Dawley Rat, M New
Zealand White rabbit, M guinea pig

GPMT

Dermal

50%

Zelga et al.
2015

ZINC

Ag

Functionalized nanoparticles had no impact on allergic response to
oxazolone in an ACD model

Zelga et al.
2015

Kim et al.
2016

TiO2

ZnO

ZnO

-
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Th2 adjuvancy, increased DNCB dermal sensitizer potency
Dermal exposure did not induce lymph node expansion, despite
irritancy response at 5% and 10%, no ear swelling, but lymph node
cell proliferation resulted following sqs injection
Exposure to 4.0 mg/mL of TiO2 prior to sensitization with DNCB
resulted in increased stimulation index

5 UV-absorbers containing nano-sized particles were assessed for
irritation and sensitization potential. Anatase TiO2 – containing
agent did not induce irritation, but caused mild sensitization

5 UV-absorbers containing nano-sized particles were assessed for
irritation and sensitization potential. Z11 modifier caused minor
dermal irritation and mild sensitization
No dermal sensitization, acute dermal toxicity, irritation, or
corrosion

Table 1.11. Summary of studies investigating metal nanomaterial immune effects in the skin and select in vitro studies using dermal immune cells, grouped
by metal. Exposure routes are denoted as id (intradermal injection), im (intramuscular injection), iv (intravenous injection), sq (subcutaneous injection).
Abbreviations: APHX anaphylaxis, APS average particle size, DNCB dinitrochlorobenzene, DTH delayed type hypersensitivity, GPMT guinea pig
maximization test, HDM house dust mite, HSEM Human Skin Equivalent Model, LLNA Local Lymph Node Assay, OVA ovalbumin, OXA oxazolone, PLNA
popliteal lymph node assay, ROS reactive oxygen species, UV ultraviolet.
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Table 1.12. Summary of Major Findings from Studies Comparing the Effects of Various Physico-Chemical Properties of Metal Nanomaterials
on Processes Involved in Dermal Allergy Grouped by Property of Interest

CRG

SOL

#

Size

Property
Investigated

Author/Year

Metal

Study Design

Property Variations

Kang et al.
2017

Ag

RBL-2H3 mast cells
F NC/Nga mouse, HDM AD: 40 µg

5, 100 nm AgNP

Nabeshi et al.
2010

Si

XS52 mouse epidermal
Langerhans cell, 0.1 – 1,000 µg/mL

70, 300, 1000 nm SiNP

Cellular uptake and cytotoxicity increased with reductions in
particle size

Yoshida et al.
2010

Si

XS52 mouse epidermal
Langerhans cell, 0 – 100 µg/mL

70, 300, 1000 nm SiNP

ROS generation by LC was higher following exposure to the
smaller amorphous SiNP

Hirai et al.
2012

Si

M NC/Nga mouse, HDM ACD
Intradermal injection: 250 µg

1136 nm SiO2NP: -33.2 mV, 264 nm SiO2NP: 25.8 mV, 106 nm SiO2NP: -24.3 mV, 76 nm
SiO2NP: -19.5 mV, 39 nm SiO2NP: -14.0 mV

Palmer et al.
2019

Si

M hairless C57BL/6 mouse
DNFB ACD

20, 400 nm SiNP

Kang et al.
2017

Au

Mouse footpad injection
OVA

7, 14, 28 nm AuNP

Size-dependent increase in cellular uptake by DC, T-cell crosspriming, and activation. After injection into footpad, higher delivery
efficiency to lymph nodes was associated larger NPs

Yanagisawa
et al. 2009

Ti

M NC/Nga mouse, HDM
Intradermal injection: 20 µg

15 nm TiO2NP – 110 m2/g
50 nm TiO2NP – 20-25 m2/g
100 nm TiO2NP – 10-15 m2/g

TiO2NP aggravated AD skin lesions, caused increased IL-4
production, IgE levels, and histamine levels, but decreased IFN-γ
expression. Effects were not dependent on size

Ilves et al.
2014

Zn

F BALB/c mice, OVA ACD
Dermal application: 16.67 mg/mL

20, 240 nm ZnONP

Smaller ZnONPs were able to penetrate the skin, larger particles
were not. Both particles diminished local skin inflammation, but
ZnONP has higher suppressive activity and increased IgE

Lehmann et al.
2018

Ag

Human primary keratinocytes,
human reconstructed epidermis

2 µm x 40 nm,
20 µm x 50 nm Ag nanowires

Intact epidermis was effective barrier preventing penetration of Ag
nanowires, but keratinocyte cytotoxicity was related to particle #

Palmer et al.
2019

Si

M hairless C57BL/6 mouse,
DNFB DTH, topical NP exposure

20 or 400 nm SiNP

SiNP exposure had preferential effect on the late phase swelling
response, which was size-dependent

Hirai et al.
2016

Ag

BALB/c mouse

10, 50, 100 nm AgNP

AgNP with LPS caused the development of allergic inflammation,
whereas the ions did not cause the same effect

Shibuya et al.
2019

Pd

Mouse allergy model
Human subjects

PtNP, PdNP, PdCl2, PtNP-containing topical
cream

PdNP only caused slight skin inflammation, which was minimal
compared to that induced by Pd salts.

Jang et al.
2012

Zn

CBA/N Mouse LLNA: 25, 50, or 100
µg/mL ; HSEM EpiDerm and
Draize skin irritation- 50 µg/mL

20 nm, 29 mV or -40 mV ZnONP
100 nm, 24 mV or -29 mV ZnONP

ZnO are not dermal sensitizers and do not induce skin irritation
irrespective of size and zeta potential, but may induce
phototoxicity

Si

M/F hairless C57BL6 mouse
DNFB ACD
Dermal application

32.7 nm SiO2 nanosphere: -25.4 mV
66.5 nm SiO2 nanosphere: -45.7 mV
69.3 nm SiO2 nanosphere: 17.7 mV
184.9 SiO2 nanosphere: -33.5 mV
440.0 nm SiO2 nanosphere: -66.0 mV

Jatana et al.
2017
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Major Findings
5nm AgNP induced increases in ROS levels, intracellular calcium,
and granule release in mast cells in vitro and earlier and more
severe lesions in an AD model in vivo

Reduction in SiO2NP size enhanced IL-18 and TSLP production,
leading to an enhanced systemic Th2 response and aggravation
of skin lesions following challenge with house dust mite
Topical exposure resulted in suppressed ACD responses

Small negative and neutral-charged nanoparticles exhibited an
immunosuppressive effect, whereas positively-charged particles
did not. Positively-charged nanoparticles penetrated skin to a
lesser extent. Studies also included 100nm TiO2NP, 20 nm AgNP,
and 20 nm AuNP

MOD

MOR

Cell morphology was disrupted by all AuNP in a dose-dependent
manner. Charged AuNPs caused dose-dependent cytotoxicity and
mitochondrial stress, causing alarmin release

Au

HaCaT human keratinocyte cells
10 µg/mL – 25 µg/mL

1.5 nm AuNP
Positive, neutral, or negatively-charged

Lee et al.
2011

Si

J774A.1 mouse macrophages:
0 – 1,000 µg/mL, 1 or 3 d
LLNA: F BALB/c, 1 mg/ear x 3 tx

100 nm spherical:
mesoporous SiO2 - 1150 m2/g
colloidal SiO2 – 40 m2/g

Higher surface area caused decreased cytotoxic and apoptotic
cell death. Similarly, higher surface area induced lower
expression of pro-inflammatory cytokines. Lower surface area Si
particles acted as an immunogenic sensitizer in the LLNA

Maquieira et al.
2012

Al

Mice and rabbits
Intradermal injection

40, 3000 nm amorphous Al2O3,
300 nm crystalline Al2O3

AlNP served as both carrier and adjuvant leading to haptenspecific antibody production dependent on size and crystallinity

100% anatase TiO2: 6.3, 10, 40, 50, 100 nm
61% anatase, 39% rutile TiO2: 39 nm
40% anatase, 60% rutile TiO2: 39 nm
75% anatase, 25% rutile TiO2: 26 nm
Amorphous TiO2: 40 nm
100% rutile TiO2: 51 nm

Both size and crystal structure contributed to toxicity in vitro.
Smaller size and less agglomeration increased cytotoxicity. 100%
anatase TiO2 particles, regardless of size, induced cell necrosis,
whereas the rutile TiO2 nanoparticles initiated apoptosis through
formation of ROS. Differential release of alarmins can impact
sensitization

Stolle et al.
2009

Ti

HEL-30 mouse keratinocytes
0 – 150 µg/mL
24 h exposure

Guo et al.
2017

Gd

F New Zealand white rabbits
Keyhole limpet hemocyanin

22 nm
Gd@C82, GD@C82(OH)

Metallofullerenol conjugated to the immunogen resulted in
antibody production to the hapten, but the hydroxyl groups and
size and shape of the carbon cage did not impact the specificity of
the antibody generated

Orlowski et al.
2013

Ag

291.03C mouse keratinocyte
1 – 10 µg/mL
24 hr exposure

Tannic acid-modified AgNP: 13, 33, and 46 nm
Unmodified AgNP: 10 -65 nm

Unmodified, but not modified, AgNP increased production of
MCP-1 by keratinocytes and upregulation of TNF-α, attributable to
increased ROS production, with potential to promote sensitization

Li et al.
2016

Si

F C57BL/6 mouse
5 mg injection

Unmodified mesoporous SiNP
PEG, PEG-RGD, PEG-RDG- modified SiNP

PEG modification significantly enhanced DC activation in vitro and
innate immune cell infiltration in vivo. PEG-modification resulted in
less recruitment of DC to area of injection

Size

CRY

SA

Schaeublin et al.
2010

Table 1.12. Summary of study design and major findings from studies comparing the effects of various physico-chemical properties of metal nanomaterials
on dermal allergy grouped by study property of interest. Properties of interest: size, CRY (crystallinity), CRG (surface charge), SA (surface area), # (particle
number), and MOD (surface modification). Reported particle size (nm), specific surface area (m 2/g), zeta potential (mV), pore volume (cm 3/g), in vitro dose
concentration (µg/mL). Abbreviations: DC dendritic cell, DNFB dinitrofluorobenzene, HDM house dust mite, LC Langerhans cell, LLNA Local Lymph Node
Assay, HSEM Human Skin Equivalent Model, OVA ovalbumin, PEG poly(ethylene glycol) modification, PEG-RDG/RGD, ROS reactive oxygen species,
TSLP thymic stromal lymphopoietin.
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Table 1.13. Metal Nanomaterials and Corresponding Physico-Chemical Properties Shown to Influence
Immunological Processes Involved in Skin Sensitization

Molecular
Initating Event
Cellular Response
Organ
Response

SENSITIZATION

Bioaccess
-ibility

AOP Step

Metal Nanomaterial Effect
Increased potential for nanomaterial penetration of intact skin
Keratinocyte tight junction compromisation
Epithelial cell cytotoxicity
Increased potential for nanomaterial penetration of damaged skin
Increased release of ions from parent nanomaterials
Accumulation of nanomaterial in follicles and skin folds
Cell-independent transport to lymph nodes
Metal antigen formation
Antigen formation:
Cryptic epitope exposure
Conjugation with hapten
Altered immunogenicity of antigens:
Adsorbed protein conformational changes > PRR recognition
Increased protease activity of antigen
Altered immunogenicity from adsorption of LPS to surface
Increased recruitment of Langerhans cells
Selective uptake by Langerhans cells
Activation of DC:
Inflammasome activation
Release of DAMPs from skin epithelial cells
Release of DAMPs from dermal immune cells
Enhanced cross-presentation by DC:
Increased endosomal escape of antigen
Autophagy-dependent cross-presentation
Accumlation in endocytic compartments > altered antigen processing
Enhanced DC migratory capacity
Altered delivery kinetics of antigen to lymph nodes:
Depot formation
Nanomaterial antigen vehicle
Polarization of DC cytokine production
Increased TH1 signaling
Enhanced presentation effiiency to lymphocytes

Metal

Property

Citation

Au
Au
Ti
Ti
Pd
Zn
Au
Ti

size, crg
mod
cry
size, cry
size
mod
size
size

(46)
(512)
(513)
(514)
(515)
(516)
(517)
(518)

Au
Au

size
-

(519)
(520)

Au
Au
Au
Ag
Si
Ti
Al
Fe
Si

size
size, mod, hyd
size
size
size, cry, mor
cry, mor
size
size, SA

(521)
(522)
(523)
(524)
(525)
(526)
(527)
(528)
(529)

Fe
Al
Si
Au

crg
mod, crg
size

(530)
(531)
(532)
(533)

Si
Ti
Ti/Ce
Co
Au

agg
SC
size

(534)
(535)
(536)
(794)
(538)

Table 1.13. Adverse Outcome Pathway (AOP) steps involved in skin sensitization, metal nanomaterials shown to
impact individual steps and cells involved, and physico-chemical properties associated with effects are shown.
Physico-chemical properties of interest include size, surface modification (mod), surface area (SA), solubility (sol),
surface charge (crg), morphology (mor), crystallinity (cry), hydrophobicity (hyd), and surface chemistry (SC).
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Table 1.14. Metal Nanomaterials and Corresponding Physico-Chemical Properties Shown to Influence
Immunological Processes Involved in Dermal Allergy Elicitation

Organism
response
Chronic
Effects

ELICITATION

AOP Step

Metal Nanomaterial Effect
Increased recruitment of inflammatory cells:
Increased permeability of endothelial cells
Increased effector T-cell recruitment
Increased number of DC for T-cell activation
Increased number of skin macrophages
Increased neutrophil influx
Increased number of skin mast cells
Altered T-cell response to mitogens/allergens
Increased IgE-independent mast cell degranulation
Compromised barrier inegrity > increased penetration of HMW allergens
Compromised skin repair mechanisms > enhanced skin permeability
Keratinocyte cytotoxicity
Aggravation of allergic lesion severity:
Increased TSLP release/production
Increased histamine release/production
Increased activation of mast cells

Metal

Property

Citation

QD
many
Si
Fe
Ti
Ag
Pd
many
Ag
Ag
Au

mod
mod
size
size, sol
size, SA, crg
size, sol
crg

(1604)
(540)
(541)
(542)
(543)
(544)
(545)
(546)
(547)
(548)
(549)

Si
Ti
Ag

size
size

(550)
(551)
(544)

Table 1.14. Adverse Outcome Pathway (AOP) steps in the elicitation phase of allergic contact dermatitis, metal
nanomaterials shown to impact individual steps and cells involved, and physico-chemical properties associated with
effects are shown. Physico-chemical properties of interest include size, surface modification (mod), surface area
(SA), solubility (sol), and surface charge (crg).
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Author/Year
Braydich-Stolle
et al. 2010

NICKEL

GOLD

IRON

COPPER

COBALT

CERIUM

Metal

ALUMINUM

Table 1.15. Summary of Major Findings from Studies Characterizing the Effect of Metal Nanomaterials on
Processes Involved in Respiratory Allergy Grouped by Metal
Material

Size

Al

48.08 ± 21.0 nm

Animal or Cell Type

Model

Exposure
Route

Dose
5-500 µg/mL
24 h

Major Findings
Exposure impaired bacterial phagocytic function, induction of NFκB
pathway, and release of cytokines with potential to promote
sensitization

Al2O3

32.71 ± 28.3 nm

A549, U937
3:1 co-culture

Cui et al.
2019

Al2O3

< 50 nm

M BALB/c mouse

OVA

it

0.5, 5.0, or 50
mg/kg/day for 3w

NP exposure caused Th1/2 imbalance, exacerbated AHR, airway
remodeling, and inflammation

Park et al.
2010

CeO2

130 nm

M ICR mouse

-

it

50, 100, 200, 400
mg/kg

Differentiation of naïve T-cells and TH1 cytokine production

Meldrum et al.
2018

CeO2

< 25 nm APS, 166.5
nm agglomerates

F BALB/c mouse

HDM

in

75 or 750 µg/kg

Repeated exposure to CeO2NP in the presence of HDM caused
increased lung eosinophils, mast cells, plasma IgE, IL-4, and goblet
cell metaplasia

Meldrum et al.
2019

CeO2

25 nm

F BALB/c mouse

HDM

in

2.5 or 75 µg/kg

HDM sensitization was altered upon simultaneous to diesel exhaust
particulate exposure, an effect further enhanced when CeNP
exposure also occurred

Cho et al.
2012

Co3O4

18.4 ± 5.0 nm

F Wistar rat

-

it

150 cm2 SA

Verstaelen et al.
2014

CoO

7.1 nm

BEAS-2B, A549
epithelial cells

Cho et al.
2012

CuO

23.1 ± 7.2 nm

F Wistar rat

-

it

150 cm2 SA

Park et al.
2015

CuO

< 50 nm

F BALB/c mouse

OVA

it

25, 50, 100 µg/kg

Lai et al.
2018

CuO

46.5 nm

C57BL/6 mouse

-

in

1, 2.5, 5, 10 mg/kg

Aggravated pulmonary inflammation, collagen accumulation and
expression of progressive fibrosis markers in lungs

Park et al.
2015

Fe2O3

101.3 ± 4.2 nm

M ICR mouse

-

it

0.5, 1, or 2 mg/kg

Th1-polarized inflammatory response, GM-CSF, MCP-1, and MIP-1
increase, and increased expression of CD80, CD86, and MHC II
expression on lung APCs

Park et al.
2010

Fe3O4

5.3 ± 3.6 nm

M ICR mouse

-

it

250, 500, 1,000 µg/kg

Gustafsson et al.
2015

α-Fe2O3

30 nm

F BALB/c mouse

OVA

it

5 mg/kg

Hussain et al.
2011

Au

40 nm

M BALB/c mouse

TDI

asp

40 µL @ 0.8 mg/kg

Peng et al.
2019

Au

-

F BALB/c mouse

OVA

in

-

AuNP exposure reduced nasal symptoms of rhinitis, decreased IL-4
production and inflammatory cell influx

Baretto et al.
2015

Au

6.3 nm

Swiss Webster and
A/J mouse

OVA

in

6, 60 µg/kg

Inhibited allergen-induced accumulation of inflammatory cells, proinflammatory cytokine production. In A/J mice, AuNPs prevented
mucus production and AHR

Cho et al.
2012

NiO

5.3 nm

F Wistar rat

-

it

150 cm2 SA

Exposure caused pulmonary alveolar proteinosis and Th1/Th17
dominant responses

Baker et al.
2016

Ni

20 nm

M C57BL/6 WT or
T-bet-/- mouse

-

asp

4 mg/kg

In vitro

1 – 60 µg/mL

In vitro
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Exposure caused pulmonary alveolar proteinosis and Th1/Th17
dominant response
Alterations in expression of genes associated with innate immunity,
T-cell activation, and leukocyte adhesion
No immunoinflammatory reaction
Increased AHR, IgE and mucus production

Increases in TH1/TH2 cytokines, B cells, and IgE levels
LN and BAL cell death was observed in sensitized mice exposed to
AlNP
3x AHR increase

Increased airway remodeling in T-bet knockout mice with
susceptibility to Th2 responses

NiO

5.3 ± 0.4 nm

F Wistar rat

-

it

50, 100, 200 cm2

Chang et al.
2017

NiO

-

M Wistar rat

-

it

0.015 – 0.24 mg/kg

PLATINUM

Park et al.
2010

Pt

20.9 ± 11.4 nm

M ICR mouse

-

it

-

Onizawa et al.
2009

Pt

2 ± 0.4 nm

DBA/2 mouse

-

in

x 3d

QD

Scoville et al.
2019

QD

12.7 nm

M A/J, C57BL/6J
mouse

HDM

asp

140 nm

Brandenberger
et al. 2013

Si

90 nm

F BALB/c mouse

OVA

in

0, 10, 100, 400 µg

Han et al.
2011

SiO2

10-20 nm

M Wistar rat

OVA

it

40 or 80 µg

SiNP exposure resulted in exacerbation of Th2 responses in OVAsensitized rats

Park et al.
2010

Ag

6 ± 0.29 nm

F C57BL/6 mouse

OVA

ih

5x 20 ppm,
40 mg/kg

Decreased AHR, Th2 cytokines, and ROS levels

Jang et al.
2012

Ag

6.0 ± 0.29 nm

F BALB/c mouse

OVA

ih

20 ppm/40 mg/kg 5x
for 24h

Su et al.
2013

Ag

33 nm

F BALB/c mouse

OVA

ih

3.3 ± 0.7 mg/m3 6h/7 x
7d

Chuang et al.
2013

Ag

33 nm

F BALB/c mouse

OVA

ih

3.3 mg/m3 6h/d x 7d

Increased Penh, recruitment of neutrophils, lymphocytes, and
eosinophils to the airways

Xu et al.
2013

Ag

141 nm

F BALB/c mouse

OVA

ip

0.4, 2, 10 mg/kg

Increased OVA-IgG and Th2 responses, local activation and
recruitment of leukocytes

Shin et al.
2012

Ag

1.5 nm

F BALB/c mouse

OVA

ih

0.1, 1, 10 ppm

Ahn et al.
2005

TiO2

0.29 µm

M Sprague-Dawley
rat

-

it

4 mg/kg

Park et al.
2009

TiO2

20 nm

ICR mouse

-

it

5, 20, or 50 mg/kg

Larsen et al.
2009

TiO2

28 nm

F BALB/c mouse

OVA

ip

2-250 µg

Rossi et al.
2010

TiO2

10x40 nm

F BALC/c/Sca
mouse

OVA

ih

2h/d, 3d/w, x4w @ 10
mg/m3

Gustafsson et al.
2011

TiO2

21 nm

M Dark Agouti rat

-

it

5 mg/kg

Hussain et al.
2011

TiO2

15 nm

M BALB/c mouse

TDI

asp

40 µL @ 0.8 mg/kg

TITANIUM

SILVER

SILICA

Lee et al.
2016
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Acute neutrophilic inflammation, and eosinophils recruited at days 3
and 4 via eotaxin release
Alterations in Th1/Th2 balance were indicative of nitrative stress
and NFk-B activation
Increase in serum IgE, lung TH2 cytokines, and decrease in CD4/8
ratio
PtNP exerted protective effects from cigarette smoke, prevented
NFk-B activation, and neutrophilic inflammation
Increased lung ILC number, IL-33 release, and MHC II hi
macrophages depending on strain
Co-exposure during sensitization caused dose-dependent
enhancement of OVA-specific IgE, lung eosinophils, mucus cell
metaplasia, and Th2/Th17 cytokine production

Suppressed mucus production via VEGF signaling alterations
Increased OVA IgE, proteins associated with immune processes
were altered

AgNP attenuated nasal symptoms of OVA-induced rhinitis, OVAspecific IgE, IL-4, and IL-10 levels
Increased BAL IL-13 levels, IL-13-producing mast cells, and goblet
cell hyperplasia
Increased BAL and serum IgE levels, altered Th1/Th2 cytokines,
increased B cell distribution
Th2 adjuvancy, increased IgE, IgG1, and eosinophil levels
Allergic pulmonary inflammation suppressed by TiO2NP
Increased eosinophil, DC numbers in lungs, lymphocytes recruited
mostly CD4+, also included CD8+ T-cells, B-cells, and CD25+ Tcells
2x increase AHR

ZINC

Scarino et al.
2012

TiO2

5 nm APS,
168/171 nm agg.

M Brown Norway
rat

OVA

ih

9.4 or 15.7 mg/m3

Jonasson et al.
2013

TiO2

21 nm

F BALB/c
mouse

OVA

ih

32 ± 1 µg

Fu et al.
2014

TiO2

21 nm

M Sprague-Dawley
rat

-

it

0.5, 4.0, 32 mg/kg
2x/w x 4w

Choi et al.
2014

TiO2

P25

-

it

10, 50, 250 µg

Gustafsson et al.
2014

TiO2

21 nm

OVA

ih

168 – 159 µg/d x 10d

Mishra et al.
2016

TiO2

4 – 8 nm

BALB/c mouse

OVA

ip

200 µg

Harfoush et al.
2019

TiO2

-

F BALB/c mouse

OVA

in

0.0125-0.025 mg

Kim et al.
2020

TiO2

19-37 nm

F BALB/c mouse

OVA

ih

200 µg/m3

Kim et al.
2017

TiO2

75 nm

F BALB/c mouse

OVA

ih

50 µg/m3
X 3d

Roy et al.
2014

ZnO

< 50 nm

F BALB/c mouse

OVA

ip

0.25, 0.5, 1, 3 mg

Roy et al.
2014

ZnO

< 50 nm

F BALB/c mouse

OVA

ip

1, 2, 4, and 12 mg/mL

Adjuvant effect on OVA allergy by signaling through TLRs and Src
kinase leading to inflammatory responses

Huang et al.
2019

ZnO

60 nm

F BALB/c, C57BL/6
mouse

OVA

asp,
dermal

Asp: 2.5 mg/m3
Dermal: hi, lo doses

Aspiration of NP enhanced asthmatic responses to OVA, but
topical exposure did not contribute to allergic airway inflammation

Huang et al.
2015

ZnO

181.5 nm low dose
360.0 nm high dose

F BALB/c mouse

OVA

asp

0.1 / 0.5 mg/kg

Exposure simultaneous to OVA sensitization resulted in eosinophil
recruitment and Th2 adjuvancy

M New Zealand
White Rabbit
M Dark Agouti rat
M Brown Norway
rat

Significantly decreased lung leukocytes and plasma/BAL IL-4, IL-6,
and IFN-γ over OVA controls
Aggravated allergic response dependent on dose and timing
Deposition in lymph nodes, increased T and B-cell proliferation
following mitogen stimulation, enhanced NK activity in spleen,
increased B-cells in the blood
Dose-dependent eosinophil influx and inflammation in the lung, but
not neutrophil or lymphocyte influx
Exposure decreased eosinophilia in OVA-sensitized DA and BN
rats, but neutrophils/lymphocyte increase in DA rats
Augmented AHR, biochemical markers of damage, and induced a
mixed Th1/Th2 response
Th2 adjuvant effect on OVA-induced asthma
NP inhalation 2hr prior to OVA challenge caused increased airway
inflammation and AHR, effects associated with neuroinflammation
Exposure exacerbated AHR and inflammation, increases in IL-1, IL18
Administration with OVA caused increased OVA-IgG1, IgE,
eosinophil and mast cell numbers in lungs and spleen

Table 1.15. Summary of findings from in vivo studies investigating immune effects of metal nanomaterials in the lung and select in vitro studies in pulmonary
cells, grouped by metal. Exposure routes are noted as in (intranasal), asp (aspiration), ih (inhalation), in (intranasal), ip (intraperitoneal injection).
Abbreviations: AHR airway hyperreactivity, APC antigen presenting cell, APS average particle size, DC dendritic cell, HDM house dust mite, IP
intraperitoneal, LPS lipopolysaccharide, MHC major histocompatibility complex, OVA ovalbumin, ROS reactive oxygen species, RSV respiratory syncytial
virus, TLR Toll-like receptor, WT wild-type.
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Table 1.16. Summary of Major Findings from Studies Comparing the Effects of Various Physico-Chemical Properties of Metal Nanomaterials on
Processes Involved in Respiratory Allergy Grouped by Property of Interest

MOD

CRG

SC

SA

Size

Property
Investigated

Author/Year

Metal

Study Design

Property Variations

de Haar et al.
2006

Ti

F BALB/cANNCrl mouse
OVA, 200µg intranasal

Fine TiO2: 250 nm, 6.6 m2/g
Ultrafine TiO2: 29.0 nm, 49.8 m2/g

Exposure to equal mass doses of fine and ultrafine TiO2 resulted
in increased Th2 cytokines and serum OVA-specific IgE and IgG1
only in animals exposed to ultrafine TiO2

Yoshida et al.
2011

Si

F BALB/c mouse, OVA
Intranasal: 10, 50, or 250 µg/
mouse x3

Amorphous silica
30, 70, 300, or 1,000 nm

Smaller particles induced higher levels of OVA-specific IgE, IgG,
and IgG1. Splenocytes from mice exposed to the smallest particle
produced higher levels of Th2 cytokines than other groups.

Liu et al.
2010

Ti

Rats, Intratracheal instillation
0.5, 5, or 50 µg/mL

5 or 200 nm TiO2

Decreased chemotactic ability, expression of Fc receptors/MHC II
by alveolar macrophages. Phagocytic function was increased at
low doses and decreased at high doses

Chang et al.
2014

Ti

M Sprague Dawley rat
Intratracheal instillation: x2, x 4 w
0.5, 4, 32 mg/kg

21 nm TiO2NP: 80% anatase, 20% rutile,
1-2 µm TiO2: anatase

Ban et al.
2013

Fe

F BALB/c mouse, OVA
Intratracheal instillation:
4x (100, 250, or 500 µg/mouse)

Submicron Fe2O3: 147 ± 48 nm, 6 m2/g
Fe2O3NP: 35 ± 14 nm, 39 m2/g

Rossi et al.
2010

Ti

F BALB/c/Sca mouse, OVA
Inhalation: 10 ± 2 mg/m3 x 12

Rutile TiO2NP: < 5 µm, 2 m2/g
Rutile TiO2NP: 10 x 40 nm, 132 m2/g

Park et al.
2015

Si

F BALB/c mouse, OVA
Intranasal inoculation

Spherical SiNP: 12.7 m2/g
Mesoporous SiNP: 70.6 m2/g
PEGylated SiNP: 12.7 m2/g

Han et al.
2016

Si

F BALB/c mouse, OVA
Intranasal inoculation: 10 mg/kg 6x

Spherical SiNP: 12.7 m2/g, 119.6 nm
Mesoporous SiNP: 70.6 m2/g, 100.5 nm
PEGylated SiNP: 12.7 m2/g, 439.1 nm

Dekkers et al.
2019

Ce
Co
Ti

F BALB/c mouse, OVA
Intranasal instillation: 200 µg NP

All 4.7 – 18.7 nm: TiO2NP,
CeO2NP, Zr-doped CeO2NP,
Co3O4NP, Fe2O3 or Fe3O4-doped Co3O4NP

Administration of NP simultaneous to intranasal OVA sensitization
caused Th2 adjuvancy, but effects were not dependent on
acellular redox activity

Seydoux et al.
2016

Au

F BALB/c mouse
AuNP intranasal instillation: 10 µg

90 nm AuNP:
NH2-PVA, 7.2 mV or COOH-PVA -8.2 mV

APCs preferentially took up cationic AuNPs, causing upregulation
of co-stimulatory molecules. Positive AuNPs enhanced OVAspecific CD4+ T-cell stimulation in lung LN

Marzaioli et al.
2014

Si

F BALB/c mouse, OVA
Intratracheal instillation: 50 µg

Amorphous SiO2NP 15 nm:
Uncoated -38 mV, PEGylated -26 mV, Phosphate 43 mV, Amino-coated 0 mV

Omlor et al.
2017

Au

F BALB/c mouse, OVA
Intranasal instillation

5 nm AuNP, PEGylated or citrated

Ilves et al.
2019

Cu

F BALB/c mouse, OVA
Aspiration: 2.5, 10, or 40 µg

6.5 – 12.0 nm CuO:
Uncoated, COOH-, NH3-, or PEG modification
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Major Findings

Increased macrophage accumulation and alteration of Th1/Th2
status
High and medium doses of both Fe particles caused decreases in
eosinophil influx and OVA-specific IgE levels but at low dose,
submicron particles had no effect on allergy, whereas NP had an
adjuvant effect on the Th2 response to OVA
Allergic pulmonary inflammation was suppressed in asthmatic
mice exposed to either size TiO2. Leukocyte number, cytokines,
chemokines, and antibodies were significantly decreased.
Acute SiNP exposure induced significant airway inflammation and
AHR. Spherical SiNPs induced the greatest degree of
exacerbation of allergic effects in the OVA model
Sensitized mice exposed to S-SiNP and M-SiNP exhibited
elevated AHR over controls. M-SiNPs induced the greatest
degree adjuvanticity, whereas PEG-SiNP caused the least toxic
effects

Uncoated SiO2NPs induced proinflammatory and
immunomodulatory effects with increases in lung inflammatory
cells, Th2 cytokines. Amino and phosphate surface mod.
mitigated these effects, whereas PEG coating did not.
Asthmatic condition increased nanoparticle uptake. Systemic
uptake higher for PEGylated AuNP compared to citrated AuNPs,
but both inhibited inflammatory infiltrates and AHR, inhibition was
more significant following exposure to citrated AuNP
PEGylation of CuONP mitigated allergic inflammation
exacerbated by other CuONP when administered during
challenge

Zr

F Wistar rat
Intratracheal instillation

APTS, TODS, PGA, or acrylic acid coated
9-10 nm ZrO2NPs

Alessandrini
et al. 2017

Ag

F BALB/c mice, OVA
Intratracheal instillation: 1-50 µg

PVP-coated AgNP: 97 nm, 6.2 m 2/g, -7 mV
PVP-coated AgNP: 134 nm, 4.5 m2/g, -7 mV
Citrate-AgNP: 20 nm, 30 m2/g, -45 mV

Seiffert et al.
2015

Ag

Brown Norway and SpragueDawley rats
Intratracheal instillation: 0.1 mg/kg

PVP-coated AgNP: 20 or 110 nm
Citrate-capped AgNP: 20 or 110 nm

Horie et al.
2015

Zn
Ti
Si

F C57BL/6N mouse, OVA
Pharyngeal aspiration: 50 µg

Rutile TiO2, Al(OH)3 surf: 30-50 nm 37.1 m2/g
ZnO: 21 nm, 49.6 m2/g
ZnO, SiO2 surface: 25 nm, unkn. SA, ZnCl2
Amor. SiO2: 7 nm 300 m2/g, 34 nm 80 m2/g

Sandberg et al.
2012

Si

LPS-primed RAW264.7 mouse
macrophages, primary rat lung
macrophages
0, 50, 100, 250, 500 µg/mL, 6 h

64 nm Si, 650 cm2/mg
369 nm Si, 90 cm2/mg
~20 nm Fumed Si (aerosol), 1880 cm 2/mg
500 nm – 10 µm Fused Si (suprasil), 23 cm2/mg

Vandebriel et al.
2018

Ti

F BALB/c mouse, OVA
Intranasal: 120 µg TiO2

Uncoated TiO2NP:
10 – 30 nm rutile or 10 – 25 nm anatase

Rutile TiO2NP caused the greatest increase in OVA-specific
serum IgE and IgG1. Neutrophils recruited by rutile, but not
anatase

Jeong et al.
2015

Co

F Rat, Intratracheal Instillation
80, 200, 800 µg/mL @ 0.5 mL

CoO: 65.4 ± 2.8 nm, 92.65% solubility

Co3O4: 20.2 ± 0.4 nm, 11.46% solubility

Soluble CoNP induced eosinophilic inflammation, whereas
insoluble CoONP induced neutrophilic inflammation

Horie et al.
2016

Ni
Zn
Cu

F C57BL/6 mouse, OVA
Aspiration

NiO <100, 600-1400 nm
Zn 21 nm, Cu 48 nm

Solubility of metal NP greatly impacted OVA allergy exacerbation

Cho et al.
2011

Zn

F Wistar rat
Intratracheal instillation

10.7 ± 0.7 nm ZnONP- 50 or 150 cm2/rat
Zn2+ ions- 92.5 µg/rat

ZnONP induced eosinophilia, proliferation of airway epithelial
cells, goblet cell hyperplasia, and increased IgE levels, and
decreased IgA- findings which were also seen following instillation
of Zn ions

CRY
SOL

SA

Size

MOD

Vennemann et al.
2017

Surface coating had minimal effects on inflammation in the lungs
of rats, but had significant effects on allergic response.
Ag50-PVP significantly reduced OVA-induced inflammatory
infiltrate in sensitized mice. Lung microbiome was altered
dependent on coating.
Smaller AgNPs increased AHR on d 1, which persisted to d 7 for
the citrate AgNPs only. 20 nm AgNP was more pro-inflammatory
but little difference between different surface coatings

Serum total and OVA IgE, IgG1 increased in mice treated with the
uncoated ZnO particle. However, ZnCl2 did not produce similar
exacerbations. TiO2 and SiO2 did not affect OVA-IgE or IgG levels.

Non-crystalline SiO2 particles in both nano and micron size
ranges induced IL-1β release from LPS-primed macrophages
following uptake, phagosomal leakage, and activation of the
NALP3 inflammasome. Particle surface area, reactivity, and
uptake all influenced the degree of mediator release by cells

Table 1.16. Summary of study design and major findings from studies comparing the effects of various physico-chemical properties of metal nanomaterials
on respiratory allergy grouped by study property of interest. Properties of interest: size, CRY (crystallinity), MOR (morphology), SC (surface chemistry), MOD
(surface modification), CRG (surface charge), and SA (surface area), and SOL (solubility). Reported particle size (nm), specific surface area (m 2/g), zeta
potential (mV), pore volume (cm 3/g), in vitro dose concentration (µg/mL). Abbreviations: AHR airway hyperreactivity, APC antigen presenting cell, APTSaminopropilsilane modification, DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin, MDDC monocyte-derived dendritic
cell, MHC major histocompatibility complex, OVA ovalbumin, PDI polydispersity index, PEG poly(ethylene glycol) modification, PGA poly(lactic-co-glycolic
acid) modification, PVA, PVP polyvinylpyrrolidone modification, ROS reactive oxygen species, TODS- tetraoxidecanoic acid modification.
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Table 1.17. Metal Nanomaterials and Corresponding Physico-Chemical Properties Shown to Influence
Immunological Processes Involved in Respiratory Sensitization

Molecular Initating
Event
Organ Response Cellular Response

SENSITIZATION

Bioaccessibility

AOP Step

Metal Nanomaterial Effect

Metal

Property

Citation

Increased potential for inhalation
Evasion of clearance/neutralization mechanisms:
Evasion of entrapment by pulmonary mucus
Evasion of clearance by pulmonary macrophages:
Selective uptake by macrophages
Macrophage cytotoxicity
Altered phagocytic activity of macrophages
Enhanced potential for interception by APC:
Anatomical location of deposition
Disruption of epithelial barrier integrity > access to intraepithelial APC
Prolonged retention in airways
Direct translocation across lung epithelial tissue to lymphatics
Release of metal ions from parent particle:
Metal antigen formation
TLR-4 agonist > enhanced immunogenicity
Metal nanomaterial interactions with macromolecules:
Mixture effects > alterations in metal surface reactivity and immunogenicity
Antigen formation by crytpic epitope exposure
Enhanced immunogenicitiyby PRR recognition
Metal nanomaterial conjugation with hapten > antigen formation
Conjugation with protein allergen > increased protease activity
Metal nanomaterial conjugation with proteins > recognition by PRR
Recruitment of increased APC and precursor cells to the lung
Pulmonary macrophage activation:
Inflammasome activation
Inudction of enhanced APC phenotype in macrophages
Pulmonary DC activation:
Inflammasome activation
Enhanced activation marker expression
Release of DAMPs and alarmins from immune cells
Release of DAMPs and alarmins from airway epithelial cells
Adsorption of LPS to nanomaterial surface > TLR-4 activation
Enhanced migration of DC to lymph nodes
Altered migration of pulmonary macrophages to lymph nodes
Increased DC presentation efficiency to CD4+ T-cells
Increased polarization of CD4+ T-cells to TH2 phenotype
Alterations in B-cell activity:
Alteration in B-cell expansion and maturation
Increased production of total IgE
Increased production of allergen-specific IgE
Increased populations of B-cells

many

dustiness

(18)

ND

size, crg

(762)

Si
Cr
Al

size, crg, mod
vol
spec

(763)
(764)
(765)

many
Zn
Al
Au

size, agg
sol
spec, mor
size, crg

(766)
(767)
(768)
(761)

Ti
Ni

size
sol

(518)
(469)

Au/Ni
Au
Au
Al
Au
Au
Al

crg
size
size
size
mod

(769)
(519)
(770)
(726)
(522)
(521)
(771)

Si
Ti
Ti
Al
Si
Cr
Ag
Au
Au
Fe
Ti
Si

size, cry, SA
size
size, cry
mor, size, cry
mod
size, vol
size, mod, SA, sol
size, hyd, mod
mod, crg
mod
size, mor, cry
size, mod, SA

(772)
(773)
(774)
(527)
(532)
(764)
(775)
(523)
(776)
(777)
(526)
(778)

Au
Pt
Zn
Ti

size
size, sol, cry
-

(779)
(780)
(781)
(782)

Table 1.17. Adverse Outcome Pathway (AOP) steps involved in the sensitization phase of asthma, metal
nanomaterials shown to impact individual steps, and physico-chemical properties associated with effects are shown.
Physico-chemical properties of interest include size, metal speciation (spec), agglomeration (agg), surface modification
(mod), surface area (SA), solubility (sol), surface charge (crg), morphology (mor), crystallinity (cry), volume (vol), and
hydrophobicity (hyd). ND (not determined) notation in metal column indicates a study demonstrating a critical role for
a specific nanomaterial physico-chemical property on the cellular event, but was demonstrated using non-metal
nanomaterials. Findings may be applicable to metals, but have not been demonstrated with individual metal
nanomaterials.
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Table 1.18. Metal Nanomaterials and Corresponding Physico-Chemical Properties Shown to
Influence Immunological Processes Involved in Asthma Elicitation
Metal Nanomaterial Effect
Recruitment of increased numbers of lung mast cells
Alterations in mast cell degranulation:
Enhanced IgE-independent activation
Enhanced IgE-dependent activation
Altered exocytic function, granule contents
Altered expression of Fc receptors on immune cells
Increased recruitment of inflammatory cells to the lung:
Increased endothelial adhesion molecule expression
Increased eosinophil recruitment
Increased neutrophil recruitment
Increased lymphocyte recruitment
Mucus hypersecretion and mucus cell metaplasia
Increased AHR
Increased airway smooth muscle contractility
Enhanced airway remodeling:
Bronchial smooth muscle cell hypertrophy
Airway epithelial cell proliferation
Increased fibroblast MMP activity extracellular matrix remodeling
Myofibroblast accumulation
Angiogenesis
AHR exacerbation
Disruption of pulmonary surfactant function
Prevention of immunological tolerance induction

Early
Phase
Late Phase

Organism Response
Chronic Effects

ELICITATION

AOP Step

Metal

Property

Citation

Ce

-

(783)

many
Au
Si
Ti

size, SA, crg
size, mod
SA
size

(546)
(784)
(785)
(786)

Al
Co
Ag
Zr
Ti
Ag
Co/Fe

sol
size, sol
mod
size, mod
-

(539)
(787)
(788)
(789)
(790)
(791)
(792)

Zn
Ni
Ti
Cu
WC/Co
Cu
Au
Ag

sol
size, cry, mor
sol, mod, size

(793)
(794)
(795)
(796)
(797)
(798)
(799)
(800)

Table 1.18. Adverse Outcome Pathway (AOP) steps involved in the elicitation phase of asthma, metal nanomaterials
shown to impact individual steps, and physico-chemical properties associated with effects are shown. Physicochemical properties of interest include size, surface modification (mod), surface area (SA), solubility (sol), surface
charge (crg), morphology (mor), and crystallinity (cry).
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Table 1.19. Summary of Studies Utilizing Metal Nanomaterials as Vaccine Adjuvants and Primary Findings
Metal
NM

Ag

Al

Au

Properties

Antigen

Model

60 nm
141 nm
Nanorod, nanosphere
25 – 100 nm
112 nm, 9.3 µm
281 nm
30-100 nm
Rod, crystallinity
7-28 nm
Sphere, rod, cube
Sphere, rod, shell, star
22-77 nm

Rabies virus
OVA, BSA
HIV
OVA
OVA, Bacillus
Hepatitis B
OVA
OVA
OVA, tumor cells
West Nile virus
B. mallei
BSA
OVA

Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Monkey
Mouse
Mouse

NP/Immunization
Route

Immune Response

Citation

ip
ip, sq
ip
oral
sq
sq
ip
ip
sq
ip
sq
ip
iv

↑ Ab response
↑ Ab/cellular response
↑ Ab/cellular response
Blocked oral tolerance
↑ Ab response
↑ Ab response
↑ Ab response
↑ Ab response
↑ cellular response
↑ Ab response
↑ Ab response
↑ Ab response
↑ cellular response

(944)
(872)
(945)
(800)
(946)
(947)
(948)
(527)
(517)
(61)
(949)
(950)
(533)

Co

18 nm

OVA

Mouse

sq

↑ Ab response

(951)

Fe

< 20 nm
Corona variations
15 nm
50 nm
59 nm
-

rMSP1 malarial protein
OVA
CMX mycobacterial protein
OVA
Tumor antigen
OVA
OVA
Tumor antigen

Mouse, Monkey
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
In vitro

ip, im, sq
iv
sq, in
sq
sq
sq
iv + ip
in vitro

↑ Ab response
↑ Ab response
↑ cellular response
↑ Ab/cellular response
↑ cellular response
↑ Ab response
↓ Ab response
↑ cellular response

(740)
(736)
(737)
(741)
(952)
(735)
(734)
(739)

2 nm

OVA

Mouse

ip

↑ cellular response

(953)

< 15 nm

rMSP1 malarial protein

Mouse

ip, im, sq

↑ Ab response

(954)

23 nm

West Nile virus

Mouse

sq

↑ Ab response

(955)

Gd
QD
Ni
Pt
Se

Si

Zn

13 nm

BSA

Rabbit

oral

↑ Ab response

(956)

5.2 nm

Hepatitis B

Mouse

oral + sq

↑ Ab response

(957)

10-20 nm
400 nm
12 nm
39 nm
33-1,074 nm
SBA-15
90 nm
50 nm
130 nm – 2 µm
SBA-15/16
10-20nm
400 nm
cationic
39 nm
21 nm
< 50 nm
< 5µm, 21 nm

OVA
OVA
Int1β venom protein
Schistosoma
OVA
BSA
OVA
Bovine viral diarrhea virus
BSA
Mycoplasma
Hepatitis B viral core
Foot-and-mouth virus
BSA
OVA
OVA
OVA
OVA

Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Guinea pig
Mouse
Mouse

oral +im
sq
sq
ip
ip
im, oral
sq
sq
ip, oral
ip
ip, sq
im
sq
oral + sq
ip
ip
oral

↑ Ab/cellular response
↑ cellular response
↑ Ab response
↑ Ab response
↑ Ab/cellular response
↑ Ab response
↑ Ab response
↑ Ab/cellular response
↑ Ab/cellular response
↑ Ab response
↑ Ab response
↑ Ab/cellular response
↑ cellular response
Blocked oral tolerance
↑ Ab response
↑ Ab response
No effect on oral tolerance

(958)
(959)
(960)
(961)
(874)
(962)
(963)
(964)
(965)
(966)
(967)
(968)
(969)
(970)
(873)
(885)
(971)

Mouse
Mouse
Mouse

Table 1.19. Studies evaluating the potential adjuvant activity of different metal nanomaterials with respect to
vaccines are summarized. Physico-chemical properties of test materials, antigen of interest, animal model,
administration route, and study results are shown. sq = subcutaneous injection, ip = intraperitoneal injections, im =
intramuscular injection, in = intranasal, iv = intravenous injection.
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Table 1.20. 2019 OSHA, NIOSH, and ACGIH 2016 Occupational Exposure
Limits for Nickel-Based Compounds (TWA)

OSHA
Permissible Exposure Limit
(General Industry)

NIOSH
Recommended Exposure
Limit

ACGIH
Threshold Limit Value®

Nickel
Carbonyl

Insoluble
Nickel Compounds

Soluble
Nickel Compounds

0.001 ppm
0.007 mg/m3

1.0 mg/m3

1.0 mg/m3

0.001 ppm
0.007 mg/m3

0.15 mg/m3

0.15 mg/m3

Elemental Ni: 1.5 mg/m3
Soluble Inorganic Ni Compounds: 0.1mg/m3
Insoluble Inorganic Compounds: 0.2 mg/m 3
Nickel Subsulfide: 0.1 mg/m3

0.05 ppm
0.12 mg/m3

Table 1.20. OSHA, NIOSH, and ACGIH-specific occupational exposure limits for nickel compounds.
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Table 1.21. Cases Reporting Adverse Immune Reactions Following Exposure to Gold
Reaction

Immune Effect
Alterations in hematopoiesis:
+ Red cell anemia
+ Aplastic anemia
+ Neutropenia
+ Pancytopenia

Respiratory
Tract

Systemic

+

Thrombocytopenia

Inciting Agent

Exposure

Citation

Sodium aurothiomalate
Gold sodium thiomalate
Sodium aurothiomalate
Gold salt therapy
Sodium aurothiomalate, auranofin
Auranofin

Parenteral
Parenteral
Parenteral
Parenteral
Parenteral
Oral

(1474)

(1477)
(1478-1480)
(1481)

Aureothiomalate
Auranofin
Sodium aurothiomalate

Parenteral
Parenteral
Parenteral

(1459, 1478)
(1482)
(1483)

Gold salt therapy
Sodium aurothiomalate
Gold salt therapy
Sodium aurothiomalate

Parenteral
Parenteral
Parenteral
Parenteral

(1459)

Gold salt therapy
Aurothiomalate
Aureothiomalate
Gold salt therapy
Shiosol
Gold salt therapy
Auranofin
Gold salt therapy
Auroanofin

Parenteral
Parenteral
Parenteral
Parenteral
Parenteral
Parenteral
Parenteral
Oral
Oral

(1486)

Gold sodium thiomalate
Metallic gold
Sodium aurothiomalate
Gold salt therapy
Gold sodium thiomalate
Dental gold
Gold sodium thiomalate
Gold jewelry
Gold jewelry
Gold jewelry
Dental gold
Sodium aurothiomalate
Auranofin
Gold jewelry

Dermal
Dermal
Parenteral
Parenteral
Parenteral
Dermal/parenteral
Dermal
Dermal
Dermal
Dermal
Dermal
Dermal
Dermal
Dermal

Gold endovascular stents
Myocrisin
Aurocad (homeopathic drug)
Gold dust
gold sodium propanol sulfonate
Myocrisin
Auranofin

Parenteral
Parenteral
Oral
Inhalation
Parenteral
Parenteral
Oral

(1497)
(1498)
(305)
(304)

Sodium aurothiomalate

Parenteral

(1502)

(1475)
(1476)

Alterations in immune cell populations/activity:

+

Eosinophilia

+ Peripheral T-cell gold reactivity
Alterations in immunoglobulin levels/activity:
+ Elevated total IgE levels
+ Au-specific IgE development
+ Decreased IgA levels
+ Panhypogammaglobulinaemia
Other:
+ Cutaneous lupus erythematosus
+ Anaphylaxis
Fibrotic alveolitis
CD4 alveolitis
BAL T-cell gold reactivity
Hypersensitivity pneumonitis
Interstitial pneumonitis
Bronchiolitis

(1479)
(1484)
(1485)

(1487)
(1478)
(409)
(404)
(406, 408)
(1488)
(1489)
(1490)

Skin

Localized reactions:
+

Localized ACD

+
+
+
+
+
+
+
+
+

Mucocutaneous lesions
Lichen planus, acne
Lichenoid seborrheic dermatitis, alopecia
Lichenoid dermal reactions
Pruritic papular dermatitis
Granulomatous contact dermatitis
Lymphoid contact dermatitis
Lymphomatoid eosinophil skin reaction
Contact gingivostomatitis

+

Pityriasis rosea, discoid eczema

+ Persistent nodular contact dermatitis
Peripheral responses:
+

Systemic ACD

+
+

Airborne ACD
Systemic lichenoid eruption

+

Stomatitis

Other:
+ Enhanced DTH sensitivity

(1470, 1491)
(1439)
(1479)
(1492)
(1493)
(1494)
(1473)
(309)
(1444)
(1442)
(1495)
(1496)
(1496)
(1445)

(1499)
(1500)
(1501)

Table 1.21. Summary of cases reporting adverse immune effects caused by exposure to gold grouped by primary
tissue of repsonse, inciting agent, and corresponding route of exposure associated with each immune effect.
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CHAPTER 1 FIGURES

Figure 1.1. Schematic for the categorization of nanomaterials based on the International Standardization
Organization (ISO) Technical Report 11360: Nanotechnologies- Methodology for the Classification and
Categorization of Nanomaterials. Four major parameters allow for classification of materials based on 1) number of
nanoscale dimensions, 2) internal and external structures, 3) chemical identity, and 4) properties and behavior.
Each category can be extensively broken into additional subcategories. Examples of nano-objects and properties
corresponding to each category are shown.
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Figure 1.2. Steps of the Adverse Outcome Pathway (AOP) for dermal sensitization proposed by the Organization
for Economic Co-operation and Development (OECD).
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Figure 1.3. Potential adverse outcomes with respect to the sensitization and elicitation phases of allergy following
exposure to immunotoxic agents. Adjuvant effects resulting from exposure prior to allergen sensitization can
manifest as increased susceptibility to sensitization. Exposure concurrent to sensitization may lower the threshold
of allergen exposure required to induce sensitization. Following sensitization to allergen, exposure to an
immunotoxic agent either in the absence or presence of allergen may result in a lower threshold of exposure
required to induce elicitation reactions or increased severity of elicitation symptoms. These effects may further
increase susceptibility to elicitation reactions as result of physiological alterations such as compromised skin barrier
integrity. Furthermore, isolated exposure to immunotoxic agents or concurrent to allergens in established allergic
disease conditions may also contribute to the progression of chronic effects, such as airway remodeling, which can
also further contribute to elicitation reactions.
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Figure 1.4. Different morphologies of metal nanomaterials are shown: graphene sheets (A), silver nanoparticles (B),
silver nanowires (C), gold nanorods (D), gold nanoparticles (E), nickel oxide nanoparticles (F), and copper oxide
nanoparticles (G).
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Figure 1.5. Metal nanomaterial/biological molecule interactions associated with different mechanisms of altered
immunological activity are summarized.
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CHAPTER 2:
Surface area- and mass-based comparison of fine and ultrafine nickel oxide lung toxicity and
augmentation of allergic response in an ovalbumin asthma model

Adapted from Roach et al. (2019):
Surface area- and mass-based comparison of fine and ultrafine nickel oxide lung toxicity and
augmentation of allergic response in an ovalbumin asthma model
Published in Inhalation Toxicology on October 4, 2019
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2.1. Abstract
Various metal nanomaterials have been shown to cause inflammatory responses in the lung and
subsequent injury to local tissue following respiratory exposure. Response severity has been consistently
demonstrated to be dependent on particle size, as exposure to mass-equivalent doses of larger forms of
the respective metal often lead to far less pronounced inflammatory effects. This discrepancy is reflective
of the exponential increase in surface area characteristically seen in materials with nanoscale
dimensions. Accordingly, exposure to surface area-normalized doses of metal nanomaterials and their
larger-scale counterparts has been shown to mitigate differences in the subsequent magnitude of
pulmonary inflammation. Although surface area has been established as a parameter critically involved
in acute lung inflammation caused by some metal nanomaterials, less information exists regarding the
impact of various dose parameters on other pulmonary responses. For example, it remains unclear if
metal nanomaterial-induced alterations in pulmonary adaptive immune responses are similarly correlated
to particle surface area, or if these effects are driven by other properties.
In this study, the role of nickel oxide (NiO) mass and surface area in the induction of pulmonary
inflammation and exacerbation of respiratory allergy was explored. To address this concept, 181 nm fine
(NiO-F) and 42 nm ultrafine (NiO-UF) particles were thoroughly characterized and incorporated into an
in vivo time course study and ovalbumin (OVA) asthma model. Particle toxicity was compared at equal
masses of 40 µg and at equal surface areas of 192 mm2. For the time course study, female BALB/c mice
were exposed once to particles or vehicle control by oropharyngeal aspiration and euthanized 1, 10, 19,
or 29 d post-exposure, which represent critical time points in the OVA model. For the OVA model, mice
were aspirated with particles on 0 d, sensitized to OVA via intraperitoneal injection on 1 and 10 d,
challenged with OVA by aspiration on 19 and 28 d, and euthanized on 29 d.
In the time course study, exposure to mass-normalized doses of NiO particles resulted in
significantly elevated lactate dehydrogenase (LDH) levels, BAL neutrophil number, and mediastinal
lymph node size in mice exposed to NiO-UF, which persisted to 29 d. However, normalization of NiO-UF
dose for NiO-F dose surface area mitigated all differences between particles, suggesting that NiO surface
area is correlated to the magnitude of pulmonary inflammation following exposure. In the OVA model,
exposure to NiO, irrespective of particle size, dose mass, and dose surface area resulted in elevations
in total IgE levels. NiO-induced alterations in the Penh response and number of BAL eosinophils appeared
to correlate with particle size. Accordingly, NiO-F exposure was associated with enhanced Penh
responses, whereas animals exposed to NiO-UF exhibited increases in BAL eosinophil burden.
Mediastinal lymph node size, BAL neutrophil number, and BALF/serum cytokine profiles were largely
conserved with respect to NiO dose surface area. Animals exposed to the higher surface area-based
dose of NiO-UF exhibited cytokine profiles consistent with polarization towards a Th1/17-dominant state,
whereas lower doses were associated with enhanced Th2 cytokine responses. These findings were
consistent with the OVA-specific IgE responses in the corresponding groups, as increased levels were
only observed in animals exposed to lower surface area-based doses of NiO-F and NiO-UF.
Overall, these findings demonstrate that surface area is the primary property responsible for
pulmonary injury and inflammation caused by NiO. Although many immune parameters involved in
asthmatic responses also correlate with NiO dose surface area, exposure-induced alterations in some
immune markers correlate better with other dose metrics. Collectively, these findings imply that surface
area-based exposure limits may be effective in protecting against acute pulmonary inflammation following
exposure to NiO nanoparticles, but may not be equally protective against immunomodulatory effects in
the context of asthma.
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2.2. Introduction
The demand for nickel nanoparticles is expected to continue increasing in the coming decade,
with potential to reach a global demand of 300 tons by 2030, according to some estimates (4).
Applications for nickel nanoparticles underlying this demand include their use as additives in ceramics,
lubricants, and magnetic coatings, as well as their incorporation into electronics and use as a catalyst
(1407). Production of nickel nanoparticles and their subsequent uses render inhalation one of the major
exposure routes of relevance for both workers and consumers. Likewise, the pulmonary toxicity of nickel
nanomaterials has been examined in numerous studies. The decreased size profile of nickel
nanomaterials has been consistently correlated with an increased magnitude of acute pulmonary injury
and inflammation; however, it remains unclear if nanoscale nickel also induces size-specific pulmonary
immune responses (1419, 1605).
This lack of knowledge is concerning, given nickel’s notable immunotoxic potential (1606). Nickel
is one of the metals most commonly associated with contact allergies, including ACD, as well as
respiratory hypersensitivity responses leading to asthmatic symptoms and rhinitis (414, 1391, 1400).
Similarly, inhalation exposure to nickel-containing materials is known to exacerbate existing asthmatic
conditions (871, 1607). The magnitude of these effects has been correlated to various physico-chemical
properties of nickel species including size, solubility, and oxidative potential (458, 1608-1610). These
observations suggest that nickel nanomaterials, which exhibit many unique physico-chemical
characteristics, may constitute novel immunotoxic agents capable of causing more detrimental allergic
effects than larger forms of nickel particles.
Characterization of nickel nanoparticles’ immunotoxic potential in the context of allergic disease
will contribute to a notable knowledge gap and help effectively protect workers and consumers from these
effects. Moreover, nickel nanoparticles also represent a material with the capacity to help delineate the
relationships between nanomaterial physico-chemical properties and immunotoxic potential. Although
several properties have been correlated to the magnitude of pulmonary inflammation caused by
nanomaterials, far less information exists pertaining to similar relationships in the context of respiratory
allergy. As a result, it remains unclear if the physico-chemical properties of metal nanomaterials
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responsible for acute pulmonary inflammation are also implicated in the induction and modulation of
pulmonary immune responses.
The goal of these studies was to characterize the pulmonary immune effects of nanoscale nickel
with respect to different dose metrics. Accordingly, two sizes of NiO particles were used in doses
normalized for mass and surface area. First, a time course study was performed to evaluate differences
in pulmonary injury and inflammation induced by the materials at time points critical to the following study.
In the second study, the materials were incorporated into an OVA asthma model to determine if exposure
to the particles prior to sensitization and elicitation, as may occur in an occupational setting, alters the
severity of OVA-induced asthmatic response. Subsequently, the impact of NiO dose surface area and
mass on both responses could be established and compared.

2.3. Materials and Methods
Material Characterization:
Two different sizes of nickel (II) oxide (NiO) particles were obtained from Sigma-Aldrich (St. Louis,
MO). The primary particle sizes were reported by the manufacturer as 50 nm (ultrafine, NiO-UF) and 325 mesh (< 44 µm, fine, NiO-F). Both materials were thoroughly characterized prior to incorporation into
in vivo studies. Specific surface area and surface chemistry were assessed on the powder form of the
particles. After suspension in delivery vehicle, size, morphology, agglomeration, zeta potential, surface
reactivity, and presence of endotoxin were assessed.
Surface Area: Surface area of the NiO particles was measured on the powder form by gas
adsorption using a Micromeritics ASAP2020 surface area analyzer and ultra-high purity nitrogen
adsorbate. Specific surface area was determined by using the multipoint Brunauer, Emmett, and Teller
(BET) method (1611).
XPS Analysis: Surface elemental composition was analyzed via X-ray Photoelectron
Spectroscopy (XPS; Rocky Mountain Laboratories Inc., Golden, CO). XPS was performed both before
and after sputter etching with a 2.0 keV Ar+ ion beam, from which approximately 500 Å of material was
removed from the surface. Analyses were performed with an Al ka x-ray source and charge neutralization
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of the sample surface was achieved with the use of a low-energy electron flood gun. Results were
reported as relative surface elemental composition of C, O, Na, Cl, Si, Ni, and Br for each sample.
Particle Preparation in Dispersion Medium: For in vivo studies, NiO particles were suspended in
a physiologically compatible vehicle for delivery to mice. Concentrated stock solutions of NiO particles
were prepared in USP-grade phosphate buffered saline (PSB) and sonicated for 10 seconds at 10 W
with a probe sonicator. Stock suspensions were then diluted into dispersion media (DM, 0.6 mg/ml mouse
serum albumin + 0.01 mg/ml dipalmitoyl phosphatidyl choline in phosphate buffered saline), designed to
mimic the biochemistry of the fluid lining the lung, prepared as described by Porter et al. (1612). Dosing
solutions were prepared at concentrations of 0.8 mg/ml for both the fine and ultrafine particles, and 0.06
mg/ml for the ultrafine particle, for delivery of a 40 µg and 3 µg dose, respectively. The 3 g dose of the
NiO-UF was calculated by normalizing the ultrafine surface area to that of the 40 g dose of the fine
particle. The samples were then sonicated at 10 W for 20 minutes on ice to dissipate heat generated
from the sonication procedure.
Primary Particle Size, Agglomerate Size, and Particle Morphology: Field emission scanning
electron microscopy (FESEM, Hitachi Model S-4800) was employed to assess primary particle size and
morphology of the particles. NiO particles were prepared in DM for microscopic analysis. Images were
collected for both particles and the diameters of 250 particles from each sample were recorded using
point count methods. Image J Software (Version X; National Institutes of Health; Bethesda, MD) was
used for analysis of mean diameter and degree of polydispersity for each particle. Additionally, NiO
particle sizes were assessed in DM using a (Nanosight NS300, Malvern Panalytical, United Kingdom).
For further analysis of average agglomerate size in delivery vehicle, samples were evaluated by dynamic
light scattering (DLS, Microtrac, Inc., San Diego, CA) and hydrodynamic diameter was recorded.
Endotoxin Contamination: Determination of endotoxin presence in NiO samples was assessed
using the Pierce Limulus Amebocyte Lysate (LAL) Chromogenic Endotoxin Quantitation Kit (Thermo
Scientific; Waltham, MA) according to the manufacturer’s protocol. The presence of bacterial endotoxin
catalyzes the activation of a proenzyme in the LAL assay, from which the substrate can be colorimetrically
measured and correlated to the activation rate, which is proportional to the level of endotoxin present in
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the sample. Both NiO samples were tested over multiple concentrations ranging from 5.0 - 0.25 µg/µl.
Concentration of endotoxin was determined using a plate spectrophotometer at absorbance wavelength
of 450 nm.
Acellular Electron Spin Resonance: Surface reactivity of NiO particles was assessed by acellular
electron spin resonance (ESR). The particles were prepared in DM at the doses to be used in the in vivo
studies and combined with hydrogen peroxide. The subsequent generation of short-lived hydroxyl
radicals were reacted with a diamagnetic compound, 5,5-dimethyl-1-pyrroline N-oxide (DMPO, spin trap)
prolonging their existence and allowing for detection using an EMX spectrometer (Bruker Instruments
Inc.; Billerica, MA) and a flat cell assembly (1613). The resultant wave forms were measured and radical
generation quantified.
Dissolution Potential: The rate of NiO dissolution was assessed for both particles in three
simulated fluids representative of various biological compartments that materials were most likely to
associate with following their aspiration. NiO-F and NiO-UF were prepared in doses and delivery vehicle
identical to those in the in vivo studies. An aliquot of each particle suspended in DM was retained for
analysis, and the remaining suspension was divided and combined with either artificial lysosomal fluid
(ALF, pH 4.5, representative of the biochemical environment following phagocytosis by alveolar
macrophages) or Gamble’s solution (GS, pH 7.4, representative of deep lung interstitial fluid), prepared
according to previously-published procedures (1614).
Triplicate samples of NiO particles suspended in DM, ALF, and GS were incubated at 37ºC and
agitated daily. At 1, 10, 19, and 29 d, samples were centrifuged at 3500 rpm for 30 minutes and 2 mL of
supernatant fluid was removed and stored at 4ºC until analysis. The concentration of soluble Ni was
assessed in each sample by inductively-coupled plasma optical emission spectrometry (ICP-OES).
Samples were diluted to 5 mL and analyzed using a Perkin Elmer Optima 5300DV ICP to determine µg
Ni/mL in each sample. Concentrations were averaged between triplicate samples and results were used
to calculate the amount of soluble nickel released from the original dose with respect to time.
Zeta Potential in Dispersion Medium: Zeta potential of NiO particles was determined by measuring
electrophoretic mobility in DM (pH 7.4). All measurements were performed at 25°C using a Malvern
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Zetasizer Nano ZS90 (Worcestershire, UK) equipped with a 633 nm laser at a 90° scattering
angle. Samples were equilibrated inside the instrument for two minutes, and five measurements
consisting of five runs each were recorded.

Animals
Specific pathogen-free female BALB/cJ mice, 6-8 weeks of age were obtained from Jackson
Laboratory (Bar Harbor, ME) for use in the time course study and allergy model. The BALB/c strain is a
Th2-responder commonly used to evaluate IgE-mediated allergy (1615, 1616). All mice were individually
housed in polycarbonate ventilated cages with HEPA-filtered air in the AAALAC-approved National
Institute for Occupational Safety and Health (NIOSH) Animal Facility, and provided food (Harlan Teklad
Rodent Diet 7913) and water ad libitum in a controlled humidity temperature environment with a 12 h
light/dark cycle. Animals were allowed to acclimate for one week in the facility prior to exposures. All
procedures in the studies comply with the ethical standards set forth by Animal Welfare Act and the Office
of Laboratory Animal Welfare (OLAW). The studies were approved by the NIOSH Health Effects
Laboratory Division (HELD) Institutional Animal Care and Use Committee within the Center for Disease
Control and Prevention in accordance with an approved animal protocol (protocol number 16-JR-M-015).

In Vivo Exposures and Study Design
Dose Determination: Occupationally relevant doses of NiO were calculated using the current
OSHA-enforced permissible exposure limit (PEL, 1.0 mg/m3 time weighted average) and NIOSH
recommended exposure limit (REL, 0.015 mg/m3 time weighted average) for insoluble nickel compounds.
Assuming a 75 kg standard worker (31% sitting, 69% light exercise) and a 50 nm NiO particle (density:
6.67g/cm2) with a deposition efficacy of 31.2 %, alveolar deposition was calculated as follows (1617):

20,000
mL/min

x

10-6
m3/mL

PEL: 1.0 mg/m3 or
x

x
REL: 0.015 mg/m3
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480
min

2.995 mg/day
x

31.2%

=
0.045 mg/day

minute
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air to liquid
volume
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exposure
time

exposure limit

deposition
efficiency

alveolar deposition
in a standard
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The daily human alveolar deposition was then normalized to the surface area of the mouse lung
and the number of exposure days at the PEL and REL were determined for a 40 µg dose using the
following equation:

2.995 mg/ day
0.045 mg/day
human alveolar
deposition

1.9 µg/ day or
x

0.065 m

2

mouse lung
surface area

=

0.29 µg/day
mouse alveolar
deposition

PEL: 21 days
/

40 µg
selected
dose

=

REL: 1400 days
representative exposure

Accordingly, the 40 µg dose of NiO administered to mice was representative of three weeks of
exposure at the current OSHA PEL and 4 years of exposure at the NIOSH REL. NiO-F and NiO-UF
surface area measurements were then used to calculate doses normalized for both surface area and
mass between particles, yielding three total NiO treatment groups: NiO-1 (40 µg NiO-F), NiO-2 (3 µg NiOUF), and NiO-3 (40 µg NiO-UF).
Time Course Study: To evaluate the role of NiO particle size, mass, and surface area on
pulmonary injury and inflammation at critical time points in the allergy model, a time course study was
conducted. On day 0, three sets of mice were exposed by oropharyngeal aspiration to vehicle control
(DM), 40 µg NiO-F, 3 µg NiO-UF, or 40 µg NiO-UF. Treatment groups and corresponding exposures are
shown in table 2.1. Mice were fully anesthetized with isoflurane, placed on a slanted board, and
suspended by the incisors. The mouth was opened, tongue moved aside, and a 50 µl aliquot of sample
was pipetted on the base of the tongue. The animal was restrained until two full breaths were completed
and returned to its cage, placed on its side, and monitored for recovery from anesthesia. Mice were
humanely euthanized with an overdose of sodium pentobarbital euthanasia solution (100-300 mg/kg body
weight; Fort Dodge Animal Health; Fort Dodge, IA) at 1 day, 10 days, 19 days, or 29 days post-exposure.
The time points were selected as they corresponded to critical time points in the sensitization and
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challenge phases of the asthma model. The lungs from one set of mice (n = 8 per group per time point)
underwent bronchoalveolar lavage (BAL) to collect fluid and cells for pulmonary toxicological analyses.
In the same group of animals, serum was collected, and the spleen and mediastinal lymph nodes were
harvested for cell counts and phenotyping. In another set of mice (n = 6 per group per time point), whole
blood was taken for immune cell phenotyping and lungs were fixed with formalin for histopathological
analysis. In the last set of mice (n = 6 per group per time point), lungs were isolated, lyophilized and used
to evaluate lung burden of NiO at the respective time points to determine particle clearance over time.
Ovalbumin Asthma Model: In order to evaluate the potential for NiO to exacerbate allergy as a
function of mass, surface area, and or size, the same NiO-F and NiO-UF doses from the time course
study were incorporated into an OVA allergy model. On day 0, mice were exposed to vehicle control or
NiO particles by oropharyngeal aspiration. On days 1 and 10, mice were sensitized to chicken egg OVA
via intraperitoneal injection with alum adjuvant (0.9 μg OVA + 0.5 mg alum in 200 μl PBS). Control animals
were injected with 200 μl USP-grade PBS. A 150 µL aliquot of blood was collected from the tail vein of
mice on day 14 to yield serum and confirm the presence of circulating OVA-specific IgE, indicative of
successful sensitization. On days 19 and 28, mice were challenged via oropharyngeal aspiration to 50 µl
sterile PBS or OVA (125 μg/50 μl sterile PBS) under isoflurane anesthetic. Directly following the second
challenge (day 28) mice underwent whole body plethysmography to assess respiratory response to
allergen challenge. Mice were euthanized on day 29 by sodium pentobarbital euthanasia solution
overdose. The study consisted of four particle exposure groups aspirated with DM, 40 µg NiO-F, 3 µg
NiO-UF, or 40 µg NiO-UF on day 0, each with a non-sensitized particle control group and OVA-sensitized
group, for a total of eight groups in the study. A schematic of the treatment groups and dosing regimen
for this study is shown in figure 2.1.

Endpoints of Assessment:
Post-Allergen Challenge Lung Function Assessment: In the asthma model, airway response to
allergen challenge was measured using an unrestrained whole body plethysmography system (Buxco
Research Systems, Wilmington, NC). Directly following the second allergen challenge on day 28, mice
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were placed in individual plethysmograph chambers and given 5 minutes to acclimate prior to the start of
measurements. Enhanced pause (Penh), an indicator of airway resistance, was measured and recorded
every 30 seconds for 6 hours for each mouse. Following the completion of measurements, mice were
returned to their cages and euthanatized the following day. Penh measurements from whole body
plethysmography were plotted for each animal, area under the curve (AUC) was calculated, and mean
AUC for each treatment group was calculated.
BAL Cellular and Fluid Analysis: BAL was performed on the lungs in a set of mice from both the
time course study and allergy model in order to obtain pulmonary cells for phenotypic analysis and fluid
for analysis of biochemical indicators of lung injury and inflammation. Following euthanasia, the trachea
was cannulated, the chest cavity was opened, and BAL was performed on the whole lungs. The acellular
fraction of the first lavage was obtained by filling the lung with 0.6ml PBS, massaging for 30 seconds,
and withdrawing. This concentrated aliquot was retained, kept separate, and designated as the first
fraction. The following aliquots were 0.6 ml in volume, instilled once with light massaging, withdrawn, and
combined until a 2.4 ml volume was obtained. For each animal, both lavage fractions were centrifuged
(10 minutes, 1600 rpm) and the cell pellets were combined and resuspended in 1 ml PBS for cell counts,
phenotyping, and microscopic analysis. The acellular fluid from the first fraction was retained for analysis
of LDH activity and quantification of cytokines.
The total numbers of BAL cells collected from mice were counted using a Coulter Multisizer II
(Coulter Electronics; Hialeah, FL) within the size range of 4.5 µm and 20 µm. 75,000 cells were spun
down onto slides for visual analysis with a Cytospin 3 centrifuge (Shandon Life Sciences International;
Cheshire, England) and labeled with Leukostat stain (Fisher Scientific; Pittsburgh, PA) to differentiate
alveolar macrophages, eosinophils, lymphocytes, and neutrophils. Another aliquot of cells were stained
for surface markers for phenotype determination via flow cytometry as described below.
Measurements of LDH activity in BALF were obtained using a Cobas Mira analyzer (Roche
Diagnostic Systems; Montclair, IN). LDH activity was quantified by detection of the oxidation of lactate
coupled to the reduction of NAD+ at 340nm.
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Whole Blood Cellular Differentials: For both studies, whole blood was collected from a set of mice
via the abdominal aorta following euthanasia. Erythrocyte, leukocyte, and platelet counts, in addition to
leukocyte differentials (lymphocytes, monocytes, neutrophils, eosinophils, and basophils) were assessed
using an Idexx ProCyte Dx Hematology Analyzer (Idexx Laboratories; Westbrook, ME).
Lymphocyte Differentials by Flow Cytometry: Lymph nodes and spleens were harvested from
mice and processed between frosted microscope slides to yield single cell suspensions in sterile PBS.
Concentrations of cells from each tissue were determined by identical methods used for enumeration of
BAL cells.
Lymphocyte phenotypes were determined for BAL, LN, and spleen cells. 500,000 cells from each
tissue were suspended in staining buffer (PBS + 1% bovine serum albumin + 0.1% sodium azide)
containing Fc receptor blocking anti-mouse CD16/32 (BD Biosciences). Cells were incubated for 5
minutes, washed, and resuspended in staining buffer containing fluorochrome-conjugated antibodies.
BAL, LN and spleen cells were stained with a panel of cell surface markers for lymphocyte-differentiation.
CD2-BV605, CD3-APC, CD4-FITC, CD8-PE, CD44-APC-R700, CD45-PerCP, CD45R(B220)-PE-Cy7,
and CD86-BV421 (BD Biosciences) were used to discriminate between populations of CD4+ Tlymphocytes, CD8+ T-lymphocytes, B-lymphocytes, and NK cells, as well as determine the
corresponding activation state. An additional aliquot of BAL cells were stained with a second panel of
markers to allow for differentiation of myeloid cell subsets. CD11b-PE-CF594, CD11c-APC-R700, CD24BV605, CD45-PerCP, CD64-PE, CD86-PE-Cy7, MHC II-BV515, Ly6G-APC, Siglec-F-APC-Cy7 (BD
Biosciences) were employed to differentiate between eosinophils, neutrophils, macrophages, and
dendritic cells (1618). Cells were incubated for 30 minutes, washed, and fixed in 100 µl Cytofix Buffer
(BD Biosciences). Compensation controls were prepared using corresponding cell types stained with a
single fluorophore. For each sample, 100,000 events were recorded on an LSR II flow cytometer (BD
Biosciences, San Diego, CA). In all analysis, doublet exclusion was performed and cellular populations
were gated on using FSC-A x SSC-A parameters, prior to subsequent analysis. All data analysis was
performed using FlowJo 7.6.5. Software (TreeStar Inc., Ashland, OR).
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BAL Fluid and Serum Proteins: Cytokines in the BAL fluid and serum of mice in the time course
study and allergy model were quantified using a Milliplex MAP Kit magnetic bead panel (EMD Millipore
Corporation, Billerica, MA) and analyzed on a Luminex 200 system (Luminex Corporation, Austin, TX).
For both studies, cytokines analyzed included interleukin (IL)-2, 4, 5, 6, 10, 12p40, 12p70, 13, 17, eotaxin,
tumor necrosis alpha (TNF-α), interferon gamma (IFN-γ), and granulocyte macrophage colony
stimulating factor (GM-CSF).
Levels of circulating total and OVA-specific IgE were assessed in mice of the allergy model by
ELISA. Serum was diluted 1:10 and total IgE was assessed using the Mouse IgE ELISA kit (Innovative
Research; Novi, MI) according to manufacturer instructions. Serum was diluted 1:25 and assessed for
OVA-specific IgE levels using the Anti-Ovalbumin IgE (mouse) ELISA Kit (Caymen Chemical Company;
Ann Arbor, MI) according to the manufacturer’s specifications.
Lung Histopathology and Particle Clearance: For histopathological analysis, whole lungs from
mice in the time course study and allergy model (n = 6 per group per time point) were inflated with 10%
neutral buffered formalin for fixation, paraffin embedded, sectioned, and stained with hemotoxylin and
eosin stain. Slides were quantitatively analyzed by a certified veterinary pathologist (Charles River
Laboratories, Frederick, MD), who was blinded to the treatment groups. Indices of inflammation, injury,
and fibrosis were scored on scale of 0-5, where 0 = no observed effect, 1 = minimal response, 2 = mild
response, 3 = moderate response, 4 = marked response, and 5 = severe response, for both studies. For
histopathology in the OVA models, additional parameters with relevance to allergic disease were
assessed, including thickening around airways (epithelium and or smooth muscle), eosinophil and
lymphocyte influx, and development of bronchus-associated lymphoid tissue (BALT).
To determine the rate of NiO-F and NiO-UF clearance from the lung, whole lungs (n = 6 per group)
from mice in the time course study were isolated, lyophilized, and weighed to obtain the dry weight.
Concentration of nickel in lung tissue 1, 10, 19, and 29 days post-exposure was determined by
inductively-coupled plasma mass spectrometry (ICP-MS; ALS Environmental, Kelso, WA) and reported
as µg Ni/mg tissue. This information was then multiplied by the dry weight of the whole lungs for each
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animal, expressed as percent Ni mass of originally-administered dose (40 µg) remaining at each time
point, and averaged for each group.

Statistical Analysis:
Statistical analyses were conducted with GraphPad Prism version 7 (San Diego, CA). Results
from all studies are expressed as means ± standard error and considered statistically significant at p <
0.05. For the time course study, treatments were compared by one-way analysis of variance (ANOVA)
followed by a post hoc Student’s t-test. All treatment groups from the allergy model, irrespective of
sensitization status, were compared using ANOVA and Student’s t-test. For some endpoints in the OVA
model, NiO-exposed/OVA-sensitized groups were analyzed independently of non-sensitized groups, and
results were presented as fold-change over OVA control levels. Histology scores were analyzed using
nonparametric Wilcoxon rank-sum tests using JMP version 13 (SAS Institute, Cary NC) (p<0.05).

2.4. Results
Material Characterization:
NiO-F and NiO-UF particles exhibited unique color characteristics that were visible upon visual
examination. NiO-F particles exhibited a bright green appearance, whereas NiO-UF particles were
black/gray. Using FESEM microscopic images, 250 particles were measured to determine average
primary particle size of both NiO particles. Measurements indicated an average primary particle size of
181 nm and 42 nm for NiO-F and NiO-UF, respectively. Average agglomerate size in DM was also
measured in the micrographs and was found to be 640 nm for NiO-F and 190 nm for NiO-UF. Microscopic
analysis of NiO-F and NiO-UF particles also revealed differing morphologies between the two materials.
NiO-F particles were generally jagged with a layered appearance (figure 2.2. A), whereas NiO-UF
particles were consistently spherical in shape (figure 2.2. B) with a comparatively smoother surface
structure.
Similar to the findings from microscopic measurements, DLS analysis also indicated a size
difference in agglomerates, reporting hydrodynamic diameters of 321 nm for NiO-F and 109 nm for NiO-
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UF (figure 2.3). Specific surface areas of the particles measured by BET analysis were 4.79 ± 0.27 m2/g
for NiO-F and 64.49 ± 2.98 m2/g for NiO-UF particles. XPS analysis showed similar surface chemistries
between NiO-F and NiO-UF particles with compositions consisting primarily of nickel and oxygen with
various trace elements detected (figure 2.4). Slight variations in nickel:oxygen ratios between NiO-F and
NiO-UF samples were observed (1:1 and 1.3:1, respectively). Assessment of endotoxin presence on NiO
particles confirmed undetectable levels (below 0.1 EU/ml) in both samples.
Surface reactivity analysis by acellular ESR resulted in no hydroxyl radical generation for both
particles in response to hydrogen peroxide (figure 2.5). NiO-F and NiO-UF dissolution kinetics were
shown to be dependent on the pH of the suspension fluid (figure 2.6). Minimal release of ions was
observed from either particle when suspended in DM or GS, irrespective of time. However, suspension
of particles in ALF was associated with increased dissolution and time-dependent increases in the
concentration of nickel ions released. No statistically significant differences in the rate of dissolution were
observed between NiO-F and NiO-UF at any time point, irrespective of physiological media type.
Collective findings from physico-chemical characterization of NiO-F and NiO-UF are summarized in table
2.2.

NiO Time Course Study:
Mice were oropharyngeally aspirated with a single dose of NiO-F or NiO-UF in doses normalized
for particle mass (40 µg) or surface area (192 mm2, 3 µg) (table 2.1). Subsequently, mice were euthanized
1, 10, 19, or 29 d post-exposure in order to evaluate pulmonary toxicity with respect to NiO dose mass
and surface area .
Evaluation of Pulmonary Injury and Inflammation: The degree of particle-induced pulmonary injury
and inflammation was assessed by quantification of lavage fluid LDH levels, total BAL cell number, and
number of BAL neutrophils at all time points (figure 2.7). No statistically significant alterations in any of
these parameters were observed 1 d post-aspiration. Among the time points examined in this study, NiOinduced injury and inflammation was greatest for all groups at 10 d post-aspiration. When administered
in mass-equivalent doses of 40 µg, NiO-UF (NiO-3 group) induced a greater degree of lung injury and
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inflammation than NiO-F (NiO-1 group). LDH was significantly elevated in the NiO-3 group compared to
all other groups at 10 and 19 d (figure 2.7. A). LDH was elevated in the NiO-1 group at 10 d, only when
compared to control, and it did not differ from the NiO-2 group, for which dose was normalized to the
surface area of NiO-1. LDH levels returned to control values by 29 d for all groups. No significant
increases in total BAL cell number (figure 2.7. B) or lung neutrophils (figure 2.7. C) were observed in the
NiO-1 or NiO-2 groups, which had similar surface area by dose, when compared to control (or each other)
at any time point in the study. However, the NiO-3 group exhibited significantly increased numbers of
total BAL cells and lung neutrophils at 10 d, and lung neutrophil number remained significantly elevated
compared to all groups for the duration of the time course.
Total Lymph Node Cell Number and Cell Phenotyping: Similar to the measures of lung injury and
inflammation, variations in mediastinal lymph node size and cellular composition were observed in
response to the mass-normalized doses of NiO-F and NiO-UF. When administered at 40 µg, NiO-UF
exposure (NiO-3 group), which had the highest surface area by dose, caused an earlier onset and
persistence of lymph node expansion, as well as a significantly greater maximal cell number at 10 and
19 d, when compared to the same mass-based dose of NiO-F (NiO-1 group) (figure 2.8). Lymphocyte
numbers in the surface area-normalized doses, NiO-1 and NiO2, significantly increased over control
beginning at 19 d, but did not differ significantly from each other at 1, 10, or 19 d. However, at 29 d lymph
node expansion continued in the NiO-2 group to a similar level as the NiO-3 group, and this did not occur
in the NiO-1 group. Despite the increases observed in total lymphocyte population cell numbers, ratios
of lymphocyte phenotypes did not differ significantly between groups at any time point (table 2.3). A
similar trend was observed with respect to lymphocyte populations in the spleen (table 2.4).
Cytokine Analysis: BALF cytokine levels in each group at each time point were consistent with
the corresponding inflammatory response illustrated by other measures of toxicity. Generally, cytokine
responses were surface area-dependent. Exposure to the higher surface area-based dose resulted in
more pronounced and persistent increases in several pro-inflammatory cytokines in the BALF (table 2.5),
including IL-6, IFN-γ, and TNF-α which persisted until the final endpoint (figure 2.9).
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Serum cytokine levels demonstrated a similar trend as BAL fluid cytokines (table 2.5). However,
significant differences over DM control levels were only observed in the NiO-3 group with respect to TNFα at 19 d and IFN-γ at 1, 10, and 19 d.
Circulating White Blood Cell Populations: Phenotypic differentiation of whole blood leukocyte
(WBC) cell populations was performed to identify any alterations in circulating immune cell frequencies
at all time points in the NiO time course study. Increased numbers of total WBC were only observed in
the NiO-2 group at 10 and 19 d, when compared to DM control numbers at corresponding time points
(table 2.6). Compared to DM controls, the percent of circulating WBC constituted by neutrophils was
significantly decreased at 1 d in the NiO-2 group and at 10 d in the NiO-3 group. At 19 d, the NiO-3 group
exhibited an elevated proportion of circulating neutrophils when compared to DM controls.
Lung Histopathology and Particle Clearance: Histopathological analysis of lung tissue from DM
controls and animals exposed to the 40 µg dose of fine particle (NiO-1) and the ultrafine particle (NiO-3)
were evaluated for markers of injury and inflammation by a board-certified veterinarian who was blinded
to treatment groups. Histopathological findings are summarized for each group at each time point in table
2.7. Results confirmed the presence of particles in alveolar macrophages of all NiO-exposed groups, the
temporal progression of which corresponded to microscopic and ICP-MS analysis and Ni clearance
findings discussed below. The degree of inflammatory cell infiltration reported by the histopathological
analysis was also in accordance with the findings from differential phenotyping performed in house.
Peribronchiolar/perivascular edema and cellular accumulation was more severe in animals exposed to
NiO-3 compared to NiO-1, and NiO-3-induced tissue injury was still prominent 29 d post-exposure.
To evaluate particle clearance over time, a separate group of animals were exposed to an equal
mass dose of 40 µg of the fine particle NiO-1 or the ultrafine particle NiO-3, and Ni lung burden was
measured at 1, 10, 19, and 29 d post-exposure. Results showed that lung Ni levels were comparable
between animals exposed to both particles 1 d post-exposure; however, by 10 d, lungs of animals
exposed to the fine particle contained 62% of the original dose, whereas lungs of animals exposed to the
ultrafine particle only contained 47% of the original dose Ni mass (figure 2.10). At 19 d and 29 d post-
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exposure, lungs from both groups contained approximately 39% and 32% of the original Ni dose mass,
respectively.
Dark field microscopy and light microscopy were used to visualize the particle burden in alveolar
macrophages with respect to time post-exposure. Collectively, the degree of particle loading and
frequency of particle-laden alveolar macrophages in each group appeared consistent with the clearance
data obtained from the whole lung Ni burden analysis. Figure 2.11 shows images of particle-laden
alveolar macrophages from each group 10 d post-exposure.

NiO OVA Asthma Model
For the OVA asthma model, animals were administered the same particle doses from the time
course study by oropharyngeal aspiration on 0 d. On 1 and 10 d, mice were sensitized to OVA (OVA,
NiO-1A, NiO-2A, and NiO-3A groups), or administered vehicle to serve as non-sensitized control groups
(DM, NiO-1, NiO-2, and NiO-3 groups). Aspiration OVA challenge occurred on 19 and 28 d, lung function
was measured following the second challenge, and mice were euthanized the following day (figure 2.1)
Day 14 Post-Sensitization Serum IgE Evaluation: Following NiO aspiration and two sensitization
procedures, levels of circulating total IgE and OVA-specific IgE were evaluated on 14 d to confirm
successful sensitization of allergy groups (figure 2.12). Total IgE levels were elevated in all sensitized
groups compared to non-sensitized groups at 14 d. The presence of OVA-specific IgE exclusively in all
sensitized groups indicated successful sensitization to OVA. No statistically significant differences in
total or OVA-specific IgE levels were observed between any groups with shared sensitization status.
Day 28 Post-Allergen Challenge Lung Function Assessment: OVA-sensitized animals were
challenged with OVA by aspiration on 19 d and 28 d, while control animals were aspirated with PBS.
Directly following the second challenge on 28 d, mice were placed in whole body plethysmography
chambers to monitor airway function, where Penh values were recorded every 30 seconds for 6 hours for
each animal. A time course depiction of Penh values for a single representative animal from DM, OVA,
and all NiO-exposed/OVA sensitized groups is shown in figure 2.13. A. Calculation of mean Penh area
under the curve (AUC) for each group showed a more robust pulmonary response to OVA challenge in
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the NiO-1 fine particle group, which was not present in either ultrafine particle group (figure 2.13. B). No
differences in airway function were observed between the non-sensitized groups (data not shown).
Day 29 Lung Cellular Influx and Phenotyping: Mice were euthanized on 29 d and the lungs were
lavaged to obtain cellular and fluid fractions for analysis. In the non-sensitized groups, there was an
increase in total BAL cells in the NiO-3 compared to all other groups, which was consistent with findings
from the time course study (figure 12.14 A). The total number of BAL cells was significantly increased in
all OVA sensitized groups compared to non-sensitized groups, but no significant differences were
observed between any sensitized groups. Phenotypical differentiation of BAL cells in the sensitized
groups showed significant increases in percent lung eosinophils (figure 2.14. B, table 2.8) in groups
exposed to NiO-UF (NiO-2A, NiO-3A), independent of dose mass or surface area. When compared to
OVA control, percent lung neutrophils (figure 2.14. C) was similar between groups exposed to surface
area-normalized doses (NiO-1A, NiO-2A). A significant increase in percent lung neutrophils was only
observed in animals exposed to the highest NiO dose with respect to surface area, the NiO-3A group,
when compared to OVA control.
Vaculoated macrophages were commonly observed in the BAL of animals, an observation most
prominently seen in animals exposed to NiO-UF (figure 2.15. A-C). Multinucleated giant cells were also
exclusively observed in animals of the NiO-3A group (figure 2.15. D).
Day 29 Lymph Node and Spleen Cell Phenotyping: Enumeration of mediastinal lymph node cells
showed that all OVA-sensitized groups had elevated total lymph node cell numbers compared to nonsensitized groups (figure 2.16). Among the NiO-exposed/OVA-sensitized animals, lymph node number
in the NiO-3A group was significantly increased when compared to all other treatment groups.
Phenotyping of lymph node cells (figure 2.16. B, table 2.9) showed consistent ratios of CD4+ T-cells,
CD8+ T-cells, and B-cells between OVA, NiO-1A, and NiO-2A groups. However, in the NiO-3A group,
the mediastinal lymph nodes contained a significantly increased proportion of CD4+ T-cells, and a
significantly decreased proportion of B-cells compared to all other OVA-sensitized groups.
In the spleen, a similar trend was observed. OVA, NiO-1A, and NiO-2A groups all had similar
proportions of CD4+ T-cells, CD8+ T-cells, and B-cells. In comparison, animals of the NiO-3A group had
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significantly lower percentages of B-cells and increased percentages of both CD4+ and CD8+ T-cells
(table 2.10).
Day 29 Serum Total and OVA-Specific IgE Levels: Total circulating IgE levels at 29 d were
significantly increased in all OVA-sensitized groups (purple bars) compared to non-sensitized groups
(orange bars), as shown in figure 2.17. Moreover, all OVA-sensitized groups exposed to NiO, irrespective
of particle size, dose mass, or dose surface area, had significantly increased total IgE levels when
compared to OVA control levels. OVA-specific IgE levels, shown as the hatched area of the bars in figure
2.17, were also quantified from serum and revealed no significant difference between the surface-area
normalized groups (NiO-1A and NiO-2A) when compared to OVA control levels. Also, when compared
to levels of serum total IgE, the proportion of OVA-specific IgE was similar between OVA control, NiO1A, and NiO-2A groups, ranging from 56-63%. Contrarily, OVA-specific IgE levels in the NiO-3A group
only comprised 19% of the total IgE and were significantly lower than the other NiO-exposed/OVAsensitized groups.
Day 29 Cytokine Analysis: Analysis of helper T-cell cytokine levels in BAL fluid showed that, when
compared to OVA control levels, alterations in cytokine expression tended to be similar among groups
exposed to equal doses of NiO with respect to surface area (table 2.11, figure 2.18). The NiO-1A and
NiO-2A groups, which were exposed to NiO-F and NiO-UF, respectively, at equivalent surface areas of
192 mm2 showed minimal changes in Th1/17 cytokine levels but robust increases in Th2 cytokines when
compared to OVA control. Notably, IL-4 levels were increased over 6-fold from OVA control and NiO-3A
levels, consistent with these groups’ elevated levels of OVA-specific IgE. Contrarily, animals of the NiO3A group that were exposed to the higher ultrafine NiO surface area-based dose of 2580 mm2 showed
minimal increases in Th2 cytokines when compared to OVA controls. Rather, Th1/17 cytokines were
significantly elevated when compared to NiO-1A, NiO-2A, and OVA control groups. While all NiO-treated
OVA-sensitized groups had elevated IL-6 levels in the BAL fluid compared to OVA control animals, the
degree of IL-6 increase appeared to be better correspond to NiO dose mass. Interestingly, the groups
exposed to the higher mass of NiO (40 µg) had lower levels of BALF IL-6 compared to the group exposed
to the lower 3 µg NiO-UF dose.
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Serum cytokine levels demonstrated a similar trend between groups exposed to NiO doses with
equivalent surface areas (figure 2.19, table 2.11). No clear trend was observed with respect to selective
modulation of Th1/17 and Th2 cytokine levels in NiO-1A and NiO-2A groups; however, exposure to the
higher NiO surface area (NiO-3A), resulted in consistent elevations in Th1/17 cytokines and modest
decreases in Th2 cytokines compared to OVA control levels- a similar pattern to that observed in the BAL
fluid. Alterations in serum IFN-γ levels appeared unique to each group, as levels decreased over 5-fold
in the NiO-1A group, remained equal to OVA control levels in the NiO-2A group, and increased 2-fold in
the NiO-3A group.
A heat map depicting control level fold-change alterations in Th1/17 and Th2 BALF/serum
cytokines in sensitized groups of the NiO OVA study are shown in figure 2.20.
Day 29 Whole Blood Cell Differentials: Circulating WBC populations were differentiated and are
shown in table 2.12.
Day 29 Lung Tissue Histopathological Analysis: Lung tissue from all groups (n = 6) was collected
for histological analysis of various parameters associated with respiratory allergy. The scores for each
animal in each category of pathology are presented in table 2.13. There were no notable observations
made with respect to asthma-associated cellular or anatomical alterations in non-sensitized groups.
In sensitized animals, histopathological analysis reported inflammatory cell infiltration that was
conducive with the differential phenotyping of inflammatory cells performed by flow cytometry.
Macrophage accumulation and vacuolation was observed in all groups, and the degree of eosinophil and
neutrophil influx varied between NiO-1A, NiO2-A, and NiO-3A groups, but corresponded with the findings
generated by flow cytometry. Hypertrophy of the bronchial epithelium was observed in all groups, but
most frequently observed in the NiO-3A group (80% incidence). Peribronchiolar edema and airway
exudate was also observed in all sensitized groups, but no significant differences between treatment
groups were noted.
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2.5. Discussion
The goal of these studies was to investigate the role of dose metrics in immune toxicity following
pulmonary exposure to NiO particles of different sizes. Specifically, studies were designed to determine
if exposure to NiO particles prior to sensitization and elicitation altered allergic responses. In the time
course study, NiO-UF exposure was associated with a greater degree of lung injury and inflammation
than NiO-F when administered in equal mass doses (NiO-3 vs NiO-1). When NiO-UF was administered
in a dose normalized for the surface area of the NiO-F dose (NiO-2), this discrepancy was mitigated.
Contrarily, in the OVA asthma model, immune endpoints related to the allergic response were
differentially impacted by multiple NiO-F and NiO-UF dose metrics. NiO exposure, irrespective of any
metric, resulted in elevated circulating total IgE levels at 29 d. Exposure to surface area-normalized doses
(NiO-1A and NiO-2A) resulted in similar responses with respect to OVA-specific IgE levels, BALF/serum
cytokines, and lung neutrophils. However, lung eosinophil and Penh response appeared better correlated
to particle size with NiO-F (NiO-1A) exposure resulting in greater airway reactivity (increased Penh) and
NiO-UF (NiO-2A and NiO-3A) resulting in increased lung eosinophil burden.
Characterization of NiO-F and NiO-UF yielded data consistent with expected results. The primary
particle size of NiO-UF (42 nm) was comparable to vendor size specifications (50 nm), whereas NiO-F
particles (181 nm) were substantially smaller than expected (vendor reporting: -325 mesh, < 44 µm).
However, NiO-F particles were still significantly larger than NiO-UF.
The average agglomerate size for both particles varied depending on the method of analysis.
According to FESEM-based measurements, the agglomerate sizes for NiO-F and NiO-UF were 640 and
190 nm, respectively. Comparatively, measurements from DLS reported sizes of 321 and 109 nm for
NiO-F and NiO-UF. This discrepancy may have arisen as a result of the different states of the particles
in each analysis. The particles were initially prepared for both analyses using identical methods; however,
microscopic analysis required drying of the particles on a filter, whereas DLS measurements were taken
while particles were still suspended in the delivery vehicle. As a result, discrepancies in the agglomerate
size reported by each method may reflect phase-specific behavior of the particles with respect to
particle/particle interactions
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Although many metal oxide nanoparticles are associated with the generation of oxygen radical
species, this behavior was not observed when both NiO particles were characterized by acellular ESR in
this study. This finding is consistent with similar findings reporting radical quenching by NiNP and
antioxidant-like behavior in an in vitro ESR assay (1619, 1620).
Ex vivo analysis of NiO-F and NiO-UF dissolution behavior generated results consistent with
previous reports (1621). The lack of significant ion release by NiO in neutral solutions has been frequently
reported. Similarly, the enhanced rate of Ni ion release observed following particle suspension in ALF
has been previously characterized by many studies (1424, 1622).
XPS analysis revealed that nickel and oxygen were the most prominent elemental constituents
present on the surface of NiO-F and NiO-UF. The peak energies generated by both samples were
consistent with a similar mixed surface composition containing NiO, Ni2O3, and Ni(OH)2. However,
differences in the proportions of these compounds were detected on the surfaces of NiO-F/NiO-UF. As
a result, the ratio of surface Ni and O content varied slightly between the two particles; NiO-F particles
exhibited a surface Ni:O ratio of 1:1, whereas the NiO-UF particles exhibited a slightly elevated proportion
of nickel on the surface and a Ni:O ratio of 1.3:1. The nickel-enriched surface chemistry of NiO-UF was
suggested to be a contributing factor in the distinct coloration observable between the two particles. NiO
particles can exhibit notable variations in coloration ranging from light green to greenish gray and black.
The stoichiometric composition of surface nickel oxide species, particle size, crystal structure, presence
of elemental contaminants, and surface irregularities are all properties associated with the coloration
discrepancies seen between different NiO powders (1409, 1623).
The nature of NiO-induced pulmonary inflammation and the kinetics of resolution observed in the
NiO time course study are consistent with other studies that have investigated NiO nanoparticle-induced
acute lung inflammation in vivo (1413, 1419, 1624-1626). Some metal nanomaterials have been
associated with the induction of eosinophil-dominant inflammation in the lung, but the neutrophilicdominant inflammation observed following NiO exposure in this study (figure 2.7) is in agreement with
other existing investigations of NiO nanoparticles (1414, 1627-1631). The magnitude of lung injury and
inflammation caused by NiO was correlated to surface area of the administered particles in this study;
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the ultrafine particle at the high dose (highest surface area and greater number of particles per mass)
caused the greatest degree of injury and inflammation (figure 2.7), followed by the fine particle at the high
dose and the ultrafine particle at an equivalent surface area-based dose, particularly at 10 d postexposure.
Although dose metrics including particle number and particle volume have been occasionally cited
as parameters predictive of the toxic potential of some meal nanomaterials, a similar association between
lung inflammation and NiO surface area has been previously reported in other studies (696, 764, 1250,
1355, 1605, 1632). Surface area has also been reported to be the dose parameter that best represents
the magnitude of acute pulmonary toxicity induced by other metal-based nanomaterials including titanium
dioxide (TiO2NP) and various carbon-based materials (35, 1633-1636). Contrarily, dose mass has been
shown to better predict the severity of lung injury caused by other metal-based nanoparticles including
zinc oxide (ZnONP), cobalt oxide (CoONP), and copper oxide (CuONP) (1637, 1638).
Inconsistencies between the dose metric best correlated to the toxic potential of different metal
nanomaterials often reflect variations in their mechanisms of toxicity. For example, particle number has
been largely implicated as a parameter best correlated to the toxic potential of nanomaterials exhibiting
long, fiber-like morphologies. Rigid nanofibers and nanowires with high aspect ratios are often associated
with the induction of frustrated phagocytosis, compromised locomotion, and or death of alveolar
macrophages following pulmonary exposure. Since a single nanofiber has the potential to trigger the
release of pro-inflammatory cytokines and damage-associated molecular patterns (DAMP) by an
individual macrophage and compromise clearance of foreign material from the airways, particle number
often reflects the magnitude of pulmonary inflammation caused by nanofibers and nanowires with high
aspect ratios (845, 1632, 1639). Comparatively, dose mass has been frequently implicated in the toxic
potential of metal nanomaterials with high dissolution potential, such asZnONP, CoONP, CuONP. These
particles often induce toxic effects resulting from the rapid release of cytotoxic metal ions from the parent
particle. Likewise, the absolute quantity of ions capable of being released from these nanomaterials is
related to the mass of the administered dose, rendering it a dose metric correlated to the degree of toxicity
driven by this mechanism (1638). Contrarily, NiO nanoparticles and other metal nanomaterials known to
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be relatively insoluble at neutral pH are frequently associated with toxic effects that emerge as a result
of particle surface-interactions. Subsequent ROS formation, oxidative stress, and perturbation of cellular
structures have been cited as mechanisms involved in their acute toxic effects on the lungs (35).
Accordingly, the surface area of the administered dose better represents the magnitude of resultant tissue
injury. Moreover, additional physico-chemical characteristics with implications for surface areadependent toxic effects have also been implicated in the toxic response. NiO nanoparticle pre-exposure
dispersion state, surface modification, and morphology have all been shown to influence the inflammatory
response caused by NiO nanomaterials in the lungs (1355, 1423, 1620, 1632). These findings also
emphasize important considerations for dosimetrics, highlighting the potential relevance of dose
parameters such as surface chemistry and particle number on a mass basis, which may be increasingly
relevant in future studies (1423).
The only marker throughout the time course study that differed between treatment groups
exposed to NiO surface area-normalized doses (NiO-1 and NiO-2) was the mediastinal LN size at 29 d
(figure 2.8). The kinetics and degree of LN expansion were similar between the NiO-1 and NiO-2 groups
until the 29 d time point, when the LN size of the NiO-2 group continued to increase, reaching values
equivalent to that of the NiO-3 group at the same time point. Contrarily, LN size at 29 d in the NiO-1 group
had decreased from the response recorded at 19 d; however, it remained significantly elevated compared
to corresponding control levels. Likewise, each group exhibited unique responses in the LN during the
time course that differed with respect to the kinetics of size increase and magnitude of this response.
Several contributing factors may be responsible for this observation, including NiO dissolution kinetics
and particle deposition/clearance patterns in relationship to immune cell signaling.
Increased LN cellularity may reflect expansion of lymphocyte populations in response to local
immune activation driven by the release of Ni ions. Both NiO particles were relatively insoluble at neutral
pH, but their dissolution was shown to be accelerated in acidic environments, as demonstrated in the
ALF (figure 2.6), which represents the environment encountered by particles following uptake by
pulmonary phagocytes. Subsequent dissolution of particles and release of toxic ions can result in proinflammatory signaling by macrophages, as well as necrotic cell death, leading to the release of DAMP
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and cytotoxic ions into the airways. All of these effects can trigger inflammatory reactions leading to
proliferation of lymphocyte populations in the lung-draining LN. In this study, ex vivo analysis showed
that dissolution was similar for NiO-UF and NiO-F in the acidic ALF solution, making it difficult to attribute
differences in dissolution rate to the variations in LN size increase between the NiO-1 and NiO-2 groups
at 29 d. However, it is important to note that while ex vivo analysis did not reveal differences in dissolution
behavior between NiO-F and NiO-UF, this approach cannot account for the numerous complexities of
the in vivo environment that can impact particle dissolution. Moreover, numerous particle-independent
factors could have contributed to differences in the rate of ion release from the surface area-normalized
doses of NiO-F and NiO-UF in vivo. For example, an increased number of alveolar macrophages in the
lungs of one group could have resulted in enhanced particle dissolution; however, at the time points
investigated in this study, cellular recruitment to the lungs did not differ between the NiO-1 and NiO-2
groups. Overall, it remains unclear if the differences in LN size increase between these groups was
reflective of differences in the rate of ion release between particles.
Comparatively, the increase in LN size may reflect the translocation of pulmonary immune cells
to the LN. Accordingly, the early LN expansion characteristic of the NiO-3 group (figure 2.8) may have
been correlated to the pulmonary clearance kinetics of the ultrafine particles versus the fine particles with
respect to dose mass (figure 2.10). Following exposure to a 40 µg dose of either particle, 47 % of the
original Ni dose remained in the lungs of the NiO-3 group at 10 d, versus 62 % in the NiO-1 group.
However, by 29 d, lung Ni burden was similar between groups. Size-specific particle deposition patterns
in the alveolar region and airways may have contributed to differences in the rate of cell-mediated particle
clearance with respect to mass. Deposition of particles in different anatomical compartments of the
respiratory tract can lead to differences in the propensity for local retention of particles in the lung
parenchyma, their likelihood for uptake by pulmonary phagocytes, potential for cell-mediated transport
via lymphatics, or physical translocation by the mucociliary escalator (20). These factors can all impact
the quantity of particles that translocate to the LN, as well as their kinetics of relocation. Many other
features of the administered dose may also impact these processes. For example, dose volume is known
to contribute greatly to the overloading of pulmonary phagocytes, which can trigger alterations in cell
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migratory potential (838). Particle number, dose mass, and surface area can also impact macrophage
responses with potential to modulate the clearance of particles. In this study, it is difficult to discern the
material properties and factors that account for the differences in temporal patterns of lymphocyte
expansion between groups. Likewise, the time-dependent increase in LN size following NiO exposure
may reflect discrepancies in the absolute quantity and time course of ion release, as well as deposition
and clearance patterns of the delivered dose as a function of particle size, mass, and/or surface area.
Although numerous studies have been conducted to help elucidate the role of various
nanomaterial physico-chemical properties on lung toxicity, there are considerably fewer studies that
examine the potential for metal nanomaterial exposure to augment immunological processes in allergy
models; moreover, even fewer studies have examined the role of nanomaterial characteristics and dose
metrics on this immunomodulatory potential. Incorporation of the NiO-F and NiO-UF particles into the
OVA study demonstrated that, contrary to the surface area-dependent general pulmonary inflammation
caused by NiO, multiple dose metrics impacted immune endpoints with implications for asthmatic
responses.
In the OVA model, the pulmonary response to allergen challenge and number of lung eosinophils
were both parameters that appeared associated with NiO particle size. Increases in lung eosinophils and
enhanced bronchoconstrictive responses are two features of allergic airway disease that generally
present simultaneously in asthma, wherein the extent of their involvement is frequently correlated to
clinical disease severity (1640). Interestingly, these responses were differentially increased as a function
of NiO particle size in the OVA model. NiO-F exposure was associated with enhanced Penh responses
compared to OVA controls (figure 2.13), whereas increased lung eosinophil recruitment occurred in
response to NiO-UF exposure (figure 2.14. B). Furthermore, the groups demonstrating the most robust
Penh and eosinophil responses in this study did not exhibit the most pronounced responses with respect
to other prototypical markers of allergic reactivity, including OVA-specific IgE and Th2 cytokine levels.
Average Penh values were only elevated in the NiO-1A group, the only group exposed to NiO-F.
As a parameter indicative of resistance to airflow, alterations in Penh may result from several different
underlying mechanisms. Non-immunological mechanisms capable of increasing resistance to airflow
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include exposure-induced structural or physiological alterations that impact the mechanics of respiration.
For example, modulation of airway smooth muscle signaling and subsequent contractility behavior has
been demonstrated following exposure to several metal nanomaterials (792, 1641, 1642). However, no
Penh alterations were observed in non-sensitized groups exposed to NiO, suggesting that the Penh
response observed in the NiO-1A group was both particle-specific and dependent on an immunologicallybased mechanism associated with the asthmatic condition.
The enhanced Penh response selectively observed in animals exposed to the larger NiO particle
may reflect interference with bronchoconstrictive responses resulting from interactions between NiO
particles and various molecular mediators of asthmatic elicitation. Microscopic analysis of lung tissue and
cells in the lavage fluid revealed that NiO particles were still abundantly present in the airways and
pulmonary phagocytes at 29 d. The presence of these particles during allergen challenge can have
notable implications for allergic processes since protein allergens, immunoglobulins, chemokines, and
cytokines have all been shown to exhibit altered biological activity upon interaction with metal
nanomaterials (522, 1643). Notably, granulocytes and IgE molecules, when pre-exposed to
nanoparticles, have been shown to exhibit compromised binding activity, preventing cellular
degranulation (916). Likewise, alterations in Penh reactivity and other markers of elicitation response
severity in the OVA model may have been subject to influence from persistent NiO particle presence in
the airways. The extent of such effects would be dependent on the burden of NiO particles remaining in
the respiratory tract (dose-dependent clearance of particles), number of particles free from cellular- or
tissue-mediated immobilization, and properties associated with the surface-loading capacity of particles,
such as surface area.
The degree of eosinophil influx to the lungs was another marker in the OVA model that correlated
with particle size. However, contrary to the enhanced Penh reaction, which was exclusively associated
with exposure to the larger particle, increased eosinophil recruitment was associated with exposure to
the smaller NiO particle (at both doses). One of the major cytokines responsible for recruitment of
eosinophils to the lungs is IL-5, a prototypical Th2 cytokine (1644). However, neither group with elevated
numbers of lung eosinophils (NiO-2A, NiO-3A) exhibited significant elevations in BALF IL-5 levels (figure
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2.18). This observation suggests that non-immunological mechanisms may be responsible for the
increase in eosinophil recruitment in these groups. In this regard, NiO nanoparticles have been shown to
recruit eosinophils to the lungs in vivo as a result of their internalization by cells, where accumulation in
acidic lysosomes facilitates the release of cytotoxic ions, causing necrotic cell death. Eotaxin is passively
released by these dying cells, triggering the local influx of eosinophils, independent of IgE-mediated or
Th2-biased mechanisms (663).
Several studies have shown that the rate of ion release from metal nanomaterials is a critical
determinant in the selective recruitment of neutrophils and eosinophils to the airways. Generally,
insoluble and highly soluble metal nanomaterials have been associated with the preferential induction of
neutrophilic- and eosinophilic-dominant inflammation, respectively (1414, 1645). A study by Jeong et al.
(2015) illustrates this concept. In the study, cobalt nanoparticles with divergent solubility profiles were
instilled into the lungs of rats, and the subsequent inflammatory responses were characterized. The
insoluble Co3O4 nanoparticles produced neutrophilic-driven inflammation, whereas the soluble CoO
nanoparticles induced eosinophilic-dominant inflammation. Moreover, the number of neutrophils
recruited to the lung was strongly correlated to the surface area of the administered Co 3O4 dose.
Comparatively, the number of eosinophils recruited to the airways by CoO strongly correlated with the
dose of cobalt ions released from the parent particles, and mirrored the inflammatory profile caused by
the highly soluble salt, CoCl2 salts (787).
Collectively, these observations suggest that the influx of phenotypically-distinct inflammatory cell
populations in healthy and allergic airways following NiO exposure may be associated with differences
in particle dissolution potential as a result of disease state-specific microenvironments. The exclusive
recruitment of neutrophils to the lungs of animals in the NiO time course study and non-sensitized groups
of the OVA model are consistent with the insoluble nature of NiO-F and NiO-UF in neutral conditions. By
comparison, the recruitment of eosinophils exclusively observed in the NiO-2A and NiO-3A groups of the
OVA model suggests that the present of established allergic airway inflammation enhanced the
dissolution potential of NiO-UF. In this study, although analysis of particle dissolution ex vivo showed that
NiO-UF and NiO-F did not differ significantly in acidic conditions over time (figure 2.6), NiO-UF showed
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a trend for a higher degree of dissolution than NiO-F. This effect may be exacerbated in vivo due to the
increased complexity of the environment in the phagolysosme, as well as potentially the increased acidic
environment of asthmatic airways (1646). Further studies are necessary to better discern the role of
particle solubility in relation to the particle size-specific inflammatory response caused by NiO in allergic
disease.
The inverse relationship between enhanced Penh reactivity and eosinophil lung burden in the OVA
model is a nonconventional finding. However, several potential mechanisms may be responsible for this
effect. For example, the release of toxic granule proteins by eosinophils has the potential to cause
significant injury to lung tissue, which can alter airflow mechanics and mask bronchoconstrictive
responses measured by whole body plethysmography. This effect could explain the increases in lung
eosinophil burden observed in the NiO-2A and NiO3-A group, despite the absence of enhanced Penh
responses. Similarly, since eosinophils can modulate neural communication with airway smooth muscle
cells, an increased lung eosinophil burden might be responsible for interference with signaling pathways
involved in allergen-induced bronchoconstriction (1647). Furthermore, since eosinophils have the
capacity to bind IgE molecules, increased numbers of lung eosinophils may have led to immobilization of
allergen or other molecular mediators involved in triggering or amplifying Penh responses (1648).
Another interesting observation in the OVA model was the impact of NiO exposure on
immunoglobulin production and specificity. At 29 d, levels of total IgE were elevated in all NiOexposed/OVA-sensitized groups, irrespective of NiO particle size, mass, or surface area (figure 2.17).
Comparatively, OVA-specific IgE levels were conserved between groups with respect to NiO surface
area. Although exposure to the smaller of the two surface area-based doses (NiO-1A and NiO-2A groups)
was associated with a minor increase compared to OVA controls, the effect was not statistically
significant. Contrarily, exposure to the larger surface area-based dose (NiO-3A group) was associated
with a significant decrease in OVA-specific IgE production compared to all other sensitized groups. This
discord between NiO dose/exposure effects on total and OVA-specific IgE levels at 29 d resulted in a
notable discrepancy in the IgE specificity ratio between groups. The NiO-1A and NiO-2A groups exhibited
a similar IgE profile as OVA controls, wherein OVA-specific IgE constituted 58%, 56%, and 63% of all
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IgE, respectively. By comparison, allergen non-specific IgE dominated the IgE repertoire of the NiO-3A
group, as only 19% of the total circulating IgE was OVA-specific.
Although NiO dose-dependent alterations in the IgE repertoire were observed at 29 d, this
response could be indicative of NiO adjuvant activity during OVA sensitization or particle-induced
modulation of the elicitation response. Therefore, IgE levels were also assessed at 14 d in order to clarify
if NiO exposure was capable of inducing sensitization-specific effects, independent of allergen challenge.
No differences in the levels of total or OVA-specific IgE were observed between NiO-exposed/OVAsensitized groups at 14 d (figure 2.12). However, differences in the proportionality of IgE specificity were
discernable between groups at 14 d. In OVA control animals, OVA-specific IgE comprised 39% of the
total IgE pool after sensitization. Comparatively, OVA-specific IgE constituted 53%, 56%, and 24% of the
total IgE in the NiO-1A, NiO-2A, and NiO-3A groups, respectively. Since antibody production, irrespective
of allergen specificity, did not differ between groups with respect to quantity, this finding implies that
pulmonary NiO exposure did not compromise the capacity for B-cells to undergo isotype switching in
response to systemic sensitization. However, the existence of differences in the proportionality of IgE
specificity between groups suggests that respiratory NiO exposure can compromise other peripheral
immune processes, such as somatic hypermutation and affinity maturation in B-cells.
In this study, NiO exposure prior to allergic sensitization was associated with a modest impact on
antibody production during allergic sensitization, as illustrated by the similar IgE levels between groups
at 14 d. By comparison, many other studies using allergy models have demonstrated that exposure to
metal nanomaterials during the sensitization phase of allergy can cause profound adjuvant effects.
TiO2NP, ZnONP, SiO2NP, and aluminum nanoparticles (AlNP) have all been shown to induce prominent
increases in antigen-specific antibody levels following both systemic and mucosal sensitization,
independent of allergen challenge (868, 874, 879, 882, 946). However, a key discriminating feature
between these studies and the current study is the exposure route associated with sensitization and
nanomaterial administration. The vast majority of existing studies have investigated the effects of metal
nanomaterials when co-administered with antigen simultaneously during sensitization. Similar to the
mechanisms of many commonly used vaccine adjuvants, the subsequent adjuvant effects are often

224

dependent on particle/antigen interactions (1649). Fewer studies have examined the potential adjuvant
effects of metal nanomaterials when administered independently from antigen (732-734, 926). Likewise,
the current study was designed to determine if a particle exposure affected subsequent encounters with
allergen, as may occur in occupational settings.
In this study, NiO particle effects appeared more prominent during the elicitation phase of the
allergic response. Exposure-dependent variations in the OVA-specific IgE response only became
apparent at 29 d, following two OVA challenges. IgE responses were consistent with the BAL fluid and
serum cytokine profiles in the respective groups, which were also conserved with respect to NiO surface
area (figures 2.18 and 2.19, table 2.11). The NiO-1A and NiO-2A groups trended together with a greater
increase in Th2 cytokines while the NiO-3A group had greater increases in Th1 cytokine levels. This
polarization pattern is also in accordance with the observation from histopathological analysis that
multinucleated giant cells were exclusively present in the NiO-3A group. Giant cells have been associated
with hard metal lung disease and Th1-dominant/delayed type hypersensitivity responses in the lung,
including hypersensitivity pneumonitis (452, 1650).
The cellular profile of the mediastinal LN was another parameter shown to be correlated to the
surface area of NiO in the OVA study (figure 2.16). The 29 d LN response showed a similar trend between
the NiO-1A and NiO-2A groups, where total cell number was increased over OVA controls, but the
increase seen in the NiO-3A group was even further elevated over all other groups. Phenotypic analysis
of LN cells revealed a pattern indicative of general expansion in the NiO-3A group, as all lymphocyte
subpopulations were present in similar proportions as non-sensitized groups. Comparatively, a similar
increase in the proportion of LN B-cells and decrease in the ratio of CD4+ T-cells was observed in the
OVA, NiO-1A, and NiO-2A groups. These three groups exhibited alterations in LN cellular composition
that would be expected in a typical IgE-mediated allergic condition, which was consistent with the
increases in OVA-specific IgE levels seen in these animals. The lack of selective B-cell expansion in LN
of the NiO-3A group also corresponded to the OVA-specific IgE response in the group, wherein levels
were not elevated in a similar manner as the other sensitized groups. However, the NiO-3A group did
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exhibit significant increases in total IgE levels, which may have been reflective of the increase in absolute
number of LN B-cells resulting from the drastic increase in LN size specifically observed in this group.
NiO nanoparticles, to our knowledge, have only been incorporated into one other asthma model
to date. Horie et al. (2016) aspirated C57BL/6 mice with NiO nanoparticles (< 100 nm) or microparticles
(600 – 1400 nm), following which, mice were sensitized to OVA by inhalation (1, 3, 5, and 7 d post NiO
exposure).. Following four OVA challenges by inhalation (14, 16, 18, 20 d), OVA-specific IgE levels were
increased exclusively in animals exposed to the smaller NiO particle (870).
The findings from our study and that of Horie et al. exhibit similarities, as well as discrepancies.
In both studies, the treatment groups associated with increased production of OVA-specific IgE exhibited
concurrent increases in Th2-dominant immune markers. In both studies, selective Th1/Th2 dominancy
was also similarly related to NiO particle size and dose surface area. However, opposing effects of NiO
size/surface area on the direction of Th1/Th2 polarization were reported by the two studies. This
discrepancy may reflect the use of different mouse strains by the two studies, as the propensity for
Th1/Th2-dominant immunity differs between BALB/c and C57BL/6 strains. Furthermore, clearance of
nanoparticles from the lung is known to differ between these strains. Since the rate of NiO clearance
appeared to contribute to variations in the LN response in the NiO time course study, this is a critical
distinction between the studies that may account for the discordant findings (904).
Another source of variability between studies that may account for the divergent relationship
between NiO size/surface area and Th1/Th2 polarization is the route of exposure used to induce OVA
sensitization. Although both studies exposed animals to NiO via aspiration a day before sensitization, our
study utilized intraperitoneal injections to induce sensitization, whereas Horie et al. induced sensitization
by inhalation of OVA. As a result, the model design employed by Horie et al. uniquely facilitated the
potential for interactions between NiO particles and OVA molecules in the lung during sensitization,
whereas our study design was not conducive with the potential for similar interactions.
Many studies have shown that physical association of nanoparticles/antigen in the lungs during
allergic sensitization can result in profound adjuvant effects (883, 1651). This response has been
attributed to the binding of antigen/nanoparticles, which can result in altered antigen uptake and
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processing by APC, augmented delivery kinetics to the LN, regional deposition within the LN, and
modulation of antigen presentation/lymphocyte stimulation. Accordingly, the magnitude of Th2 adjuvancy
has been correlated to the surface loading capacity of nanoparticles, increases in which facilitate the
binding of larger quantities of antigen. Physico-chemical properties of metal nanomaterials that have
been associated with this mechanism of IgE/Th2 response amplification (when administered
simultaneously with antigen during sensitization) include decreased particle size, increased surface area
and porosity, and specific surface modifications (882, 883). The magnitude of Th2 adjuvant activity
induced by many of these nanoparticles has also been shown to be dose-dependent, as larger doses
facilitate the binding of higher quantities of antigen. Correspondingly, attenuation of metal nanomaterialinduced Th2 adjuvant activity has been correlated to increases in particle agglomeration, as well as
surface properties associated with compromised antigen binding affinity/saturation (879, 1652, 1653).
Collectively, these findings demonstrate that physical interactions between antigen/nanoparticles can
facilitate adjuvant effects on sensitization, and various physico-chemical properties of nanomaterials can
further influence the magnitude of this effect. The association between decreased NiO particle size and
increased OVA-specific IgE levels reported by Horie et al. is consistent with this mechanism of
immunomodulation. Moreover, many of these studies have also demonstrated that the Th2 adjuvant
activity of the nanomaterial is abolished if exposure occurs during the challenge phase of allergy. These
findings highlight the existence of different mechanisms capable of augmenting allergic processes, and
further emphasizes the importance of nanomaterial exposure occurrence with respect to the different
phases of allergic disease (783, 887).
In contrast to the findings reported by Horie et al., exposure to higher doses of NiO with respect
to surface area caused exacerbation of Th1-driven inflammation in our OVA model. This effect was likely
related to the persistent pro-inflammatory/Th1 pulmonary immune status in animals exposed to the high
dose of NiO-UF on 0 d. As demonstrated in the NiO time course study, exposure to this dose (NiO-3
group) was associated with persistent elevations in several notable pro-inflammatory/Th1 cytokines
(figure 2.9) that were still significantly elevated at time points corresponding to time points of allergen
challenge in the OVA model (19 and 29 d). The existence of an established Th1-polarized immune status
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in the airways could have limited the magnitude of allergen-induced Th2 responses mounted by the NiO3A group, and/or further exacerbated the Th1 response. Comparatively, the resolution of NiO-induced
pulmonary inflammation before OVA challenge in the NiO-1A and NiO-2A groups was associated with
increases in OVA-specific IgE and Th2 cytokine levels. Several other studies have reported a similar
induction of neutrophil-dominant lung inflammation by nanoparticles that correspondingly results in
attenuation of Th2-driven allergic inflammation following systemic sensitization (896, 897, 1654).
Differences in the routes of exposure employed by these two studies likely contributed to the
conflicting findings regarding the impact of NiO size on the amplification of Th2-dominant allergic
responses. This discriminating feature confers differential potential for particle/antigen interactions during
sensitization, an effect which is known to impact the magnitude and nature of subsequent adaptive
immune responses. Likewise, the findings from the two studies likely involve different immunological
mechanisms of NiO-induced OVA allergy modulation, wherein these processes exhibit variations in
susceptibility to influence from specific dose metrics and NiO particle characteristics. The correlation
between decreased particle size and Th2 adjuvancy reported by Horie et al. is consistent with interactions
between NiO/OVA in the lung during sensitization, leading to alterations in antigen delivery, and
subsequent promotion of Th2-dominant response development. By comparison, the correlation between
increased NiO surface area and Th1-dominant immune reactivity in our study is consistent with surface
area-driven polarization of pulmonary immunity towards a pro-inflammatory state, predisposing for Th1dominant reactivity upon allergen exposure.
In addition to the findings from these two asthma models, a few other studies have demonstrated
results indicative of the potential for NiO nanoparticles to augment respiratory allergy by other
mechanisms. For example, disruption in the pulmonary immune Th1/Th2 balance has been correlated to
a varying degree of nitrative stress induced by different sizes of NiO nanoparticles (1655). The
preferential induction of Th1/Th17-dominant lung inflammation by NiO nanoparticles has been shown in
numerous studies to cause the subsequent development of inflammatory reactions resembling delayedtype hypersensitivity reactions in the airways. Characteristic features of pulmonary alveolar proteinosis
and hypersensitivity pneumonitis have been reported following NiO nanoparticle exposure in vivo (537,
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1627). Accordingly, respiratory exposure to NiO nanoparticles may present concerns with respect to both
IgE-mediated and T-cell-mediated allergic responses in the lungs (1414, 1630, 1645).
Respiratory NiO nanoparticle exposure was also shown in one study to induce alterations in
several systemic immune markers following chronic low dose exposure in vivo. The authors observed
lymph node follicular expansion, alterations in the maturation status of splenic lymphocyte populations,
and enhanced eosinophil responses in rats following exposure to 23 nm NiO nanoparticles for up to 10
months. The authors concluded that these effects were indicative of the development of an allergic
syndrome to specific to nickel (1656). Although these systemic immune alterations may, in fact, contribute
to the development of nickel-specific allergic disease, these effects may also result in an increased
susceptibility to sensitization by other allergens, exacerbation of existing allergic disorders, or the
development of other immune disorders. This observation also emphasizes that the potential adverse
immune effects caused by respiratory exposure to NiO nanoparticles (and other nanomaterials) are not
anatomically-restricted to the respiratory tract.
The effect of NiO nanoparticles on allergic airway inflammation was examined in another study,
where a T-bet-/- mouse model was used. This mouse model exhibits compromised Th1 cell development
and subsequent predisposition for Th2-biased immunity, leading to the spontaneous generation of many
pathophysiological characteristics of asthma, independent of allergen exposure. Many of these asthmatic
features were shown to be exacerbated following exposure of mice to 20 nm NiO nanoparticles.
Increased influx of lung eosinophils, mucus cell metaplasia, and elevations in Th2 cytokine levels were
all observed, as well as chronic alveolitis. These findings suggest the potential for NiO nanoparticles to
exacerbate Th2-driven inflammation in the elicitation phase of asthma, as well as potentially accelerate
the development of airway remodeling in chronic asthmatic conditions (934).
Collectively, these existing studies emphasize that respiratory NiO nanoparticle exposure can
modulate many aspects of pulmonary immunity. In naïve lungs, size-dependent skewing of immunity
towards Th1 or Th2-dominancy may lead to the development of delayed-type hypersensitivity responses
or enhance susceptibility for IgE-mediated allergic sensitization, respectively. Adjuvant effects on allergic
sensitization and exacerbation of asthmatic elicitation responses can also emerge as a result of
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respiratory NiO exposure. Exacerbation of respiratory allergy can involve the modulation of any number
of diverse immunological mechanisms, some of which are specific to the sensitization phase of allergy,
whereas others are specific to the elicitation phase. Likewise, the immunomodulatory potential of NiO
may differ depending on the sensitization status of the exposed individual. Moreover, as emphasized by
the results from our study, specific physico-chemical properties may be differentially implicated in the
immunological activity of NiO nanoparticles depending on the phase of allergic disease during which
exposure occurs, the route of exposure, and the existence of concomitant disease states.

2.6. Conclusion
The results from the NiO time course study are consistent with existing studies, demonstrating a
correlation between the surface area of metal nanomaterials and subsequent inflammatory response
severity. However, the OVA study indicated that, in addition to surface area, other metrics related to NiO
size were influential in the alteration of both local and systemic immune markers associated with IgEdependent asthmatic responses. Further study is needed to determine role of dissolution as it relates to
surface area and particle toxicity, particularly in different compartments in the lung such as acidic
environments such is in the macrophage vacuoles. Since toxic effects of nanomaterials are heavily
dependent on the biochemical properties of their environment, this observation emphasizes that the
altered chemistry of asthmatic airways may implicate different mechanisms of toxicity than those typically
observed in non-asthmatic lungs. This finding is likely applicable to other disease states, wherein the
toxic effects of metal nanomaterials may be differentially correlated to physico-chemical properties in
healthy and diseased tissues.
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CHAPTER 2 TABLES

Table 2.1. NiO Time Course Study Treatment Groups
Particle

Primary
particle
size

Dose
mass

Dose
SA

DM

-

-

-

-

NiO-1

NiO-F

181 nm

40 µg

192 mm2

NiO-2

NiO-UF

42 nm

3 µg

192 mm2

NiO-3

NiO-UF

42 nm

40 µg

2,580 mm2

Treatment
Group

Table 2.1. NiO time course study treatment groups and corresponding exposure particle, size, dose mass, and
dose surface area (SA).
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Table 2.2. Summary of NiO-F and NiO-UF Characterization Results
NiO-F

NiO-UF

-325 mesh

50 nm

green

black/gray

181 ± 37 nm

42 ± 7 nm

FESEM

640 nm

190 nm

DLS

321 nm

109 nm

irregular, jagged

spherical

4.79 ± 0.27

64.49 ± 2.98

Ni : O ratio

1:1

1 : 1.3

Endotoxin level

ND

ND

-8.42 ± 2.20

-6.23 ± 2.45

Vendor size specification
Particle color
Primary particle size (FESEM)
Average agglomerate size:

Morphology
Specific surface area (m2/g)

Zeta Potential (mV)

Table 2.2. Summary of NiO-F and NiO-UF characterization data. ND- Not Detected.
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Table 2.3. NiO Time Course Study
Lymph Node Cell Phenotypes by Percent of Total Cells
Time

1d

10d

19d

29d

Group
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3

Total Cell #
(x106)

Cell Populations by Phenotype (% of total cells)
CD4+ T-cells

CD8+ T-cells

B-cells

Other

3.33
4.70
4.81
5.70

±
±
±
±

1.51
1.61
1.44
2.20

51.6
52.3
53.4
49.7

±
±
±
±

4.56
6.21
4.14
7.85

21.1
19.8
20.0
21.2

±
±
±
±

2.33
2.98
3.02
2.24

15.1
14.2
16.5
12.3

±
±
±
±

2.22
2.10
3.12
1.74

12.2
13.7
10.1
16.8

±
±
±
±

3.2
2.1
1.8
2.1

3.09
5.08
5.22
11.96

±
±
±
±

1.51
1.62
1.64
3.11 *

51.8
48.6
49.9
47.5

±
±
±
±

5.55
5.47
5.12
6.23

20.6
23.4
20.8
20.9

±
±
±
±

2.56
3.02
3.11
2.13

14.4
15.5
17.7
16.4

±
±
±
±

2.01
1.66
1.04
3.17

13.2
12.5
11.6
15.2

±
±
±
±

2.2
2.1
2.0
2.2

3.64
8.27
8.41
13.28

±
±
±
±

1.34
2.17 #
3.29 #
2.34 *

53.0
50.7
50.1
51.1

±
±
±
±

7.45
5.12
6.11
5.23

24.5
22.1
22.7
20.8

±
±
±
±

3.64
3.02
2.99
2.47

15.0
15.2
14.2
16.2

±
±
±
±

2.25
2.77
2.09
2.11

7.5
12.0
13.0
11.9

±
±
±
±

1.5
2.6
2.7
1.9

2.98
6.26
9.51
10.71

±
±
±
±

1.02
1.97 #
2.11 ^
3.31 ^

54.0
50.0
52.2
53.1

±
±
±
±

4.11
6.10
5.05
4.99

20.9
21.9
21.1
20.3

±
±
±
±

2.66
3.07
4.03
2.70

15.5
14.2
13.9
12.8

±
±
±
±

1.98
2.08
1.46
1.77

9.6
13.9
12.8
13.8

±
±
±
±

1.8
1.1
2.9
3.0

Table 2.3. Lymphocyte differentials for each treatment group at each time point in the NiO time course study
expressed as a percentage of total lymph node cells. n = 8 per group, p < 0.05. * indicates statistical significance
over all other groups at the corresponding time point; # indicates statistical significance over DM; ^ indicates
statistical significance over DM, NiO-1.
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Table 2.4. NiO Time Course Study
Spleen Cell Phenotypes by Percent
Time

1d

10d

19d

29d

Group

DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3

CD4+ T-cells

CD8+ T-cells

B-cells

NK Cells

Other

17.8

±

2.4 %

12.2

±

1.2 %

56.1

±

14.2 %

2.31

±

0.2 %

11.6

±

1.2 %

16.4

±

3.1 %

15.4

±

1.3 %

55.6

±

9.8 %

3.12

±

0.1 %

9.5

±

1.0 %

19.2

±

2.5 %

13.4

±

1.1 %

53.3

±

12.4 %

3.02

±

0.1 %

12.1

±

1.5 %

15.4

±

1.9 %

14.6

±

1.0 %

55.4

±

8.5 %

2.98

±

0.2 %

7.8

±

1.0 %

16.4

±

1.8 %

12.2

±

1.6 %

54.7

±

9.6 %

3.46

±

0.4 %

13.2

±

2.0 %

14.9

±

1.7 %

14.8

±

1.9 %

56.7

±

8.7 %

4.10

±

0.6 %

9.5

±

1.1 %

13.7

±

1.6 %

13.9

±

1.2 %

57.2

±

7.0 %

2.39

±

0.1 %

12.8

±

1.3 %

16.4

±

2.0 %

12.9

±

1.7 %

55.5

±

8.8 %

2.77

±

0.3 %

12.4

±

1.2 %

16.9

±

2.0 %

14.0

±

2.0 %

53.3

±

6.5 %

3.46

±

0.2 %

12.3

±

2.0 %

17.7

±

2.0 %

15.0

±

1.8 %

54.7

±

11.1 %

4.11

±

0.5 %

8.5

±

2.1 %

16.4

±

1.9 %

11.9

±

0.9 %

56.5

±

10.2 %

4.09

±

0.4 %

11.1

±

1.6 %

15.0

±

1.6 %

12.9

±

1.7 %

58.7

±

8.5 %

3.67

±

0.6 %

9.7

±

0.8 %

16.7

±

2.1 %

13.5

±

2.0 %

55.7

±

6.7 %

2.88

±

0.1 %

11.2

±

1.1 %

16.0

±

1.8 %

13.6

±

1.3 %

55.2

±

8.8 %

3.46

±

0.2 %

11.7

±

1.7 %

15.2

±

2.2 %

16.6

±

1.3 %

55.9

±

8.1 %

3.44

±

0.5 %

8.9

±

2.1 %

14.4

±

1.8 %

15.8

±

1.4 %

57.8

±

9.9 %

2.77

±

0.4 %

9.2

±

0.7 %

Table 2.4. Spleen cell phenotypes for each group at each time point in the NiO time course study expressed as a
percent of total cells in the spleen. n = 8 per group.
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Table 2.5. NiO Time Course Study: Serum/BALF Cytokine Levels (pg/mL)
IFN-γ

IL-2

IL-12p40

IL-17

IL-12p70

TNF-α

GM-CSF

IL-4

IL-5

IL-13

Eotaxin

IL-6

IL-10

29d

19d

10d

1d

Serum
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3

10.1
11.2
14.9
20.7
16.4
11.7
12.2

DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3

2.3
2.0
2.1
3.1

±
±
±
±
±
±
±

2.1
2.5
3.3
5.2^
2.4
2.0
2.5

4.4
3.0
5.9
4.0
2.3
3.9
1.7

±
±
±
±
±
±
±

1.4
1.4
2.2
2.1
1.0
0.6
0.6

43.2
56.2
61.4
66.6
40.7
50.1
52.9

±
±
±
±
±
±
±

16.2
17.1
26.7
15.5
14.1
16.1
14.2

25.7
24.9
19.6
30.2
25.6
24.7
22.3

±
±
±
±
±
±
±

13.6
6.6
5.7
6.9
6.1
8.5
12.7

30.9 ± 5.7*
11.8 ± 1.5
9.6 ± 2.2

5.0 ± 0.5
2.3 ± 0.5
2.2 ± 0.4

53.4 ± 15.5
49.8 ± 14.7
51.7 ± 15.4

28.4 ± 10.7
22.7 ± 6.2
23.8 ± 4.9

8.7
22.1
8.7
7.6

2.0
2.9
4.4
7.1

56.2
39.6
55.2
67.1

22.1
28.8
19.8
18.7

±
±
±
±

0.8
0.7*
1.5
1.6

9.3 ± 2.0
12.7 ± 2.3

±
±
±
±

0.7
0.6
0.9
2.0

±
±
±
±

12.0
16.1
12.7
24.2

2.9 ± 1.0
3.7 ± 1.7

43.2 ± 26.1
55.5 ± 26.5

5.6
6.4
8.1
9.1

14.2
18.7
15.2
20.1

±
±
±
±

5.8
4.7
3.0
6.9

12.0
10.3
8.6
6.7
11.0
11.7
6.4

±
±
±
±
±
±
±

1.7
3.0
1.8
1.1
2.9
3.2
2.7

8.2 ± 2.9
9.6 ± 4.1
8.3 ± 2.8
7.7
11.2
10.3
5.5

21.3 ± 5.8
24.1 ± 4.2

±
±
±
±

2.9
1.8
4.1
2.6

7.8 ± 1.5
9.1 ± 3.2

8.0
6.4
7.6
4.6
10.5
11.7
6.1

±
±
±
±
±
±
±

2.4
1.9
1.8
1.1
0.9
1.7
1.1

34.2
30.1
28.8
29.0
26.0
24.2
32.1

±
±
±
±
±
±
±

5.0
7.1
4.7
7.9
3.4
4.5
6.6

7.6
5.1
4.8
5.9
5.4
4.7
6.0

±
±
±
±
±
±
±

2.1
2.4
2.7
1.0
2.0
1.2
2.0

31.4
40.2
32.7
28.9
36.7
28.8
29.1

±
±
±
±
±
±
±

5.1
9.6
8.5
5.9
4.2
7.0
8.0

50.1
45.2
40.1
52.3
45.6
46.7
61.2

±
±
±
±
±
±
±

16.2
17.4
16.1
14.0
11.8
9.4
147

420
504
525
539
552
550
456

±
±
±
±
±
±
±

45.2
50.1
36.6
29.8
28.5
37.2
49.6

42.3
41.1
29.8
34.7
26.8
30.7
28.6

±
±
±
±
±
±
±

15.4
14.0
6.5
10.0
9.1
6.5
7.1

16.0
15.7
20.9
14.4
15.2
16.9
17.4

±
±
±
±
±
±
±

2.1
3.0
8.9
3.2
3.4
2.1
2.2

17.1 ± 3.0
10.2 ± 2.1
6.2 ± 0.6

31.7 ± 5.9
30.1 ± 5.0
30.9 ± 8.7

8.1 ± 3.1
3.1 ± 1.0
2.9 ± 0.9

30.7 ± 5.1
31.8 ± 5.0
26.8 ± 4.5

53.2 ± 20.1
55.8 ± 18.5
49.6 ± 12.7

439 ± 53.0
504 ± 31.1
433 ± 55.4

32.1 ± 4.7
35.5 ± 8.3
41.2 ± 8.4

22.1 ± 2.9
20.0 ± 2.7
16.7 ± 2.5

5.7
20.7
11.4
7.7

26.7
27.1
25.7
29.9

5.5
4.7
6.1
2.3

29.7
31.1
30.6
26.5

48.8
53.2
52.3
55.4

512
485
487
463

40.3
33.9
30.2
40.1

17.2
19.9
16.0
14.3

±
±
±
±

1.0
1.9*
2.3
2.6

12.2 ± 2.1
9.6 ± 0.9

±
±
±
±

6.4
4.9
5.1
8.3

33.7 ± 6.4
31.0 ± 6.7

±
±
±
±

0.5
0.7
0.5
0.5

3.9 ± 1.1
4.8 ± 1.0

±
±
±
±

3.7
3.6
5.1
7.0

±
±
±
±

15.5
16.3
15.7
14.5

±
±
±
±

65.6
20.0
68.7
37.4

32.7 ± 5.0
27.1 ± 4.4

46.2 ± 13.2
49.8 ± 18.8

503 ± 45.0
522 ± 26.0

88.8
90.5
101
108

12.2
12.3
12.0
12.0

25.2
30.2
25.7
22.3

±
±
±
±

7.7
7.1
10.5
6.1

29.8 ± 5.2
33.6 ± 8.8

±
±
±
±

4.8
4.6
3.7
4.2

21.1 ± 5.5
18.1 ± 2.6

29d

19d

10d

1d

BALF
±
±
±
±

0.7
0.8
0.5
0.2

3.9 ± 0.9
4.0
5.9
16.2
3.0
7.5

±
±
±
±
±

0.6
1.5
4.7*
1.0
3.1

9.7 ± 1.5#
22.9 ± 4.2*
2.0
3.0
1.9
20.1

±
±
±
±

0.3
0.2
0.6
5.6*

±
±
±
±

3.2
2.3
3.8
4.7

4.4 ± 0.6
6.5
5.0
10.1
2.1
5.4

±
±
±
±
±

0.5
0.4
0.9*
0.6
0.5

4.8 ± 0.4
11.9 ± 0.9
5.2
6.7
5.9
8.8

±
±
±
±

1.4
2.9
0.9
0.8

±
±
±
±

4.5
3.4
1.9
3.9

5.1
6.1
7.0
6.3

±
±
±
±

3.6
2.9
2.0
1.9

0.9
1.0
1.2
1.3

±
±
±
±

0.2
0.3
0.1
0.2

15.3 ± 4.5

6.7 ± 2.9

1.1 ± 0.2

16.7
29.7
22.7
17.3
37.4

5.2
4.1
5.0
5.1
6.2

1.7
3.8
2.1
2.0
1.3

±
±
±
±
±

2.9
3.4^
5.7
4.2
5.8*

±
±
±
±
±

2.4
2.9
3.7
2.5
2.9

±
±
±
±
±

0.1
1.0
0.2
0.3
0.3

21.5 ± 3.2
18.7 ± 2.1

5.1 ± 3.4
4.1 ± 2.7

1.8 ± 0.4
5.2 ± 0.5*

16.7
22.2
18.1
21.1

4.8
5.4
6.2
8.7

1.8
2.5
1.3
3.8

±
±
±
±

3.4
2.5
1.2
6.3

±
±
±
±

4.1
2.9
1.9
3.0

±
±
±
±

3.2
3.0
2.1
4.0

±
±
±
±

0.3
0.4
0.5
1.2

4.1 ± 1.4
5.1
2.3
11.7
5.0
3.2

±
±
±
±
±

2.2
1.3
3.9*
1.4
0.5

2.9 ± 0.9
12.0 ± 5.0*

0.2
4.0
0.6
2.5
0.5
6.1
0.6+ 10.2

±
±
±
±

1.0
0.4
0.9
2.8*

Th1/17 Cytokines

2.4
3.6
3.4
3.7

±
±
±
±

0.4
0.2
0.6
0.5

35.6
36.1
40.3
30.9

±
±
±
±

11.4
9.9
6.9
5.9

±
±
±
±

11.2
15.4
12.7
16.2

±
±
±
±

1.9
2.3
3.2
4.0

±
±
±
±

2.9
4.8
5.8
6.0

2.0 ± 0.2

30.3 ± 5.8

92.8 ± 15.4

12.0 ± 2.3

26.3 ± 5.5

2.2
2.9
2.9
1.9
2.0

29.2
34.9
31.8
34.8
42.7

78.4
77.9
115
102
108

12.7
11.9
10.9
10.8
21.1

39.6
31.4
27.5
26.9
24.7

±
±
±
±
±

0.1
0.2
0.2
0.3
0.5

±
±
±
±
±

5.4
6.0
4.1
3.9
8.2$

±
±
±
±
±

16.2
10.9
9.5
8.5
11.4

±
±
±
±
±

4.1
2.9
2.8
5.1
4.0*

±
±
±
±
±

3.9*
4.5
8.8
9.5
6.6

5.2
5.2
6.7
9.3

±
±
±
±

1.0
1.0
1.0
2.0

6.3 ± 1.0
5.6
6.4
15.5
5.9
4.7

±
±
±
±
±

0.7
1.5
3.0*
0.2
1.4

21.0
20.9
22.1
22.3

±
±
±
±

3.6
3.9
2.8
5.2

19.8 ± 3.4
28.7
20.6
24.3
19.1
24.8

±
±
±
±
±

3.5+
4.5
5.5
2.8
6.5

2.7 ± 0.2
3.8 ± 0.1

55.1 ± 8.6$
30.1 ± 9.1

170 ± 21.4+ 11.6 ± 3.2
96.4 ± 12.5 12.7 ± 2.0

26.5 ± 5.2
25.0 ± 6.7

6.5 ± 1.2
8.0 ± 3.3

22.6 ± 4.4
23.0 ± 3.2

3.0
2.4
2.5
4.0

29.8
33.3
34.0
30.5

102
85.7
95.7
94.7

22.3
22.1
22.9
23.8

4.3
4.1
4.9
9.8

23.0
22.1
28.9
25.1

±
±
±
±

1.0
0.6
0.5
0.4

±
±
±
±

8.5
10.1
8.0
5.9

±
±
±
±

14.0
16.5
18.5
12.8

12.1
10.8
11.5
11.4

±
±
±
±

Th2 Cytokines

1.9
2.2
2.3
3.7

±
±
±
±

5.2
3.2
3.6
3.9

±
±
±
±

0.6
0.7
0.6
2.4*

±
±
±
±

3.4
5.5
2.2
3.1

Other

Table 2.5. Raw values of serum and BALF cytokine levels for each treatment group at 1, 10, 19, and 29 days post NiO aspiration in the NiO time course
study. n = 8 per group, p < 0.05. * indicates statistical significance over all other groups at the corresponding time point; # indicates statistical significance
over DM; ^ indicates statistical significance over DM, NiO-1; + indicates significance over DM, NiO-2; $ indicates statistical significance over DM and NiO-3.
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Table 2.6. NiO Time Course Study
Whole Blood Cell Differentials
RBC WBC
(M/uL) (k/uL)

1d

10d

19d

29d

DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3
DM
NiO-1
NiO-2
NiO-3

Cell Number (k/uL)
Neutr Lymph Mono Eos

Baso

% of Total WBC
Neutr Lymph Mono Eos

Baso

9.27

2.18

0.77

1.38

0.01

0.02

0.00

35.32% 63.30%

0.46%

0.92%

0.00%

9.65

2.48

0.88

1.56

0.01

0.03

0.00

35.48% 62.90%

0.40%

1.21%

0.00%

9.76

2.00

0.54

1.44

0.01

0.01

0.00

27.00% 72.00%

0.50%

0.50%

0.00%

9.55

2.54

0.99

1.51

0.02

0.02

0.00

38.98% 59.45%

0.79%

0.79%

0.00%

9.67

2.17

1.02

1.09

0.02

0.03

0.01

47.00% 50.23%

0.92%

1.38%

0.46%

9.65

2.48

1.11

1.33

0.02

0.02

0.00

44.76% 53.63%

0.81%

0.81%

0.00%

9.76

3.59

1.56

1.99

0.03

0.01

0.00

43.45% 55.43%

0.84%

0.28%

0.00%

9.81

2.78

1.10

1.65

0.01

0.01

0.01

39.57% 59.35%

0.36%

0.36%

0.36%

9.13

2.29

1.02

1.24

0.01

0.02

0.00

44.54% 54.15%

0.44%

0.87%

0.00%

9.15

2.87

1.26

1.56

0.02

0.03

0.00

43.90% 54.36%

0.70%

1.05%

0.00%

9.52

3.15

1.46

1.66

0.02

0.01

0.00

46.35% 52.70%

0.63%

0.32%

0.00%

9.87

2.32

1.19

1.11

0.01

0.01

0.00

51.29% 47.84%

0.43%

0.43%

0.00%

9.31

2.28

0.99

1.25

0.01

0.02

0.01

43.42% 54.82%

0.44%

0.88%

0.44%

9.55

3.15

1.34

1.78

0.00

0.03

0.00

42.54% 56.51%

0.00%

0.95%

0.00%

9.46

2.57

1.09

1.46

0.01

0.01

0.00

42.41% 56.81%

0.39%

0.39%

0.00%

9.60

3.09

1.49

1.55

0.02

0.02

0.01

48.22% 50.16%

0.65%

0.65%

0.32%

Table 2.6. Whole blood cellular differentials from the NiO time course study at each time point for each treatment
group. Number of red blood cells (RBC) and white blood cells (WBC) are reported in addition to absolute number of
neutrophils (neutr), lymphocytes (lymph), monocytes (mono), eosinophils (eos), and basophils (baso) and percent
of each cell type comprising the total WBC population. n = 8 per group.
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1d

10d

19d

29d

DM
NiO-1
NiO-3
DM
NiO-1
NiO-3
DM
NiO-1
NiO-3
DM
NiO-1
NiO-3

Hemorrhage

Foreign
material
Airways

Exudate
airways

Infiltration
Neutrophil
peribronchiolar/
perivascular

Edema
peribronchiolar/
perivascular

Infiltration
mixed cell
peribronchiolar/
perivascular

Black/brown
particles in
In alveolar
macrophages

Accumulation
alveolar
macrophages

Table 2.7. NiO Time Course Study
Lung Histopathology Summary

1,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,0,0,0,0,0

1,1,1,1,1,1 #

0,0,0,0,0,0

2,0,0,0,0,0

2,0,0,0,0,0

3,0,0,0,0,0

2,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,1,1,1,1,1 #

1,1,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,1,1,1,1,1 #

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,1,1,0,0,0

1,1,1,1,1,1 #

3,3,2,1,1,0 *

1,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,1,1,1,1,1 #

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,1,0,0,0,0

1,1,1,1,1,1 #

2,2,2,1,1,1 *

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,1,1,1,1,1 #

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,0,0,0,0,0

1,1,1,1,1,1 #

2,1,1,0,0,0 *

1,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

2,0,0,0,0,0

Table 2.7. Summary of histopathological findings from lungs of DM, NiO-1 (40 µg fine particle), and NiO-3 (40 µg
ultrafine particle) groups at 1, 10, 19, and 29 days post-exposure in the NiO time course study. Scores for each
animal are compiled for each treatment group and histopathological finding. Scale: n = normal, 1 = minimal, 2 = mild,
3 = moderate, 4 = marked, 5 = severe. n = 6 per group, p < 0.05. # indicates statistical significance over DM at the
corresponding time point; * indicates significance over all groups.
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Table 2.8. Day 29 NiO OVA Asthma Model
BAL Cell Differentials
Absolute Number
Group
DM
NiO-1
NiO-2
NiO-3
OVA
NiO-1A
NiO-2A
NiO-3A

Total BAL Cells

AM

Lymph

PMN

Eos

1,187,750 ±

213,023

1,187,026

± 37,985

2,724

±

423

12,455

±

988

541

±

89

1,437,375 ±

199,621

1,385,205

± 60,949

9,958

±

1,222

42,212

±

6,215

411

±

51

1,437,375 ±

333,101

1,385,205

± 81,727

9,958

±

1,556

42,212

±

4,179

351

±

64

1,965,125 ±

210,009

1,907,258

± 76,290

17,783

±

2,477

40,084

±

3,210

711

±

101

2,933,923 ±

321,117

1,165,248

± 25,632

182,631

±

22,455

1,354,392

±

142,102

231,652

±

29,666

3,009,237 ±

314,455

1,507,294

±

48,322

190,982

±

33,899

1,014,414

±

130,220

296,547

±

33,710

3,404,743 ±

288,917

1,602,344

± 65,969

201,247

±

37,411

1,002,411

±

99,851

598,741

±

46,600

3,466,690 ±

356,098

1,021,951

± 31,680

332,331

±

29,100

1,505,600

±

165,740

606,808

±

52,179

Percentage
DM
NiO-1
NiO-2
NiO-3
OVA
NiO-1A
NiO-2A
NiO-3A

1,187,750 ±

213,023

1,437,375 ±

199,621

1,437,375 ±

333,101

1,965,125 ±

210,009

2,933,923 ±

321,117

3,009,237 ±

314,455

3,404,743 ±

288,917

3,466,690 ±

356,098

98.7
96.3
96.3
97.0

±
±
±
±

3.2 %
4.4 %
5.9 %
4.0 %

0.2
0.7
0.7
0.9

±
±
±
±

0.0 %
0.1 %
0.1 %
0.1 %

1.0
2.9
2.9
2.0

±
±
±
±

0.0 %
0.3 %
0.2 %
0.1 %

0.0
0.0
0.0
0.0

±
±
±
±

0.0 %
0.0 %
0.0 %
0.0 %

39.7
50.1
47.1
29.5

±
±
±
±

2.2 %
3.2 %
4.1 %
3.1 %

6.2
6.3
5.9
9.6

±
±
±
±

0.6 %
0. 7%
0.7 %
0.8 %

46.2
33.7
29.4
43.4

±
±
±
±

3.3 %
4.1 %
5.1 %
6.1 %

7.9
9.9
17.6
17.5

±
±
±
±

0.8 %
1.1 %
3.1 %
2.1 %

Table 2.8. BAL cell differentials for each treatment group at 29 d in the NiO OVA model by absolute number and
percent of total BAL cells. AM = alveolar macrophage, lymph = lymphocytes, PMN = neutrophils, Eos = eosinophils.
n = 8 per group.
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Table 2.9. Day 29 NiO OVA Asthma Model
Lymph Node Cell Phenotypes by Percent of Total Cells
Group
DM
NiO-1
NiO-2
NiO-3
OVA
NiO-1
NiO-2
NiO-3

Total LN Cells
3,873,973
5,856,315
5,428,942
7,552,486
11,756,798
16,192,731
18,874,551
30,939,970

±
±
±
±
±
±
±
±

499,632
569,478 c
442,989 c
1,110,222 b
1,420,407 a
2,033,177 d
1,956,100 d
6,296,222 e

CD4+ T-cells
55.2
54.8
55.9
57.9
36.8
38.5
35.9
55.5

±
±
±
±
±
±
±
±

CD8+ T-cells

4.1%
3.0%
3.2%
2.9%
3.0% f
2.9% f
2.8% f
4.1%

14.2
15.2
13.7
15.3
13.3
15.1
14.3
13.6

±
±
±
±
±
±
±
±

3.1%
2.3%
2.0%
2.8%
1.9%
2.8%
2.7%
1.7%

B-cells
26.1
27.9
30.2
28.0
44.3
45.0
48.5
31.8

±
±
±
±
±
±
±
±

3.0%
2.9%
3.5%
2.5%
4.0% f
3.9% f
5.0% f
4.2%

Other
4.5
5.0
6.3
5.7
5.6
4.4
6.3
6.1

±
±
±
±
±
±
±
±

1.4%
1.0%
2.5%
2.4%
1.8%
0.8%
1.6%
1.4%

Table 2.9. Total cell number in the mediastinal lymph nodes and percentages of each lymphocyte population for
each treatment group at 29 d in the NiO OVA model. n = 8 per group, p < 0.05. a indicates statistical significance
over all non-sensitized groups; b indicates statistical significance over DM, NiO-1, NiO-2; c indicates statistical
significance over DM; d indicates statistical significance over all non-sensitized groups, OVA; e indicates statistical
significance over all other groups; f indicates statistical significance over all non-sensitized groups, NiO-3A.
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Table 2.10. Day 29 NiO OVA Asthma Model
Spleen Cell Phenotypes by Percent of Total Cells
Group
DM
NiO-1
NiO-2
NiO-3
OVA
NiO-1A
NiO-2A
NiO-3A

CD4+ T-cells

CD8+ T-cells

B-cells

NK Cells

Other

31.2
32.1
28.1
25.1

±
±
±
±

3.4 %
3.1 %
2.7 %
3.0 %

12.1
14.3
11.1
15.0

±
±
±
±

1.0 %
1.4 %
1.0 %
2.0 %

52.1
49.1
55.2
55.4

±
±
±
±

10.2 %
9.9 %
7.1 %
5.5 %

2.3
1.9
2.2
2.0

±
±
±
±

0.2 %
0.2 %
0.1 %
0.0 %

2.3
2.6
3.4
2.5

±
±
±
±

0.1 %
0.1 %
0.2 %
0.0 %

27.7
24.1
26.6
38.2

±
±
±
±

2.1 %
1.9 %
1.7 %
2.9 %

9.4
8.7
14.0
20.2

±
±
±
±

1.1 %
1.3 %
1.4 %
1.7 %

60.1
61.2
55.9
38.1

±
±
±
±

6.6 %
10.7 %
7.7 %
8.9 %

1.3
3.0
1.9
1.7

±
±
±
±

0.0 %
0.1 %
0.2 %
0.1 %

1.5
3.0
1.6
1.8

±
±
±
±

0.1 %
0.2 %
0.3 %
0.2 %

Table 2.10. Spleen cell differentials for each treatment group at 29 d in the NiO OVA model expressed as percent
of total spleen cells.
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Table 2.11. Day 29 NiO OVA Model: Serum/BALF Cytokine Levels (pg/mL)
IFN-γ

IL-2

IL-12p40

IL-12p70

IL-17

TNF-α

GM-CSF

IL-4

IL-5

IL-13

Eotaxin

IL-6

IL-10

SERUM
DM
NiO-1
NiO-2
NiO-3
OVA
NiO-1A
NiO-2A
NiO-3A

12.9
10.5
13.8
10.3
14.7

±
±
±
±
±

3.0
3.1
3.3
2.3
2.0

4.1
3.7
5.6
4.2
6.2

±
±
±
±
±

2.1
2.6
1.6
1.2
1.7

42.2
35.2
35.7
46.0
109

±
±
±
±
±

19.2
14.5
10.7
13.7
19.2a

22.2
26.8
29.7
30.1
66.5

±
±
±
±
±

4.0
8.6
6.2
5.8
15.2a

12.2
14.9
9.9
10.1
13.7

±
±
±
±
±

2.0
1.6
0.6
2.8
2.9

3.1 ± 0.5e
10.0 ± 1.6
23.4 ± 3.2e

7.9 ± 1.8
11.1 ± 3.0a
18.7 ± 2.0e

109 ± 31.1a 160 ± 15.5e 18.8 ± 3.2
132 ± 41.0a 123 ± 17.6d 22.1 ± 3.6g
230 ± 44.7e 98.7 ± 17.8a 16.6 ± 3.2

4.4 ± 1.0
2.7 ± 1.2
2.6 ± 0.9

5.6 ± 2.5
6.7 ± 1.8
10.1 ± 2.2

14.8 ± 3.6
15.5 ± 3.1
14.2 ± 2.0

9.7 ± 3.0
4.2 ± 2.0
6.5 ± 2.0

1.6 ± 0.5
1.4 ± 0.3
1.4 ± 0.7

11.0
22.3
15.2
13.9
54.8

13.2
19.8
15.5
16.0
25.4

7.1
4.7
3.5
5.2
6.7

1.6
1.2
2.0
2.1
5.5

6.5
8.8
5.7
10.0
34.7

±
±
±
±
±

2.0
2.4
2.9
3.6
3.9a

25.3 ± 5.4a
29.2 ± 4.5a
40.1 ± 6.4h

33.1
32.2
28.0
28.0
175

±
±
±
±
±

4.9
10.2
5.3
6.6
15.1a

170 ± 14.7a
176 ± 16.6a
181 ± 15.4a

6.9
4.8
5.7
4.0
3.0

±
±
±
±
±

2.4
1.3
1.4
0.5
2.0

5.2 ± 1.7
6.1 ± 1.7
2.8 ± 1.1i

32.4
41.1
39.1
39.9
206

±
±
±
±
±

11.9
12.0
20.0
13.1
16.5a

49.8
52.5
46.8
49.0
553

±
±
±
±
±

12.1
21.0
19.7
18.1
56.4a

464
502
498
526
1002

±
±
±
±
±

99.1
93.2
64.1
82.4
100a

214 ± 17.1a
220 ± 15.5a
141 ± 18.0e

518 ± 51.1a
596 ± 50.2a
510 ± 44.7a

989 ± 96.4a
896 ± 88.7a
999 ± 102a

33.3 ± 6.2
45.2 ± 10.4
33.2 ± 11.0

102 ± 19.8
99.8 ± 20.1
77.5 ± 15.2

13.4 ± 3.3
14.0 ± 4.2
12.5 ± 5.0

25.5 ± 3.0
24.5 ± 4.0
23.7 ± 6.9

40.8
78.4
572
568
117

105
472
512
501
452

14.4
25.5
32.7
29.1
18.3

22.1
70.9
74.9
80.1
82.3

34.5
30.7
27.3
29.6
37.1

±
±
±
±
±

6.8
4.4
5.4
4.0
6.7

39.1 ± 13.8
47.1 ± 13.9
24.1 ± 5.6j

17.6
17.5
18.5
15.1
112

±
±
±
±
±

8.1
5.1
5.5
6.6
12.8a

105 ± 11.2a
130 ± 18.4a
88.4 ± 9.1a

BALF
DM
NiO-1
NiO-2
NiO-3
OVA
NiO-1A
NiO-2A
NiO-3A

12.2
7.1
6.5
9.9
32.1

±
±
±
±
±

2.2b
3.1b
1.0a
2.1b
8.1e

±
±
±
±
±

3.1
5.3a
4.8k
3.1 l
8.1e

±
±
±
±
±

4.9
4.5
4.2
4.0
6.7a

±
±
±
±
±

2.8
2.0
1.0
2.1
2.8

±
±
±
±
±

0.5
0.4
0.5
0.5
1.2e

4.2 ± 1.5
2.2 ± 1.1
4.8 ± 1.2
11.1
17.0
15.4
16.2
18.8

±
±
±
±
±

5.1 ± 1.1
3.2 ± 1.0
5.1 ± 2.2

2.8b
3.2b
2.4b
2.7b
2.7b

4.2
10.1
8.2
9.1
6.3

Th1/17 Cytokines

±
±
±
±
±

2.0
2.9a
2.8a
2.0a
3.2

±
±
±
±
±

9.8
16.4a
165g
175g
19.2d

±
±
±
±
±

30.2
65.1a
119a
108a
123a

±
±
±
±
±

Th2 Cytokines

3.2
5.0a
5.2a
6.7a
4.1m

±
±
±
±
±

5.0
11.4a
12.7a
20.2a
38.1a

3.5 ± 1.3
4.4 ± 1.2
6.5 ± 1.0
8.5
58.9
111
356
99.8

±
±
±
±
±

3.7
14.7a
22.2d
93.2e
20.7d

25.2 ± 5.0
21.0 ± 4.0
19.1 ± 3.3
18.2
41.4
44.0
45.1
36.2

±
±
±
±
±

5.0
6.6a
10.7a
11.8a
7.7a

Other

Table 2.11. Raw values of serum and BALF cytokine levels for each treatment group at 29 d of the NiO OVA model. n = 8, p < 0.05. a indicates statistical
significance over all non-sensitized groups; b indicates statistical significance over DM, NiO-1, NiO-2; d indicates statistical significance over all nonsensitized groups, OVA; e indicates statistical significance over all other groups; g indicates statistical significance over all non-sensitized groups, OVA, NiO3A; h indicates statistical significance over all non-sensitized groups, NiO-1A; i indicates statistical significance over all non-sensitized groups, NiO-2A; j
indicates statistical significance over OVA, NiO-1A, NiO-2A; k indicates statistical significance over DM, NiO-1; l indicates statistical significance over DM,
NiO-1, OVA.
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Table 2.12. Day 29 NiO OVA Asthma Model
Whole Blood Cell Differentials
RBC WBC
(M/uL) (k/uL)
DM
NiO-1
NiO-2
NiO-3
OVA
NiO-1A
NiO-2A
NiO-3A

9.74
9.73
9.94
9.69
9.60
9.78
9.97
9.88

2.08
2.20
1.64
2.12
2.17
2.45
2.72
2.64

Cell Number (k/uL)

% of Total WBC

Neutr Lymph Mono

Eos

Baso

Neutr Lymph Mono

Eos

Baso

0.76

1.19

0.03

0.10

0.00

36.54% 57.21% 1.44%

4.81%

0.00%

1.11

1.05

0.01

0.03

0.00

50.45% 47.73% 0.45%

1.36%

0.00%

0.56

1.01

0.06

0.01

0.00

34.15% 61.59% 3.66%

0.61%

0.00%

1.03

0.99

0.08

0.02

0.00

48.58% 46.70% 3.77%

0.94%

0.00%

0.44

1.56

0.07

0.09

0.01

20.28% 71.89% 3.23%

4.15%

0.46%

0.52

1.78

0.08

0.05

0.02

21.22% 72.65% 3.27%

2.04%

0.82%

0.56

2.01

0.09

0.05

0.01

20.59% 73.90% 3.31%

1.84%

0.37%

0.61

1.88

0.08

0.06

0.01

23.11% 71.21% 3.03%

2.27%

0.38%

Table 2.12. Whole blood cellular differentials from the NiO OVA model for each treatment group. Number of red
blood cells (RBC) and white blood cells (WBC) are reported in addition to absolute number of neutrophils (neutr),
lymphocytes (lymph), monocytes (mono), eosinophils (eos), and basophils (baso) and percent of each cell type
comprising the total WBC population. n = 6 per group.
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Infiltration
mixed cell
peribronchiolar/perivascular

Black/brown particles in
In alveolar macrophages

Accumulation
Macrophages, eosinophil, neutrophil
in alveolar lumens

Bronchiole epithelium hypertrophy

Multi-nucleated giant cells

Macrophage vacuolation

Edema
peribronchiolar/perivascular

Exudate
airways

Macrophages, neutrophils
at terminal bronchiole/alveolar duct

Hemorrhage

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,1,0,0,0,0

0,0,0,0,0,0

1,1,0,0,0,0

1,1,1,1,1,1 c

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,0,0,0,0,0

0,0,0,0,0,0

1,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,1,1,1,1 c

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,0,0,0,0,0

1,0,0,0,0,0

0,0,0,0,0,0

1,1,1,1,1,0 b

1,1,1,1,1,1 c

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

1,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

2,2,2,2,2,2 a

0,0,0,0,0,0

1,1,1,1,1,1 c

1,1,1,1,1,1 a

1,1,1,1,1,1 a

0,0,0,0,0,0

1,1,1,1,1,1 a

0,0,0,0,0,0

1,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

2,2,2,2,2,1 a

0,0,0,0,0,0

1,1,1,1,1,1 c

2,1,1,1,1,1 a

1,1,1,1,1,0 a

0,0,0,0,0,0

1,1,1,1,1,1 a

1,1,0,0,0,0

1,1,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

2,2,2,2,2,2 a

0,0,0,0,0,0

1,1,1,1,1,1 c

1,1,1,1,1,1 a

1,1,1,1,0,0 a

0,0,0,0,0,0

1,1,1,1,0,0 a

1,1,0,0,0,0

1,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

3,2,2,2,2,1 a

0,0,0,0,0,0

1,1,1,1,1,1 c

2,1,1,1,1,0 a

1,1,1,1,1,0 a

1,1,0,0,0,0

1,1,1,1,1,1 a

1,1,1,0,0,0

1,1,0,0,0,0

0,0,0,0,0,0

0,0,0,0,0,0

Accumulation
alveolar macrophages

Infiltration
eosinophil, mononuclear
peribronchiolar/perivascular

Table 2.13. Day 29 NiO OVA Asthma Model
Lung Histopathology Summary

DM
NiO-1
NiO-2
NiO-3
OVA
NiO-1A
NiO-2A
NiO-3A

Table 2.13. Summary of histopathological findings from lungs of all groups at day 29 in the NiO OVA model. Scores for each animal are compiled for each
treatment group and histopathological finding and compared to corresponding control (DM for non-sensitized groups, OVA for sensitized groups). Scale: n
= normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = marked, 5 = severe. n = 6, p < 0.05. a indicates statistical significance over all non-sensitized groups; b
indicates statistical significance over DM, NiO-1, NiO-2; c indicates difference over DM.
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Table 2.14. NiO Time Course Study and NiO OVA Asthma Model
Summary of Results
Dose Metric

Correlated Endpoint

Effect

NiO Time Course Study

Surface Area

→

↑ SA = ↑ LDH
↑ SA = ↑ BAL Cell #
↑ SA = ↑ Lung neutrophils
↑ SA = ↑ LN Cell #

LDH
Total BAL Cell #
Lung neutrophils
Total LN Cell #

NiO OVA Asthma Model
NiO Exposure

Surface Area

Particle Size
Mass

NiO exposure = ↑ total IgE in
OVA-sensitized animals

→

Serum Total IgE

→

Lung neutrophils
BALF cytokines
Serum OVA-specific IgE

→
→

Lung eosinophils
Penh

↓ particle size = ↑ lung eosinophils
↑ particle size = ↑ Penh

BALF IL-6

↓ mass = ↑ lavage fluid IL-6 levels

↑ SA = ↑ lung neutrophils
↑ SA = Th2 cytokines, ↓ SA = Th1/17 cytokines
↓ SA = ↓ OVA-specific IgE levels

Table 2.14. Summary of results from the NiO time course study and the NiO OVA asthma model illustrate
associations between individual dose metrics and specific endpoints, and subsequent immune effects.
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CHAPTER 2 FIGURES

Figure 2.1. Treatment groups, corresponding exposures, and timeline of treatments in the OVA asthma model. Two
groups of mice were exposed to dispersion medium (DM) or NiO particles at doses identical to those of the time
course study on day 0 via oropharygenal aspiration (asp). One group of each treatment was not sensitized to OVA
to serve as non-sensitized particle control groups and another group of each treatment was sensitized to OVA.
Accordingly, on days 1 and 10, mice were intraperitoneally injected (i.p.) with PBS (non-sensitized) or OVA + alum
in PBS (sensitized). On day 14, 150 µL blood was collected via the tail vein to evaluate circulating OVA-specific IgE
levels, indicative of successful sensitization to OVA (green circle). On days 19 and 28, mice were aspirated with
OVA or PBS and placed in whole body plethysmography (WBP) chambers to assess airway response to allergen
challenge (blue circle). On day 29, all mice were euthanized.
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Figure 2.2. Scanning electron micrographs of NiO-F and NiO-UF at identical magnifications (A, B; scale bar- 1µm)
and size-adjusted magnifications (C, D). Magnified images showing particle surface detail for NiO-F (E, F) and NiOUF (G, H).
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A

B

Figure 2.3. Dynamic light scattering (DLS) analysis of NiO-F (A) and NiO-UF in DM (B).
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B

A

C

Material
NiO-F
NiO-UF

Relative Elemental Composition (Atom %)
C

O

Na

Cl

Si

Ni

Br

7.2
8.0

45
39

1.1
-

0.7

2.6
-

45
51

0.5

Ni:O
ratio
1:1
1:1.3

Figure 2.4. XPS hi-res spectrum of NiO-F (A) and NiO-UF (B). Relative elemental composition of carbon, oxygen,
sodium, chloride, silicon, nickel, and bromine in NiO-F and NiO-UF samples and ratio of nickel to oxygen on the
surfaces of each material (C).
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Figure 2.5. ESR spectra for dispersion media (A), chromium (VI) (B, positive control), NiO-F (C), and NiO-UF (D).
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Figure 2.6. Rate of dissolution for NiO-F (solid lines) and NiO-UF (dotted lines) in different simulated biological fluids
shown as percent of the original Ni concentration measured as soluble fraction. Purple lines represent particles
suspended in dispersion media (DM, pH 7.2), pink lines indicate particles suspended in Gamble’s solution (GS, pH
7.4), and orange lines indicate particles suspended in artificial lysosomal fluid (ALF, pH 4.5). n = 3, p < 0.05, *
indicates statistically different from the same particle in GS and DM suspensions.

250

Figure 2.7. Markers of pulmonary injury and inflammation measured in mice from the NiO time course study at 1,
10, 19, and 29 days post NiO exposure following bronchoalveolar lavage (BAL). A) Lung lactate dehydrogenase
(LDH) levels in BAL fluid, B) total cell number in BAL, and C) total neutrophil number in BAL are shown for DM
control (gray), NiO-1 (green), NiO-2 (blue), and NiO-3 (red) groups. n = 8 per group, p < 0.05, * indicates statistically
significant from all other groups, # indicates statistically significant from DM control.
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Figure 2.8. A) Total cell number in the mediastinal lymph node recovered from each group and B) cell phenotypes
by absolute number at 1, 10, 19, and 29 days post-exposure in the NiO time course study. n = 8 per group, p <
0.05, * indicates statistically significant from all other groups, # indicates statistically significant from DM, ^ indicates
statistically significant from DM and NiO-1.
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Figure 2.9. Levels of several notable Th1/pro-inflammatory cytokines that were elevated in the BALF of animals in
the NiO time course study. BALF IL-6 (A), IFN-γ (B), and TNF-α (C) responses were generally conserved with
respect to NiO surface area, wherein the higher dose (NiO-3) caused more pronounced and persistent increases.
n = 8, p < 0.05, * indicates statistical significance over all other groups at the corresponding time point, # indicates
statistical significance over DM only.
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Figure 2.10. Whole lung nickel levels following aspiration of 40 µg the NiO-1 fine particle (green) or the NiO-3
ultrafine particle (red) in mice were measured by ICP-MS on dried lung tissue at 1, 10, 19, and 29 days postexposure. Data is expressed as a percentage of the originally-administered dose. n=6, p < 0.05, * indicates
statistically significant difference between particles at the same time point.
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Figure 2.11. Dark field and light micrographs of alveolar macrophages recovered by BAL from each group at 10
days post-exposure. Images of macrophages isolated from the DM (A-C), NiO-1 (D-F), NiO-2 (G-I), and NiO-3 (JL) groups showed variations in the degree of particle loading at 10 day, and size/morphology of internalized
particles.
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Figure 2.12. Levels of circulating total (n = 3-5) and OVA-specific (n = 8) IgE from serum of mice collected on day
14 of the OVA allergy model, following NiO aspiration and two sensitization procedures. Sensitized groups are
shown in purple and non-sensitized groups are shown in orange. Total IgE levels are represented by the entire bar,
OVA-specific IgE levels are represented by the hatched portion of the bar, and OVA-specific : total IgE ratio is
expressed as a percentage over the corresponding bars. p < 0.05, a indicates statistically significant from all nonsensitized groups.
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Figure 2.13. Whole body plethysmography results at day 28 of the OVA model. Penh was recorded every 30 seconds
for 6 hours immediately following OVA aspiration challenge for each mouse. A time course view of the P enh response
is shown for a single, representative animal from the DM, OVA, NiO-1A, NiO-2A, and NiO-3A groups in panel A.
Area under the curve was calculated, and averaged for animals from each group and expressed as fold-change
over OVA control average (B). n = 8, p < 0.05, A indicates fold-change with statistical significance over all other
groups.
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Figure 2.14. A) Total cell number and fraction of eosinophils (pink), polymorphonuclear cells (orange), lymphocytes
(red), and alveolar macrophages (yellow) recovered from BAL at day 29 in the OVA asthma model. n = 8, p < 0.05,
a indicates total BAL cell number significant over all sensitized groups, b indicates significance over DM, NiO-1,
and NiO-2. Percent eosinophils (B) and neutrophils (C) of total BAL cells are expressed as fold change over OVA
control levels (dotted line). n = 8, p < 0.05. A indicates fold change significantly different from all other groups, B
indicates fold change significantly different from NiO-1A.
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Figure 2.15. Vacuolated macrophages were most prominently observed following exposure to the 40 µg dose of
NiO-UF in the NiO OVA asthma model. Red arrows indicate observable vacuolation in alveolar macrophages in the
lung tissue (A) and lavage fluid (B, C) of an animal from groups NiO-3 (B) and NiO-3A (A, C). Histopathological
analysis of lung tissue from the NiO OVA study also reported the presence of multinucleated giant cells (yellow
arrow) exclusively observed in the lung tissue of NiO-3A animals (D).
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Figure 2.16. Total number of cells (whole bar) and phenotypes [CD4+ T-cells (orange), CD8+ T-cells (red), and Bcells (yellow)] collected from the mediastinal lymph nodes at day 29 in the OVA asthma model (A). The table (B)
shows the absolute number of cells in each lymphocyte population in the OVA-exposed groups at day 29. n = 8 per
group, p < 0.05. a indicates statistical significance over all non-sensitized groups; b indicates statistical significance
over DM, NiO-1, NiO-2; c indicates statistical significance over DM; d indicates statistical significance over all nonsensitized groups, OVA; e indicates statistical significance over all other groups; f indicates statistical significance
over all non-sensitized groups, NiO-3A.
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Figure 2.17. Levels of circulating total and OVA-specific IgE from serum of mice collected on day 29 of the OVA
allergy model following NiO aspiration, two sensitization procedures, and two OVA challenges. Sensitized groups
are shown in purple and non-sensitized groups are shown in orange. Total IgE levels are represented by the entire
bar, OVA-specific IgE levels are represented by the hatched portion of the bar, and OVA-specific : total IgE ratio is
expressed as a percentage over the corresponding bars. n = 8, p < 0.05. a indicates statistical significance over all
non-sensitized groups; d indicates statistical significance over all non-sensitized groups, OVA; f indicates statistical
significance over all non-sensitized groups, NiO-3A.
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Figure 2.18. Th1/17 and Th2 cytokine levels in BAL fluid collected at day 29 from NiO-exposed/OVA-sensitized
mice expressed as fold change over OVA control values. n = 8, p < 0.05. A indicates fold-change with statistical
significance over all other groups; C indicates fold-change with statistical significance over OVA, NiO-3A; D
indicates fold-change with statistical significance over OVA, NiO-2A.
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Figure 2.19. Th1/17 and Th2 cytokine levels in serum from NiO-exposed/OVA-sensitized mice expressed as fold
change over OVA control values. n = 8, p < 0.05. A indicates fold-change with statistical significance over all other
groups; C indicates fold-change with statistical significance over OVA, NiO-3A; E indicates fold-change with
statistical significance over OVA.
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Figure 2.20. Fold change in cytokine levels in BALF and serum of NiO-exposed mice compared to OVA control
levels. n = 8, p < 0.05. A indicates fold-change with statistical significance over all other groups; C indicates foldchange with statistical significance over OVA, NiO-3A; D indicates fold-change with statistical significance over
OVA, NiO-2A, E indicates fold-change with statistical significance over OVA.

264

CHAPTER 3:
Evaluation of the skin sensitizing potential of gold nanoparticles
and the impact of established dermal sensitivity on the pulmonary immune response
to various forms of gold
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3.1. Abstract
Gold nanoparticles (AuNP) are largely biocompatible, and overt toxic responses are rarely
reported following exposure; however, several studies have shown the potential for AuNP to modulate
immune cell functions, accumulate in lymphoid organs, and augment allergic responses to environmental
allergens. These observations are concerning since gold salts have been historically implicated in a
number of adverse immune effects, including the development of gold-induced ACD. Despite this
knowledge, the potential for AuNP to cause allergic disease has yet to be investigated.
In order to address this knowledge gap, three studies were performed in vivo. First, the skin
sensitizing potential of different forms of gold was assessed by incorporating soluble gold salts (AuCl 3)
and increasing concentrations of gold particles (Au, 942 nm), and gold nanoparticles (AuNP, 30 nm) into
a Local Lymph Node Assay (LLNA). Next, the pulmonary immune effects of AuNP (10 µg, 30 µg, 90 µg)
were assessed 1 d, 4 d, 8 d post-aspiration. Finally, in accordance with the recent recognition of the
frequency of gold contact allergy in the general population, an allergy study was performed in order to
assess the impact of existing dermal sensitivity to gold on the pulmonary immune response to the
materials. In this study, mice were dermally sensitized to gold by similar methods used in the LLNA (d 13), then aspirated once (d 10), twice (d 10, d 14), or three times (d 10, d 14, d 18) with gold particles then
euthanized the day after the final aspiration. Subsequent responses were evaluated with respect to mass
and surface area of the administered gold dose according to three treatment groups: 30 µg Au, a massequivalent dose of AuNP, or a surface area-normalized dose of AuNP (0.8 µg).
In the LLNA study, AuCl3 had a stimulation index (SI) of 10.9, in accordance with its known potent
sensitizing capacity. Although the SI of AuNP (2.3) was higher than that of Au (1.1), a three-fold increase
in lymphocyte proliferation was not observed for either particle. In the dose-response study, AuNP was
not associated with increases in any markers of lung injury or inflammation, irrespective of dose and time.
However, following exposure to the highest dose of AuNP (90 µg), a significant increase in the total
number of cells in the mediastinal lymph nodes was observed at 8 d, wherein selective expansion of
CD4+ T-cell and B-cell populations was seen. In the allergy study, no alterations in any immune
parameters were observed at any time point amongst the groups of animals that had not been previously
sensitized to gold. Comparatively, after the second and third gold aspirations, a significant increase in
the number of BAL lymphocytes was seen in all previously-sensitized/gold-aspirated groups, the
magnitude of which correlated to surface area of the administered dose. Animals aspirated with the 30
µg AuNP dose exhibited the greatest number of total BAL lymphocytes, as well as a selective increase
in the number and proportion of CD8+ T-cells. In the lymph nodes of these animals, CD8+ T-cells
constituted a larger percent of the total lymphocyte population and exhibited higher levels of activation
marker expression. Comparatively, aspiration with the lower surface area-based doses of Au/AuNP
resulted in the preferential influx of CD4+ T-cells to the lungs, exposure-dependent elevations in serum
IgE levels, and selective expansion/activation of CD4+ T-cells and B-cells within the lymph nodes.
The findings from this study suggest that AuNP do not constitute a notable risk for allergic
sensitization. However, established contact sensitivity to gold is associated with increased immune
reactivity following pulmonary exposure to the metal. Subsequent immune effects appear directionally
polarized in a surface area-dependent manner, wherein responses resembling delayed-type
hypersensitivity reactions occur following exposure to higher doses. Collectively, these findings suggest
that individuals exhibiting dermal sensitivity to gold may be more susceptible to adverse pulmonary
immune effects following exposure to AuNP.
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3.2. Introduction
Like many other metal nanomaterials, gold nanoparticles (AuNP) have utility as catalysts,
electrochemical sensors, and antimicrobial additives, and are they becoming increasingly used in fuel
cell applications, biological imaging, and the electronics industry (1657, 1658). However, the highest
demand for this material originates in the biomedical sector, as AuNP are one of the few metal
nanomaterials being used extensively in medical applications (1349). AuNP exhibit general
biocompatibility, are easily synthesized, and their physico-chemical properties can be easily manipulated,
all of which are characteristics that facilitate its utility in this field. Accordingly, AuNP have been employed
as a vaccine platform, diagnostic imaging agent, drug delivery vehicle, and adjuvant in cancer therapy,
among other novel uses (63, 1433, 1566, 1659).
Current applications for AuNP and the corresponding increase in material demand will inevitably
lead to increases in AuNP exposure. Workers involved in the manufacture, handling, and transport of
AuNP are likely to be exposed to the materials by dermal contact and inhalation. These routes of
exposure also constitute the majority of potential exposures to AuNP in its current markets. Uses in
medical settings render healthcare workers a population of individuals potentially susceptible to AuNP
exposures, but also constitute a risk for patients (1172). Patients may also be uniquely subjected to AuNP
exposures by parenteral routes, given that many of the biomedical applications of AuNP implicate their
systemic administration.
Larger forms of particulate gold materials and objects containing metallic gold exhibit a relatively
low degree of toxic potential, especially when compared to other metals. However, some gold-containing
agents have been associated with adverse health effects, many of which implicate the immune system.
Contact sensitivity to gold is one such response. Since the development of gold-specific adaptive immune
responses most commonly occurs following penetration of the skin by gold ions, soluble gold salts are
often implicated in cases of ACD caused by gold (1536, 1660). Although skin contact is the most common
route of exposure associated with sensitization in the general population, the development of gold allergy
following systemic administration of gold-based therapeutics is also commonly reported (1458).
Subsequent dermal eruptions frequently occur, constituting one of the major complications presenting in
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patients undergoing gold therapy. Other adverse immune reactions in these patients include alterations
in circulating white blood cell populations, compromised antibody production, and the development of a
delayed-type hypersensitivity response in the airways leading to a condition termed ‘gold lung’ (408,
1476, 1530, 1661)
Despite the current applications for AuNP and the established immunotoxic potential of gold, the
allergenic potential of AuNP remains unknown. To begin addressing this knowledge gap, three studies
were conducted using a mouse model. First, the potential for AuNP to induce dermal sensitization was
investigated using the LLNA and compared to the immunogenic activity of soluble gold salts. Next, the
pulmonary immune effects of AuNP were assessed in vivo with respect to dose and time. Lastly, the
impact of established dermal sensitivity on the pulmonary immune response to gold was investigated.
Mice were aspirated with gold particles or AuNP in mass- and surface area-normalized doses to
determine if these parameters were related to subsequent biological effects. Collectively, the findings
from these studies will help determine if AuNP present a risk for the development of gold-specific allergic
disease and if individuals with existing gold contact allergy constitute a population vulnerable to adverse
immune effects following respiratory exposure to AuNP.

3.3. Materials and Methods
Material Characterization
Gold particles (<10 µm, Au) and gold (III) chloride (AuCl3) were obtained from Sigma-Aldrich in
powder form. Gold nanoparticles (AuNP) were obtained from the National Institute of Standards and
Technology (NIST) Standard Reference Materials Program. Reference Material 8012 is a wellcharacterized citrate-stabilized AuNP (30 nm nominal diameter) received at a concentration of 20% (w/v)
in aqueous suspension (1662). Physico-chemical properties of both particulate gold materials were
characterized prior to incorporation into in vivo studies.
Primary Particle Size, Agglomerate Size, and Particle Morphology: Field emission scanning
electron microscopy (FESEM, Hitachi Model S-4800) was employed to assess primary particle size and
morphology of Au and AuNP. Particles were prepared in distilled water for microscopic analysis. Images

268

were collected for both particles and the diameters of 250 particles from each sample were recorded
using point count methods. Image J Software (Version X; National Institutes of Health; Bethesda, MD)
was used for analysis of mean diameter and degree of polydispersity for each particle.
Surface Area: Surface area of the Au particles (in powder form) was measured by gas adsorption
using a Quantachrome NOVA 2200e surface area analyzer and ultra-high purity nitrogen adsorbate.
Specific surface area (SSA) was determined by using the multipoint Brunauer, Emmett, and Teller (BET)
method (1611). Since AuNP were received in aqueous suspension, geometric calculations were used to
determine the surface area of this material using the particle sizes generated from microscopic
measurements and the known density of gold (19.32g/cm3). The same approach was employed with Au
to confirm the results of gas adsorption analysis.
Endotoxin Contamination: Endotoxin presence in Au and AuNP samples was evaluated using the
Pierce Limulus Amebocyte Lysate (LAL) Chromogenic Endotoxin Quantitation Kit (Thermo Scientific;
Waltham, MA) according to the manufacturer’s protocol. The presence of bacterial endotoxin catalyzes
the activation of a proenzyme in the LAL assay, from which the substrate can be colorimetrically
measured and correlated to the activation rate, which is proportional to the level of endotoxin present in
the sample. Both Au samples were tested over multiple concentrations ranging from 5.0 - 0.25 µg/µl.
Concentration of endotoxin was then determined using a plate spectrophotometer at absorbance
wavelength of 450 nm.
Zeta Potential in Vehicle: Zeta potential of AuNP particles was determined by measuring
electrophoretic mobility in distilled water (pH 7.1). All measurements were performed at 25°C using a
Malvern Zetasizer Nano ZS90 (Worcestershire, UK) equipped with a 633 nm laser at a 90° scattering
angle. Samples were equilibrated inside the instrument for two minutes, and five measurements
consisting of five runs each were recorded.

Animals
Specific pathogen-free female C57BL/6J mice, 8-12 weeks of age, were obtained from Jackson
Laboratory (Bar Harbor, ME) for use in all studies. All mice were housed 4 per cage in polycarbonate
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ventilated cages with HEPA-filtered air in the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC)-approved National Institute for Occupational Safety and Health (NIOSH) Animal
Facility, and provided food (Harlan Teklad Rodent Diet 7913) and water ad libitum in a controlled humidity/
temperature environment with a 12 h light/dark cycle. Animals were allowed to acclimate for four weeks
in the facility prior to exposures. All procedures in the studies comply with the ethical standards set forth
by Animal Welfare Act and the Office of Laboratory Animal Welfare (OLAW). The studies were approved
by the NIOSH Health Effects Laboratory Division (HELD) Institutional Animal Care and Use Committee
within the Center for Disease Control and Prevention in accordance with approved animal protocols (13SA-M-022, 18-001).

In Vivo Exposures and Study Design
Local Lymph Node Assay: The Local Lymph Node Assay (LLNA) was performed in accordance
with previously-established standardized protocols (1663). Accordingly, mice were exposed topically to
vehicle control (50% DMSO), increasing concentrations of Au or AuNP, or positive control (10% AuCl3)
on the dorsal sides of both ears (25 µl per ear) for three consecutive days (days 1, 2, 3) (figure 3.1).
Following two days of rest, on day 6, mice were injected intravenously via the lateral tail vein with 20 µCi
[3H]-thymidine (Dupont NEN, specific activity 2 Ci/mmol). Five hours after the [3H]-thymidine injection,
mice were euthanized via CO2 asphyxiation and the left and right cervical lymph nodes (CLN) were
excised from each mouse and pooled for each treatment group. Single cell suspensions were prepared,
and following overnight incubation in 5% trichloroacetic acid (TCA), samples were analyzed using
Packard Tri-Carb 2500TR liquid scintillation counter. Stimulation indices (SI) were calculated by dividing
the mean disintegrations per minute (DPM) per test group by the mean DPM for the vehicle control group.
AuNP Dose Response Study: AuNP were incorporated into a dose response time course study
in order to evaluate pulmonary toxicity and determine optimal doses for incorporation into the allergy
study. AuNP were diluted in distilled water at concentrations of 0.2, 0.6, and 1.8 mg/mL and sonicated
for 10 seconds at 10 W with a probe sonicator. On day 0, mice (n = 8 per group per time point) were
exposed by oropharyngeal aspiration to 50 µL of either solution to constitute 3 AuNP doses: 10, 30, or
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90 µg per mouse. Mice were fully anesthetized with isoflurane, placed on a slanted board and suspended
by the incisors. The mouth was opened and tongue moved aside, while a 50 µl aliquot of sample was
pipetted on the base of the tongue. The animal was restrained until two full breaths were completed and
returned to its cage, placed on its side, and monitored for recovery from anesthesia. Mice were humanely
euthanized with an overdose of sodium pentobarbital euthanasia solution (100-300 mg/kg body weight;
Fort Dodge Animal Health; Fort Dodge, IA) at 1 day, 4 days, or 8 days post-exposure. Blood was collected
from the abdominal aorta, bronchoalveolar lavage (BAL) was performed, and mediastinal lymph nodes
(MLN) and spleens were collected for analysis.
Au Allergy Study: In order to determine the effects of pre-existing dermal sensitivity to gold on the
pulmonary response to different forms of gold materials, an allergy study was conducted using 8
treatment groups (n = 4 per group per time point). Starting on day 1, all mice were either dermally
sensitized to gold or exposed to vehicle to serve as non-sensitized control groups. Dosing solutions were
prepared using identical methods from the LLNA study. Accordingly, on days 1, 2, and 3, mice were
dermally exposed on the ears to 50% DMSO (groups 1-4) or 10% AuCl3 (groups 5-8). After 6 days of
rest, different groups of mice were exposed via aspiration to gold particles in varying doses once (10 d),
twice (10 and 14 d), or three times (10, 14, 18 d). Exposure solutions were distilled water (vehicle control
[VC], groups 1 and 5), 30 µg Au (groups 2 and 6), or AuNP at doses normalized for the mass (30 µggroups 3 and 7) or surface area (9.90x10-6 m2- groups 4 and 8) of the Au exposures. On the day following
the final aspiration for each group (11, 15, or 19 d), mice were euthanized, serum was collected, lungs
were lavaged, and immune tissues were collected for analysis. Treatment groups and schedule of
exposures are shown in figure 3.2.

Toxicology and Immune Response Parameters
BAL Cellular and Fluid Analysis: BAL was performed on the lungs of mice from both the AuNP
dose response study and Au allergy study in order to obtain pulmonary cells for phenotypic analysis and
fluid for analysis of biochemical indicators of lung injury and inflammation. Following euthanasia, the
trachea was cannulated, the chest cavity was opened, and BAL was performed on the whole lungs. The
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acellular fraction of the first lavage was obtained by filling the lung with 0.6ml PBS, massaging for 30
seconds, and withdrawing. This concentrated aliquot was retained, kept separate, and designated as the
first fraction. The following aliquots were 0.6 ml in volume, instilled once with light massaging, withdrawn,
and combined until a 2.4 ml volume was obtained. For each animal, both lavage fractions were
centrifuged (10 minutes, 1600 rpm) and the cell pellets were combined and resuspended in 1 ml PBS for
cell counts, phenotyping, and microscopic analysis. The acellular fluid from the first fraction (BALF) was
retained for analysis of LDH activity and quantification of cytokines.
The total BAL cell number was determined using a Coulter Multisizer II (Coulter Electronics;
Hialeah, FL) by quantifying the number of events within the size range of 4.5 µm and 20 µm. Myeloid
immune cells in the BAL were quantified by spinning down 75,000 cells from each sample onto
microscope slides using a Cytospin 3 centrifuge (Shandon Life Sciences International; Cheshire,
England), then cells were labeled with Leukostat stain (Fisher Scientific; Pittsburgh, PA). Microscopic
analysis allowed for differentiation between alveolar macrophages, eosinophils, lymphocytes, and
neutrophils. An aliquot of BAL cells was also stained for surface markers to allow for phenotypic
differentiation of lymphoid immune cell populations by flow cytometry, using procedures described below.
Measurements of LDH activity in BALF were obtained using a Cobas Mira analyzer (Roche
Diagnostic Systems; Montclair, IN) as an index of lung injury. LDH activity was quantified by detection of
the oxidation of lactate coupled to the reduction of NAD+ at 340nm.
Lymphocyte Differentials by Flow Cytometry: For the AuNP dose response study and Au allergy
study, lymph nodes and spleens were harvested from mice for characterization of the immune cell
populations within these tissues. In the AuNP dose response study, only the MLN, which drain the lungs,
were collected. In the Au allergy study, both the MLN and CLN were collected in order to compare cellular
profiles in the local lymphoid tissues corresponding to the different sites of gold exposure. Spleens and
lymph nodes were processed between frosted microscope slides to yield single cell suspensions in sterile
PBS. Concentrations of cells from each tissue were determined by identical methods used for the
enumeration of BAL cells.
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For flow cytometric analysis, 500,000 cells from each tissue were suspended in staining buffer
(PBS + 1% bovine serum albumin + 0.1% sodium azide) containing Fc receptor blocking anti-mouse
CD16/32 (BD Biosciences). Cells were incubated for 5 minutes, washed, and resuspended in staining
buffer containing fluorochrome-conjugated antibodies.
Lymphocyte phenotypes were determined for BAL, lymph nodes, and spleen cells using a staining
panel containing CD2-BV605, CD3-APC, CD4-FITC, CD8-PE, CD44-APC-R700, CD45-PerCP,
CD45R(B220)-PE-Cy7, and CD86-BV421 (BD Biosciences). These markers allowed for discrimination
between populations of CD4+ T-lymphocytes, CD8+ T-lymphocytes, B-lymphocytes, and NK cells, as
well as determine the corresponding activation state of the T-cells and B-cells.
Another aliquot of BAL cells was stained using a second panel of markers to allow for
differentiation of myeloid cell subsets. CD11b-PE-CF594, CD11c-APC-R700, CD24-BV605, CD45PerCP, CD64-PE, CD86-PE-Cy7, MHC II-BV515, Ly6G-APC, Siglec-F-APC-Cy7 (BD Biosciences) were
employed to differentiate between eosinophils, neutrophils, macrophages, and dendritic cells (1618).
Cells were incubated for 30 minutes with the respective staining cocktails, washed, and fixed in
100 µl Cytofix Buffer (BD Biosciences). Compensation controls were prepared using corresponding cell
types stained with a single fluorophore. For each sample, 100,000 events were recorded on an LSR II
flow cytometer (BD Biosciences, San Diego, CA). In all analysis, doublet exclusion was performed and
cellular populations were gated on using FSC-A x SSC-A parameters, prior to subsequent analysis. All
data analysis was performed using FlowJo 7.6.5. Software (TreeStar Inc., Ashland, OR).
Whole Blood Cellular Differentials: In the AuNP dose response and Au allergy studies, blood was
drawn from the abdominal aorta directly following euthanasia. A 100 µL aliquot of whole blood was
retained in order to quantify circulating immune cells, and the serum fraction was separated from the
remaining blood volume for protein analysis. Using the aliquot of whole blood, erythrocyte and leukocyte
number was determined for each sample, and leukocytes were differentiated (lymphocytes, monocytes,
neutrophils, eosinophils, and basophils) using an Idexx ProCyte Dx Hematology Analyzer (Idexx
Laboratories; Westbrook, ME).
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BAL Fluid and Serum Proteins: The BALF and serum cytokine profiles of animals from the AuNP
dose response study and Au allergy study were characterized using a Milliplex MAP Kit magnetic bead
panel (EMD Millipore Corporation, Billerica, MA) and analyzed on a Luminex 200 system (Luminex
Corporation, Austin, TX). For both studies, prototypical T-helper (Th)1/17 and Th2 cytokines were
quantified. Specific analytes included interleukin (IL)-2, 4, 5, 6, 10, 12p40, 12p70, 13, 17, eotaxin, tumor
necrosis alpha (TNF-α), interferon gamma (IFN-γ), and granulocyte macrophage colony stimulating factor
(GM-CSF).
In the Au allergy study, serum was also used to assess levels of circulating IgE. Serum was diluted
1:10 and total IgE was assessed by ELISA using the Mouse IgE ELISA kit (Innovative Research; Novi,
MI) according to manufacturer instructions.

Statistical Analysis
Statistical analyses were conducted with GraphPad Prism version 7 (San Diego, CA). Results
from all studies are expressed as means ± standard error and considered statistically significant at p <
0.05. For all studies, all treatments were compared by one-way analysis of variance (ANOVA) followed
by a post hoc Student’s t-test.

3.4. Results
Material Characterization:
Transmission and scanning electron micrographs of both gold particles are shown in figures 3.3
and 3.4, respectively, illustrating a notable difference in size between the particulate constituents of the
two materials. FESEM micrographs were used to measure primary particle size from 250 particles for
each material, which was determined to be 942.1 nm for Au, and 29.7 nm for AuNP. The Au and AuNP
particles exhibited similar spherical morphologies and smooth surface textures.
Gas adsorption was performed on the Au powder, and BET analysis revealed a SSA of 0.46 ±
0.13 m2/g. Using the particle sizes determined from microscopy, geometric calculations indicated a SSA
of 10.46 m2/g for AuNP. Consistent with the results from gas adsorption/BET analysis, a SSA of 0.33
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m2/g was calculated for Au using the same approach. No detectable levels of endotoxin were present in
either sample. Zeta potential was determined to be -26.4 ± 5.1 mV for Au and -33.6 ± 6.9 mV for AuNP.
Results from the physico-chemical characterization of Au and AuNP are summarized in table 3.1.

Au LLNA Study:
Using 10% AuCl3 as a positive control, the capacity for Au and AuNP to induce dermal
sensitization was assessed using a standard procedure for the LLNA (107). Mice were topically exposed
to Au or AuNP in concentrations of 2.5, 5.0, or 10.0% and subsequent lymphocyte proliferation was
determined by measuring 3H-thymidine levels in the CLN (figure 3.5). AuCl3 had a stimulation index (SI)
of 10.9, in accordance with its known potent sensitizing capacity (657). Although the SI of AuNP (2.3)
was higher than that of Au (1.1), a three-fold increase in lymphocyte proliferation was not observed for
either particle, indicating a lack of sensitizing potential.

AuNP Dose Response Study:
The effect of AuNP exposure on the lungs was investigated in a dose-response time course study.
Mice were aspirated with vehicle control (VC), 10 µg, 30 µg, or 90 µg AuNP and euthanized 1, 4, or 8
days post-aspiration to evaluate markers of pulmonary injury and inflammation. Overall, AuNP caused
minimal lung injury and inflammation, as indicated by no elevations in BALF LDH levels at any time points,
irrespective of dose (table 3.2). Similarly, total BAL cell number and BAL neutrophil number were not
significantly increased in any groups 1, 4, or 8 d post-aspiration.
There was a significant increase in MLN total cell number following exposure to 90 µg AuNP at 4
and 8 d post-exposure (figure 3.6). Phenotypic analysis of the lymphocyte populations in the MLN
revealed that the increase in MLN size was associated with increases in selective populations of
lymphocytes (table 3.3, figure 3.7). Exposure to the highest dose of AuNP led to a significant increase in
the proportion of CD4+ T-cells (65.75% compared to 61.93, 62.53, and 61.78%) and B-cells (16.01%
compared to 12.85, 11.79, and 11.06%) at 8 d compared to all other groups. Simultaneously, a decrease
in the proportion of CD8+ T-cells (16.73% compared to 23.26, 22.55, and 22.58%) was observed.
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Despite alterations in the lymphocyte population frequencies in the MLN of animals exposed to
the 90 µg AuNP dose, a similar response was not observed in the spleen. No alterations in proportions
of CD4+ T-cells, CD8+ T-cells, B-cells, or NK cells were seen in the spleen of any groups at any timepoint
(table 3.4).
Differentiation of circulating immune cells revealed no significant changes in the number or
percentage of any cell phenotype between any groups at any time point (table 3.5). Similarly, no
differences were observed in the levels of any cytokines measured in the BALF (table 3.6) or serum (table
3.7) between groups at any time point.

Au Allergy Study:
Next, an allergy study was conducted in order to determine if existing dermal sensitivity to gold
impacted the response following pulmonary Au or AuNP exposure. In order to evaluate the role of particle
size, dose mass, and surface area on any subsequent effects, mass and surface area-normalized doses
of Au and AuNP were used in this study. Treatment groups for the Au allergy study, corresponding
Au/AuNP dose parameters, and a timeline of exposures are shown in figure 3.2.
Quantification of total BAL cells revealed no differences in cell number between any nonsensitized groups (groups 1-4), irrespective of the number of gold aspirations (table 3.8). In goldsensitized mice (groups 5-8), total BAL cell number and subpopulations of specific cells did not differ
between any other groups after a single aspiration (11 d). However, following two aspirations (15 d), total
BAL cell number became significantly elevated in all gold-aspirated groups when compared to group 5
control levels (figure 3.8), and group 7 levels were further elevated over group 6. In response to an
additional gold aspiration (19 d), total BAL cell number remained elevated over group 5 control in all goldaspirated groups and the number of BAL cells in group 7 was became significantly increased over all
other groups.
Differentiation of BAL cell phenotypes showed similar increases in the number of BAL neutrophils
in all sensitized/gold-aspirated groups at 15 d, however after the third aspiration (19 d), the number of
neutrophils became further elevated in groups 6 and 7 (figure 3.9 A). BAL eosinophils were only elevated
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in group 7 at 15 d, but at 19 d, group 6 values also became significantly increased over group 5 (figure
3.9 B). Absolute values for all BAL cell populations in sensitized/gold-aspirated groups are shown in
figure 3.9 C.
The total number of lymphocytes recovered from the BAL of the sensitized/gold-aspirated groups
increased with each successive aspiration of gold (figure 3.10 A). The extent of lymphocyte influx
appeared dependent on the surface area of the administered dose of gold, and accordingly, the highest
number of BAL lymphocytes was consistently seen in group 7. Differentiation of BAL lymphocyte
subpopulations further revealed that group 7 also exhibited a selective propensity for the recruitment of
CD8+ T-cells to the lung. After three aspirations, the increase in number and proportion of BAL CD8+ Tcells in group 7 (table 3.8) was responsible for a drastic decrease in the group’s BAL CD4+ to CD8+ Tcell ratio (figure 3.10 B and C). By comparison, the BAL lymphocyte CD4:CD8 ratio was conserved
between all other sensitized groups, despite the increase in total BAL lymphocyte number in groups 6
and 8.
Similar to the cellular responses observed in the lung, there were no alterations in MLN cell
number or ratios of cell populations in non-sensitized groups (groups 1-4) at any time points (table 3.9).
In sensitized groups, no alterations occurred after a single aspiration, but several features of the MLN
cellular profile were altered after two and three gold aspirations. On 15 d, the total number of MLN cells
was significantly increased in groups 6 and 7 compared to groups 5 and 8 (figure 3.11 A). However,
lymphocyte population ratios changed only in group 7. The MLN exhibited a lower proportion of CD4+ Tcells and higher proportion of CD8+ T-cells and non-lymphoid cells when compared to all other groups
at this time point. Group 7 animals also exhibited higher levels of CD4+ and CD8+ T-cells bearing a
CD44hi phenotype. Interestingly, group 8 animals exhibited the highest proportion of CD44hi CD4+ Tcells among all groups.
After the third aspiration, MLN size remained elevated in groups 6 and 7, and while a slight
increase in MLN size was observed in group 8, the response was not statistically significant over group
5 controls. At 19 d, all three sensitized/gold-aspirated groups showed elevated levels of activated CD4+
T-cells, CD8+ T-cells, and B-cells compared to group 5 controls. However, a higher proportion of
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activated CD4+ T-cells and B-cells was observed in groups 6 and 8, whereas the highest prevalence of
activated CD8+ T-cells was seen in group 7. Numbers of activated CD4+ and CD8+ T-cells in the MLN
of all sensitized groups are shown in figure 3.12 A and B. The gating strategy used to identify CD44
expression levels is shown in figure 3.12 C and D.
In addition to the MLN, CLN were also collected in the Au Allergy study. The total CLN cell number
was significantly increased in all dermally sensitized groups compared to all non-sensitized groups at all
time points, consistent with their sensitized status (table 3.10). Animals that had been dermally sensitized
with gold also exhibited an elevated proportion of CD4+ and CD8+ T-cells and decreased ratio of B-cells
when compared to non-sensitized groups. However, no differences in lymphocyte population ratios were
observed amongst the sensitized groups at any time points.
In the spleen, no alterations in lymphocyte populations or activation status were observed
between groups until 15 d (table 3.11). At this time point, the only observable alteration was the
percentage of activated CD4+ T-cells, which was elevated only in group 7 animals. By 19 d, this group
also exhibited an elevated proportion of CD8+ T-cells, higher levels of activated CD8+ T-cells, and a
lower proportion of B-cells compared to all other sensitized groups. At the time point, an increase in the
number of B-cells expressing a CD86hi phenotype was observed in groups 6 and 8.
Circulating immune cell populations were not altered in any group at any time point in the allergy
study (table 3.12).
As illustrated in figure 3.13, quantification of serum IgE revealed that prior sensitization with gold
was associated with elevations in circulating IgE. After a single aspiration (11 d), all sensitized groups
(groups 5-8) exhibited higher IgE levels than those measured in non-sensitized groups (groups 1-4), but
no differences were observed amongst the sensitized groups. No alterations in levels were observed
following the second and third gold aspirations in any non-sensitized groups or groups 5 and 7. By
comparison, IgE levels increased in groups 6 and 8 with each successive aspiration, leading to
significantly higher levels than those seen in groups 5 and 7.
Levels of several notable Th1/17 and Th2 cytokines were quantified in the serum of animals from
the allergy study. No alterations in any cytokine levels were observed between any non-sensitized groups
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at any time points, as shown in table 3.13. In previously-sensitized groups, the only significant change
observed at 15 d was IL-4 level in group 6 animals, which was significantly increased over all other
sensitized groups. A similar increase was seen in group 8, but not until the 19 d time point. At the same
time point, IL-10 levels also became significantly elevated in groups 7 and 8, while increases in IL-5 were
exclusively seen in group 6.
Cytokine levels were also assessed in the BALF and are shown in table 3.14. No significant
differences in the levels of any cytokines were seen between non-sensitized groups at any time point.
Among dermally-sensitized groups, the only significant changes observed at 15 d included an increase
in group 7 GM-CSF and group 6 IL-6 levels. Following the third aspiration (19 d), BALF IL-12p70 and IL2 levels became significantly increased in groups 7 and 8. IFN-γ levels were increased in all three
sensitized/gold-aspirated animals over group 5 controls, and further elevations were seen in the animals
of groups 6 and 8.

3.5. Discussion
Three studies were conducted to evaluate the potential immune effects of AuNP exposure,
specifically in relation to allergic disease. First, since soluble gold salts are known to be potent dermal
sensitizers, Au and AuNP were incorporated into an LLNA to evaluate their skin sensitizing potential and
compare these responses to that of AuCl3. Neither particulate material was associated with significant
expansion of the lymph nodes following exposure at the selected doses (2.5 – 10%), indicating minimal
risk for the development of gold-induced ACD. Next, a pulmonary dose response study was performed
to evaluate the potential for AuNP to induce pulmonary injury/inflammation or other alterations in local
immune reactivity in the airways. Even at the highest dose of 90 µg, AuNP aspiration did not induce
increases in any markers of inflammation in the airways over the 8 d time course. However, the high dose
of AuNP did cause an increase in MLN size 4 and 8 d post exposure, wherein the expansion was
associated with an elevated proportion of B-cells and CD4+ T-cells. Finally, a third study was performed
to evaluate the effects of gold respiratory exposure in a state of established skin sensitivity. The results
from this study demonstrated that dermal sensitization to gold prior to pulmonary exposure greatly
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impacted the biological activity of gold in the lung. Furthermore, several local and peripheral immune
markers were differentially impacted by various parameters of the administered dose of gold.
In the LLNA study, the different gold materials exhibited varying degrees of lymphocyte
stimulation following topical applications (figure 3.5). AuCl3 demonstrated a SI of 10.9, which is consistent
with existing knowledge derived from animal studies and human data. Gold (III) chloride was associated
with the highest stimulation index among 12 different metal salts in the LLNA previously conducted by
Basketter et al. (657). Similarly, gold sodium thiomalate was shown in the guinea pig maximization test
(GPMT), LLNA, and mouse ear swelling test (MEST) to be a potent skin sensitizer (1540). In human
subjects with suspected contact sensitivity to gold, formulations comprised of gold sodium thiosulfate,
gold sodium thiomalate, and gold trichloride have all been demonstrated to effectively elicit ACD
responses (1467, 1534).
By comparison, the Au particles (942 nm average particle size) did not generate any level of
lymphocyte expansion compared to vehicle control (SI = 1.1). This observation is consistent with reports
of an inability for metallic, non-ionized gold particles to induce skin sensitization (1664). The lack of
immunogenicity associated with metallic gold is also reflected by the relatively few reports of ACD caused
by jewelry items comprised of pure gold (1664).
Although other metal nanomaterials have been previously incorporated into the LLNA to evaluate
their skin sensitizing potential, this is the first study that has investigated the potential for skin sensitization
by AuNP. Although AuNP induced a slightly elevated degree of lymphocyte expansion over vehicle
controls and Au (SI = 2.3), dermal sensitizers are classified by their capacity to induce a three-fold
increase in lymphocyte proliferation over vehicle control responses in the LLNA, a response which was
not observed following AuNP exposure. Several factors may be responsible for the lack of sensitizing
potential seen following skin exposure to AuNP.
Sensitization to gold and the subsequent development of gold-induced ACD has been most
frequently associated with soluble gold compounds. Since metal-induced ACD is driven by the
immunogenic activity of haptenic metal ions, their propensity to release large quantities of ions is
conducive with increased allergenic potential (289). Haptenic gold ions are able to penetrate the stratum
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corneum and permeate into lower epidermal layers populated with resident immune cells, facilitating the
interactions with APC required for sensitization. Gold ions also must interact with skin proteins and form
haptenic ion/carrier complexes large enough to be recognized by the innate immune system. Since these
processes are required for the induction of allergic sensitization, gold-containing items or chemical
formulations that readily shed ions present an inherent risk for allergic responses following skin contact.
These early events of sensitization also illustrate why metallic gold and insoluble particulates of gold are
less frequently associated with ACD. Their exceptional chemical stability results in the release of far fewer
ions than soluble gold compounds. Furthermore, their large size renders the stratum corneum a physical
barrier that effectively restricts their passage into deeper layers of skin where APC interactions may
occur.
Given these observations, the lack of lymphocyte proliferation in response to topical AuNP
exposure in the LLNA study is likely attributable, largely, to the physico-chemical properties of the
particles. The colloidal AuNP used in this study are citrate-stabilized, insoluble particulates compromised
of metallic gold, all of which are properties that confer minimal potential for dissolution. As a result, AuNP
appear to constitute an ineffective source of haptenic gold ions at the doses used in the study. However,
AuNP did induce a greater degree of lymphocyte proliferation than Au, suggesting the possible release
of larger quantities of gold ions than the larger gold particle. This effect is substantiated by the established
correlation between increased particle surface area of nanoparticles and an increased rate of dissolution
observed with soluble metal nanoparticles (1665). Accordingly, equivalent doses of Au/AuNP in the LLNA
study (administered as a percent particle weight to volume vehicle), when considered in particle surface
area-derived metrics, implicate doses differing by orders of magnitude between the two particles.
Irrespectively, the potentially accelerated rate of dissolution associated with AuNP did not result in the
generation of gold ions in a dose adequate enough to induce dermal sensitization.
Despite an apparent lack of skin sensitizing potential, evidence suggests that AuNP may still be
capable of causing gold-specific ACD responses. It is well-established that the elicitation phase of ACD
can be triggered by significantly lower doses of metal ions than those required to induce sensitization. As
demonstrated with nickel, the quantity of ions required to induce sensitization was reported to be 100-
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fold to 1,000-fold less than the dose required to trigger elicitation reactions (1666). A similar effect may
be responsible for the conflicting findings regarding the potential for metallic gold to cause ACD. Metallic
gold has been consistently shown to pose a minimal risk for skin sensitization. Contrarily, numerous
reports have demonstrated the potential for metallic gold to elicit ACD reactions in sensitized individuals
(1438). Metallic gold (in the form of 24 karat gold earrings and metallic gold patch test agents), has been
shown to trigger localized ACD reactions, implying a variation in the exposure thresholds associated with
allergic sensitization and elicitation (1493, 1660). Accordingly, while dissolution behavior appears critical
in the propensity for gold-containing objects to induce dermal sensitization, it appears less important with
respect to the elicitation of ACD. These observations suggest that although AuNP did not induce skin
sensitization in the LLNA study, exposure to the same doses may be capable of eliciting ACD responses
in subjects with existing gold sensitivity.
In the AuNP dose response study, aspiration of AuNP was not associated with any signs of overt
pulmonary injury or inflammation at any time points, irrespective of dose (table 3.2). This finding is
consistent with other studies that have demonstrated general biocompatibility of AuNP in the respiratory
tract (1572, 1583, 1587). The only immune parameter altered in response to AuNP aspiration was the
MLN size at 4 and 8 d in animals exposed to the highest dose (figure 3.6). All groups exhibited similar
proportions of non-lymphoid cell populations (denoted as ‘other’) in the MLN at all time points, suggesting
that the increase in LN size in animals exposed to the 90 µg AuNP dose was not reflective of pulmonary
phagocyte-mediated clearance of particles from the lungs to the MLN. Comparatively, lymphocyte
populations expanded in the MLN of animals exposed to the 90 µg AuNP dose at 8 d, wherein a selective
increase in the proportions of CD4+ T-cells and B-cells were observed (figure 3.7). Although the
implications of this observation are unclear, polarization of cell populations towards a Th2-dominant state
may have implications for subsequent antigen exposures. Several studies have demonstrated the
capacity for pulmonary AuNP exposure to promote the development of antigen-specific humoral
responses in the respiratory tract (776, 950). Likewise, the increase in MLN size and elevated proportions
of CD4+ T-cells and B-cells in the dose response study suggests a potential for immunomodulatory
activity of AuNP that appears to be dose-dependent.
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Although the increase in CD4+ T-cell and B-cell populations in the MLN following exposure to the
highest dose of AuNP resembles characteristic features associated with aeroallergen sensitization and
elicitation of asthmatic responses, it is unlikely that this response was reflective of the development of an
adaptive immune response in this study. Metals known to induce respiratory sensitization have been
shown to cause profound increases in BALF and serum Th2 cytokine levels, as well as increased
recruitment of eosinophils to the airways following exposure, responses which were not observed in this
study (1667). However, Ni and Co compounds have been shown to induce the development of T-cellmediated allergic reactions in the lungs of guinea pigs, responses which occurred up to 8 weeks postexposure (1668). Accordingly, results from the AuNP dose response study suggest an unlikely potential
for acute AuNP exposure to induce sensitization of the respiratory tract; however, additional studies are
required to more definitively assess the potential for development of gold-specific allergic responses in
the lungs.
Collectively, the results from the LLNA and AuNP dose response studies indicated that AuNP are
not likely to induce allergic sensitization via the skin or respiratory tract. However, given the increasing
prevalence of contact allergy to gold in the general population, the potential for respiratory AuNP
exposure to selectively impact these individuals is a concern. Several reports have described cases of
human subjects with established metal-specific ACD who subsequently developed pulmonary allergic
reactions to the same metal. The existence of ACD has been demonstrated to precede the development
of immediate-type IgE-dependent asthmatic reactions induced by metals including nickel, cobalt, and
chromium (288, 414, 454, 1669). Established skin sensitivity has also been suggested to be risk factor
for the development of delayed-type, T-cell-mediated mechanisms in the lungs as demonstrated by cases
caused by nickel, platinum, chromium, and cobalt (294, 295, 400, 403, 422, 428). These findings imply
that gold may have potential to induce similar effects, wherein subjects with existing contact allergy to
gold may develop delayed-type hypersensitivity reactions in the lung following respiratory exposure.
In the allergy study, mice were dermally sensitized to soluble AuCl3 and subsequently aspirated
with different forms of gold particles to evaluate the impact of an existing allergic state on the immune
response. In order to determine the role of particle properties and dose parameters on these effects, mice
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were aspirated with the larger Au particles or mass- or surface area-equalized doses of AuNP. Nearly all
endpoints assessed in the Au Allergy study remained unaltered in all non-sensitized groups, irrespective
of gold aspirations (groups 1-4). Contrarily, animals that had been previously sensitized to gold via the
skin exhibited heightened reactivity to pulmonary gold exposure.
Total BAL cell number increased in all sensitized, gold-aspirated groups with each successive
aspiration (figure 3.8). The magnitude of this increase appeared associated with the surface area of the
administered gold dose, as the greatest increase in BAL cell number was seen in group 7 animals, which
were exposed to the largest surface area-based dose (30 µg AuNP). Interestingly, analysis of BAL cell
subpopulations revealed that the increase in BAL neutrophil number seen at 19 d was conserved
between the groups exposed to mass-normalized doses of gold. Groups 6 and 7, which were exposed
to Au and AuNP in 30 µg doses, respectively, exhibited the most pronounced increases in lung
neutrophils number. Although BAL neutrophil number was elevated in group 8 animals over group 5
controls, the response was not as robust as groups 6 and 7. Since no neutrophil recruitment was
observed in the corresponding non-sensitized, the dose mass-dependent recruitment of lung neutrophils
was also dependent on sensitization state.
Similar to the increase in total BAL cell number, the number of lymphocytes present in the BAL
also appeared correlated to the surface area of the aspirated gold dose (figure 3.10). Group 7 animals,
which were exposed to the higher surface area-based dose of AuNP, exhibited consistently heightened
numbers of BAL lymphocytes when compared to the other sensitized groups. Moreover, the phenotype
of T-cell subpopulations recruited to the airways also differed with respect to gold surface area. A
selective increase in BAL CD8+ T-cells was seen in group 7, whereas the increase in BAL lymphocytes
in groups 6 and 8 consisted primarily of CD4+ T-cells. Consequently, the BAL CD4:CD8 T-cell ratio
remained similar between group 5 controls and groups 6 and 8 at all time points, while a significant
decrease was observed exclusively in group 7 at 19 d. This may represent a notable finding, as
lymphocyte subpopulations present in the BAL are often used as diagnostic criteria for various pulmonary
immune responses.
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Although the majority of metals capable of inducing respiratory allergy are associated with
immunological mechanisms mediated by metal-specific IgE molecules, some metals are known to induce
T-cell-mediated hypersensitivity responses in the lungs. Beryllium is the prototypical metal associated
with this type of allergic response. The pathogenesis of chronic beryllium disease (CBD) involves
delayed-type hypersensitivity-like mechanisms primarily mediated by beryllium-reactive CD4+ T-cells
(477, 1670). Likewise, hallmark features of CBD include significant increases in the number and
proportion of BAL T-cells, as well as enhanced proportions of cells with elevated activation status. CD8
+ T-cells are less frequently-implicated in respiratory hypersensitivity responses caused by metals, but
evidence from several human case reports suggests this lymphocyte population may be of specific
importance with respect to gold.
Nearly all adverse pulmonary effects associated with gold have been reported in human subjects
receiving systemic gold therapy. Although alveolitis, bronchiolitis, and pulmonary fibrosis have all been
reported following the systemic administration of gold salts, one of the most distinctive reactions is an
adaptive immune-mediated response referred to as ‘gold lung’ (1478, 1671). Gold lung resembles a form
of hypersensitivity pneumonitis wherein antigen-specific T-cells accumulate in the airways leading to
adaptive immune-mediated inflammation of the alveolar mucosa (1650, 1672). This condition most
frequently emerges in patients exhibiting positive patch test reactivity to gold and or established contact
allergy to gold, a complication frequently associated with gold therapy. The development of both CD4+
and CD8+ gold-specific T-cells as a result of gold therapy often manifests in clinical presentations
resembling ACD skin eruptions (407, 408). However, evidence suggests that the same pool of goldspecific effector T-cells may be responsible for the development of gold lung, explaining the existence of
skin reactions as a predisposing factor for gold lung. Patients with gold lung exhibit higher numbers of
lymphocytes in the BAL, as well as increased numbers of activated lymphocytes. BAL lymphocytes, as
well as peripheral lymphocytes, both exhibit reactivity to gold in individuals with gold lung. However, a
unique dependence on the CD8+ subsets of gold-specific T-cells has been observed in gold lung, as
patients often exhibit an inverted CD4:8 ratio. A significant decrease in the BAL CD4:CD8 T-cell ratio (<
1) is a biomarker frequently used to confirm suspected cases of gold lung (407, 409).
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The decreased BAL CD4:CD8 T-cell ratio in group 7 animals of the allergy study suggests a
potential hypersensitivity response in the lungs involving similar immunological mechanisms as those
responsible for cases of gold lung. Although the increase in CD8+ BAL T-cells in patients with gold lung
exhibit specificity for recognition of gold, T-cell reactivity was not evaluated in this study. Likewise, it
remains unclear if the influx of CD8+ T-cells to the airways in the allergy study involved exposure-induced
recruitment of gold-reactive cells previously generated in response to dermal sensitization. However, the
magnitude of skin reactivity to gold test agents in ACD patch tests has been correlated to the surface
area of contact (1673). Given this observation, the surface area-dependent influx of CD8+ T-cells
suggests that lymphocytes recruited in response to gold aspiration may exhibit gold specificity.
Pulmonary CD8+ T-cell recruitment was not observed in the groups exposed to the smaller surface areabased doses of Au/AuNP (groups 6 and 8), suggesting that this response may be subject to an elicitation
threshold correlated to the surface area of the gold dose. Contrarily, exposure to the lower doses of gold
surface area may have been associated with the preferential recruitment of gold-reactive CD4+ T-cells.
Similar to BAL neutrophil number, MLN total cell number at 15 d was similar between massnormalized exposure groups. Exposure to 30 µg Au or AuNP in groups 6 and 7, respectively, resulted in
similar increases in MLN size after the second aspiration of gold. After the third gold aspiration, an
increase in MLN size was seen in group 8 animals; however, it was not significantly elevated over group
5 controls. Although the kinetics and magnitude of MLN size increase appeared correlated to the mass
of Au/AuNP dose administered, phenotypic analysis of lymphocyte populations revealed similar
population-specific effects with respect to gold surface area. Animals exposed to the highest surface area
of gold particles (group 7) exhibited higher numbers of and proportions of CD8+ T-cells compared to all
other groups, similar to the BAL lymphocyte response in group 7. Moreover, the group’s CD8+ T-cell
populations were associated with an elevated percent of cells expressing a CD44hi activation phenotype.
Comparatively, exposure to the lower surface area-normalized doses of gold did not cause alterations in
relationships between cell populations in the lymph nodes; however, the percentage of both CD4+ Tcells and B-cells expressing high levels of activation marker expression were significantly increased in
groups 6 and 8.
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MLN were collected from mice in the Au allergy study in order the characterize responses in local
lymphoid tissue following pulmonary exposure to gold. In addition, the CLN, which drain the site of dermal
exposure used to sensitize mice to gold, were also collected. Lymphocyte populations were analyzed in
the CLN at all time points in order to determine if aspiration of gold had any effect on peripheral lymphoid
tissues and residual activity associated with the dermal sensitization procedure. CLN of sensitized
animals were significantly larger, exhibited higher percentages of CD4+ and CD8+ T-cells, and lower
proportions of B-cells than non-sensitized groups. These observations are consistent with the clonal
expansion of gold-specific T-cells following AuCl3 exposure. However, no differences in any parameters
were observed between groups 5-8, indicating a lack of reactivity in the CLN in response to pulmonary
gold exposure. The notable differences between the cellular profile of the MLN in these groups implies a
greater reactivity of local lymphoid tissues to the effects of gold aspiration, as well as enhanced
involvement as mediators of the subsequent pulmonary immune response.
The immunological mechanisms responsible for metal-induced ACD are primarily Th1-driven,
cell-mediated responses, and many of the mediators involved in these responses negatively regulate
humoral/Th2-biased responses (1674). Given this knowledge, the finding that all dermally-sensitized
groups exhibited higher levels of serum IgE than non-sensitized groups was a surprising finding in the
allergy study. The expansion of gold-specific T-cells following skin sensitization was paralleled with a
decrease in the proportion of B-cells in the CLN, a response which would be expected to attenuate IgE
production. However, a similar increase in IgE levels following dermal sensitization with gold sodium
thiosulfate has been previously reported (1540). Gold has rarely been associated with immediate type
hypersensitivity responses or development of gold-specific IgE, and the specificity of IgE was not
determined in this study, so the implications of this observation remain unknown.
The group-dependent alterations in IgE production observed in the allergy study are also
particularly interesting when compared to findings from the AuNP dose response study. Exposure to
lower doses of gold surface area in the allergy study resulted in expansion of CD4+ T-cell and B-cell
populations in the MLN, similar to the responses seen following exposure to the highest surface areabased dose of gold in the AuNP dose response study. Accordingly, gold surface area appeared to induce
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divergent responses on lymphocyte expansion depending on sensitization status. In the absence of
established dermal sensitivity, exposure to higher surface area-based doses of gold appeared to promote
Th2-polarized responses, whereas the same dose was correlated to the attenuation of Th2 reactivity in
sensitized animals.
Discrete alterations in the BALF and serum cytokine profiles were observed in sensitized groups
of the Au allergy study. Although no general trends were discernable with respect to changes in collective
groups of Th1/17 and Th2 cytokines, a few individual cytokines appeared selectively modulated following
aspiration of gold. In the serum, IL-10 levels were elevated in groups 7 and 8 at 19 d. This increase
appeared associated with particle size, as the increase was only observed in animals aspirated with
AuNP, irrespective of dose. Immune cells isolated from donors with suspected gold sensitivity have been
shown to selectively increase IL-10 release following challenge with gold salts in vitro, supporting a
potential role for this cytokine in the gold allergy study (1675). Group-specific alterations in serum IL-4
levels were also observed in the allergy study. Increased production of IL-4 was observed in group 6 at
15 d and in groups 6 and 8 at 19 d. Similar IL-4 responses between these groups implies a surface areadependent effect wherein increased expression is associated with exposure to lower surface area-based
doses of gold. IL-4 is a cytokine critically involved in Th2-driven immune responses, wherein its functions
include stimulating isotype switching of B-cells, a mandatory step required for the production of IgE.
Accordingly, the increase in serum IL-4 seen in groups 6 and 8 of the allergy study is consistent with the
increase in circulating IgE levels observed in these groups.
BALF cytokine analysis demonstrated occasional alterations in levels of IL-6 and GM-CSF in
some groups. However, the cytokines associated with the most consistent and pronounced alterations in
the BALF were IFN-γ, IL-2, and IL-12. Levels of IL-2 and IL-12 were increased at 19 d in groups 6 and 8,
suggesting a relationship between the production of these two cytokines with gold dose surface area. A
similar surface area-dependent increase in the level of BALF IFN-γ was seen. Although all
sensitized/gold-aspirated groups exhibited increased BALF IFN-γ levels compared to group 5 controls,
the most robust response was seen in groups 6 and 8. IL-6 levels were also shown to be increased in
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the BALF of animals in group 6, but only at the 15 d time point. Interestingly, several of these cytokines
have been previously associated with gold allergy.
In one study, lymphocytes were isolated from individuals with confirmed sensitivity to gold, as well
as control subjects, and stimulated ex vivo. Subsequent cytokine secretion was monitored, which
revealed a selective increase in IL-2 and IFN-γ production exclusively by gold-reactive cells (1533, 1676).
However, IFN-γ was identified as the cytokine exhibiting the most accurate predictive potential to identify
gold reactivity, and correspondingly, has been proposed to have utility as a diagnostic marker for
identification of subjects with gold-induced ACD (1507). IFN-γ production by BAL lymphocytes has also
been implicated in CBD, where beryllium-specific CD4+T-cells in the lung secrete high levels of this
cytokine (503). Accordingly, the elevated levels of IFN-γ in the BALF of all sensitized/gold-aspirated
groups in the allergy study suggest the presence of gold-specific T-cells in the airways, which may have
been stimulated by aspirated gold particles. The existence of a similar mechanism as that seen in CBD
is further supported by the existence of higher IFN-γ levels in groups 6 and 8, which exhibited preferential
expansion of CD4+ T-cell subtypes.
An interesting discrepancy observed between the results of the AuNP dose response study and
allergy study suggests that the immune effects of gold may be equally as dependent on the timing and
frequency of exposure as the total dose administered. Despite administration of the same cumulative
AuNP dose (90 µg), the increase in MLN size and the alterations in lymphocyte subpopulations observed
in the 90 µg exposure group in the dose response study was not observed in group 2 animals in the
allergy study. This finding may reflect a dependence of MLN alterations on the administration of AuNP
as a single bolus dose. Since the animals of the allergy study were aspirated three times with AuNP at
doses of 30 µg, four days apart, the timing and number of exposures may also impact the immune
response to AuNP in the lungs.

3.6. Conclusion
Overall, the results from these studies suggest that on intact skin, ~30 nm AuNP do not constitute
a significant risk for dermal sensitization following acute exposure. Similarly, respiratory AuNP exposure
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was not associated with significant pulmonary injury or inflammation at a range of doses, and no overt
immune reactivity was observed. However, the highest dose of AuNP caused expansion of MLN, wherein
a disproportionate increase in CD4+ T-cell and B-cell populations was seen. This observation suggests
the potential for AuNP exposure to modulate immune reactivity or the nature of immune responses
following subsequent antigen exposures. Although these findings indicate minimal risk for sensitization
of the skin and respiratory tract by AuNP, several notable immune effects were observed in response to
pulmonary AuNP exposure when animals had been previously sensitized to gold via the skin. These
effects appeared best correlated to the surface area of the administered dose of gold, wherein the higher
surface area-based dose was associated with many effects resembling those seen in T-cell-mediated
hypersensitivity responses of the lungs.
Collectively, these findings suggest that individuals with existing gold contact allergy may be at
increased risk for adverse immune effects following respiratory exposure to AuNP or other gold materials.
Although additional studies are required to fully characterize the allergenic potential of AuNP, these
findings emphasize the potential importance of pre-existing disease states on the biological activity of
nanomaterials and highlight the need for future studies that consider potentially vulnerable populations.
Moreover, the sensitization state-dependent immune responses induced by AuNP may be pertinent to
other allergenic metals, as well. Many metals known to induce contact allergy are being manufactured in
nanoparticulate forms, and individuals with existing skin sensitivity to nickel, cobalt, and chromium may
be exceptionally vulnerable to allergic effects following inhalation of nanoparticles containing these
metals. Accordingly, as efforts to characterize the immunotoxic potential of nanomaterials continue, the
prevalence of metal hypersensitivity should be considered and evaluated as a potential risk factor for
immune responses caused by metal nanomaterial exposure.

290

CHAPTER 3 TABLES

Table 3.1. Summary of Au and AuNP Characterization Results
Au

AuNP

Vendor size specification

< 10 µm

30 nm

Material form

Powder

Citrate-stabilized in H2O
(20% w/v)

942.1 ± 42.1 nm

29.7 ± 1.2 nm

spherical

spherical

0.46 ± 0.13 m2/g

-

0.33 m2/g

10.46 m2/g

Not detected

Not detected

-26.4 ± 5.1

-33.6 ± 6.9

Primary particle size
Morphology
SSA: Gas adsorption/BET (powder)
SSA: Geometric calculation
Endotoxin level
Zeta Potential (mV)

Table 3.1. Summary of physico-chemical characterization of gold particles (Au) and nanoparticles (AuNP).
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Table 3.2. AuNP Dose Response Study
Markers of Pulmonary Inflammation
Time
Point

1d

4d

8d

Treatment Group

LDH

Total # BAL Cell

Total # BAL Neutrophils

VC
10 µg AuNP
30 µg AuNP
90 µg AuNP
VC
10 µg AuNP
30 µg AuNP
90 µg AuNP
VC
10 µg AuNP
30 µg AuNP
90 µg AuNP

73.1 ± 3.9
84.9 ± 1.8
76.5 ± 6.3
73.0 ± 1.4
76.4 ± 4.4
67.8 ± 3.4
78.5 ± 3.9
72.0 ± 4.1
79.3 ± 2.8
76.3 ± 3.0
80.8 ± 3.4
77.8 ± 3.2

1,153,929 ± 62,306
1,094,438 ± 42,333
1,057,350 ± 43,786
1,103,788 ± 61,314

7,709 ± 978
7,334 ± 827
6,262 ± 759
6,058 ± 661

(0.7%)
(0.7%)
(0.6%)
(0.6%)

1,097,086 ± 65,567
1,147,800 ± 61,494
1,142,613 ± 53,542
1,168,300 ± 76,462
1,131,214 ± 70,708
1,080,338 ± 45,117
1,105,313 ± 61,021
1,256,250 ± 79,916

5,199 ± 305
7,095 ± 935
6,229 ± 572
6,673 ± 693
6,650 ± 586
6,782 ± 859
7,031 ± 651
7,016 ± 880

(0.5%)
(0.7%)
(0.6%)
(0.6%)
(0.6%)
(0.6%)
(0.7%)
(0.6%)

Table 3.2. BALF lactate dehydrogenase (LDH) levels, total BAL cell number, and total BAL neutrophil number (and
percent of total BAL cells) for each treatment group at 1d, 4d, and 8d post-AuNP aspiration in the AuNP dose
response study. n = 8 per group.
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Table 3.3. AuNP Dose Response Study
Mediastinal Lymph Node Cell Phenotypes by Percent
Time
Point

1d

4d

8d

Treatment Group

VC
10 µg AuNP
30 µg AuNP
90 µg AuNP
VC
10 µg AuNP
30 µg AuNP
90 µg AuNP
VC
10 µg AuNP
30 µg AuNP
90 µg AuNP

CD4+
T-cells

CD8+
T-cells

B-Cells

Other

62.32 %
61.41 %
61.95 %
61.36 %

22.54 %
22.71 %
22.52 %
22.38 %

12.52 %
12.79 %
12.28 %
12.17 %

3.12 %
3.68 %
2.71 %
3.92 %

61.17 %
61.82 %
62.34 %
63.90 %

22.63 %
23.33 %
22.82 %
20.81 %

12.89 %
12.36 %
12.22 %
12.80 %

3.65 %
2.86 %
2.80 %
2.69 %

61.93 %
62.53 %
61.78 %
65.75 %*

23.26 %
22.55 %
22.58 %
16.73 %*

12.85 %
11.79 %
11.06 %
16.01 %*

3.50 %
3.41 %
3.83 %
2.25 %

Table 3.3. Immune cell phenotypes in the mediastinal lymph nodes expressed as a percentage are shown for each
group at each time point. n = 8 per group, p < 0.05, * indicates statistically significant from all other groups at the
corresponding time point.
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Table 3.4. AuNP Dose Response Study
Spleen Cell Phenotypes by Percent
Time
Point

1d

4d

8d

Treatment Group

VC
10 µg AuNP
30 µg AuNP
90 µg AuNP
VC
10 µg AuNP
30 µg AuNP
90 µg AuNP
VC
10 µg AuNP
30 µg AuNP
90 µg AuNP

CD4+
T-cells

CD8+
T-cells

B-Cells

NK Cells

Other

15.02 %
15.09 %
14.71 %
15.12 %

8.24 %
9.04 %
8.45 %
7.96 %

62.12 %
60.83 %
61.41 %
62.00 %

2.01 %
1.95 %
1.87 %
2.11 %

8.92 %
10.21 %
10.62 %
9.75 %

14.84 %
15.36 %
14.96 %
15.25 %

7.90 %
9.11 %
8.21 %
8.64 %

61.24 %
60.43 %
59.71 %
60.72 %

2.03 %
1.67 %
1.85 %
1.96 %

9.84 %
10.26 %
10.37 %
9.91 %

15.17 %
15.80 %
14.80 %
15.33 %

8.53 %
8.42 %
7.82 %
8.90 %

60.79 %
61.18 %
62.19 %
61.57 %

2.07 %
2.10 %
1.89 %
1.94 %

10.12 %
9.84 %
9.92 %
10.44 %

Table 3.4. Immune cell phenotypes in the spleen expressed as a percentage for each group at each time point. n
= 8 per group, p < 0.05, * indicates statistically significant from all other groups at the corresponding time point.
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Table 3.5. AuNP Dose Response Study
Whole Blood Cell Differentials
Time
Point

1d

4d

8d

Treatment
Group

RBC

WBC

(M/uL)

(k/uL)

Neutr

Lymph

Cell Number (k/uL)
Mono

Eos

Baso

Neutr

Lymph

% of Total WBC
Mono

Eos

Baso

VC
10 µg AuNP
30 µg AuNP
90 µg AuNP
VC
10 µg AuNP
30 µg AuNP
90 µg AuNP
VC
10 µg AuNP
30 µg AuNP
90 µg AuNP

9.85
9.65
9.74
9.70
9.56
9.63
9.84
9.97
9.85
9.67
9.71
9.68

2.33
2.22
2.54
2.18
2.18
1.85
2.02
1.99
1.97
2.11
2.49
2.33

0.85
0.99
1.23
0.80
0.96
0.75
0.71
0.73
0.81
0.88
1.02
1.00

1.45
1.19
1.28
1.34
1.17
1.08
1.27
1.20
1.13
1.19
1.41
1.29

0.02
0.01
0.02
0.02
0.01
0.01
0.02
0.03
0.01
0.02
0.03
0.01

0.01
0.02
0.01
0.02
0.03
0.01
0.02
0.02
0.01
0.02
0.03
0.02

0.00
0.01
0.00
0.00
0.01
0.00
0.00
0.01
0.01
0.00
0.00
0.01

36.48%
44.59%
48.43%
36.70%
44.04%
40.54%
35.15%
36.68%
41.12%
41.71%
40.96%
42.92%

62.23%
53.60%
50.39%
61.47%
53.67%
58.38%
62.87%
60.30%
57.36%
56.40%
56.63%
55.36%

0.86%
0.45%
0.79%
0.92%
0.46%
0.54%
0.99%
1.51%
0.51%
0.95%
1.20%
0.43%

0.43%
0.90%
0.39%
0.92%
1.38%
0.54%
0.99%
1.01%
0.51%
0.95%
1.20%
0.86%

0.00%
0.45%
0.00%
0.00%
0.46%
0.00%
0.00%
0.50%
0.51%
0.00%
0.00%
0.43%

Table 3.5. Whole blood cell differentials for each group at each time point in the AUNP dose response study. RBC
= red blood cells, WBC = white blood cells, Neutr = neutrophils, Lymph = lymphocytes, Mono = monocytes, Eos =
eosinophils, Baso = basophils. n = 8 per group.
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Table 3.6. AuNP Dose Response Study
BALF Cytokine Levels (pg/mL)
IFN-γ
1d

4d

8d

VC
10 µg
30 µg
90 µg
VC
10 µg
30 µg
90 µg
VC
10 µg
30 µg
90 µg

4.1
3.2
3.0
3.1
3.2
3.2
3.4
3.1
2.9
2.8
3.1
3.2

±
±
±
±
±
±
±
±
±
±
±
±

0.8
0.7
0.9
0.8
0.8
0.7
0.5
0.6
0.6
0.6
0.5
0.5

IL-2
6.1
6.5
6.4
5.8
5.7
5.1
6.0
6.2
6.0
6.1
5.7
5.5

±
±
±
±
±
±
±
±
±
±
±
±

1.1
1.2
1.0
1.9
2.1
2.0
1.5
1.9
2.2
1.6
1.5
1.4

IL-12p40

IL-12p70

98.5
86.4
88.2
90.7
100
109
88.6
94.1
97.6
95.5
86.1
100

35.2
30.4
31.1
28.6
29.6
27.1
32.2
33.4
30.8
31.9
33.6
28.1

±
±
±
±
±
±
±
±
±
±
±
±

12.3
15.2
10.4
11.9
12.5
20.1
16.6
15.7
14.7
20.9
15.5
14.5

±
±
±
±
±
±
±
±
±
±
±
±

3.2
3.6
5.1
4.0
3.3
3.6
3.9
3.8
5.1
4.4
4.7
4.2

IL-17
0.8
1.0
1.1
1.3
1.4
1.0
1.2
1.1
0.9
1.1
0.9
1.3

±
±
±
±
±
±
±
±
±
±
±
±

0.1
0.2
0.3
0.5
0.2
0.1
0.2
0.2
0.1
0.1
0.1
0.3

TNF-α
4.2
4.1
3.8
3.7
3.6
4.1
4.2
4.0
3.7
3.8
3.7
3.9

±
±
±
±
±
±
±
±
±
±
±
±

GM-CSF

1.1
1.2
1.0
1.0
1.1
1.2
1.6
1.4
1.1
1.2
1.0
0.9

Th1/17 Cytokines

3.1
3.0
2.7
2.6
3.9
4.0
3.5
3.6
2.9
2.7
3.0
4.1

±
±
±
±
±
±
±
±
±
±
±
±

1.0
0.5
0.6
0.7
0.8
0.9
0.5
0.5
0.6
0.4
0.2
0.5

IL-4
6.1
6.3
5.5
5.9
6.2
6.0
5.7
5.8
5.9
6.1
6.2
4.9

±
±
±
±
±
±
±
±
±
±
±
±

1.3
1.2
1.1
1.0
1.0
1.2
1.1
0.9
0.8
1.1
1.0
1.6

IL-5
5.0
6.1
6.0
5.7
5.4
5.5
5.0
6.1
6.2
5.0
5.3
5.7

±
±
±
±
±
±
±
±
±
±
±
±

1.2
1.3
1.0
1.2
2.1
2.0
1.5
1.6
0.9
1.1
1.5
1.4

IL-13
2.5
2.6
2.9
3.1
3.3
2.8
3.7
3.3
3.4
3.0
3.1
2.8

±
±
±
±
±
±
±
±
±
±
±
±

0.3
0.2
0.4
0.5
0.3
0.3
0.4
0.5
0.3
0.3
0.2
0.4

Eotaxin
3.0
3.2
3.0
3.1
2.9
2.8
3.7
3.3
3.4
3.0
3.1
2.8

±
±
±
±
±
±
±
±
±
±
±
±

Th2 Cytokines

Table 3.6. BALF cytokine levels for each treatment group at each time point of the AuNP dose response study. n = 8 per group.

296

0.3
0.2
0.4
0.2
0.2
0.1
0.3
0.3
0.2
0.2
0.2
0.3

IL-6
2.2
4.1
3.3
3.0
3.4
3.1
3.9
2.5
2.8
2.7
3.2
3.3

±
±
±
±
±
±
±
±
±
±
±
±

0.2
0.4
0.2
0.3
0.3
0.3
0.2
0.4
0.2
0.3
0.3
0.2

Other

IL-10
1.8 ± 0.1
1.2 ± 0.2
1.9 ± 0.2
2.2 ± 0.3
2.3 ± 0.4
2.0 ± 0.2
2.1 ± 0.2
1.8 ± 0.3
2.4 ± 0.2
1.7 ± 0.1
1.5 ± 0.1
2.1 ± 0.3

Table 3.7. AuNP Dose Response Study
Serum Cytokine Levels (pg/mL)
IFN-γ
VC
10 µg
1d
30 µg
90 µg
VC
10 µg
4d
30 µg
90 µg
VC
10 µg
8d
30 µg
90 µg

6.2
5.4
7.1
6.4
6.5
4.9
8.0
7.1
6.0
5.2
4.9
5.0

±
±
±
±
±
±
±
±
±
±
±
±

1.2
0.9
0.8
1.2
1.3
1.8
1.9
1.5
1.6
0.9
0.8
0.6

IL-2
11.4
12.5
13.0
10.9
12.7
14.0
13.2
11.7
14.5
13.9
12.7
12.5

±
±
±
±
±
±
±
±
±
±
±
±

1.2
2.3
2.6
1.7
1.3
1.9
2.2
2.0
3.4
4.2
1.9
2.8

IL-12p40
100
126
95.7
99.1
111
125
120
100
100
114
98.5
99.6

±
±
±
±
±
±
±
±
±
±
±
±

13.5
14.9
20.5
16.4
19.5
18.2
23.4
20.1
14.2
15.4
9.6
9.0

IL-12p70
45.6
40.1
39.7
38.8
55.6
51.7
48.6
55.1
42.1
45.2
46.3
41.7

±
±
±
±
±
±
±
±
±
±
±
±

5.2
6.4
4.2
5.6
5.8
6.7
4.6
5.0
4.2
4.0
3.6
3.9

IL-17
15.0
13.3
14.9
11.7
9.9
11.2
10.7
13.6
10.2
11.6
12.7
13.0

±
±
±
±
±
±
±
±
±
±
±
±

2.6
3.4
2.5
2.0
1.8
1.6
1.3
1.1
1.1
1.2
1.1
2.0

TNF-α
32.9
60.7
28.4
29.6
36.7
40.1
42.9
41.7
30.1
42.5
39.6
34.2

±
±
±
±
±
±
±
±
±
±
±
±

4.5
5.2
6.2
2.3
3.1
3.0
2.9
2.4
4.1
5.2
6.3
6.0

GM-CSF
205
198
175
203
183
197
209
215
188
196
182
206

Th1/17 Cytokines

±
±
±
±
±
±
±
±
±
±
±
±

25.6
30.1
33.2
23.9
23.5
25.4
36.4
45.2
22.7
20.5
23.3
30.6

IL-4
2.4
2.5
3.6
3.1
3.9
4.1
3.0
4.9
4.2
4.1
3.6
4.5

±
±
±
±
±
±
±
±
±
±
±
±

0.5
0.6
0.4
0.2
0.6
0.4
1.0
1.4
1.0
1.1
0.9
0.4

IL-5
19.6
21.7
20.6
20.7
22.7
26.7
26.4
21.7
20.0
21.8
25.4
24.7

±
±
±
±
±
±
±
±
±
±
±
±

2.1
2.2
3.0
1.9
2.5
4.6
2.3
3.0
2.2
3.5
2.0
2.9

IL-13
369
351
360
376
350
389
347
350
325
333
326
364

±
±
±
±
±
±
±
±
±
±
±
±

45.6
50.2
61.1
60.2
51.2
46.3
39.4
35.5
29.6
30.4
31.1
58.4

Eotaxin
645
602
622
651
609
623
620
654
592
612
631
622

±
±
±
±
±
±
±
±
±
±
±
±

Th2 Cytokines

Table 3.7. Serum cytokine levels for each treatment group at each time point of the AuNP dose response study. n = 8 per group.
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125
120
199
264
201
165
145
132
133
175
145
148

IL-6
35.9
30.4
27.8
31.5
36.5
40.1
46.7
39.2
40.1
36.6
37.8
34.0

±
±
±
±
±
±
±
±
±
±
±
±

3.5
3.0
3.2
4.5
4.1
3.8
3.0
3.2
3.3
4.5
5.7
3.2

Other

IL-10
99.2
98.5
86.7
79.1
101
117
96.5
115
96.5
101
115
109

±
±
±
±
±
±
±
±
±
±
±
±

6.5
8.4
9.1
10.2
11.2
10.5
13.9
14.5
15.1
15.2
20.7
10.9

Table 3.8. Au Allergy StudyBAL Cell Phenotypes by Percent
Cell Phenotype
Day 11
Total BAL Cell #
Macrophages
Neutrophils
Eosinophils
Lymphocytes
CD4+ T-cells
CD8+ T-cells
B-Cells
Other

Group
5

1

2

3

4

6

7

8

1,140,500
94.01 %
0.99 %
0.52 %
3.79 %
2.39 %
0.80 %
0.60 %
1.02 %

1,098,750
93.65 %
1.17 %
0.67 %
3.80 %
2.61 %
0.71 %
0.48 %
0.89 %

1,125,000
92.78 %
1.01 %
0.61 %
3.75 %
2.50 %
0.74 %
0.51 %
1.15 %

1,120,500
93.01 %
1.22 %
0.62 %
3.65 %
2.36 %
0.77 %
0.52 %
1.42 %

1,141,000
93.24 %
1.25 %
0.67 %
3.55 %
2.01 %
0.89 %
0.65 %
1.29 %

1,113,250
92.15 %
1.20 %
0.51 %
3.59 %
2.22 %
0.85 %
0.52 %
2.55 %

1,191,500
93.54 %
0.97 %
0.56 %
3.82 %
2.45 %
0.82 %
0.55 %
1.11 %

1,168,250
93.11 %
1.11 %
0.58 %
4.00 %
2.62 %
0.80 %
0.58 %
1.20 %

1,152,250
92.58 %
1.30 %
0.56 %
3.71 %
2.50 %
0.66 %
0.55 %
1.25 %

1,098,000
93.33 %
1.20 %
0.57 %
3.61 %
2.44 %
0.69 %
0.48 %
1.29 %

1,109,600
93.07 %
1.06 %
0.64 %
3.82 %
2.62 %
0.71 %
0.49 %
1.41 %

1,165,200
92.57 %
0.99 %
0.63 %
3.93 %
2.59 %
0.74 %
0.60 %
1.21 %

1,170,400
94.12 %
0.99 %
0.60 %
3.58 %
2.33 %
0.75 %
0.50 %
0.71 %

1,540,000*
93.34 %
1.20 %
0.55 %
3.88 %
2.44 %
0.85 %
0.59 %
1.03 %

2,079,750*
92.56 %
1.12 %
0.54 %
3.86 %
2.58 %
0.67 %
0.61 %
1.92 %

1,709,250*
93.17 %
1.13 %
0.49 %
3.96 %
2.60 %
0.80 %
0.56 %
1.25 %

1,145,200
94.17 %
0.96 %
0.66 %
3.87 %
2.55 %
0.71 %
0.62 %
1.01 %

1,119,500
93.54 %
1.12 %
0.59 %
3.68 %
2.58 %
0.65 %
0.45 %
1.07 %

1,096,000
92.85 %
0.91 %
0.55 %
3.82 %
2.62 %
0.69 %
0.51 %
1.18 %

1,165,250
93.11 %
1.27 %
0.64 %
3.81 %
2.49 %
0.82 %
0.50 %
1.17 %

1,162,600
93.56 %
1.15 %
0.66 %
3.21 %
2.55 %
0.66 %
0.57 %
1.42 %

1,835,750*
92.87 %
1.37 %
0.60 %
3.86 %
2.51 %
0.75 %
0.60 %
1.30 %

2,367,750**
89.74 %
1.26 %
0.52 %
4.53 %
2.65 %
2.10 %**
0.45 %
3.28 %**

1,806,000*
93.11 %
1.04 %
0.54 %
4.12 %
2.44 %
0.81 %
0.87 %
1.19 %

Day 15

Total BAL Cell #
Macrophages
Neutrophils
Eosinophils
Lymphocytes
CD4+ T-cells
CD8+ T-cells
B-Cells
Other
Day 19

Total BAL Cell #
Macrophages
Neutrophils
Eosinophils
Lymphocytes
CD4+ T-cells
CD8+ T-cells
B-Cells
Other

Table 3.8. BAL cell total number and cell phenotypes by percent for all groups at all time points in the Au Allergy
study. n = 4 per group, p < 0.05, * indicates statistically significant from group 5 control at the corresponding time
point; ** indicates statically significant from all other groups at the corresponding time point.
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Table 3.9. Au Allergy Study
Mediastinal Lymph Node Cell Phenotypes by Percent
Cell
Phenotype

Group
1

2

3

4

5

6

7

8

Day 11
Total LN Cell #
CD4+ T-cells

3,303,500

3,320,500

3,370,250

3,130,500

3,268,000

3,204,500

3,365,000

3,376,250

62.24 %

63.35 %

63.01 %

61.49 %

63.21 %

62.22 %

61.17 %

62.59 %

CD44hi

1.23 %

2.22 %

1.49 %

0.87 %

1.17 %

2.04 %

2.39 %

1.37 %

22.4 %

21.19 %

20.58 %

22.96 %

22.19 %

21.17 %

23.69 %

22.01 %

CD8+ T-cells
CD44hi

B-cells

2.14 %

1.47 %

3.10 %

2.85 %

2.00 %

3.15 %

1.85 %

1.96 %

12.55 %

11.96 %

13.22 %

12.84 %

12.22 %

11.39 %

22.01 %

12.50 %

CD86hi

3.27 %

4.18 %

2.97 %

3.11 %

3.19 %

2.87 %

3.64 %

2.45 %

Other
Day 15
Total LN Cell #
CD4+ T-cells

2.22 %

3.02 %

2.35 %

2.45 %

2.38 %

3.10 %

1.69 %

2.90 %

3,252,750

3,419,500

3,235,500

3,263,750

3,457,000

4,967,750*

5,683,500*

3,195,850

62.50 %

62.59 %

63.17 %

61.97 %

62.25 %

63.12 %

58.64 %**

62.79 %

2.12 %

2.14 %

0.85 %

1.49 %

1.22 %

3.36 %

7.47 % #

12.15 %**

21.89 %

22.59 %

23.70 %

22.60 %

22.89 %

22.96 %

26.12 %**

21.47 %

1.80 %

1.66 %

2.58 %

3.10 %

1.47 %

2.59 %

12.54 %**

3.98 %

CD44hi

CD8+ T-cells
CD44hi

B-cells

13.21 %

12.45 %

12.40 %

11.88 %

12.45 %

11.24 %

10.23 %

11.95 %

CD86hi

3.00 %

2.67 %

2.41 %

1.92 %

2.22 %

2.68 %

2.77 %

3.28 %

Other
Day 19
Total LN Cell #
CD4+ T-cells

2.77 %

3.08 %

3.19 %

2.71 %

2.79 %

2.68 %

6.01 %**

2.79 %

3,381,750

3,466,500

3,590,750

3,561,000

3,565,250

5,585,500*

6,443,000^

4,226,250

59.64 %

61.27 %

62.89 %

62.99 %

61.87 %

62.39 %

55.10 %**

61.88 %

1.90 %

0.85 %

2.60 %

2.31 %

2.29 %

26.9 % @

14.23 %*

24.47 % @

21.90 %

22.48 %

23.57 %

24.06 %

22.89 %

20.47 %

31.12 %**

23.41 %

1.88 %

1.75 %

1.67 %

2.91 %

2.05 %

4.58 %

35.21 %**

5.12 %

12.56 %

12.56 %

13.14 %

11.90 %

12.45 %

12.52 %

9.56 %

13.07 %

CD44hi

CD8+ T-cells
CD44hi

B-cells
CD86hi

Other

2.25 %

2.49 %

1.58 %

0.88 %

1.44 %

25.51 % @

5.55 %*

20.19 % @

3.21 %

1.86 %

2.54 %

2.31 %

2.79 %

3.21 %

4.22 %

1.64 %

Table 3.9. Mediastinal lymph node cell phenotypes by percent for all groups at all time points in the Au Allergy
study. n = 4 per group, p < 0.05, * indicates statistically significant from group 5 control; ** indicates statistically
significant from all other groups; # indicates statistically significant from groups 5 and 6; ^ indicates statistically
significant from groups 5 and 8; @ indicates statistically significant form groups 5 and 7.
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Table 3.10. Au Allergy Study
Cervical Lymph Node Cell Phenotypes by Percent
Cell Phenotype
Day 11
Total LN Cell #
CD4+ T-cells
CD8+ T-cells
B-cells
Day 15
Total LN Cell #
CD4+ T-cells
CD8+ T-cells
B-cells
Day 19
Total LN Cell #
CD4+ T-cells
CD8+ T-cells
B-cells

Group
1

2

3

4

5

6

7

8

3,256,100

3,125,000

3,459,100

3,346,200

15,236,000 a

16,457,000 a

14,598,000 a

17,458,000 a

62.2%
20.5%
15.2%

63.0%
22.4%
13.2%

61.1%
21.7%
14.0%

60.8%
22.2%
14.1%

66.7% a
29.6% a
8.2% a

67.0% a
28.8% a
9.0% a

68.2% a
28.4% a
9.6% a

66.9% a
30.1% a
9.4% a

2,986,500

3,125,600

3,233,000

3,410,600

16,785,000 a

15,498,000 a

14,987,000 a

16,674,000 a

63.3%
21.4%
13.5%

61.4%
20.8%
14.1%

60.8%
22.7%
12.9%

62.2%
21.1%
13.7%

68.8% a
30.2% a
8.5% a

67.8% a
28.8% a
9.3% a

69.0% a
28.6% a
10.4% a

67.7% a
27.9% a
9.9% a

3,220,100

3,005,100

3,259,000

2,986,400

15,268,000 a

14,985,000 a

17,458,000 a

16,475,000 a

60.7%
19.8%
12.8%

61.4%
21.5%
13.0%

63.4%
22.0%
14.1%

60.7%
21.8%
13.6%

67.4% a
27.7% a
9.6% a

68.1% a
28.4% a
8.7% a

70.1% a
31.0% a
8.2% a

69.2% a
30.2% a
9.6% a

Table 3.10. Cervical lymph node cell phenotypes by percent for all groups at all time points in the Au Allergy study.
n = 4 per group, p < 0.05. a indicates statistically significant from all non-sensitized groups (groups 1-4).
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Table 3.11. Au Allergy Study
Spleen Cell Phenotypes by Percent
Cell Phenotype

Group
1

2

3

4

5

6

7

8

Day 11
CD4+ T-cells

14.23 %

15.01 %

15.24 %

14.87 %

14.93 %

15.11 %

15.09 %

15.03 %

CD44hi

1.12 %

2.05 %

1.48 %

1.72 %

1.28 %

2.14 %

2.03 %

2.09 %

CD8+ T-cells

8.55 %

9.12 %

9.07 %

8.61 %

8.78 %

8.69 %

9.13 %

9.07 %

CD44hi

2.18 %

1.44 %

1.82 %

1.37 %

1.52 %

1.58 %

1.34 %

2.11 %

B-cells

62.14 %

60.76 %

62.37 %

63.41 %

59.87 %

62.22 %

60.39 %

60.47 %

CD86hi

1.56 %

1.44 %

1.08 %

0.96 %

1.47 %

1.58 %

2.05 %

1.88 %

NK Cells
Other
Day 15
CD4+ T-cells

1.94 %
10.11 %

1.85 %
11.23 %

2.01 %
11.31 %

2.13 %
10.98 %

2.24 %
11.25 %

1.89 %
12.09 %

1.96 %
10.43 %

1.87 %
10.56 %

15.20 %

14.96 %

14.87 %

15.03 %

15.11 %

14.52 %

14.62 %

15.07 %

CD44hi

1.46 %

1.82 %

0.89 %

1.62 %

1.66 %

2.25 %

1.54 %

0.97 %

CD8+ T-cells

9.12 %

9.23 %

8.87 %

8.96 %

9.14 %

8.54 %

8.93 %

9.11 %

CD44hi

B-cells

2.02 %

2.37 %

1.82 %

1.77 %

0.95 %

2.22 %

10.27 %**

1.84 %

61.14 %

62.52 %

60.74 %

59.89 %

61.56 %

62.54 %

61.33 %

60.94 %

CD86hi

1.28 %

1.35 %

1.64 %

1.40 %

2.47 %

6.12 %

1.57 %

4.98 %

NK Cells
Other
Day 19
CD4+ T-cells

2.10 %
11.21 %

2.00 %
11.29 %

2.04 %
11.23 %

1.89 %
12.01 %

2.14 %
10.45 %

1.74 %
12.41 %

2.07 %
11.79 %

1.93 %
10.85 %

14.96 %

14.85 %

15.02 %

15.11 %

15.12 %

14.60 %

15.22 %

14.75 %

CD44hi

1.58 %

1.43 %

1.79 %

0.98 %

1.77 %

2.24 %

1.47 %

1.16 %

CD8+ T-cells

9.30 %

9.15 %

8.88 %

8.74 %

8.96 %

9.22 %

12.04 %**

8.57 %

CD44hi

B-cells
CD86hi

NK Cells
Other

2.10 %

2.07 %

1.68 %

1.05 %

0.69 %

1.14 %

12.41 %**

1.98 %

62.32 %

63.45 %

62.14 %

61.17 %

63.14 %

62.12 %

58.62 %**

61.17 %

2.09 %

2.27 %

1.39 %

1.16 %

1.17 %

7.68 %*

2.05 %

4.87 %*

2.16 %
11.26 %

2.01 %
10.54 %

2.22 %
11.74 %

1.91 %
11.03 %

2.44 %
12.47 %

2.12 %
11.40 %

1.85 %
10.63 %

1.93 %
12.07 %

Table 3.11. Spleen cell phenotypes by percent for all groups at all time points in the Au Allergy study. n = 4 per
group, p < 0.05. * indicates statistically significant from group 5 control; ** indicates statistically significant from all
other groups.
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Table 3.12. Au Allergy Study
Whole Blood Cell Differentials
Time
Point

11d

15d

19d

Tx
Group

1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8

RBC

WBC

(M/uL)
9.84
9.68
9.75
9.70
9.85
9.67
9.66
9.68
9.82
9.91
9.89
9.82
9.65
9.66
9.74
9.77
9.78
9.82
9.80
9.96
9.93
9.83
9.81
9.81

(k/uL)
2.12
2.09
2.13
2.44
2.25
2.04
2.12
2.38
2.12
2.14
1.92
2.07
1.94
1.97
2.13
2.34
2.27
2.13
1.86
1.85
2.23
2.24
2.17
2.04

Cell Number (k/uL)
Neutr
0.89
0.85
0.93
1.20
1.18
1.07
1.11
1.09
1.03
0.96
0.84
0.93
0.79
0.85
1.02
1.26
1.10
1.14
0.95
0.96
1.14
1.20
1.01
1.07

Lymph
1.20
1.21
1.17
1.19
1.03
0.95
0.97
1.24
1.06
1.15
1.05
1.11
1.12
1.08
1.09
1.04
1.14
0.95
0.87
0.86
1.07
1.00
1.12
0.94

Mono
0.01
0.01
0.02
0.03
0.01
0.01
0.01
0.03
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.01
0.02
0.02
0.02
0.01
0.02
0.02
0.01

Eos
0.01
0.01
0.01
0.02
0.02
0.01
0.02
0.01
0.01
0.02
0.02
0.02
0.02
0.02
0.01
0.02
0.01
0.01
0.02
0.01
0.01
0.02
0.01
0.01

% of Total WBC
Baso
0.01
0.01
0.00
0.00
0.01
0.00
0.01
0.01
0.01
0.00
0.00
0.00
0.00
0.01
0.00
0.00
0.01
0.01
0.00
0.00
0.00
0.00
0.01
0.01

Neutr

Lymph

Mono

Eos

Baso

41.98%
40.67%
43.66%
49.18%
52.44%
52.45%
52.36%
45.80%

56.60%
57.89%
54.93%
48.77%
45.78%
46.57%
45.75%
52.10%

0.47%
0.48%
0.94%
1.23%
0.44%
0.49%
0.47%
1.26%

0.47%
0.48%
0.47%
0.82%
0.89%
0.49%
0.94%
0.42%

0.47%
0.48%
0.00%
0.00%
0.44%
0.00%
0.47%
0.42%

48.58%
44.86%
43.75%
44.93%
40.72%
43.15%
47.89%
53.85%

50.00%
53.74%
54.69%
53.62%
57.73%
54.82%
51.17%
44.44%

0.47%
0.47%
0.52%
0.48%
0.52%
0.51%
0.47%
0.85%

0.47%
0.93%
1.04%
0.97%
1.03%
1.02%
0.47%
0.85%

0.47%
0.00%
0.00%
0.00%
0.00%
0.51%
0.00%
0.00%

48.46%
53.52%
51.08%
51.89%
51.12%
53.57%
46.54%
52.45%

50.22%
44.60%
46.77%
46.49%
47.98%
44.64%
51.61%
46.08%

0.44%
0.94%
1.08%
1.08%
0.45%
0.89%
0.92%
0.49%

0.44%
0.47%
1.08%
0.54%
0.45%
0.89%
0.46%
0.49%

0.44%
0.47%
0.00%
0.00%
0.00%
0.00%
0.46%
0.49%

Table 3.12. Analysis of whole blood for all groups at all time points in the Au Allergy study. Red blood cell number
(RBC), total white blood cell (WBC) number, and differentials of WBC populations are shown. Populations of
neutrophils (neutr), lymphocytes (lymph), monocytes (mono), eosinophils (eos), and basophils (baso) are
expressed as absolute number and as a percent of total WBC. n = 4 per group.
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Table 3.13. Au Allergy Study
Serum Cytokine Levels (pg/mL)
Time
Point

11d

15d

19d

Tx
Group

1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8

IFN-γ

IL-2

IL-12p40

IL-12p70

IL-17

TNF-α

GM-CSF

IL-4

IL-5

IL-13

Eotaxin

IL-6

IL-10

5.5 ± 1.1
5.2 ± 1.3

12.0 ± 2.3

108 ± 11.2

49.8 ± 4.0

12.4 ± 2.2

36.1 ± 4.0

175 ± 22.3

3.0 ± 0.4

20.7 ± 2.2

411 ± 85.2

704 ± 95.3

36.5 ± 2.8

85.6 ± 9.6

10.4 ± 1.5

87.7 ± 10.1

55.7 ± 5.1

16.1 ± 1.9

29.4 ± 4.5

196 ± 31.8

2.5 ± 0.5

17.0 ± 1.9

364 ± 54.0

655 ± 120

30.2 ± 3.0

84.1 ± 8.8

5.3 ± 1.2

11.8 ± 2.4

91.0 ± 10.1

61.0 ± 5.7

15.7 ± 3.0

37.0 ± 3.3

210 ± 29.9

2.4 ± 0.6

15.6 ± 2.0

385 ± 27.4

663 ± 94.2

31.1 ± 3.2

78.1 ± 7.1

6.1 ± 2.0

10.0 ± 2.0

96.5 ± 15.6

46.5 ± 4.9

14.4 ± 1.8

33.4 ± 2.9

207 ± 18.7

1.9 ± 0.5

18.4 ± 1.6

399 ± 36.6

680 ± 76.0

29.9 ± 2.7

92.2 ± 7.7

4.8 ± 1.6

14.7 ±1.4

105 ± 15.5

45.5 ± 4.1

15.5 ± 1.7

30.5 ± 2.8

200 ± 24.5

2.2 ± 0.3

19.9 ± 1.7

421 ± 41.2

710 ± 110

42.1 ± 6.1

107 ± 11.4

4.9 ± 1.2

12.2 ± 2.1

102 ± 17.5

55.7 ± 5.0

15.0 ± 1.9

41.1 ± 4.5

189 ± 20.3

2.3 ± 0.4

22.1 ± 1.5

404 ± 40.7

685 ± 103

40.0 ± 5.2

111 ± 10.5

5.2 ± 1.0

13.3 ± 2.2

111 ± 20.1

52.9 ± 7.4

15.0 ± 1.8

32.2 ± 5.1

182 ± 15.6

3.1 ± 1.0

21.7 ± 3.4

371 ± 39.5

660 ± 99.7

38.8 ± 3.5

87.4 ± 6.2

5.6 ± 0.9

10.9 ± 1.7

96.6 ± 14.4

56.6 ± 6.0

13.7 ± 2.3

37.0 ± 3.8

194 ± 19.1

2.6 ± 0.6

20.1 ± 2.1

385 ± 28.8

693 ± 85.4

35.0 ± 4.0

90.0 ± 7.4

5.1 ± 0.8

11.9 ± 2.0

99.7 ± 16.2

45.6 ± 5.0

11.9 ± 2.0

35.5 ± 2.4

205 ± 18.8

2.7 ± 0.2

18.8 ± 2.3

412 ± 51.1

711 ± 129

28.8 ± 5.1

80.2 ± 5.5

6.1 ± 1.1

14.1 ± 2.2

95.5 ± 15.2

53.2 ± 5.1

14.4 ± 2.0

30.5 ± 3.0

211 ± 20.0

3.2 ± 0.4

20.7 ± 2.7

386 ± 35.5

666 ± 120

32.7 ± 4.5

91.1 ± 4.8

5.9 ± 1.4

15.2 ± 3.4

107 ± 11.2

55.1 ± 7.1

13.3 ± 1.8

29.6 ± 2.8

188 ± 16.4

3.1 ± 0.5

22.1 ± 3.0

377 ± 27.4

685 ± 55.7

40.2 ± 6.2

90.7 ± 9.0

5.7 ± 1.0

12.2 ± 2.2

111 ± 20.7

50.0 ± 4.2

12.2 ± 3.0

31.1 ± 3.7

190 ± 20.3

1.9 ± 0.3

16.6 ± 3.1

407 ± 33.3

714 ± 76.4

34.4 ± 4.0

76.4 ± 5.6

4.8 ± 1.0

14.0 ± 2.2

94.4 ± 10.2

49.9 ± 3.9

10.9 ± 2.1

30.1 ± 1.9

166 ± 21.1

4.0 ± 2.4

18.5 ± 2.0

401 ± 40.2

701 ± 102

36.6 ± 4.1

102 ± 13.4

4.9 ± 0.9

13.9 ± 2.4

95.6 ± 9.9

50.0 ± 5.1

13.4 ± 4.1

28.8 ± 2.5

203 ± 20.1

8.5 ± 1.8*

19.6 ± 2.1

412 ± 36.4

700 ± 85.2

35.8 ± 2.8

111 ± 24.1

5.1 ± 1.4

11.7 ± 1.8

112 ± 14.5

51.2 ± 4.0

11.8 ± 2.7

34.4 ± 3.2

202 ± 16.5

3.5 ± 0.9

20.1 ± 2.2

388 ± 28.5

688 ± 84.5

41.1 ± 3.3

89.7 ± 7.4

5.2 ± 2.0

12.2 ± 2.0

109 ± 12.2

46.6 ± 3.7

14.0 ± 2.1

30.0 ± 2.8

189 ± 27.4

4.6 ± 0.8

19.7 ± 3.0

375 ± 30.0

690 ± 71.1

40.7 ± 2.9

92.2 ± 12.7

5.5 ± 1.6

11.9 ± 1.8

111 ± 10.2

50.1 ± 4.7

12..2 ± 2.3

36.6 ± 2.1

210 ± 22.1

3.2 ± 0.3

17.9 ± 3.1

370 ± 32.1

665 ± 74.1

29.8 ± 1.8

101 ± 9.9

5.6 ± 1.5

10.7 ± 0.9

101 ± 7.7

52.3 ± 6.0

13.0 ± 2.0

33.2 ± 3.0

196 ± 24.7

3.3 ± 0.2

18.4 ± 2.1

366 ± 40.1

674 ± 101

31.0 ± 2.7

85.6 ± 7.7

6.1 ± 1.4

13.3 ± 1.3

92.2 ± 7.6

60.7 ± 7.1

14.1 ± 2.5

32.7 ± 1.9

185 ± 30.2

4.1 ± 0.6

19.5 ± 2.4

405 ± 62.1

712 ± 54.1

37.4 ± 4.4

76.3 ± 6.1

6.0 ± 1.5

14.1 ± 2.2

90.7 ± 6.6

48.5 ± 5.8

12.9 ± 1.9

37.4 ± 3.5

178 ± 25.1

4.2 ± 1.1

20.7 ± 1.9

400 ± 36.1

720 ± 64.2

35.5 ± 3.5

80.1 ± 7.1

4.7 ± 1.0

10.9 ± 1.8

88.7 ± 9.2

55.6 ± 6.1

11.7 ± 2.0

29.9 ± 4.1

213 ± 26.4

3.6 ± 0.8

20.1 ± 2.2

408 ± 29.6

704 ± 52.3

29.9 ± 3.1

89.9 ± 6.5

5.0 ± 0.9

11.4 ± 2.0

80.1 ± 10.2

54.4 ± 6.1

12.2 ± 1.5

35.5 ± 3.0

222 ± 31.4

9.7 ± 1.3*

28.3 ± 2.1*

419 ± 40.5

685 ± 58.1

33.0 ± 3.2

90.2 ± 6.4

5.3 ± 0.8

12.2 ± 1.8

116 ± 12.3

50.7 ± 7.1

13.3 ± 2.9

34.7 ± 3.0

187 ± 20.0

3.1 ± 0.4

19.5 ± 2.7

395 ± 40.1

700 ± 88.4

34.7 ± 2.6

127 ± 9.1*

5.5 ± 1.4

13.3 ± 2.7

110 ± 13.0

48.7 ± 4.4

15.5 ± 3.0

36.6 ± 2.8

196 ± 18.5

5.0 ± 0.8*

23.5 ± 3.0

378 ± 45.2

699 ± 85.8

38.8 ± 5.0

135 ± 16.7*

Th1/Th17 Cytokines

Th2 Cytokines

Other

Table 3.13. Serum cytokine levels for each treatment group at each time point of the Au Allergy study. n = 4 per group, p < 0.05. * indicates statistically
significant over group 5 control.
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Table 3.14. Au Allergy Study
BALF Cytokine Levels (pg/mL)
Time
Point

11d

15d

19d

Tx
Group

1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8

IFN-γ

IL-2

IL-12p40

IL-12p70

IL-17

TNF-α

GM-CSF

IL-4

IL-5

IL-13

Eotaxin

IL-6

IL-10

3.3 ± 0.3

6.0 ± 0.4

112 ± 15.4

36.4 ± 3.0

1.2 ± 0.1

4.0 ± 0.3

3.3 ± 0.3

5.5 ± 0.4

5.2 ± 0.4

2.6 ± 0.6

3.4 ± 0.5

2.5 ± 0.2

2.0 ± 0.2

2.9 ± 0.4

5.5 ± 0.3

101 ± 9.6

29.8 ± 1.8

0.9 ± 0.1

3.6 ± 0.3

2.8 ± 0.2

6.2 ± 0.7

6.1 ± 0.8

3.0 ± 1.0

3.5 ± 0.3

3.1 ± 0.3

2.1 ± 0.3

2.2 ± 0.2

5.4 ± 0.3

98.5 ± 7.7

31.1 ± 3.0

1.0 ± 0.2

3.8 ± 0.4

2.4 ± 0.1

6.0 ± 1.1

5.8 ± 0.5

2.5 ± 0.4

3.0 ± 0.2

3.0 ± 0.2

2.2 ± 0.2

2.4 ± 0.2

6.1 ± 1.0

95.4 ± 8.0

32.2 ± 2.8

1.3 ± 0.2

4.2 ± 0.5

3.0 ± 0.3

5.9 ± 0.7

5.5 ± 0.8

3.2 ± 0.3

3.1 ± 0.3

2.8 ± 0.2

2.2 ± 0.3

3.0 ± 0.2

5.2 ± 0.6

88.7 ± 9.5

35.5 ± 3.3

2.0 ± 0.2

4.5 ± 0.2

4.2 ± 0.9

4.8 ± 0.4

7.1 ± 0.5

3.0 ± 0.2

2.8 ± 0.3

2.6 ± 0.4

1.8 ± 0.2

3.2 ± 0.4

5.5 ± 0.5

80.1 ± 7.7

27.7 ± 2.9

1.3 ± 0.2

4.0 ± 0.3

3.6 ± 0.5

4.9 ± 0.5

6.5 ± 0.5

3.1 ± 0.2

4.1 ± 0.4

3.3 ± 0.3

3.2 ± 0.3

2.4 ± 0.2

6.1 ± 0.6

114 ± 12.3

34.0 ± 2.5

1.1 ± 0.1

3.9 ± 0.3

2.9 ± 0.8

5.2 ± 0.5

5.9 ± 0.5

1.9 ± 0.2

4.0 ± 0.5

3.0 ± 0.3

3.0 ± 0.3

2.7 ± 0.1

5.8 ± 0.4

122 ± 10.4

33.3 ± 2.8

2.1 ± 0.3

2.8 ± 0.3

3.1 ± 0.6

5.5 ± 0.4

6.0 ± 0.5

2.2 ± 0.2

3.3 ± 0.3

3.1 ± 0.5

1.9 ± 0.4

2.8 ± 0.2

4.8 ± 0.5

120 ± 12.2

30.1 ± 2.5

0.8 ± 0.1

4.0 ± 0.4

3.3 ± 0.5

6.1 ± 0.5

5.7 ± 0.3

2.8 ± 0.3

4.2 ± 0.6

3.3 ± 0.5

2.6 ± 0.5

3.0 ± 0.3

6.2 ± 0.8

122 ± 15.4

30.0 ± 3.5

0.9 ± 0.2

3.5 ± 0.3

3.6 ± 0.4

6.6 ± 0.7

4.9 ± 0.6

2.9 ± 0.2

5.0 ± 0.8

2.9 ± 0.2

2.2 ± 0.1

3.1 ± 0.3

6.0 ± 0.8

104 ± 10.7

28.8 ± 3.5

0.8 ± 0.2

3.2 ± 0.3

4.4 ± 0.8

5.3 ± 0.5

7.2 ± 0.5

1.8 ± 0.3

2.8 ± 0.3

3.0 ± 0.5

2.5 ± 0.3

2.5 ± 0.2

5.5 ± 1.0

98.7 ± 12.2

29.9 ± 2.8

1.4 ± 0.3

3.1 ± 0.3

2.9 ± 0.3

4.8 ± 0.4

6.6 ± 0.4

3.3 ± 0.3

3.3 ± 0.3

3.5 ± 0.8

3.1 ± 0.3

2.6 ± 0.2

5.4 ± 0.5

92.5 ± 8.5

35.5 ± 4.0

1.5 ± 0.2

4.2 ± 0.3

2.6 ± 0.3

5.7 ± 0.5

5.9 ± 0.4

1.9 ± 0.2

4.0 ± 0.4

2.8 ± 0.4

2.6 ± 0.2

2.7 ± 0.3

4.9 ± 0.5

90.1 ± 8.5

28.6 ± 2.9

0.9 ± 0.1

4.4 ± 0.4

3.0 ± 0.2

5.5 ± 0.5

5.5 ± 0.5

2.5 ± 0.3

4.2 ± 0.4

16.2 ± 2.5*

2.7 ± 0.3

2.4 ± 0.3

6.1 ± 0.8

96.6 ± 10.0

31.1 ± 3.5

0.8 ± 0.1

4.5 ± 0.5

10.1 ± 0.8*

6.3 ± 0.6

5.0 ± 0.4

2.7 ± 0.2

3.9 ± 0.4

4.0 ± 0.6

2.9 ± 0.3

2.5 ± 0.2

5.5 ± 0.5

116 ± 13.3

32.2 ± 2.7

1.0 ± 0.3

3.7 ± 0.3

3.2 ± 0.5

6.0 ± 0.3

6.8 ± 0.5

2.2 ± 0.1

5.0 ± 0.4

3.9 ± 0.3

2.4 ± 0.2

3.0 ± 0.3

5.2 ± 0.4

96.7 ± 8.6

32.2 ± 3.5

1.0 ± 0.1

5.0 ± 0.5

2.8 ± 0.4

6.1 ± 0.5

5.9 ± 0.6

2.9 ± 0.3

5.1 ± 0.6

4.1 ± 0.6

2.5 ± 0.2

3.1 ± 0.4

4.8 ± 0.6

100 ± 8.6

29.6 ± 2.0

1.1 ± 0.2

4.0 ± 0.4

2.6 ± 0.5

5.7 ± 0.5

4.8 ± 0.4

3.3 ± 0.2

4.4 ± 0.5

3.2 ± 1.0

2.6 ± 0.2

2.8 ± 0.3

5.8 ± 0.6

119 ± 9.6

36.7 ± 4.0

1.3 ± 0.2

3.9 ± 0.4

3.5 ± 0.3

4.7 ± 0.5

6.2 ± 0.5

3.0 ± 0.3

4.4 ± 0.6

2.8 ± 0.2

3.3 ± 0.4

2.9 ± 0.2

6.3 ± 0.9

111 ± 7.4

32.2 ± 2.9

1.2 ± 0.1

4.4 ± 0.5

4.1 ± 0.6

4.9 ± 0.5

7.0 ± 0.6

4.1 ± 0.3

3.8 ± 0.7

2.9 ± 0.3

3.1 ± 0.5

3.5 ± 0.6

6.8 ± 1.2

88.5 ± 6.4

31.1 ± 4.2

1.8 ± 0.2

4.6 ± 0.4

3.6 ± 0.8

6.6 ± 0.7

5.8 ± 0.3

2.6 ± 0.2

2.9 ± 0.3

3.2 ± 0.3

2.0 ± 0.1

17.0 ± 3.2@

5.7 ± 0.5

113 ± 15.4

28.8 ± 3.0

2.2 ± 0.1

5.2 ± 0.5

3.5 ± 0.7

5.5 ± 0.6

5.5 ± 0.3

2.5 ± 0.2

3.6 ± 0.4

6.2 ± 1.0

2.2 ± 0.2

6.2 ± 1.5*

15.5 ± 2.5*

107 ± 10.6

62.1 ± 4.5*

0.8 ± 0.2

5.0 ± 0.3

5.4 ± 0.8

5.4 ± 0.5

6.6 ± 0.3

3.6 ± 0.3

4.1 ± 0.4

4.2 ± 0.8

3.0 ± 0.3

14.7 ± 2.0@

11.9 ± 1.6*

95.5 ± 8.7

55.6 ± 4.9*

1.4 ± 0.2

3.8 ± 0.4

4.0 ± 0.8

6.3 ± 0.6

6.9 ± 0.6

3.3 ± 0.3

5.2 ± 0.5

4.4 ± 0.6

2.8 ± 0.2

Th1/Th17 Cytokines

Th2 Cytokines

Other

Table 3.14. BALF cytokine levels for each treatment group at each time point of the Au Allergy study. n = 4 per group, p < 0.05. * indicates statistically
significant over group 5 control; @ indicates statistical significance over groups 5 and 7.
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CHAPTER 3 FIGURES

Figure 3.1. Timeline of exposures for the Local Lymph Node Assay (LLNA). Mice were dermally exposed to vehicle
control (50% DMSO), positive control (10% AuCl3), or 2.5, 5.0, or 10% Au or AuNP for three consecutive days (1d,
2d, 3d) on the dorsal sides of both ears. Following two days of rest, mice were injected intravenously with 3Hthymidine, euthanized 5 hours later, and lymph nodes were harvested for analysis.
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A

B
Treatment Groups in the Au Allergy Study and
Corresponding Exposures
Treatment Group
Non-sensitized vehicle control
Non-sensitized Au
Non-sensitized AuNP mass
Non-sensitized AuNP SA
Sensitized vehicle control
Sensitized Au
Sensitized AuNP mass
Sensitized AuNP SA

Group #

1
2
3
4
5
6
7
8

Days 1-3
(dermal)

Days 10, 14, 18
(aspiration)
Particle

Dose Mass

Dose SA

DMSO

VC
Au
AuNP
AuNP

30 µg
30 µg
0.8 µg

9.90x10-6 m2
3.14x10-4 m2
9.90x10-6 m2

10% AuCl

VC
Au
AuNP
AuNP

30 µg
30 µg
0.8 µg

9.90x10-6 m2
3.14x10-4 m2
9.90x10-6 m2

Figure 3.2. Schedule of exposures for the Au allergy study (A) and treatment groups with corresponding exposures
(B). Mice were treated dermally with DMSO vehicle control (VC) or 10% AuCl3 on days 1, 2, and 3 to establish
contact allergy to gold in one set of animals (groups 5-8) and generate a set of non-sensitized control animals
(groups 1-4). After 6 days of rest, mice were aspirated with H2O (VC), Au particles, or AuNP in mass- and surface
area-normalized doses beginning on day 10. Groups 2, 3, 6, and 7 were administered 30 µg mass-equivalent doses
of Au (groups 2 and 6) and AuNP (groups 3 and 7). Groups 2, 4, 6, and 8 were exposed to 9.90x10-6 m2 surface
area-normalized doses of Au (groups 2 and 6) and AuNP (groups 4 and 8). After the first aspiration on day 10, a
set of mice (n = 4) was euthanized the following day (day 11). The remaining mice were aspirated again with
identical treatment doses on day 14, and a set of mice (n = 4) was euthanized the following day (day 15). The last
group of mice were aspirated a third time on day 18 and euthanized the following day (day 19).
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A

B

C

D

Figure 3.3. Transmission electron micrographs of Au (A, C) and AuNP (B, D). Particles are shown at equal
magnifications (A, B; scale bar = 500 nm) and in size-specific detail (C- 1µm scale bar, D- 50 nm scale bar).
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Figure 3.4. Scanning electron micrographs of Au and AuNP at identical magnifications (A, B; scale bar- 1µm) and
size-adjusted magnifications (C, D). Magnified images showing particle surface detail for Au (E, F) and AuNP (G,
H).

308

Figure 3.5. In the LLNA study, the exposure site-draining lymph nodes were excised and 3H-thymidine incorporation
was assessed (expressed as disintegrations per minute; DPM). Treatment groups included vehicle control (gray,
50% DMSO); Au particles at 2.5, 5.0, or 10% w/v (purple); AuNP particles at 2.5, 5.0, or 10% w/v (yellow); and 10%
AuCl3 positive control (gray). Stimulation index was calculated for each material and is shown over the
corresponding bars. n = 8 per group, p < 0.05, * indicates statistically significant from all other groups.
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A

Figure 3.6. Total mediastinal lymph node cell number for each treatment group (black = vehicle control, red = 10 µg
AuNP, green = 30 µg AuNP, blue = 90 µg AuNP) at each time point of the AuNP dose response study. n = 8 per
group, p < 0.05, * indicates statistically significant from all other groups.
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Figure 3.7. Mediastinal lymph node cell phenotypes from the AuNP dose response study. The proportion pf
lymphocyte phenotypes (yellow = CD4+ T-cells, orange = CD8+ T-cells, red = B-cells, gray = other cell type) with
respect to total number are shown for each time point in A (1 d), B (4 d), and C (8 d). Absolute values for each cell
population are shown in D. n = 8 per group, p < 0.05, * indicates statistically significant from all other groups at the
corresponding time point.
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Figure 3.8. Total number of BAL cells in all sensitized groups at all time points in the Au Allergy study. n = 4 per
group, p < 0.05, * indicates statistically significant over group 5 control; ** indicates statistically significant from all
other groups; # indicates statistically significant from groups 5 and 6.
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Figure 3.9. Total number of BAL neutrophils (A) and eosinophils (B) in all sensitized groups at all time points in the
Au Allergy study and total cell number for all BAL cell populations (C). n = 4 per group, p < 0.05, * indicates
statistically significant over group 5 control; ** indicates statistically significant from all other groups; # indicates
statistically significant from groups 5 and 6; ^ indicates statistically significant from groups 5 and 8.
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Figure 3.10. Total number of BAL lymphocytes in all sensitized groups at all time points (A) in the Au Allergy study
and time-dependent alterations in BAL lymphocyte CD4 : CD8 T-cell ratio (B and C). n = 4 per group, p < 0.05, *
indicates statistically significant over group 5 control; ** indicates statistically significant from all other groups at the
corresponding time point.
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Figure 3.11. Total cell number in the mediastinal lymph nodes of all sensitized groups at all time points (A) in the
Au Allergy model and corresponding cellular differentials (B). n = 4 per group, p < 0.05. * indicates statistically
significant from group 5 control; ** indicates statistically significant from all other groups; ^ indicates statistically
significant from groups 5 and 8.
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Figure 3.12. Percent of mediastinal lymph node CD4+ T-cells (A) and CD8+ T-cells (B) expressing a CD44hi
phenotype, indicative of activation, at all time points of the Au Allergy study for all sensitized groups. n = 4, p < 0.05.
* indicates statistically significant from group 5 control; ** indicates statistically significant from all other groups; #
indicates statistically significant from groups 5 and 6; @ indicates statistically significant from groups 5 and 7. Flow
cytometry gating strategy and population shift with respect to CD44 expression by group 6 CD3+CD4+ cells at 11d
(C) and 19 d (D). The proportion of the total cell population expressing a CD44 hi phenotype was determined by
quantification of events falling with the black box.
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Figure 3.13. Circulating IgE levels in all groups of the Au Allergy study at all time points. Color-matched lines
represent sensitized (solid line) and non-sensitized (dotted line) Au treatment-matched groups. n = 4 per group, p
< 0.05, * indicates statistically significant over group 5 control, “a” indicates statistically significant from all nonsensitized control groups.
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CHAPTER 4:
General Discussion
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Two major studies were designed to begin addressing increasingly relevant knowledge gaps
associated with the immunotoxic potential of metal nanomaterials. The overarching goals of these studies
were 1) to investigate specific nanomaterials containing metal constituents with known allergic effects, 2)
identify any particle size-specific immune effects, and 3) determine the relationship between these effects
and various physico-chemical properties.
The first set of studies investigated the potential for pulmonary NiO exposure to cause acute lung
inflammation and augment OVA-induced asthma with respect to mass and surface area as dose metrics.
Although all indices of pulmonary inflammation correlated with the administered surface area of NiO in
the time course study, exposure-induced alterations in immune parameters of the OVA study did not
exhibit a similar degree of dose metric exclusivity. Many allergic markers were similarly modulated
amongst groups exposed to surface area-normalized doses of particles, suggesting underlying
mechanisms subject to NiO surface area-dependent modulation. By comparison, some immune
parameters were conserved with respect to particle size or NiO exposure, irrespective of any dose metric.
The second set of studies was designed to investigate the potential for AuNP to induce dermal
sensitization and alterations in pulmonary immunity. Furthermore, the impact of established contact
sensitivity on respiratory responses to different forms of gold was investigated. Subsequently, irrespective
of differences in particle size, metallic AuNP and Au particles both exhibited a lack of skin sensitizing
potential, and AuNP aspiration was not associated with any notable inflammatory effects in the lung.
However, exposure to the highest dose of AuNP was associated with an increase in lymph node size at
8 d. In the Au allergy model, Au/AuNP aspiration did not lead to any detectable alterations in any immune
parameters in animals that had not been previously dermally-sensitized to gold. Comparatively,
sensitized animals exhibited increased numbers of BAL lymphocytes with each successive aspiration.
The degree of lymphocyte influx was correlated to dose surface area, and animals exposed to the highest
AuNP dose also exhibited a selective increase in the number of BAL CD8+ T-cells to the airways. In
accordance with the preferential expansion and activation of specific lymphocyte subpopulations within
the lymph nodes, BAL/serum cytokine profiles, and serum IgE levels, higher surface area-based doses
of AuNP were generally associated with the development of Th1-polarized immune responses with many
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features resembling those seen in hypersensitivity pneumonitis. Contrarily, lower surface area-based
doses of Au/AuNP were associated with polarization of immune responses towards a Th2-dominant
state.
Collectively, the results from the NiO and AuNP studies exhibit several notable discrepancies, as
well as many similarities regarding the effects of metal nanomaterials on allergic disease.
The NiO and Au studies, reported herein, were employed to investigate different aspects of
allergic disease. The NiO studies were performed to assess augmentation of IgE-mediated allergic
responses to the protein allergen, OVA, in the respiratory tract. Comparatively, the Au studies were
executed to characterize the potential for AuNP to cause dermal sensitization and elicit T-cell-mediated
metal allergy in the context of both dermal and respiratory exposures.
Within these studies, both test materials were incorporated into a time course model to
characterize their inflammatory potential in the lungs with respect to critical windows in the ensuing allergy
models. Although NiO-UF was associated with much more pronounced toxic effects than AuNP following
respiratory exposure, the degree of acute pulmonary inflammation following exposure to both materials
exhibited similar dose-responsive relationships with respect to the surface area of the administered
doses.
Similarly, despite variations in the immunomodulatory mechanisms being investigated, model
allergens, tissues of involvement, and underlying hypersensitivity types between the two studies, the NiO
and Au studies also both demonstrated an association between the immunological effects of the particles
and their surface area. However, the strength of this association was not as robust as the observed
relationship between surface area and magnitude of acute pulmonary inflammation. All markers of toxicity
measured in the NiO and AuNP time course studies exhibited dose-responsive relationships with respect
to material surface area. While many immune parameters of the allergy models were similarly conserved
with respect to surface area, some allergic markers appeared better correlated with other dose metrics.
For example, in the NiO OVA study, alterations in Penh responses and lung eosinophil burden were
conserved between groups with respect to particle size. In the Au allergy study, the number of BAL
neutrophils correlated better with the mass of Au/AuNP administered to sensitized animals.
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The NiO and Au particles were also both shown to induce alterations in Th1/2 balance in their
respective allergy models. Furthermore, the directionality of this polarization was consistently correlated
to dose surface area in both studies. In the NiO allergy study, exposure to larger surface area-based
doses of NiO resulted in Th1-dominant polarization of OVA-specific responses. Th2 adjuvant effects were
correlated to the lower surface area-based doses of NiO. Similarly, in the Au allergy study, sensitized
animals that were exposed to larger surface area-based dose of AuNP exhibited comparable responses
involving preferential expansion of many Th1-related immune markers. The lower doses of Au/AuNP
surface area were associated with increases in IgE production and expansion of CD4+ T-cell and B-cell
populations in the lymph nodes, characteristics of Th2-dominant responses.
Interestingly, the directionality of immune polarization following AuNP aspiration appeared to be
dependent on sensitization status. In the AuNP dose response study, exposure to the highest mass- and
surface area-based dose of AuNP was associated with the preferential expansion of lymphocyte
populations more commonly implicated in Th2-mediated immune responses. Accordingly, increased
numbers of lymph node CD4+ T-cells and B-cells were exclusively observed in the 90 µg AuNP exposure
group at 8 d. Although this effect demonstrates a similar surface area-based dose-responsive tendency
as the immune responses seen in the Au allergy model, the two responses exhibit divergent
directionalities of polarization. In the allergy model, the higher surface area-based dose of AuNP was
associated with development of Th1-dominant effects in pre-sensitized animals, whereas the same dose
caused expansion of Th2-associated lymphocyte populations in naïve animals of the time course study.
Collectively, these observations imply that AuNP exposure can cause divergent immunological
responses, the nature of which depends on the sensitization status of the host.
Other studies that have investigated the immunomodulatory potential of AuNP in the context of
allergic disease have actually generated similar findings regarding sensitization status-dependent
immune responses to AuNP. In one study, intranasal administration of AuNP with OVA during
sensitization was been shown to promote the expansion of antigen-specific CD4+ T-cells in the lymph
nodes (1677). This observation is consistent with the findings from the AuNP dose response study, which
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suggested the potential for AuNP to enhance IgE-mediated, Th2-dominant immune effects in naïve
subjects.
By comparison, AuNP have also been studied in two asthma models that incorporated their
exposure into the challenge phase. Accordingly, respiratory exposure to both 5 and 6.3 nm AuNP were
shown to attenuate many aspects of allergic airway inflammation following allergen challenge (891, 892).
Exposure was associated with decreased inflammatory cell recruitment, compromised ROS production,
and inhibition of airway hyperreactivity. In these cases, the diminishment of Th2/IgE allergic reactivity
following AuNP exposure was associated with a pre-established state of OVA sensitivity. Although the
type of allergic responses examined in these asthma models and the Au allergy study presented in
Chapter 3 differ, all of the studies similarly demonstrate a selective attenuation of Th2 responses by
AuNP in cases of established allergic sensitivity.
The results from the NiO and Au studies, in combination with existing literature, suggest several
specific metal nanomaterial physico-chemical properties with notable implications for allergic disease.
However, these properties may be differentially implicated with respect to 1) metal-specific allergy or
hypersensitivity responses to non-metal allergens, 2) T-cell-mediated or IgE-mediated allergic processes,
3) allergic responses of the skin or respiratory tract, and 4) immunological processes specific to the
sensitization or elicitation phase of allergic disease.
In the context of metal allergy, all knowledge regarding physico-chemical properties of importance
pertains to T-cell-mediated allergic responses. The potential for metal nanomaterials to cause IgEmediated metal-specific allergic responses remains completely uninvestigated, and likewise, physicochemical properties with potential to contribute to such responses remain unknown.
Accordingly, ample evidence suggests that the development of metal-specific immunological
memory following skin contact with metal nanomaterials is heavily dependent on the dissolution potential
of the materials. When comprised of allergenic metal constituents, nanomaterials that exhibit high
dissolution potential are capable of releasing higher concentrations of haptenic metal ions, increasing
sensitizer bioavailability. In accordance with established knowledge that metal salts exhibit enhanced
potential to cause skin sensitization over metallic and particulate metal particles, highly soluble metal
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nanomaterials appear far more likely to induce dermal sensitization than insoluble metal nanoparticles
(671).
With respect to metal ACD elicitation, the dissolution potential of metal nanomaterials also
appears to be critically influential. The importance of this property is illustrated by the observation that
that Pd salts and PdNP induced differing degrees of contact allergy elicitation reactions in vivo and metalspecific lymphocyte activation in vitro (545, 672). However, since it is known that the exposure threshold
required to incite allergic elicitation reactions is orders of magnitude lower than that required to induce
sensitization, the dissolution potential of metal nanomaterials may be less critical in the elicitation phase
of contact allergy than the sensitization phase (91, 1666).
Although meal-induced T-cell-mediated hypersensitivity reactions of the respiratory tract are not
as well-understood as dermal responses occurring by the same mechanism, this type of response does
occur (452, 1678). Moreover, metal nanomaterials have not been extensively studied in this context.
However, the results of the Au allergy study suggest that inhalation exposure to metal nanomaterials may
result in local recruitment of metal-reactive T-cells in individuals with established populations, like those
present in cases of contact sensitivity. The observed association between aspirated-gold surface area
and the magnitude of T-cell influx to the airways, Th1/2 BALF cytokine levels, and IgE production implies
that this property may have specific implications for metal-specific T-cell-mediated respiratory allergy.
The majority of existing knowledge regarding metal nanomaterial physico-chemical properties
implicated in allergic effects pertains specifically to their allergy-augmenting effects. In this context,
nanomaterial characteristics implicated in immunomodulation can differ depending on the underlying
immunological mechanisms subject to disruption, and likewise, specific phases of allergy. This concept
is illustrated by several studies that demonstrate potential for the same material to exhibit no effect,
enhance, or attenuate allergic markers depending on exposure occurrence in relation to the phases of
allergy (783, 879, 896, 897). Metal nanomaterials and physico-chemical properties that have been
correlated to immunomodulatory potential during specific phases of asthma, ACD, and atopic dermatitis
models are shown in figure 4.1 (534, 544, 551, 624, 723-725, 781, 783, 789, 812, 882, 883, 887, 891,
903, 1652, 1679-1681).
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The majority of existing studies have examined the effects of metal nanomaterial properties on
the augmentation of IgE-mediated asthma. As demonstrated by the NiO OVA model presented previously
in Chapter 2, metal nanomaterial exposure prior to allergic sensitization can result in modulation of
numerous immune parameters following the subsequent induction and elicitation of IgE-mediated
respiratory allergy. The nanomaterial characteristics most closely related to the modulatory effects seen
in this study were particle size and surface area. These properties appeared to contribute to
immunomodulatory effects reflective of their association with the inflammatory potential of NiO particles
in the lung. Innate immune stimulation, inflammatory reactions, and subsequent local tissue damage can
prime the respiratory immune system for the development of Th1/Th2-skewed immune responses.
Accordingly, since the magnitude of these inflammatory responses has been associated with properties
like size and surface area of NiO and other insoluble metal nanomaterials, these properties may also be
implicated in allergy augmentation by this mechanism (1355, 1682).
Additional studies have reported observations consistent with these findings from the NiO OVA
study. For example, surface area dose-dependent innate immune responses induced by SiNP, FeNP,
and TiO2NP have been associated with attenuation of subsequently-induced Th2-driven allergic airway
inflammation (896, 897, 1651, 1653). Accordingly, higher doses of these materials have been correlated
to Th1-dominant immune states in allergic conditions, whereas Th2 adjuvancy has been selectively
observed following exposure to lower doses of the materials.
Other physico-chemical properties have been shown to be influential when metal nanomaterial
exposure occurs simultaneous to allergic sensitization. In this context, extensive evidence suggests that
metal nanomaterials can modulate adaptive immune response generation as a result of physical
interactions with antigen that result in altered delivery kinetics and presentation efficiency (1683).
Accordingly, sensitization to protein allergens in the presence of metal nanomaterials, irrespective of
whether sensitization is achieved by respiratory, systemic, or dermal exposure, has been consistently
shown to be impacted in a size-, surface area-, crystallinity-, and surface modification-dependent manner
(534, 624, 887, 946, 1651). Since these properties are directly related to nanomaterial surface-loading
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capacity and binding activity, their correlation with modulation of sensitization when administered with
antigen is consistent with this mechanism.
Metal nanomaterial exposure after sensitization, but prior to allergen challenge, has been
frequently reported to involve similar mechanisms of immune modulation as those implicated in effects
of exposure prior to sensitization. Accordingly, many of the same physico-chemical properties have been
shown to be influential in this context. For example, inflammatory cell phenotypes recruited to the airways
following exposure to ZrNP, AgNP, and AuNP have been shown to differ with respect to surface
modification and dose (903). This preferential recruitment of specific immune cell populations prior to
allergen challenge has been shown to facilitate alterations in the nature of allergen-induced airway
inflammation, as well as response severity and duration (789, 891).
Metal nanomaterial exposure simultaneous to allergen challenge has been shown to result in
modulation of asthmatic elicitation responses involving two distinct underlying mechanisms.
First, the early airway response may be subject to interference by metal nanomaterials. This
phase of the elicitation response is primarily mediated by IgE-induced degranulation of mast cells, a
process with potential for nanomaterial-induced disruption that is best illustrated by several in vitro studies
(182). For example, AuNP have been shown to interact with mast cell surface receptors and IgE
molecules, leading to alterations in binding capacity, and subsequent degranulation behavior (784).
Similarly, AuNP have also been shown to interact with protein allergens in a manner that results in
modulation of basophil activation (522). In accordance with these mechanisms, metal nanomaterial size
and surface chemistry are properties with potential implications for modulation of the early phase
asthmatic response.
The other mechanism of metal nanomaterial-induced elicitation response augmentation involves
the late phase asthmatic response, which is associated with the recruitment, infiltration, and activation of
inflammatory cells in the airways (189). Metal nanomaterial size and surface area appear critically
influential in this aspect, as nanomaterials can adsorb many biological molecules involved in inflammatory
cell recruitment, the extent to which is dependent on these properties. For example, TiO2NP have been
shown to bind CXCL8, neutralizing its biological activity, which includes neutrophil recruitment (1015).
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It has been proposed that pulmonary oxidative stress is a critical mediator of the late phase
asthmatic response (1684). Likewise, oxidative potential has also been corelated to alteration of
elicitation reactions by metal nanomaterials. Properties including surface modification and charge have
been shown to modulate inflammatory cell recruitment in the context of oxidative stress (789, 812, 906).
Moreover, metal nanomaterials with properties associated with increased antioxidant potential have been
shown to attenuate allergic inflammation when administered with allergen during challenge (1685).
Compared to IgE-mediated respiratory allergy, less is known regarding the physico-chemical
properties of metal nanomaterials implicated in the modulation of T-cell-mediated ACD. Metal
nanomaterial exposure prior to dermal sensitization has been associated with alterations in skin immune
status and resident immune cell activity. As a result, modulation of the early events of ACD development
have been shown to be dependent on parameters including particle size and dose (723, 1680).
Surface modification and dissolution potential of metal nanomaterials have been correlated to
allergy-modulating potential in the elicitation phase of ACD. Antigen-specific T-cell reactivity has been
shown to be differentially augmented with respect to variations in the chemistry of metal nanomaterial
surface-bound functional groups, as well as the propensity for ion release from the parent material (1074,
1118). These observations substantiate other findings that have correlated the capacity for metal
nanomaterials to modulate T-cell intracellular glutathione levels and cell signaling pathways, leading to
alterations in cytokine production, and subsequent effector functions following allergen challenge (1102).
Skin sensitization leading to the development of IgE-mediated atopic dermatitis has been shown
to be modulated by metal nanomaterials exhibiting many of the same properties implicated in their
modulatory effects on sensitization in the context of asthma. Similar mechanisms of nanomaterialmediated alterations in antigen transport implicate size, surface area, and agglomeration status as
properties of particular importance in this type and phase of skin allergy (534, 544, 550).

Conclusion
There is a growing amount of toxicological data demonstrating the potential for metal
nanomaterial exposure to cause significant immunotoxic effects. Many of these effects have been

326

associated with modulation of various immunological processes implicated in allergic disease.
Accordingly, metal nanomaterials represent an emerging class of potential immunotoxicants, some of
which may cause allergic sensitization, exacerbate the severity of elicitation reactions, or accelerate the
progression of chronic allergic conditions.
Despite existence evidence of these detrimental immune effects, numerous studies have also
demonstrated mechanisms by which the immunological activities of metal nanomaterials may be
beneficial to humans. Recent progress in our understanding of the relationships between metal
nanomaterial physico-chemical properties and their corresponding interactions with the immune system
has already led to numerous biomedical advancements with potential to revolutionize modern healthcare.
For example, metal nanomaterials have been intentionally employed to develop novel approaches to
drug delivery, in vitro diagnostics, and immunotherapy (527, 946, 951, 975, 1145, 1686-1691).
Although allergic adjuvancy was discussed herein as a largely unfavorable consequence of metal
nanomaterial exposure, similar immunological mechanisms are responsible for the efficacy of commercial
vaccine adjuvants, which are critical for the development of pathogen-specific immunological memory.
Among the most commonly-used adjuvants approved for use in humans, the majority, including
aluminum-based adjuvants, are associated with the preferential induction of Th2-dominant, humoral
immune responses. The development of adjuvants that selectively promote Th1-dominant, cellular
immune responses has been a historically challenging endeavor for immunologists. However, many
metal nanomaterials, including CoNP and AlNP, have been proposed to have potential utility in this
regard, exhibiting the capacity to overcome many of the barriers responsible for the limited success of
previous efforts (527, 951, 1692). Likewise, metal nanomaterials have the potential to enhance the
efficacy of many existing vaccine formulations, as well as facilitate the development of novel vaccines to
protect against pathogens and other antigens of interest.
Paradoxically, many nanotechnological advances have led to utilization of metal nanomaterials
for the prevention and treatment of allergic disease. Although some metal nanomaterials have been
shown to exhibit immunostimulatory effects responsible for the exacerbation of allergic responses, others
have been associated with attenuation of allergic inflammation. For example, AuNP and AgNP have been
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shown, in some cases, to mitigate allergic inflammation in the context of asthma (891, 892, 898, 1685).
ZnONP and AgNP have both been shown to alleviate allergic inflammation in the skin, and topical creams
containing AgNP have been shown to effectively minimize symptoms of ACD (624, 666, 1681). Similarly,
semi-metallic nanoparticles comprised of CaCO3 and CaPO4 have been shown to effectively prevent
nickel-induced ACD elicitation reactions. The increased surface area of these nanoparticles was
exploited to facilitate the binding of haptenic metal ions, effectively neutralizing their immunogenic activity
(727). Collectively, these observations have led to suggestions that metal nanomaterials may have
notable therapeutic utility in the context of allergic disorders.
Similarly, immunotoxicological advancements using nanomaterials have also contributed to the
preliminary development of pharmaceutical agents capable of inhibiting allergen-specific IgE-mediated
responses. “Nanoallergens” are comprised of multivalent antigenic epitopes that irreversibly bind IgE,
preventing cellular degranulation, and subsequent clinical manifestations of allergy (1693). Furthermore,
SiNP have been used to develop a vaccine to reduce allergic inflammation caused by HDM. Exposure to
small quantities of antigen, using SiNP as a delivery vehicle, has been shown to enhance the production
of allergen-specific IgG in vivo (986). As the major therapeutic goal of traditional immunotherapy
approaches, the production of allergen-specific IgG results in neutralization of allergen-specific IgE,
decreasing allergen reactivity. Accordingly, metal nanomaterials present a promising avenue for
advances in immunotherapeutic options with potential to benefit individuals suffering from allergic
disease.
Overall, metal nanomaterials have been associated with diverse immune effects, some of which
can lead to detrimental health effects, and others which may prove beneficial to humans. In order to
protect against the adverse immune effects caused by metal nanomaterials, as well as effectively harness
their beneficial immunological potential, existing knowledge gaps in this field should not continue to
remain overlooked. The capacity for metal nanomaterials to induce sensitization, elicit allergic reactions
in cases of existing sensitivity, and cause adverse allergic responses following systemic exposure remain
largely unknown. Additionally, a more complete understanding of the role of physico-chemical properties
in both innate and adaptive immune responses is needed. Minimization of these knowledge gaps by
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future efforts will help maintain the safety of the general population and workers, as well as catalyze the
biomedical advancements emerging from the promising field of nanotechnology.
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CHAPTER 4 FIGURE

Figure 4.1. Augmentation of respiratory and dermal allergy associated with specific metals, physico-chemical properties, underlying mechanisms, and
exposure occurrence with respect to the sensitization and elicitation phases of allergy are shown. SA (surface area), por (surface porosity), agg
(agglomeration), cry (crystallinity), crg (surface charge), diss (dissolution potential), mod (surface modification).
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